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Ich wohne in meinem eignen Haus 
Hab Niemandem nie nichts nachgemacht 
Und – lachte noch jeden Meister aus 
Der nicht sich selber ausgelacht. 
 
-Friedrich Nietzsche- 
 
 
Unsere Wissenschaft ist in jedem Augenblick nur die Hypothese dessen,  
was bis zu diesem Augenblick kein Experiment falsifiziert. 
Die endgültige wissenschaftliche Summe wird nie mehr sein als das geltende  
Vorurteil in dem Moment, in dem die Menschheit verlischt. 
(translated from the Spanish) 
 
-Nicolás Gómez Dáliva- 
 
 
I went to the woods because I wished to live deliberately, to front only the essential 
facts of life, and see if I could not learn what it had to teach, and not, when I came to 
die, discover that I had not lived. I did not wish to live what was not life, living is so 
dear; nor did I wish to practice resignation, unless it was quite necessary. I wanted to 
live deep and suck out all the marrow of life, to live so sturdily and Spartan-like as to 
put to rout all that was not life, to cut a broad swath and shave close, to drive life into 
a corner, and reduce it to its lowest terms, and, if it proved to be mean, why then to 
get the whole and genuine meanness of it, and publish its meanness to the world; or if 
it were sublime, to know it by experience, and be able to give a true account of it in 
my next excursion. 
 
-Henry David Thoreau- 
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1
  Genesymbols and their related gene names, mentioned in the text and tables, are listed in the appendix and not in the list 
abbreviations. Genesymbols are written in respect to the “Guidelines for Nomenclature of Genes, Genetic Markers, Allelles, and 
Mutations in Mouse and Rat”(www.informatics.jax.org/mgihome/nomen/gene.shtml), beginning with an uppercase letter, followed 
by all lowercase letters/numbers (e.g. Timp1). 
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SUMMARY 
 
The major aims of this work included the evaluation of urinary protein markers, transcriptional analysis of the 
underlying mechanism of Vancomycin-induced nephrotoxicity based on gene expression analysis, the evaluation and 
generation of reliable transcriptional biomarkers. In addition, the utility of an in vitro test system to produce in vivo like 
responses to nephrotoxin treatment was tested. Therefore, several questions, important for the further enhancement of 
preclinical safety assessment as well as the understanding of the underlying mechanism of drug-induced nephrotoxicity, 
were addressed. 
For urinary biomarker analysis three well known nephrotoxins (Vancomycin, Cisplatin and Puromycin) were used. The 
urinary proteins Kim-1, Clusterin and Osteopontin were clearly identified as the most predictive biomarkers for tubular 
degeneration, while 2-microglobulin and Cystatin C can be used to discriminate glomerular induced proteinuria. In 
addition, exploratory urinary biomarkers like Timp-1, NGAL, Calbindin and VEGF showed great potential to deliver 
further information about the underlying mechanism of toxicity, the area of damage or potential gender differences. 
However, there are several limitations associated with these new markers and therefore, further investigations and 
improvements are still needed. The urine dipstick assay for Kim-1, as a quick and easy to use method, was compared to 
the multiplex Luminex assay. The data showed a clear limitation in sensitivity when there are only slight alterations in 
urinary Kim-1 levels. In cases where there are strong changes, the results showed a good correlation and can therefore 
be recommended as general screening tool. 
More traditional detection systems, in this case immunohistochemical analysis, can help the identification of early renal 
changes in a reliable way. This could be especially shown for Kim-1 and Clusterin, while the interpretation of renal 
expression of Osteopontin was hindered because of strong basal expression and therefore background staining. 
The transcriptomic analysis was performed primarily to obtain further insights into the underlying mechanism of 
Vancomycin-induced nephrotoxicity. Several potential key pathways and processes, which can be considered to be a 
good starting point for further investigations, were identified. For example, the inflammatory processes, characterized 
by an activation of the complement system, leukocyte extravasations and several processes involving the transcription 
factor NF-B, seems to play an important role in the nephritis induced by Vancomycin. In addition, a Fas-induced and 
caspase-dependent apoptosis was identified, which overlaps to the already mentioned inflammatory processes. The 
regenerative properties of the kidney, also reflected by the urinary protein biomarkers as well as almost all histo- and 
clinical-pathological observations, can be due to the important position of integrin-signaling and Rho-GTPase-induced 
actin remodeling. These processes lead to cellular shape restoration and cell migration.  
The hypothesis that transcriptional changes reflect renal (and other organs) pathological changes is well accepted. 
Therefore, a commercial test system provided by Compugen Ltd. (based on the measurement by SYBR
®
 green 
detection of several specific genes, in combination with a related software tool) was tested for its predictive power. 
Three independent rat studies were chosen for this approach, namely Gentamycin, 3-pyrrolidineacetic acid, 5-[[[4_-
[imino[(methoxycarbonyl) amino]methyl] [1,1_-biphenyl]-4-yl]oxy]methyl]-2-oxo-, methyl ester,(3S-trans) (FP007SE/ 
BI-3), and aristolochia acid. The results indicated a good reflection of Gentamycin induced nephrotxicity, while 
FP007SE and aristolochic acid delivered unclear results. Several animals within the FP007SE and aristolochic acid 
studies were identified as positive for renal insult, but without any histopathological correlation. Because of the time- 
and/or dose-dependent increase in incidence, it was hypothesized that a real prediction, i.e. identification of substance 
induced alteration with no manifested morphological changes, could be possible.  
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Three published transcriptional biomarker lists (containing, 4 genes, 19 genes, and 45 genes) were evaluated for their 
potential to predict the outcome of our Vancomycin study. In addition, the methodological independence of such 
publicly available biomarker lists could be assessed. From these three gene lists a new “best predictor” biomarker list 
was created, by also taking the observations from the mechanistic gene expression analysis into account. This final list 
contains 40 individual transcripts which were grouped into 10 functional categories and reflect the biological reality in 
more detail. These can now be used in further exploratory or pre-clinical routine studies for the prediction of rodent 
specific nephrotoxicity. 
Finally, a proof-of-principal investigation was conducted with the aim to study whether or not a renal cell line (NRK-
52E) can reflect transcriptional changes in a comparable way to those observed in rat in vivo after treatment with 
nephrotoxins. 192 Significantly altered genes were identified over all positive substances (AmphotericinB, 
Doxorubicin, Puromycin, and Paracetamol); where 44 genes (~23%) have been frequently reported in the literature to 
be associated with renal cell damage. Nine of these genes, including Cd44, Cyr61 and Cdkn1a, were of special interest 
since they were some of the most prominently deregulated in vivo genes and a possible mechanistic relation was 
identified within this study. 
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ZUSAMMENFASSUNG 
 
Das primäre Ziel dieser Arbeit umfasste die Evaluierung von urinären protein- und gewebebasierten transkriptionellen 
Biomarkern, die Analyse von Genexpressionsveränderungen zur näheren Charakterisierung des toxikologischen 
Mechanismus von Vancomycin und einen proof-of-principal Ansatz mit dem Ziel des Nachweises der Vergleichbarkeit 
von Genexpressionsveränderungen nach Behandlung mit Nephrotoxinen in der renalen Zelllinie NRK-52E und 
Nierengewebe der Ratte. In diesem Sinne konnten noch offene Fragen bezüglich der oben genannten Bereiche, welche 
sowohl für die weitere Verbesserung und Entwicklung von toxikologischen Sicherheitsbeurteilungen als auch für das 
Verständnis der zugrunde liegenden toxischen Mechanismen, beantwortet bzw. neue Lösungsansätze aufgezeigt 
werden. Für die Untersuchung der urinären Proteinbiomarker wurden drei gut beschriebene Nephrotoxine - nämlich 
Vancomycin, Cisplatin und Puromycin - verwendet. Die Proteine Kim-1, Clusterin und Osteopontin konnten über alle 
drei Studien als die prädiktivsten Biomarker für tubuläre Degenerationen identifiziert werden. Für glomeruläre Schäden 
war der Nachweis mit 2-microglobulin und Cystatin C am bedeutendsten. Weitere explorative urinäre 
Proteinbiomarker wie z.B. Timp-1, NGAL, Calbindin oder VEGF zeigten ebenfalls das Potential, weitere 
Informationen über den zugrunde liegenden Mechanismus, den Bereich der Schädigung innerhalb des Nephrons oder 
aber geschlechtsspezifische Reaktionen zu detektieren. Dies muss jedoch in weiteren Studien näher untersucht werden. 
Für die Messung der einzelnen Proteine wurde ein multiplexing immunoassay verwendet, welcher die parallele 
Detektion von mehreren Proteinen in einer Probe erlaubt, sowie ein Urinteststreifen für Kim-1, welcher als schnelle und 
einfache Methode evaluiert wurde. Das Ergebnis war eine limitierte Sensitivität, welche sich in kein bis geringen 
Änderungen des Urin-Kim-1 Levels bei leichten tubulären Veränderungen wiederspiegelte. Im Falle von starken 
tubulären Einflüssen waren die ermittelten Daten jedoch gut vergleichbar, womit durchaus eine Empfehlung zur 
Verwendung des Teststreifens als Standardanalyse gegeben werden kann. 
Zusätzlich zum Nachweis der Proteine im Urin wurden die drei prädikativsten Marker auch mittels 
immunohistochemischer Analysen evaluiert, mit dem Ergebnis, dass sowohl renal expremiertes Kim-1- und Clusterin-
Protein zum frühen und spezifischen Nachweis von tubulären Schäden verwendet werden kann. Die Interpretation von 
renal expremiertem Osteopontin-Protein war durch die stärkere Hintergrundfärbung erschwert, aber dennoch möglich. 
Die transcriptomics-Analysen, welche u.a. zum Ziel hatten, den mechanistischen Hintergrund von Vancomycin-
induzierten Nierenschäden, über den auf molekularer Ebene noch relativ wenig bekannt ist, zu untersuchen, lieferte 
mehrere potentiell wichtige Signalwege und Prozesse, welche in künftigen wissenschaftlichen Untersuchungen näher 
betrachtet werden sollten. So wurde der Einfluss von inflammatorischen Prozessen näher beschrieben. Charakteristische 
Mechanismen, welche als Schlüsselfunktion der Vancomycin-induzierten Nephritis identifiziert wurden, waren die 
Aktivierung des Komplementsystems und Leukozyten-Extravasation unter Beteiligung des Transkriptionsfaktors NF-
B. Darüber hinaus konnte die Fas-vermittelte und Caspase-abhängige Apoptose näher charakterisiert werden, welche 
einige Parallelen zu den bereits erwähnten inflammatorischen Prozessen vermuten lässt. Die auffallende Regeneration 
des geschädigten renalen Gewebes nach behandlungsfreien Perioden konnte auf den Einfluss von Integrin-vermittelten 
Signalwegen zurückgeführt werden, welche unter Beteiligung von Rho-GTPasen in der Actin-Neubildung und -
Umgestaltung involviert sind. Diese Prozesse führten zur Wiederherstellung der charakteristischen zellulären Form 
sowie der Wiederbesiedlung durch migrierende Zellen. Da die den Ergebnissen zugrunde liegenden Daten größtenteils 
auf Genexpressionsveränderungen beruhen, lässt sich dementsprechend keine finale Aussage über den Mechanismus 
machen. Es wurden jedoch mehrere wissenschaftlich gestütze Hypothesen aufgestellt, welche für weitere 
Untersuchungen als Anhaltspunkt in Betracht gezogen werden sollten. 
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Im Gegensatz dazu ist die Verwendung von transkriptionellen Alterationen als Biomarker zur Reflextion von renalen 
pathologischen Veränderungen ohne weiteres möglich. Aus diesem Grund wurde zum einen ein Testsystem der Firma 
Compugen Ltd., basierend auf einer SYBR
®
 green Messung von 6 Transkripten in Kombination mit einem 
Softwarepacket auf ihre Prädiktivität getestet. Drei unabhängige Rattenstudien unter Verwendung von Gentamycin, 3-
pyrrolidineacetic acid, 5-[[[4_-[imino[(methoxycarbonyl) amino]methyl] [1,1_-biphenyl]-4-yl]oxy]methyl]-2-oxo-, 
methyl ester,(3S-trans) (FP007SE/ BI-3) und Aristolochiasäure wurden hierfür herangezogen. Es zeigte sich innerhalb 
der Gentamycin-Studie eine gute Übereinstimmung der histopothologischen Befunde mit den Ergebnissen des 
Testsystems, während innerhalb der FP007SE- und Aristolochiasäure-Studie ambivalente Resultate auftraten. Diese 
waren derart, dass einzelne Tiere als positiv affektiert eingestuft worden, ohne dass eine entsprechende Korrelation auf 
histopathologischer Ebene nachweisbar war. Da jedoch die Inzidenz mit der Zeit und/oder Dosis anstieg, konnte 
geschlussfolgert werden, dass es sich hierbei um eine Prädiktion von substanzinduzierten Veränderungen auf 
molekularer Ebene handelt, welche noch keine Ausprägung auf morphologischer Ebene hat. 
Zusätzlich zu diesem Ansatz wurden auf Basis der Genexpressionsdaten der Vancomycin-Studie, drei 
Transkriptbiomarkerlisten auf ihre Prädiktivität und methodische Souveränität hin untersucht. Auf Grundlage der 
Untersuchung und des Vergleiches dieser Listen, welche aus 4-, 19-, und 45 Genen bestand, sowie der Einbeziehung 
der Erkenntnisse aus den mechanistischen Analysen, konnte eine finale Biomarkerliste abgeleitet werden. Diese aus 40 
Transkripten bestehende Liste wurde in 10 funktionale Kategorien unterteilt, um eine mechanistisch-toxikologische 
Ableitung zu ermöglichen. Diese so establierte Liste kann im Folgenden für weitere exploratorische oder aber 
präklinische Standardstudien verwendet und weiter optimiert werden. 
Eine proof-of-principal Analyse basierend auf einem in vitro Testsystem wurde durchgeführt mit dem Ziel, den 
Nachweis zu erbringen, ob die renale Zellinie NRK-52E vergleichbare Genexpressionsveränderungen nach Behandlung 
mit Nephrotoxinen aufweist, wie bei Verwendung von renalem Gewebe behandelter Ratten beobachtet wurde. Es 
konnten 192 signifikant veränderte Transkripte identifiziert werden, wobei 44 (~23%) dieser bereits häufig in der 
Literatur im Zusammenhang mit renalen zellularen Schäden in vivo erwähnt wurden. Für neun dieser Gene konnte eine 
besondere Evidenz aufgezeigt werden, da diese eine mechanistische Relation sowohl zueinander als auch der zugrunde 
liegenden Pathologie zuließen. 
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1.1 Toxicogenomics and Biomarker Discovery 
 
1.1.1 Toxicology 
 
“All things are poison, and nothing is without poison; only the dose permits something not to be poisonous” (german: 
Alle Dinge sind Gift und nichts ist ohne Gift; allein die Dosis macht, dass ein Ding kein Gift ist.) [Marquardt et al., 
2004]. No other sentence is as closely related to toxicology as this dictum from Philippus Theophrastus Aureolus 
Bombast von Hohenheim (also known as Paracelsus). It still reflects the general principals of modern toxicology. 
Toxicology can be described as the study of mechanisms, treatments, symptoms and detection of adverse events of 
chemical and biological compounds on living organisms and the environment. These harmful effects on health depend 
on the route and time of exposure as well as the concentration to which the organism is exposed [Marquardt et al., 
2004]. Over the last few decades toxicology has evolved in to an independent, complex and varied scientific discipline. 
The main task of modern toxicology is to assess and describe the risk of the exposure to humans and the environment 
and to approximate the potential magnitude of an insult as well as to discover the underlying mechanism. Protection, 
precautions and treatment of adverse events are also part of the toxicologist’s range of tasks. Applications in toxicology 
include testing of potential drug candidates in the pre-clinical development, implementation of measures for industrial 
safety, identification and treatment of adverse events in clinical toxicology, and clarification of the harmful impact of 
environmental chemicals in the field of ecotoxicology [Hodgson, 2010]. For the detection and classification of any kind 
of insult, toxicology is divided in several subfields, focused on a multitude of potential endpoints. These range from the 
general detection of compounds and there metabolites in body fluids and tissue, changes of the general health condition, 
clinical-chemical parameters, pathological/ morphological tissue alterations up to lethality [Forth, 2001]. To achieve 
this, there are many layers of possible testing methods available to the toxicologist: in silico (computational based 
simulations), in vitro (based on cell- and tissue cultures) and in vivo (based on animal testing) methods. Currently the 
regulatory standard for the approval of novel drugs is the use of animal models, on which most of the methods in 
toxicology are based [Hayes, 2007]. In vivo studies are designed to translate the intended medical conditions to a 
mechanism of the drug and to approximate the potential risk for humans. When a substance is administered to an 
animal, many chemical and physiological changes can occur. Therefore, it can interact at many places throughout the 
whole body, and effects upon one process in one organ can cause unexpected consequences in another. By studying 
adverse effects of chemicals or drugs by using animals is critical because such complexity cannot be duplicated in in 
vitro systems. However, the question of the cellular interaction on a molecular level remains mostly unanswered, 
predominantly because most traditional methods rely on analyzing only the resulting pathology. Despite intensive 
efforts, unexpected side effects after the application and exposure of humans to chemicals and drugs cannot be 
guaranteed. Figure 1-1 gives an overview of a toxicokinetic (TK) and toxicodynamic (TD) workflow and the field in 
which modern molecular toxicology can deliver additional information. 
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Figure 1-1 Overview of additional usefulness of molecular toxicology. The term toxicokinetic 
includes the uptake, transport, metabolism, transformation, sequestration and excretion of a 
compound, while toxicodynamic gives information about the binding, interacting and toxic effects 
of a compound to the organism. Especially on the (sub-)cellular and early effect level, novel 
technologies can deliver further information about the properties of a studied compound. 
 
In addition, the question arises about the ethical use of animal testing. In this context the 3R-prinicals were first 
suggested by William Russel and Rex Burch in 1959 [Russel et al., 1959]. The maxim of this principal is that dependent 
on the current state of the art in technology; animal tests should be refined to obtain as much information as possible 
and concurrently to minimize suffering of the test animals. In addition animal tests or even the number of used animals 
should be reduced and if possible replaced by alternative methods (in silico or in vitro). Therefore, it is a major 
challenge in toxicology to establish and use state of the art methods and technologies to increase the quality and density 
of information produced, with simultaneous consideration of the regulatory requirements and the validity of the data. 
The development of novel alternative methods for animal testing and the establishment of new methods to increase the 
productivity of animal tests as well as to deliver further information besides traditional approaches comprise molecular 
and cellular biology. These new methods and an increased understanding of molecular mechanisms will result in fewer 
wrongly classified compounds in early phases of drug/chemical development. Figure 1-2 gives an overview of a 
simplified decision tree in a toxicological approach. If clear signs of toxicity appear in two different species, normally 
the developmental process will stop. If no signs of toxicity are observed, the compound enters the clinical phases. In 
“real-life” this is usually in between these two scenarios. Based on the all available data the drug developmental process 
will continue or stop. This can lead, as a consequence, to the loss of a potentially safe drug, which does not enter 
clinical trials. Or, on the other hand to the development of a toxic drug, which will fail in later phases of clinical 
development, something that is extremely expensive. In addition, toxicology is confronted with a problem of increasing 
costs in clinical and pre-clincal studies, prolonged developmental times as well as failure of drug candidate in late 
phases of drug development [Allen et al., 2008]. The United States Food and Drug Administration (US-FDA) reacted to 
this trend in 2004 with a White paper [FDA, 2004] in which this problem was summarized and the suggestion of 
integrating novel technologies into the drug developmental process was formulated. In 2007 the establishment of novel 
technologies was powered by the report “Toxicity Testing in the 21st Century: A Vision and a Strategy” from the 
National Research Council (NRC). Also the European Medical Agency (EMA) joined in this venture by founding the 
Innovation Task Force (ITF), who offers their expertise in the application and handling of new technologies within the 
EMA and to serve as a consultant and center of information concerning regulatory requirements [EMA, 2009]. 
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Figure 1-2 Decision tree in toxicology. Depending on the toxicological results, a drug-developmental 
process can be stopped or be continued. If clear signs of toxicity appear in two different species, normally a 
compound will fail. If no signs of toxicity are observed, the compound enters clinical development 
[modified by Fuchs et al., 2011a]. 
 
A new research approach of “integrative biology”, also called “systems biology”, aims to understand the entire 
biological nature of a cell, tissue, organ or even an organism [Pujol et al., 2010]. In contrast to the reductionist approach 
of classical biology, which focuses on selected partial aspects; it should be made possible to understand the entire 
system in a better way and to make more reliable predictions of potential toxicoloigal outcomes. Omics technologies 
represent a subset of the methods used in systems biology. With these methods it is possible to analyze global changes 
in cellular systems or tissues on a transcriptional (Genomics), protein (Proteomics) or endogenous metabolite 
(Metabolomics) level. By parallel detection of changes in the expression level of thousands of genes (Transcriptomics) 
several kinds of interactions and early changes caused by compounds, pathogens or the environment can be identified. 
 
 
1.1.2 Toxicogenomics 
 
The term “toxicogenomics“ is an amalgamation of the word “toxicology”, which describe the science of compound 
induced adverse/ toxic effects on living systems or the environment, and the word “genomics” which is a hyponym for 
the genetic discipline focused on studying the whole genome of an organism [Waters et al., 2004]. It is a relatively 
young branch of toxicology which is defined as the investigation between the structure and activity of the genome and 
adverse biological effects with exogenous stressors [Aardema et al., 2002].  
Toxicogenomics deals with the discovery and understanding of the influence of toxins on the regulation of genes and 
their involvement in a potential adverse outcome. The focus is formally, but not limited to, the study of messenger RNA 
(mRNA) which can be changed depending on the treatment with toxins (Figure 1-3). The aim of toxicogenomics 
analysis is to identify the mode of action (MoA) by which a compound or class of compounds cause a toxic or adverse 
effect [Edwards et al., 2008]. However, the detection of genomic alterations, e.g. changes of transcriptomics, makes it 
possible to study global changes and to derive a holistic pathway which can describe potential mechanisms which 
subsequently lead to morphological/ physiological changes. In this case transcriptional alterations can be based or be 
correlated to the MoA, the phenotype and/or the toxicological mechanism.  
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Figure 1-3 Alteration in gene expression depending on the dose of a compound. Depending on the exposure of a living system to 
a xenobiotic, adaptive systems try to stabilize the homeostatic status. After exceeding of a threshold, gene expression changes can 
be related to toxic effects [adapted by Fuchs et al., 2013]. 
 
Figure 1-4 gives an overview of different groups of transcript classification and there meaning for analysis. In this case 
it should be mentioned that it is important to distinguish between the pharmacological/ toxicological effect of a drug 
and their action. The effect is the measurable or observable consequence of the MoA or secondary mechanisms. The 
action itself is the biochemical/ physiological mechanism of the drug, which underlies the response in an organism to 
the drug. 
The effect is the measurable or observable consequence of the MoA or secondary mechanisms. The action itself is the 
biochemical/ physiological mechanism of the drug, which underlies the response in an organism to the drug. 
In addition to the identification of characteristic molecular pathways specific transcripts, involved in one of the classes 
mentioned above, can be used as mechanistic or predictive bioindicators or biomarkers for organ- or disease-specific 
toxicological alterations. [A more detailed discussion on biomarkers will be given in 1.1.3.1 Definition of Biomarkers]. 
In 2005 a published Guideline be the FDA [FDA, 2005] suggested that data from these kind of technologies could be 
submitted on a voluntary basis and shall promote the pharmaceutical industry to use them in routine drug development. 
In the last few years many new projects were initiated to evaluate the suitability of Omics technologies, including 
toxicogenomics, in the field of pharmaceutical and chemical safety assessments. 
Some of these initiatives include; the “EU Innovative Medicines Initiative” (IMI,) founded in Europe (2008), the 
“National Toxicology Program” in the USA (2004) and the “Conditioning and usage of hepatic in vitro systems for the 
identification of liver carcinogens using toxicogenomics methods” by the German Federal Ministry of Education and 
Research (BMBF) in Germany (2007). This development of public funded projects, as well as individual academic and 
industrial research investigations is still in progress. Several cooperations are still running or planned for the future. 
Table 1-1 gives an overview of some important, planned, passed or progressing projects and their aims.  
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Figure 1-4 Classification of gene expression profiles. Transcript alteration after compound exposure can be related to several 
changes. On one hand transcripts can correlate to the toxic mechanism. These kinds of transcripts can be used to analyse the pathway 
induced by a potential drug candidate or serve as mechanistic biomarkers. On the other hand alterations can also be correlated to the 
Mode of Action (MoA) [adapted by Fuchs et al., 2013]. 
 
Another field of application of these Omics technologies is the comparison of test models. In this case differences in the 
sensitivity of species, strains, genders, age groups or even in vitro and in vivo models can be discovered and can be 
incorporated into risk assessment processes. 
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Table 1-1 Overview of national and international initiatives which focus on biomarker discovery using omics-technologies. 
Consortium or international 
initiative Describtion References 
      
7th Framework Programme (EU) In the 7th Framework Programme all research-related EU initiatives are bundled. 
The initiative already runs is Predict-IV, focused on the establishment of new in vitro toxicity screening 
model including toxicogenomic, toxicoproteomic and metabolomic observation. 
www.predict-iv.toxi.uni-
wuerzburg.de 
Critical Path Initiative (US-FDA) In March 2004 the Critical Path Initiative was founded. In addition to the release of a white paper by the 
US-FDA was the reaction to a decline in the number of medical product submitted for approval. The effort 
to stimulate the development of the scientific processes through which a medical product can be transferred 
from the discovery phase to the "proof of concept" into the market release. 
www.fda.gov/oc/initiatives/ 
criticalpath/ 
Critical Path Institute/ Predictiv 
Safety Testing Consortium (USA) 
The Critical Path Institute (C-Path) has the goal to identify and therefore reduce toxic effect by drug 
interactions and to improve therapeutic outcomes. Several working groups focused on nephrotoxicity, 
hepatotoxicity, and genotoxicity were established, working on the identification of novel biomarkers for 
the early detection of these toxicities. 
www.C-Path.org/pstc.cfm 
Toxicogenomics Project (Japan) In 2002 the Toxicogenomics Project was founded with the aim to create a toxicology database for Nephro- 
and Hepatotoxicity that enables forward and reverse toxicology. The cooperative research project joined 
private and national companies. 
www.tgp.nibio.go.jp 
International Life Science Institute/  
Health and Environmental 
Sciences Institute (international) 
As a non-profit institution of the International Life Science Institute (ILSI) the Health and Environmental 
Sciences Institute (HESI) was initiated as an international forum for e.g. safety assessment and toxicology 
to enhance the understanding of the underlying scientific issues. Several working groups are working on 
different kinds of toxicity. The most developed results were published by the "Nephrotoxicity Working 
Group" who started the first systematic approach to understand the mechanism of nephrotoxicity and to 
identify diagnostic biomarkers using genomics technologies. 
www.ilsi.org 
www.hesiglobal.org 
Innomed Consortium (EU) The InnoMed PredTox project was a joint collaboration between the European Commission and Industry 
to enhance drug safety. 3 technology providers, 3 academic institutions and 10 pharmaceutical companies 
analysed hundreds of samples by using toxicogenomics, metabonomics and -proteomics technologies to 
discover biomarkers for nephro- and hepatotoxicity and to pre-validate biomarkers identified. Also the 
toxic mechanism of the failed drug-candidates provided by the pharmaceutical partners was studied. 
www.innoMed-PredTox.com 
Netherlands Toxicogenomics 
Centre  
(Netherland/ international) 
The Netherlands Toxicogenomics Center (NCT) is a collaboration of international academic and industrial 
partners. The First projects of the NTC were started in 2004 with the aim to increase the basic 
understanding of toxicological mechanisms by using toxicogenomics technologies. In this case the main 
focus was to develop new alternative methods that reflect the risks of chemical compounds in a similar or 
even better way than traditional animal testing approaches. 
http://www.toxicogenomics.nl/ 
2
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Figure 1-5 Integration of toxicogenomics in toxicological routine studies. Shown is an integrated approach for the inclusion of novel 
Omics data in the toxicological safety assessment and the identification and implementation of novel biomarkers into the standard 
battery or for the submission to the FDA/EMA qualification process. Figure adapted by Fabre et al., 2009. 
 
All of this takes into account the already mentioned 3R-prinicpal, by which the earlier identification of characteristic 
gene expression profiles can lead to the replacement of a long-term toxicity study by short-term or single dose studies or 
by a reduction in the number of animals needed per study. The usefulness of an integrated approach of toxicogenomics 
into the drug development process and the risk assessment of drug candidates in pre-clinical trials is illustrated in Figure 
1-5. The use of toxicogenomics in combination with in vitro screening systems can also be a powerful tool which can 
enable the prioritization of a high number of potential drug candidates. Here, the most promising candidates can be 
studied first in vitro which can reduce the number of animal studies performed. Subsequently, the optimum range of 
dosing can be approximated so that high dosing and unnecessary suffering of the test animals can be avoided. Not only 
in drug development but also in the risk assessment of chemicals, cosmetics and nutritional supplements these novel 
technologies have been established [Cunningham et al., 2003; Oberemm et al., 2005]. By passing the new EU chemical 
regulation REACH (Registration, Evaluation, Authorization and Restriction of Chemicals) on June 1
st
 of 2007, 
toxicogenomics and in vitro systems gained in importance [European Commision, 2007]. Independent of the use of 
toxicogenomics in pharmaceutical drug development or chemical risk assessment, it has to be mentioned that the 
experimental design of a toxicogenomics study has to be planned very carefully, because experience clearly shows that 
relatively minor changes can have a strong impact on the transcriptome [Fuchs et al., 2013]. The number of microarrays 
used, time points of treatment, replicates as well as statistical analysis has to be accurately defined at the beginning of 
the experiment. 
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1.1.3 Biomarkers in Toxicology 
 
1.1.3.1 Definition of Biomarkers 
 
Biomarkers in general can be defined as measurable, biological indicators of the actual condition of a living system. 
Therefore, they can deliver information about a normal biological, pathological or pharmacological process. The use of 
biomarkers is not limited to safety assessment (safety biomarkers) but can also be used for efficiency evaluation in drug 
targeting and lead discovery/ optimization [Wang, 2008]. Consequently biomarkers can be traditional parameters like 
blood-pressure, weight loss or pyrexia. But also single molecules which show a increase or decrease in abundance in a 
tissue or body fluid can serve as biomarkers for a disease, for example. An increase in blood glucose level in diabetes 
mellitus or the appearances of phenylketons in urine in case of phenylketonuria are examples of such biomarker 
molecules. Novel molecular biomarkers are defined as parameters that can be discovered by using technologies such as 
toxicogenomics and proteomics.  
Biomarkers can be identified on the in vivo and in vitro level. Independent of the model or technology used, different 
questions can be addressed by gene expression profiling concerning biomarker discovery (see Figure 1-4). In case of 
toxicogenomics, pathway analysis, target validation or the identification of potential, surrogate biomarkers can be 
studied. Figure 1-4 gives an overview of the single fields of transcriptional analysis and there overlap. Mechanistically 
based biomarkers, for example, can be defined as altered transcripts related to the underlying mechanism and the 
toxicologic/ pathologic phenotype.  
Biomarker techniques are not limited to transcriptomics but they can also include proteomics, metabolomics or 
functional assays. Biomarkers range from simple biofluid biochemical endpoints to more complex assessments. In the 
following description biomarkers will be used synonymously for protein or transcriptional biomarkers, if not mentioned 
otherwise. 
There are some fundamental characteristics a good safety biomarker must have, independent of the molecular class, the 
used technology or the matrix used for detection
2
: 
 Indicative after active observable damage or real predictive (biomarkers should be appear prior to 
histopathalogical changes) 
 Highly sensitive in correlation with the area and severity of damage 
 Specific for a organ, tissue or special kind of injury/ mechanism 
 Independent of age, gender and other external factors (e.g. diets, exercise) 
 Ideally it should be accessible in body-fluids like urine or blood (if this is not possible also peripheral tissue is 
acceptable for potential translational usability) 
 It should be bridge across species and be translational for humans 
 The mechanism of biomarker induction/ release should be known 
In the past a combined strategy for biomarker discovery has proven successful. The increased role of biomarkers in 
pharmaceutical drug development is reflected by the number of FDA approvals using biomarkers to enhance the 
scientific outcome of these studies. The use of biomarkers in drug development is formally based on the aim to 
                                                 
2 The following list is adapted by Robinson et al., 2008. 
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accelerate the development of potential drug candidates and simultaneously to enhance our knowledge of the safety 
profile. This can lead in consequence to a cost reduction because of a fewer drug failures in late phases of the clinical 
drug development. Therefore, it is of major interest for pharmaceutical companies to identify novel sensitive and 
specific safety biomarkers and develop cost efficient detection methods which can be easily implemented in both 
routine preclinical and clinical studies [Marrer et al., 2009]. 
There are a multitude of biomarkers used in the drug developmental process. In the field of personalized medicine, for 
example, disease specific biomarkers are used for a pre-selection of patients by assessing whether it is likely they will 
respond or not to a specific drug [Hodgson et al., 2009]. Diagnostic biomarkers can be used to identify a given 
pathological stage, while prognostic biomarkers enable the monitoring of a progression of a disease or healing process 
[Arthur et al., 2008]. Biomarkers have been used to assess the absorption, distribution, metabolism and excretion 
(ADME) of compounds by measuring transporters or xenobiotic metabolizing enzymes [Grossman, 2009]. By studying 
these processes, drug-drug interactions or the half-life in plasma of certain substances can be extrapolated to individual 
patients groups. 
In toxicology it is the aim to identify biomarkers specific for certain mechanisms and/ or organ specific toxicities that 
can be implemented in early preclinical phases. Furthermore, predictive biomarkers could be used to predict compound-
induced injury based on molecular events, even before morphological change appear. Biomarkers based on gene 
expression analysis are promising candidates because the appearance of mRNA are not directly linked to physiological 
processes but they are usually responded as a functional upstream processor and therefore appear very early. As 
mentioned above a good marker has to be specific and sensitive for a defined damage and/ or tissue. Consequently a 
biomarker should be sensitive enough to detected even small alterations. Furthermore, an ideal biomarker should also 
reflect different stages of an insult to enable one to monitor a time- and/ or dose-dependent progression [Huzarewich et 
al., 2010]. 
For preclinical safety evaluations it is also of importance that the biomarkers are easy to detect and to be able to screen 
hundreds of samples in an easy, fast and cost efficient way [Hewitt et al., 2004]. Of special interest for the 
translatability to clinical trials, but also for preclinical studies taking account of the 3R principals (Toxicogenomics and 
Biomarker Discovery), is the accessibility of biomarkers in a non-invasive way. The challenge of using body fluids is to 
make sure that the origin of the biomarker is based on a target specific mechanism or the target is the origin of the 
biomarker itself. Interference of a biomarker with other organs or mechanisms can lead to reduced sensitivity or 
specificity which can lead to false positive or false negative results, respectively. 
 
 
1.1.3.2 Traditional biomarkers for the detection of renal damage 
 
In toxicological studies it is routine to examine organs and tissues histopathologically after a defined and strictly 
regulated period of time. In this case it is possible to observe the area or the extent of damage visually. This is the 
reason why histopathology is the “gold standard” in the detection of substance induced organ damage [CDER, 2006]. 
The major limitation in histopathalogical assessments is the large number of animals needed to observe a time-course 
for example. In this case an individual animal per time point would be needed. Therefore, clinical-chemical (clinical-
pathological) parameters were used for many years to allow interim observations without further need of additional 
animals. For example, most of the parameters for the detection and monitoring of renal function are serum parameters, 
first serum creatinine (SerCrea) and blood urea nitrogen (BUN) [Fuchs et al., 2011b]. The importance of these markers 
is reflected in their routine use in clinical trials for monitor chronic kidney disease (CKD). Both compounds are 
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metabolites which normally are eliminated by the kidney, where they are freely filtered by the glomerulus and then 
enter the urine. If the function of the kidney is affected, the glomerular filtration rate (GFR) decreases and the amount 
of creatinine and BUN in the blood increase [Stevens et al., 2006]. The major disadvantage of these markers is that they 
are linked to renal function. Because the kidneys have high capacities to compensate mass loss, a decline of 
functionality is only detectable after the loss of 2/3 of healthy renal tissue [Pfaller et al., 1998; Amin et al., 2004]. This 
means that these markers cannot be detected in acute renal injury (AKI) were the function of the kidneys is normally 
not or only slightly affected. 
Additionally, these kidney clinical-chemical parameters have proved to be sensitive for detecting other physiological or 
pathological conditions and are therefore considered to be unspecific. BUN as well as serum creatinine are described to 
increase after congestive heart failure or shock [Schrier, 2008]. Also normal physiological or anatomical differences can 
affect these markers. Creatinine level, a break-down product of muscle tissue, strongly depends on age, gender; weight 
and muscle mass [Fuchs et al., 2011a+b]. Another disadvantage of these markers is that they give no further information 
about the area of damage within the kidney. A localization of the initial part within the nephron where damage takes 
place is therefore not possible. 
Urine analysis is also a common method to determine several other parameters to achieve further information about the 
health status of the kidney. Visual (urine volume, cloudiness, coloration), olfactory (odor) and chemical analysis, such 
as the detection of osmolarity, pH value, electrolytes, glucose level or total amount of urinary protein can be performed 
[Fuchs et al., 2011b]. All of these parameters can deliver further information about any renal damage but are not or only 
have limited suitability for the early detection of acute renal alterations. 
Other renal specific enzymes have also been measured as markers for renal function. One example of such an enzyme is 
γ‐glutamyltransferase (GGT), located in the brush border of proximal tubular cells. An increase of this enzyme in urine 
is a warning of a direct break-down of the tubular epithelia [Greco et al., 1985; Liangos et al., 2007]. 
 
 
1.1.3.3 Novel protein and transcriptional biomarkers 
 
With an increasing awareness for the need and the key benefits of organ specific safety biomarkers, multiple national 
and international projects were founded by different academic/ industrial institutions, as well as a health authorities, to 
evaluate the capability of omics-technologies to enhance our toxicological knowledge and to identify novel, sensitive 
and specific biomarkers. 
One of the first projects was the HESI Application of Genomics to Mechanism-Based Risk Assessment Technical 
Committee” founded in 1999 by merger of the International Life Sciences Institute / Health and Environmental Sciences 
Institute“ (ILSI/HESI) and several partners from industry as well as public and academic research facilities. The project 
group of the ILSI/HESI-Nephrotoxicity Working Group had set itself the task of identifying renal specific biomarkers, 
on a transcriptional and protein level, by microarray analysis. Therefore, gene expression data were generated from 
three rat toxicity studies with three well described model compounds and in addition compared with traditional 
toxicological end points, including histopathology and clinical-chemical parameters [Amin, et al., 2004; Kramer et al., 
2004; Thompson et al., 2004]. Male Sprague Dawley rats were treated with 2, 20, 80 or 240 mg/kg Gentamycin (7 
days), 0.3, 1 or 5 mg/kg Cisplatin (single dose) and 5 or 20 mg/kg puromycin (21 days). Several, important deregulated 
genes could be identified including Havcr1, Clu, Spp1 and Lcn2. Subsequently, a significant increase in the urinary 
level of Clusterin, α-GST, μ-GST und RPA-1 could be detected, some of which had better diagnostic performance over 
the traditional markers SerCrea and BUN. As a consequence, the Nephrotoxicity Working Group submitted a claim in 
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May 2008 to the US-FDA and EMA for the use of these four urinary proteins as potential biomarkers for the early 
detection of nephrotoxicity.  
The European contribution to the identification of novel safety biomarkers was initiated in 2005 by the forerunner of the 
Innovative Medicine Initiative (IMI) in the form of the Innomed/PredTox (Predictive Toxicology) project, which aimed 
to improve the safety profile of novel drug candidates [Innomed-PredTox Project 2005-2009]. This cooperation, 
consisting of 12 pharmaceutical companies, three universities and two small technology suppliers, investigated 16 
compounds with known nephrotoxic and hepatotoxic safety profiles. Of particular interest was the fact that only two out 
of the 16 compounds were well described “model compounds” (gentamycin and troglitazone) while the other 14 
compounds were rejected drugs from the pharmaceutical partners which failed during drug development because of 
nephrotoxic, hepatotoxic effects or both. Also in this initiative the overall aim was to identify and evaluate the 
usefulness of specific biomarkers by using a combination of traditional and omics techologies to enhance the prediction 
in preclinical rat toxicity studies. The test compounds were administered to male Wistar rats in two doses for up to 1, 3 
and 14 days [Suter et al., 2011]. 
The largest toxigocenomics project that has been funded is the Toxicogenomics Project in Japan (TGPJ). This 5 year 
collaboration project started in 2002 with the National Institute of Health Sciences and 17 pharmaceutical companies, 
with the aim to elucidate the interrelationship between gene expression changes and toxicants and to build up a publicly 
available database. Here, 150 chemicals were used for studying gene expression changes in rats (kidney and liver) and 
rat/ human primary hepatocytes [Toxicogenomics Project in Japan, 2002-2007]. A database was created by providing 
almost all gene expression data as well as histopathological and clinical-pathological data (TG-GATES DB). This kind 
of information allows the researcher to study the mechanism of a compounds toxicity, to identify biomarkers, or build 
up computer-based prediction models from all information of thousand of samples and therefore millions of transcript 
datapoints [Kondo et al., 2009]. 
Another project, finally leading to the first qualification process of novel safety biomarkers, is based on the approach of 
the Predictive Safety Testing Consortium (PSTC) funded in 2006 by the Critical Path Institute (C-Path) [PSTC-
webpage]. The project members, consisting of world leading pharmaceutical companies and public institutions under 
the roof of the regulatory agency US-FDA, aimed to validate novel biomarkers and methods to enhance the usefulness 
in routine preclinical safety approaches. Five areas of interest were defined; carcinogenicity, hepato-, nephro-, myo- and 
vasculotoxicity. 
The nephrotoxicity working group investigated 8 nephrotoxic compounds (gentamycin, cisplatin, puromycin, 
Vancomycin, doxorubicin, furosemid, lithiumcarbonat and tracolimus) as well as 2 hepatotoxic compounds 
(methyapyrilen and α‐Naphthyisocyanat) which served as negative controls. Male Sprague-Dawley and Wistar rats 
were treated with 4 different doses up to 14 days. As a result of toxicological observations and omics studies 23 
potential urinary protein biomarkers and many transcriptional biomarkers were validated. In the following qualification 
process 7 out of the 23 urinary biomarkers were qualified by the FDA, EMA and PMDA for the use in acute rat toxicity 
studies up to 14 days [Fuchs et al., 2011b]. 
Table 1-2 gives an overview of the urinary protein biomarkers analyzed in this study with their qualification status and 
their ability to detected renal damage of specific nephron segments. 
An increasing number of in vitro based projects have been funded over the last few years. The main problem with in 
vitro models, especially models based on cell lines, is that they deliver only limited significance for the underlying 
mechanism of the in vivo situation. This becomes particularly obvious by the fact that biomarkers identified in vivo are 
not necessarily translational into the in vitro situation [Dere et al., 2006]. Subsequently, there are no consistent 
biomarkers described so far which deliver reliable data over in vivo and in vitro models or even between different in 
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vitro models. Even primary cells, directly isolated from the tissue of interest, show significant differences by comparing 
gene expression profiles with those from the whole organ treated with the same toxin [Boess et al., 2003].  
Therefore, on one hand it is possible to identify and evaluate specific endpoint biomarkers, based on fundamental 
cellular functionalities for a defined in vitro model, in which particular attention may be given to the specific 
mechanism. In this case the studied endpoint must be very detailed in its content. On the other hand, the stringent 
comparison of already mentioned omics- data on a global basis and subsequently a detailed characterization of the used 
in vitro model can enhance the usability of a given in vitro system for a more holistic and global, mechanistically 
analysis [Tuschl et al., 2009]. 
Beside the already mentioned TGPJ project, several other projects have focused on different in vitro models, like the 
European ACuteTox-Project. It started a trial to optimize and revalidate in vitro testing strategies to predict human 
acute toxicity [Clemedson, 2008]. This integral EU project started in 2005 under the 6
th
 Framework program of which 
also the Innomed/ PredTox project belongs. During the course of this project no omics-technologies were used, but 
different cytotoxicity assays, like the detection of intracellular ATP, neutral red uptake, cytokine release or substance 
induced alterations of the transepithelial electrical resistance in combination with different cell lines. PredictIV, another 
EU funded project, was initiated within the 7
th
 Framework program. PredictIV is more focused on biomarker discovery 
and is analyzing a direct comparison of the in vivo and in vitro systems [PredictIV-webpage]. The methodology 
includes genomics and proteomics but also kinetic observations based on different cell systems. The aim is to identify 
the most suitable in vitro test system for human hepato- nephro- and neurotoxicity, with an integrated in vitro exposure 
measurement. Additionally, the systems shall be tested for their ability to mimic long-term repeated dose studies. 
 
In the following section, the ten urinary protein biomarkers evaluated in this project shall be shortly presented. For more 
detailed information, refer to the literature given in (Table 1-2). 
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Table 1-2 Overview of the measured biomarkers, the presumed prediction of the damage-location and their status of acceptance by 
the US-FDA and EMA. Exploratory biomarkers are not accepted but with promising results in pre-clinical observation. (PT= 
proximal tubule, DT= distal tubule, CD= collecting duct) 
Measured markers and the acceptance state by US-FDA/ EMA 
   
Protein Regulatory status References 
      
PT damage   
Cystatin C Accepted 
Colle, et al., 1990; Conti, et al., 2006; Schaefer et al., 1994; Uchida et al., 
2002; Vaidya et al., 2008b, Fuchs et al., 2011a, Fuchs et al., 2012, Dieterle et 
al., 2010 
 
Kim-1 Accepted 
Ichimura et al., 2008; Liangos et al., 2007; Prozialeck et al., 2007; Rached, et 
al., 2008; Sieber, et al., 2009; Vaidya, et al., 2008; van Timmeren et al., 2007; 
Wang, et al., 2008; Zhou et al., 2008, Fuchs et al., 2011a, Fuchs et al., 2012, 
Dieterle et al., 2010 
 
β2-microglobulin Accepted 
Chen et al., 2008; Gatanaga et al., 2006; Hofstra et al., 2008; Morel et al., 
2005; Rached, et al., 2008; Zhu et al., 2009, Fuchs et al., 2011a, Fuchs et al., 
2012, Dieterle et al., 2010 
 
α–GST Exploratory 
Prozialeck et al., 2009; Usuda et al., 1998; Lebeau et al., 2005; Thukral et al., 
2005; Branten et al., 2000; Bruning et al., 2001; Kilty et al. 1998, Fuchs et al., 
2011a, Fuchs et al., 2012,  
 
Timp-1 Exploratory 
Chromek et al., 2003; Chromek et al., 2004; Horstrup et al., 2002; Huang et 
al., 2001; Kharasch et al., 2006; Rached, et al., 2008; Sieber, et al., 2009; 
Wang, et al., 2008; Wasilewska et al., 2008, Fuchs et al., 2011a, Fuchs et al., 
2012 
   
DT damage   
Calbindin Exploratory 
Takashi et al., 1998; Hoffmann et al., 2010 Fuchs et al., 2011a, Fuchs et al., 
2012 
   
general damage   
Clusterin Accepted 
Dvergsten et al., 1994; Hidaka et al., 2002; Ishii et al., 2007; Rached, et al., 
2008; Shannan et al., 2006; Sieber, et al., 2009; Wang et al., 2008, Hoffmann 
et al., 2010; Fuchs et al., 2011a; Fuchs et al., 2012 
 
Osteopontin Exploratory 
Alchi et al., 2005; Lim et al., 2004; Rached, et al., 2008; Wang, et al., 2008; 
Hoffmann et al., 2010; Fuchs et al., 2011a; Fuchs et al., 2012 
 
NGAL Exploratory 
Flo et al., 2004; Bennett et al., 2008; Mishra et al., 2004; Mishra et al., 2003; 
Rached, et al., 2008; Sieber, et al., 2009; Vaidya, et al., 2008; Wang, et al., 
2008; Wheeler et al., 2008; Hoffmann et al., 2010; Fuchs et al., 2011a; Fuchs 
et al., 2012 
 
VEGF Exploratory 
Avihingsanon et al., 2006; Kim et al., 2005; Ogutmen et al., 2006; Peng et al., 
2007; Shihab et al., 2001; Vaidya, et al., 2008; Wakelin et al., 2004; 
Hoffmann et al., 2010; Fuchs et al., 2011a; Fuchs et al., 2012 
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Cystatin C  
The 13 kDa Cystatin C protein is a major inhibitor of extracellular cystein proteases, expressed in nucleated cells 
[Manabe et al., 2011]. Because of its small size and its relatively constant blood level, which is in contrast to creatinine 
and independent of muscle mass, gender and age, it is freely filtered from the glomerulus and almost completely 
reabsorbed [Uchida et al., 2002, Fliser et al., 2001, Bokenkamp et al., 1998]. Before Cystatin C was identified as a 
potential urinary protein biomarker for nephrotoxicity, it was used as a serum parameter for the estimation of the 
glomerular filtration rate. 
The fact that Cystatin C also can be used as urinary protein biomarker is based on its almost complete lysosomal 
degradation. Therefore, the urinary Cystatin C level will increase when the proximal tubular cells, containing the 
highest amount of lysosomes, are degraded and therefore no absorption can take place. There is some evidence that 
urinary Cystatin C only shows alteration after proximal tubular damage [Conti et al., 2006], however, it has also been 
shown that Cystatin C increases in glomerular induced proteinuria [Dieterle et al., 2010]. A definitive mechanism for 
this observation has not been formulated so far. 
 
Kidney Injury Molecule-1 
The protein encoded from the Havcr1 gene, known as kidney injury molecule-1 (Kim-1) or T-cell immunoglobulin 
mucin (Tim-1) is probably the most promising of the new urinary protein biomarker. It is a 100 kDa, transmembrane 
glycoprotein of the immunoglobulin superfamily, and is involved in several intra- and intercellular processes. Kim-1 
was first described in relation to an immune response, especially  Th1 and Th2 mediated immunity [Mcintire et al., 
2003, Mariat et al., 2005, Curtiss et al., 2007], or as a receptor for the hepatitis A virus [Kaplan et al., 1996].  
During acute kidney injury, Kim-1 has been postulated to be involved in cell regeneration, due to its structural 
similarity to cell adhesion molecules like integrins, selectins and cadherins [Fagotto et al., 1996, Sastry et al., 1993]. 
The expression of Kim-1 is limited to proliferating and dedifferentiated epithelial cells of the S3 segment of the 
proximal tubulus [Ichimura et al., 1998]. This gives further support to the hypothesis that Kim-1 is related to 
regenerative processes after a renal insult. In addition, Kim-1 has a very low expression in healthy kidneys, therefore an 
early upregulation (both transcript as well as protein) and its detectability in urine, are additional advantages. In contrast 
to other urinary proteins, Kim-1 is not secreted into the tubular convolute. After damage to proximal tubule cells of the 
S3 segment, the ectodomain is cleaved by matrix metalloproteases (MMP) and the soluble form of Kim-1 is shed into 
the urine [Bailly et al., 2002]. However, the whole mechanism of the induction and repair functions of Kim-1 in relation 
to other survival and apoptotic factors is not yet fully understood. In addition to the already mentioned regenerative 
processes, Kim-1 may also play a role in the prevention of kidney injury [Fuchs et al., 2011] via clearance of apoptotic 
cells. Kim-1 has phosphatidylserine receptor properties and can recognize the epitopes on the surface of apoptotic cells 
by conversion of epithelial cells to a phagocytic phenotype [Ichimura et al., 2008]. 
 
2-microglobulin 
2-microglobulin (2m) is a plasma protein, expressed on the surface of nucleated cells and functions as a soluble 
subunit of the major histocompatibility complex class I (MHC-I) and has therefore an antigen-presenting role. 2m has 
not been described to be upregulated in renal cells after an insult, nor on mRNA neither on protein level. Therefore, its 
physiological role is not related to its property as a biomarker of kidney injury. The specificity of 2m for renal damage 
seems to be based on the fact that it is released into the blood in response to cellular turnover. Because 2m is only an 
11.8-kDa monomeric protein it is freely filtered by the glomerulus. By entering the tubular convolute 2m is absorbed 
by proximal tubular cells and catabolized by lysosomal degradation [Miyata et al., 1998]. Like Cystatin C, 2m has 
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been described to appear in the urine after the proximal tubular protein reabsorption complex is disturbed by tubular cell 
break-down induced by nephrotoxin exposure [Chapelsky et al., 1992]. Therefore, 2m has been classified as a specific 
urinary protein biomarker for proximal tubular damage [Rached et al., 2008, Hofstra et al., 2008, Gatanaga et al., 2006]. 
However, because of the non-renal origin of 2m there is some evidence that this filtered protein may lack sensitivity 
for the detection of proximal tubular damage [Hoffmann et al., 2010, Fuchs et al., 2012] and could also be used as a 
biomarker for glomerulus induced proteinuria [Dieterle et al., 2010]. 
 
Alpha Glutathione S-transferases  
Several classes of Glutathione S-transferases (GSTs) have been described. They are involved in detoxification 
processes, by conjugation of GSH to xenobiotics. Consequently, the highest expression of these important cytosolic 
Phase II xenobiotic metabolism enzymes is seen in the liver, kidneys, gut, lungs and heart. However, general GSTs, 
such as -GST, are expressed in almost all tissues. Very high amounts of -GST are expressed in liver hepatocytes and 
in renal proximal tubular cells, leading and having been used as a sensitive marker for liver tissue damage following 
acute liver injury and acute kidney injury [Beckett et al., 1985, Redl et al., 1995]. It has been reported that -GST enters 
the urine after drug-induced proximal tubular cell break-down and can be therefore used as biomarker for proximal 
tubular damage [Bruning et al., 2001, Lebeau et al., 2005, Branten et al., 2000, Usuda et al., 1998]. 
The fact that -GST shows an overlap in expression between kidney and liver cells and exclusive kidney damage 
without any impact on the liver is very rare, a rise in blood -GST during hepatic insult cannot be excluded. 
Consequently, it must be assumed that also an increase in urinary -GST may also be to hepatotoxicity. For this reason 
the submission from the ILSI/HESI consortium to qualify -GST as an acute kidney injury biomarker was rejected 
[EMA, 2010].  
 
Tissue Inhibitor of Matrix Metalloproteases-1 
The tissue inhibitor of matrix metalloproteases-1 (Timp-1) is a specific inhibitor of MMPs, which are related to the 
extracellular matrix equilibrium [Brew et al., 2000]. Timp-1 shows the highest affinity of the Timp family and therefore 
the strongest binding to MMP-9. The interruption of the equilibrium of these two molecules can lead to different 
pathological outcomes. Consequently, the deregulation of MMPs can cause an accumulation of Timps and lead to the 
progression of renal injury, and is often observed during tubulointerstitial fibrosis [Horstrup et al., 2002]. 
Timp-1 itself is a 28.5 kDa glycoprotein expressed in several different cell types, including fibroblasts, osteoblasts and 
epithelial cells and consequently appears in many tissues and body fluids [Lambert et al., 2004]. Therefore, an elevation 
of Timp-1 in urine could also be observed as a consequence of acute and chronic organ toxicities [Liu et al., 2006]. In 
addition to the inhibition of MMPs, Timp-1 also has been described to stimulate cell proliferation, as well as preventing 
apoptosis [Schnaper et al., 1995]. As for all ubiquitous proteins with a size below the filtration barrier of the 
glomerulus, the origin of Timp-1 in urine still needs to be confirmed, because tissue remodeling processes and damage 
in other tissues can also elevate the amount of Timp-1 in the blood and subsequently in urine [Barton et al., 2003]. 
 
Calbindin 
Calbindin or Calbindin28k (~28kDa) belongs to the vitamin D-dependent calcium-binding protein family. This family 
is characterized and further sub-divided based on the number of Ca
2+
-binding EF-hand domains. Physiologically, they 
are involved in the transport of calcium ions [Kojetin et al., 2006]. Members of this family have been observed in the 
kidney and intestine. In rat, the localization of Calbindin was found at epithelial cells of the distal tubules, where they 
are responsible for the transport of Ca
2+
 ions out of the primary urine back into the tubular cells. Based on the 
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localization, and (pre-) clinical observations, Calbindin can be assumed to be a promising urinary biomarkers specific 
for distal tubular injury [Hasegawa et al., 1993, Takashi et al., 1998, Hoffmann et al., 2010]. Even though there has 
been promising data reported, there are still questions, which have to be addressed. Calbindin has been described to 
decrease in relation to drug-induced renal insult, on both the gene expression as well as protein expression level 
[Matheis et al., 2011, Wang et al., 2008, Hoffmann et al., Fuchs et al., 2012]. Owing to its involvement in calcium 
homeostasis and that extracellular calcium is an important factor of cellular stress; further mechanistic studies should be 
performed to investigate this interaction. 
 
Clusterin  
Clusterin, also named glycoprotein 80, apolipoprotein J or serum protein 40, is a glycoprotein expressed in many 
different tissues and secreted in body fluids. Therefore, Clusterin, which formally appears as an abdimer, is involved in 
many different physiological processes, including lipid transport, cell aggregation and the complement system 
[Rosenberg et al., 1995, Shannen et al., 2006]. The highest expression of Clusterin has been observed in differentiating 
and proliferating cells [French et al., 1993]. Clusterin also has anti-apoptotic, as well as pro-apoptotic properties, 
depending on the intracellular form [French et al., 1994, Hara et al., 2001, Trougakos et al., 2005]. Based on these 
characteristics, Clusterin has been identified in several studies focused on kidney diseases, like glomerulonephritis, 
renal tumors but also in drug-induced tubular damage, as a good biomarker, both on the transcript as well as protein 
level [Correa-Rotter et al., 1998, Eti et al., 1993, Hidaka et al., 2002, Witzgal et al., 1994, Yang et al., 2007]. The fact 
that Clusterin is upregulated on the protein level and is secreted directly into the urine after renal insult, is one of the 
major benefits of this protein.  
 
Osteopontin 
The gene product of the Spp1 gene, Osteopontin, also known as secreted phosphoprotein 1, uropontin or early 
T-lymphocyte activation-1, is a multifunctional glycoprotein. It was discovered in 1986 from osteoblasts [Oldberg et al., 
1986]. Osteopontin is involved in the mineralization process of bones, where the highest expression can be observed. 
However, it is also expressed in several other epithelial cells such as liver, lung, urinary bladder, skin, pancreas and 
kidney [Brown et al., 1992] The molecular mass of Osteopontin is on average 44 kDa, but varies depending on its 
glycosylation and phosporylation state. In case of kidney damage the physiological function of Osteopontin seems to be 
related to regeneration of cells after an insult and the accumulation of macrophages and monocytes, responsible for the 
clearance of apoptotic cells [Xie et al., 2001]. Osteopontin has also been reported to have anti-apoptotic properties and 
has been reported to be involved in several tumors. The mechanism leading to a protective effect against apoptosis 
involves the activation of NF-B, by interacting with v2 integrin of endothelial cells [Mazzali et al., 2002]. 
Additionally, Osteopontin is also involved in the prevention of kidney stones, by inhibition of the formation of oxalate 
crystals [Wesson et al., 2003]. 
The specific upregulation of Osteopontin in renal tissue was shown in preclinical rat disease models, including 
nephrocarcinoma, interstitial nephritis, glomerulonephritis, [Xie et al., 2001, Persy et al., 1999] as well as in drug-
induced kidney injury [Iguchi et al., 2004, Thukral et al., 2005, Wang et al., 2008]. Subsequently, the increase in 
Osteopontin protein has also been observed in urine [Khan et al., 2002, Shui et al., 2007]. Owing to the localization of 
the Osteopontin protein, which has been described to be the highest in the descending limb of the loop of henle within 
rat kidneys, it is used as a marker for damage to the loop of Henle. However, the release of Osteopontin seems also take 
place after proximal and distal tubule damage, and can be therefore classified as a general tubular marker [Hoffmann et 
al., 2010]. 
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Lipocalin-2/ NGAL  
Lipocalin-2 or Neutrophil gelantinace associated lipocalin-2 (NGAL) is a member of the lipocalin family. Members of 
this family are characterized by their small, -barrel structure containing eight -strands [Flower et al., 1993]. This 
calyx enables the Lipocalin members, which are formally localized extracellularly, to bind small hydrophobic molecule 
and translocate them into cells [Kjeldsen et al., 1993, Goetz er al., 2002]. In case of NGAL, it is responsible for the 
transport of siderphores, which are produced by prokaryotes during an infection, leading to a reduction of iron uptake of 
the bacteria and as a consequence to an inhibition in their growth [Goetz er al., 2002, Flo et al., 2004]. Therefore, 
NGAL is strongly involved in the immune response after an infection, which is also reflected by expression of this 
protein by neutrophils and epithelial cells as an early response to cellular stress. Within the kidney the expression of 
NGAL, both mRNA and protein, is very low when no pathological alterations are taking place, while in cases of tubular 
damage it is strongly elevated [Mishra et al., 2004]. An increase in NGAL could be observed in many renal diseases 
[Wagener et al., 2008, Mishra et al., 2003, Ding et al., 2007, Bennett et al., 2008]. There is evidence that NGAL has a 
protective effect on renal cells. It has been shown that the NGAL protein, administered exogenously, has a protective 
effect against ischemic kidney injury in mice [Mori et al., 2005]. The response of NGAL to renal injury is very early 
and therefore highly sensitive. However, the fact that NGAL is expressed in several tissues during acute stress and 
released into the blood, together with the small size of this protein, means that it freely enters the tubular convolute and 
consequently the urine, leads to the assumption that there is a lack in specificity.  
 
Vascular Endothelial Growth Factor  
Vascular endothelial growth factor (VEGF or VEGF-A) is a member of multipotent cytokines [Ferrara et al., 2001]. By 
alternative splicing the VEGF gene can be transcribed into six different isoforms [Neufeld et al., 1999]. The 
physiological function of VEGF is wide, including the increase vascular permeability, support of vascular survival, the 
stimulation of endothelial cell differentiation and cell proliferation, mediation of endothelium-dependent vasodilatation 
and prevention of apoptosis [Ferrara et al., 2001, Neufeld et al., 1999]. In addition, VEGF is also involved in matrix 
remodeling, expression of adhesion molecules and chemotaxis of monocytes [Schrijvers et al., 2004]. Therefore, VEGF 
has been described to have renal protective properties [Matsumoto et al., 2003]. Consequently, VEGF has been 
described in a multitude of renal diseases to show an increase (transcriptionally and on protein level), for example in 
diabetic nephropathy [Braun et al., 2001], high protein-induced nephropathy [Schrijvers et al., 2002], nephron reduction 
[Flyvbjerg et al., 2002] and glomerulonephritis [Matsumoto et al., 1997a+b+c, Matsrumoto et al., 1999, Matsumoto et 
al., 2001]. VEGF has been described to be produced by adjacent podocytes. It is required to maintain normal fenestrated 
endothelial function of the glomerulus and is particularly important for normal functioning of the glomerular basement 
membrane [Sugimoto et al., 2003]. However, less information is available for the performance of VEGF in preclinical 
rat toxicity studies to serve as a urinary biomarker. Data available so far do not show a clear conclusion for the 
performance of VEGF [Hoffmann et al., 2010, Fuchs et al., 2012]. 
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1.2 The Kidney 
 
1.2.1 General Function of the Kidney 
 
The kidney is the major organ of excretion of xenobiotics (drugs, chemicals, environmental toxins) as well as their 
metabolites. The general functionalities of the kidney are based on blood filtration, secretion and reabsorption of 
molecules by the glomerulus and the tubular system. The whole mechanism of filtration of water and soluble 
reabsorption is a complex interaction of the highly specialized tubular cells and salt gradients over the different 
segments of the kidney. At this point a detailed description is not warrented. Single aspects are described in the special 
sections 1.2.2 Morphology and Cell types of the Kidney. 
The kidney has a high metabolic activity and transporter capacity which enables the metabolic inactivation of 
compounds as well as increases their water solubility, enabling an enhanced elimination via the urine. Therefore, the 
kidney is essential for the regulation of the water-, electrolyte and acid-base homeostasis within the body. Furthermore, 
the kidney is responsible for the synthesis of the hormone erythropoietin and in this case is directly involved in the 
formation of erythrocytes [Sands et al., 2005]. Another central position of the kidney is based on the synthesis of the 
endopeptidase renin, which is the major stimuli of the renin-angiotensin-aldosterone system, which is the most 
important regulator of the blood pressure and in cases of the need of water storage. 
 
 
1.2.2 Morphology and Cell types of the Kidney 
 
1.2.2.1 Macroscopic Structure 
 
The kidney is a paired, bean-shaped organ, which is located in the abdominal cavity. Each kidney has a concave and 
convex surface. The renal hilum, located at the concave surface is the point at which the ureter and the renal vein leave 
the organ, while the renal artery enters it. The whole kidney is surrounded by the renal capsule, a fibrous tissue. 
Morphologically the kidney can be divided into the lighter, superficial area of the renal cortex and the darker, deep 
medulla. Both structures together build up the renal lobes. These structures build the renal pyramids which contain the 
surrounding cortex a portion of the medulla (Figure 1-6). At the end of these pyramids the renal papilla enters the minor 
calyces which again enter the major calyx to release the urine into the renal pelvis [Schmidt et al., 2004].  
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Figure 1-6 The Kidney. Shown is a multilobular left kidney with a 
coronal section. The anatomic structure, including the renal cortex and 
medullar forming the renal pyramids, the calyxces, the renal pelvis, artery 
and vein as well as the ureter are displayed [modified by Standford School 
of Medicine, 2012]. 
 
1.2.2.2 The Nephron 
 
The nephron is the functional subunit of the Kidney (Figure 1-7). The total number of nephrons in humans is about 1 
million, while rat only have approximately 30,000. Depending on their location within the kidney it can be 
discriminated between common cortical (formally located in the cortex) and juxtamedular (formally located in the 
medulla) nephrons [Schmidt et al., 2004]. The nephron is the area where the primary urine is built up as well as where 
essential blood components like glucose, amino acids and salts are reabsorbed. Both types of nephrons can be sub-
divided in four major sections which differ in their functions, locations and out of this in their cell types. 
The blood filtration occurs in the glomerulus. During this process the primary urine enters the tubular system. It can be 
roughly separated in to the proximal tubulus, the loop of henle and the distal tubulus. The final urine enters the 
collecting ducts which lead to the renal calyces. In the following sections the single parts of the nephron shall be 
described in more detail depending on their significant as major targets of compound induced renal damage. 
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Figure 1-7 The nephron. Given is a nephron with its specific subunits, the glomerulus within the 
Bowman´s capsule, the proximal tubule, the Loop of Henle (roughly subdivided in the ascending 
and descending linb), the distal tubule and the collecting duct. Also shown is the renal system of 
tiny blood vessels traveling alongside the nephron, the Preitubular capillaries [modified by Ken 
Pitts, 2011] 
 
1.2.2.3 The Glomerulus 
 
The glomerulus, or the renal corpuscle, consists of two structures, the Bowman´s capsule and the actual glomerulus. In 
the proper sense the glomerulus describes a capillaries bed between the arterioles Vas affernece and Vas efference. The 
glomerulus is enclosed in the Bowman´s capsule, a cup-like sac, which is one of the filtration barriers responsible for 
the filtration of the blood. Figure 1-8 gives a schematic overview of the anatomic structure as well as the buildup of the 
barrier forming compartments within the Bowmans capsule. 
The Bowman´s capsule has an outer parietal and an inner visceral layer. Both composed of squamous epithelium, while 
the visceral layer is lined by podocytes which contact the capillary bed, forming filtration slits by their foot processes 
[Schmidt, 2004]. Therefore, three filtration barriers can be discriminated: The fenestrated capillaries (barrier for cellular 
components), the glomeruli basal membrane (pore size: 240 – 340 nm) and the visceral layer (filtration slits: ~25 nm). 
All layers together provide barrier properties of the glomerulus for molecules >70 kDa [Greaves, 2011]. Therefore, in 
healthy kidneys, molecules exceeding this size cannot enter the primary urine. Beside this molecular size exclusion, the 
electrical charge also plays a pivotal role. Uncharged or positively charged molecules are filtered more easily. The 
reason for this is the negatively charged surface of the endothelial cells. Albumins for example have a molecular mass 
66 (on average) and are therefore under the barrier properties of the glomerulus. Because of the strong negative charge 
the impermeability of the glomerular barriers for albumin is still at 99.97% [Klinke, 2004]. The primary urine formed 
by the glomerulus enters the proximal tubular system (1.2.2.4 The Tubular System), in which essential compounds and 
water are reabsorbed. 
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Figure 1-8 The Glomerulus. A schematic drawing shows the afferent and efferent arteriole entering 
and leaving the glomerulus. The glomerulus is covered by podocytes within the Bowman´s capsule. 
In addition the Macula densa and the Mesangial cells between the distal tubule and the glomerulus is 
given. [modified by Haussecker, 2012]. 
 
 
1.2.2.4 The Tubular System 
 
Directly behind the glomerulus the primary urine enters the proximal tubulus. This tubular part can be subdivided into 
two sections, the pars convoluta and the pars recta. The pars convoluta are confined entirely to the renal cortex while 
the pars recta descend into the outer medulla. [Boron et al., 2008]. Regarding functional properties and ultrastructure the 
proximal tubules can also be divided into three segments (S1, S2 and S3) where the segments S1 and S2 belong to the 
pars convoluta and S3 segment belongs to the pars recta. Although the cellular complexity increases from the S1 to the 
S3 segments, the cellular structure is similar over the individual segments. The proximal tubular cells (PTCs) are 
characterized by a luminal surface covered with densely packed microvilli. This brush border increases the luminal 
surface, depending on there resorptional functionality and a putative flow sensing within the lumen [Wang, 2006]. In 
addition the PTCs are highly packed with mitochondria which are needed to supply energy to various ATP-dependent 
transport processes but also protein synthesis. One of the key ATP-dependent transport processes is the sodium 
transport out of the PTCs via the Na/ K-ATPase. This energy consuming transport builds-up a concentration gradient 
which therefore leads to water reabsorbtion by passive diffusion, following the sodium along its concentration gradient. 
In addition, various secretion processes are taking place. Most of the ammonium eliminated in the urine is formed in the 
proximal tubule by cleaving of glutamine to α-ketoglutarate [Rennke et al., 2009]. But also a multitude of drug is 
transported by the proximal tubules into the lumen to allow the elimination via the urine. 
The next tubular region is the so called loop of Henle. The main function of the loop of Henle is to create a 
concentration gradient in the medulla by achieving a high sodium concentration near the collecting ducts in order to 
reabsorb water passively by moving down its concentration gradient [Eaton et al., 2004]. 
Therefore, this part can be roughly divided into two portions; the descending limb, which is the first part after the 
proximal tubulus and the ascending limb of the loop of Henle. Subdivisions into five parts depending on there 
morphological structure and the location within the kidney are prominent: 
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1. Thick descending limb 
2. Thin descending limb 
3. Thin ascending limb 
4. Thick ascending limb 
5. Cortical thick ascending limb 
 
Both the thick and thin descending limbs are highly permeable to water while the permeability for urea and ions is quite 
low. In the renal medulla a sharp bend is the border from the descending and the ascending limbs. The thin ascending 
limb is characterized by its impermeability to water but not to ions. Similarly, the thick ascending limb is responsible 
for the reabsorption of Na
+
, K
+
 and Cl
2+
 by the passive transport via NKCC2 (Na-K-2Cl symporter) [Lytle et al., 1995]. 
The final area of the loop of Henle, the cortical thick ascending limb, drains the urine into the distal tubular convolute. 
The distal tubular cells (DTCs) are responsible for the regulation of several electrolytes like Na
+
, K
+
 and Ca
2+
 and also 
the pH by absorbing and secreting bicarbonate and protons. In contrast to the PTCs the DTCs do not have an apical 
brush border and are under strong hormone control. Therefore, aldosterone increases sodium reabsorption. Sodium and 
potassium levels are also controlled by secreting K
+
 and absorbing Na
+
.  
Followed by the distal tubule, the urine enters the collecting duct. In this compartment, which is formally not part of the 
nephron, the fine adjustment of concentration via water absorption is performed. All the processes in the collecting duct 
are controlled by the hormones aldosterone and antidiuretic hormone (ADH).  
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1.3 Nephrotoxicity 
 
The kidney is one of the most affected target organs of xenobiotic-induced organ toxicity [Emeigh-Hart et al., 2005]. A 
very large number of therapeutic compounds (aminogykosides, NSAIDs, ACE inhibitors) as well as chemicals (heavy 
metals like cadmium and cobalt) lead to excessive tissue damage in renal tissue. The high rate of substance-induced 
renal damage can be explained by the central role of the kidney in xenobiotic elimination processes. Therefore, a high 
number of drugs are eliminated via the kidney excreted through the urine. Additionally, the high blood flow rate of the 
kidney, which is about 1.2 liters per minute (1700 liter per day), that corresponds to a value of 25% of the cardiac 
output, leads to an extraordinary exposure to xenobiotic compounds [Klinke et al., 2004]. 
The kidney has, beside liver and gut, one of the highest activities of phase I and phase II xenobiotic metabolizing 
enzymes [Lohr, 1998]. Consequently, several harmless compounds can be activated and toxified within the kidney itself 
[Emeigh-Hart et al., 2005]. Also extrarenal, hepatic activated substances can enter the kidney.  
Based on the physiological functionality of the kidney to reabsorbed essential blood components, the cells of the 
proximal and distal tubulus are very rich in active and passive transporters. This leads to the fact that several xenobiotic 
compounds are taken up by the tubular cells, which can lead to the accumulation of these compounds (aminoglykosids, 
platinum complexes) – potentially increasing toxicity [Anzai et al., 2007]. 
The glomerulus filters approximatly 120 mL primary urine per minute. This leads to a total daily amount of ~170 L 
primary urine entering the tubular system, which is concentrated down to ~1.5 L daily urinary output. This means as a 
consequence the concentration of xenobiotics can also increase up to 100 fold compared the serum level. Combined 
with the metabolic activity and the transport capacity even very small administered doses can exceed tolerable 
concentrations within renal tissue. All this leads to an increasing number of acute kidney injury (AKI) and chronic 
kidney diseases (CDK). AKI describes the reversible insufficiency of the glomerular and tubular excretion function. 
Consequently, anuria tubular symptoms can appear [Marquardt et al., 2004]. Overall, 1-7% of patients with a long-term 
hospitalization develop AKI [Hou et al., 1983; Edwards et al., 1994; Nash et al., 2002; Liangos et al., 2006] while the 
number in patients in an intensive care unit increases up to 25% [Chertow et al., 1998; de Mendonca et al., 2000]. 50-
70% of adults and 30% of pediatric patients with AKI die of the disease annually [Minejima et al., 2011]. One of the 
reasons for AKI is the nephrotoxic potential of a multitude of drugs. The number which can lead to drug-induced AKI 
varies in literature. Between 8 and 60% of the reported cases can lead back to Nephrotoxins [Hou et al., 1983, Nash et 
al., 2002; Uchino et al., 2005]. This underpins the importance of identifying and evaluating novel methods for the early 
prediction of renal damage, not only in toxicology but in clinical trials. 
Pathological changes associated with AKI or general nephrotoxicity can be caused by several factors and include a 
multitude of different mechanisms. The manifested pathology can vary depending on the underlying effect on renal 
cells and the area within the nephron. This may be due to the heterogenic construction of the nephron, which includes 
several different cell types which are separated and have defined localizations within the kidney. It can be discriminated 
between pre-, intra-, and post-renal causes, while compound induced renal damage accounts for the group of intra-renal 
causes. A general overview is given in Figure 1-9. A common pre-renal cause of acute kidney injury is azotemia, which 
can be induced by diuretics or other antihypertensive drugs [Wilcox, 1999]. Intrarenal toxicity can manifest after 
cardiovascular damage, direct tubular injury, interstitial damage and glomerular injury. 
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Figure 1-9 Overview of the three major causes of acute kidney injury (AKI). Pre-, intra- and, 
postrenal causes can be discriminated. The most important alteration in case of drug-induced 
kidney injury is the intrarenal acute tubular necrosis. [modified by Dermirjian et al., 2012] 
 
While vascular injury, associated with primary endotheilial damage, leading to platelet aggregation/ consumption and 
consequently to renal vascular injury [Choudhury et al., 2006], tubular injury is characterized by direct injury of tubular 
cells. This damage itself can be caused by toxic, inflammatory, ischemic or obstructive mechanisms.  
A common cause of drug-induced renal interstitial inflammation is an increasing number of lymphocytes, monocytes, 
eosinophils and plasma cells within the renal interstitium [Choudhury et al., 2006]. This can be induced by compounds 
leading to immune reactions, which then localizes within the interstitium. Another cause is the binding of renal tubular 
cell antigens by drugs. Also in some glomerular alterations, inflammatory processes have been described to play a 
pivotal role [Kleinknecht, 1995]. Drugs that alter the glomeruli and subsequently lead to an elevated permeability often 
cause proteinuria. Glomerular damage can be caused by different mechanisms. Therefore, glomerulonephritis, which 
describes the inflammation of the membranous tissue and glomeruloslerosis, which is the scarring of small renal blood 
vessels, can be discriminated. These pathologies are all acute events. However, chronic nephrotoxicity must not be 
forgotten, and describes the situation of prolonged exposure of the kidney to a compound. The underlying mechanisms 
of the compounds used within this project will be described in more detail under 1.3.1 Nephrotoxins. 
 
 
1.3.1 Nephrotoxins 
 
Four general mechanisms leading to renal damage are known, based on the role of the kidney within an organism and 
the functional properties (see Figure 1-10), whereby it should be noted that in most cases a combination of these will 
appear in an in vivo situation. First, a compound can enter the cell by diffusion or by active uptake and can interact 
there, without metabolism, with intracellular macromolecules. Another possibility is the intracellular formation of 
reactive oxygen species (ROS), which causes oxidative stress and cellular damage. On the other hand a compound can 
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be metabolized intrarenally to form toxic metabolites which can interact with cellular compartments or lead to lipid 
oxidation. The last possibility of a direct mechanism leading to drug-induced kidney injury is via extrarenal toxification 
(usually hepatic) of drugs which subsequently enters the kidney [Greaves, 2011]. Because of the central role of the 
kidney within the body several other secondary mechanisms can be lead to AKI or CKD based on the extrarenal organ 
damage, such as hepatorenal syndrome [Arroyo et al., 1996]. 
In the following section the used compounds within this scientific approach shall be introduced and the underlying 
mechanism, as far as known, shall be described in more detail. 
 
 
Figure 1-10 General mechanisms of drug-induced renal damage. Based on the structure, the physicochemical properties, the 
toxicokinetic and toxicodynamics a drug can directly interact with cellular compartments or induce secondary cellular responses, like 
ROS. Other drugs maybe intra- or extrarenally activated and therefore lead to renal injury. The blue arrows indicate steps without 
direct, harmful impact on the kidney. The red arrows show direct detrimental effect of either the drug or its metabolites. The green 
arrows indicate metabolic activation of the original drug. 
 
Compounds used in vivo 
 
 Vancomycin 
Vancomycin is a large, rigid glycopeptides that inhibit bacterial cell wall peptidoglycan synthesis. The 
mechanism is based on its three-dimensional structure, containing a cleft into which the L-lysine-D-alanyl-D-
alanine amino acid sequence fits, which is highly specific for bacterial cell walls [Reynolds et al, 1989]. 
Vancomycin is a known nephrotoxin, if special importance in nosocomial infection patient populations. 
[Toyoguchi et al., 1997]. Because Vancomycin is a drug of last resort for gram-positive bacterial infections 
[Cui et al., 2006] nephrotoxic side effects have been frequently reported in humans. The nephrotoxicity varies 
from in 0–17% in case of Vancomycin monotherapy and 7-35% in cases of co-administration with other 
antibiotics (e.g., aminoglycoside) [Rybak et al., 2009]. However, the full mechanism of toxicity is still not 
completely understood. The basic mechanism of Vancomycin nephrotoxicity depends on an energy-dependent 
uptake from the blood over the basolateral membrane of tubular cells [Dieterich et al., 2009]. It is suggested 
that Vancomycin alters the energy dependent renal reabsorption function of the proximal tubule cells, by 
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detrimentally affecting mitochondrial function [King et al, 2004]. Oxidative stress might be involved in the 
pathogenesis of Vancomycin induced renal damage as mitochondria represent a major site of ROS production. 
In addition, the induction of several antioxidants, serving as potential protective factors, has been reported 
[Celik et al., 2005]. Vancomycin is reported to show pathological changes in tubulus of kidney in animals 
treated intraperitoneal (i.p.) with 200 mg/kg/day. Cellular oedema, cell necrosis and tubular atrophy were the 
most evident changes [Naghibi et al., 2007]. Therefore, 300 mg/kg/day Vancomycin (i.p.) was used in this 
study to induce server toxic effects. As a low dose, were no-to-minimal alterations were expected, 50 
mg/kg/day Vancomycin was used. 
 
 Cisplatin 
Platinum compounds are widely used drugs for the treatment of several kinds of cancers [Kelland, 2007]. The 
most common members of the group of platinum compounds are Cisplatin, oxaliplatin and Carboplatin. The 
cytotoxic potential of this class of compounds is based on their ability to induce DNA cross-links [Poklar et al., 
1996; Rudd et al., 1995]. Cisplatin, for example, reacts preferably with the N7-atom of adenine and guanine 
because of the high electophilicity of the water-Cisplatin complex. In this way intra- and inter-strand links are 
formed, eventually leading to an inhibition of DNA synthesis [Huang et al., 1995; Takahara et al., 1996]. 
Additionally, Cisplatin induces point mutations and the generation of superoxide radicals, as well as inhibiting 
DNA repair mechanisms and telomerase activity [Barabas et al 2008]. Apoptosis has also been reported, and it 
is worth noting that several signaling and apoptosis pathways are induced by Cisplatin. Therefore, p53, p21 or 
caspase dependent and independent pathways, as well as Bax, FasL and other death agonistic molecules, can 
be involved in Cisplatin induced apoptosis. The exposure of tubular cells to Cisplatin activates several 
signalling pathways that lead to tubular cell injury and death but also induces injury in renal vasculature. This 
results in decreased blood flow and ischemic injury of the kidneys, contributing to a decline in glomerular 
filtration rate (GFR). These events, taken together, culminate in the loss of renal function during Cisplatin 
nephrotoxicity and can be considered to be a multifactorial process, finally triggering acute renal failure [Pabla 
et al., 2008]. 
The dose limiting effect in the administration of Cisplatin is the nephrotoxic potential, specifically the severe 
injury of the S3 segment of the proximal tubulus [Cristofori et al., 2007]. The basolateral drug transport via the 
organic cation transporter-2 (OCT2) seems to play a key role in the accumulation of Cisplatin in proximal 
tubular epithelial cells. After entering the PTCs Cisplatin is activated by an aquation reaction, i.e. substitution 
of the two chloride groups with hydroxyl ligands, which only enables binding to two sites in DNA. 
In clinical trials, Cisplatin nephrotoxicity is often seen after 10 days of administration and is manifested as 
higher serum creatinine, reduced serum magnesium and potassium levels as well as a lower glomerular 
filtration rate. The long-term effects of Cisplatin on renal function are not completely understood, but it is 
expected that Cisplatin treatment may lead to sub-clinical, permanent reduction in GFR [Koch Nogueira et al., 
1998]. 
Because of the high specificity of Cisplatin to cause damage to the proximal tubular cells, mainly of the S3 
segment, this compound has been used to study the specific, but slight effects, on this area. Therefore, the high 
dose used was chosen as 0.6 mg/kg based on the dose-rang finding study [Fuchs et al., 2012] where 0.5 mg/kg 
caused no tubular necrosis or degeneration, while 1 mg/kg lead to moderate to massive alterations after 28 days 
of treatment. The low dose was 0.3 mg/kg and was chosen to observe if even no to minimal histopathological 
alterations can be detected at early time points by the evaluated urinary biomarkers. 
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 Puromycin 
Puromycin is an aminonucleoside antibiotic, which inhibits protein synthesis in vivo as well as in cell-free 
systems [Darken, 1964]. As an aminoacyl-tRNA analogue, it leads to the premature release of unfinished 
polypeptide chains as polypeptidyl-puromycin derivatives. In addition, Puromycin serves as an acceptor of the 
peptidyl chain from peptidyl-tRNA in the P site, in a reaction in which peptidyl chains are attached to the free 
ammonium group of Puromycin catalyzed by peptidyl transferase [Azzam et al, 1973]. 
To date the nephrotoxic mechanism of Puromycin is not yet understood. However, it is known that it induces a 
nephritic syndrome in humans [Kihara et al., 1995]. The MAP kinase pathway, which induces apoptotic 
processes, is also known to be involved in the development of renal damage after Puromycin treatment 
[Servais et al., 2008]. Puromycin is described to induce PPARγ in podocytes, which is the primary event in 
early development of glomerulosclerosis, as this increase is counter regulated and might promote podocyte 
healing and repair [Kiss-Toth et al, 2008]. Based on literature data from repeated dose studies using Puromycin 
[Nosaka et al., 1997; Amin et al. 2004] and a previous performed in-house dose range finding study a high 
dose of 30 mg/kg and a low dose of 10 mg/kg were used. 
 
 Gentamycin 
The broad spectrum antibiotic, Gentamycin, is produced by fungi suchas Mikromonospora purpurea and 
Mikromonospora echinospora. This aminoglycoside antibiotic, consisting of a mixture of three slightly 
different compounds, is hydrophilic because of several OH-groups, which leads to a strongly reduced uptake 
into body cells, with the exception of proximal tubular cells [Aktories et al., 2011]. Therefore, Gentamycin 
only works for the treatment of extracellular pathogenic germs. The importance of this antibiotic is its wide 
spectrum of effect, reaching from gram-negative rods to gram-positive cocci. Because of the missing 
reabsorption after oral application, the efficiency is limited to local function. However, by intra muscular 
injection the reabsorption of Gentamycin is about 90% [Mutschler et al., 2008]. Because of its relatively low 
plasma binding, Gentamycin is usually glomerular filtrated and eliminated in the urine without changes 
[Aktories, et al., 2011]. Even for Gentamycin, one of the most studied nephrotoxic drugs on the market, the 
underlying toxic mechanism is still not yet completely understood. It is known that glomerular atrophy, tubular 
fibrosis/ necrosis as well as epithelial oedema of proximal tubules and inflammation are associated with 
Gentamycin induced-renal damage [Ozbek et al., 2009; Balakumar et al., 2010]. On a molecular basis, a 
multitude of processes seems to be involved in the outcome of renal damage. For example, lysosomal 
phospholipidosis and apoptosis, which have been suggested to play key roles [Ali, 1995; El Mouedden et al., 
2000]. In addition, inflammatory driven renal damage, initiated by Gentamycin–induced tubular cell necrosis, 
leads to a progression in renal pathogenesis [Geleilete et al., 2002]. Also oxidative stress induced by ROS 
seems to play a pivotal role in the renal cortex, eventually leading to renal deterioration [Walker et al., 1999]. 
Finally, it has been reported that Gentamycin-induced nephrotoxicity seems to be associated with the over 
expression of NFB- and p38/ MAPK pathways [Ozbek et al., 2009] 
 
 Aristolochic acid 
Aristolochic acid (AA) is a mixture of structurally related nitrophenanthrene carboxylic acid derivatives, 
primarily AA I and AA II, which occur as secondary metabolites in plants of the genus aristolochia. It is 
described to be a rodent carcinogen and a highly nephrotoxic compound [Mengs et al., 1982, Mengs et al., 
1993]. In humans, exposure to AA has been linked to the pathogenesis of Chinese herb nephropathy (CHN), a 
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rapidly progressive interstitial nephropathy associated with the intake of Chinese herbs mistakenly containing 
Aristolochia fangchi [Depierreux et al., 1994, Vanherweghem et al., 1993]. Based on the striking similarities to 
CHN, including an association with increased risk for the development of urothelial malignancies, AA has also 
been suspected to be a causative agent for Balkan endemic nephropathy, a chronic tubulointerstitial kidney 
disease which occurs in geographically limited areas of the Balkan region, presumably through contamination 
of flower with seeds of Aristolochia clematitis growing on the fields [Grollman et al., 2007]. AA mediated 
nephrotoxicity in rodents is characterized by progressive loss of the proximal tubule brush border and necrosis 
of the renal tubule epithelium within the outer stripe of the outer medulla and the medullary rays [Lebeau et al., 
2005]. The mechanism of AA nephrotoxicity and carcinogenicity is not fully understood but is thought to 
involve metabolic activation to a cyclic N-acylnitrenium ion which forms covalent DNA adducts [Debelle et 
al., 2004, Yang et al., 2007]. 
 
 FP007SE (BI-3) 
BI-3 3-pyrrolidineacetic acid, 5-[[[4'-[imino[(methoxycarbonyl) amino]methyl] [1,1'-biphenyl]-4-
yl]oxy]methyl]-2-oxo-, methyl ester,(3S-trans) is a compound used in the previously described 
Innomed/Predtox project. This compound was selected for the project based on previous knowledge of its 
toxicity to the liver and kidney. Doses were suggested on the basis of a previous 4 week toxicity study at 
Boehringer Ingelheim Pharma GmbH & Co.KG. During this study clear liver and kidney toxicities were shown 
at 1000 mg/kg/day. 100 mg/kg/day were selected as a low dose, based on that 30 mg/kg/day was derived as 
NOAEL and 180 mg/kg/day showed first signs of toxicity. 1000 mg/kg/day were chosen as the high dose. 
Important information about the nephrotoxic potential of BI-3 was published in 2011 [Hoffmann et al., 2011; 
Matheis et al. 2011]. 
 
Compounds used in vitro 
 
 Acetyl-para-Aminophenol 
Acetaminophen (Paracetamol) is a popular analgesic and antipyretic drug widely used in the treatment of 
pains, headaches and fever [Prescott, 2000]. In contrast to other common analgesics like ibuprofen or aspirin, 
acetaminophen has no effect on platelet function or anti-inflammatory properties and is therefore not a member 
of non-steroidal anti-inflammatory drugs or NSAIDs [Marquad et al., 2004]. In standard doses Acetaminophen 
is a very safe drug. However, because of its wide availability, overdoses, accidental or suicidal, are very 
common [Hobson, 1997]. Acetaminophen is thought to act primarily in the central nervous system (CNS), 
increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1 and COX-2, enzymes 
involved in prostaglandin synthesis [Graham et al., 2005]. Acetaminophen does not inhibit COX in peripheral 
tissues and therefore has no peripheral anti-inflammatory affects. In contrast to aspirin, acetaminophen 
indirectly blocks COX in a way that this blockade is ineffective in the presence of peroxides [Boutaud et al., 
2002]. This might explain why acetaminophen is effective in the central nervous system and in endothelial 
cells but not in platelets and immune cells which have high levels of peroxides. Studies also report that 
acetaminophen selectively blocks a variant of the COX enzyme that is different from the known variants COX-
1 and COX-2. This enzyme is now referred to as COX-3 [Chandrasekharan et al., 2002]. 
Acetaminophen toxicity is mostly reported in context of excessive liver, but also kidney, damage after 
overdosing [Tarloff et al., 1996]. Acetaminophen itself is not toxic. However, approximately 90 to 95% of a 
dose is metabolized in the liver via the cytochrome P450 enzyme pathways, followed by conjugation with 
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glucuronic acid, sulfuric acid or cysteine. An intermediate metabolite (NAPQI) is hepatotoxic and most likely 
nephrotoxic and can accumulate after the primary metabolic pathways have been saturated.  
 
 Doxorubicin 
Doxorubicin is a widely used, quinine-containing anthracycline antibiotic, used in cancer treatment. The 
mechanism of action is based on the intercalation of Doxorubicin into DNA double stands and by the 
inhibition of macromolecular biosynthesis [Fornari et al., 1994]. Therefore, DNA replication is inhibited by 
Doxorubicin by stabilization of the topoisomerase II complex, built after it has broken the DNA chain for 
replication. The structure of Doxorubicin can be divided into two major groups, a planar aromatic 
chromophore which intercalates between two base pairs and the daunosamine (six membered sugar) which fits 
into the minor groove of the double helix and interacts with further base pairs [Frederick et al., 1990]. Its use in 
chemotherapy is limited by several side effects, including cardiac-, testicular-, pulmonary- and nephrotoxicity 
[Singal et al., 1987; Fadillioglu et al., 2003]. The area of kidney injury includes tubular atrophy and glomerular 
capillary permeability [Wapstra et al., 1999]. 
So far it is believed that the major processes within renal tissue related to Doxorubicin toxicity is the formation 
of free radicals, protein oxidation, iron-dependent oxidative damage of cellular macromolecules and 
lipid/membrane peroxidation mediated by an imbalance in oxidant-antioxidant homeostasis [Liu et al., 2007]. 
On potential source of free radicals described to play a role, is nitric oxide syntheses (NOS) via a stimulation 
of NO production [Radi et al., 1991]. In addition, mitochondrial toxicity as well as transmembrane arginine 
transport on a subcellular level is described for doxorubicin [Cendan et al., 1995]. 
 
 Amphotericin B 
The polyene antifungal drug, AmphotericinB is a widely used fungicide for internal and external treatment. It 
is ~95% bound on plasma proteins like albumin, which leads to an almost complete distribution within the 
whole organism [Marquardt et al., 2004; Brajtburg et al., 1996]. Its fungistatic activity is based on its high 
affinity against ergosterol, a steroid integrated exclusively within the membrane of fungi. AmphotericinB 
induces the formation of a membrane pore, leading to the loss of the membrane integrity by perforation. 
Subsequently, mono- and bivalent ions, notably sodium and calcium ions, start to leak out due to increased 
permeability. Because the specificity of AmphotericinB to bind exclusively to ergosterol is low, mammalian 
cell membranes, containing cholesterol, are also attacked leading to reduced membrane integrity. Because of 
the continuous loss of ions, which play a crucial role in the functionality of the kidney, apoptosis of renal 
tubular cells is induced as a consequence. However, the affinity to ergosterol compared to cholesterol is 
significant higher [Brajtburg et al., 1996; Sawaya et al., 1995]. Why the major side effect of AmphotericinB is 
nephrotoxic is not yet completely understood. One hypothesis for the selective side effects in vivo is the 
relative low pH of renal cells, which is around 5.5 – 6. This causes a reduced uptake of calcium ions. Walev 
and colleagues could show that cells treated with AmpothericinB recovered when an extracellular pH of 7-7.4 
was used, while the cellular damage showed a further procession at a pH of 6.6 [Walev et al., 1996]. 
 
 Puromycin 
See the description of Puromycin under 1.3.1 Nephrotoxins. 
 
 d-Mannitol 
Mannitol, as well as its isomer sorbitol, is alcoholic sugars, often used as sweeteners for people with diabetes 
or as general food supplements [Roempp et al., 1992]. In addition, Mannitol is used in several medical 
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applications, like cardiopulmonary bypasses [Carcoana et al., 2003], Alzheimer´s disease, chemotherapy 
[Ikeda et al., 2002], and cystic fibrosis [Jaques et al., 2008]. One of the most important applications is its use in 
patients with oliguric renal failure [Atherton et al., 1968]. Because of the free filtration and the inability of the 
PTCs and DTCs to reabsorb Mannitol from the tubular lumen after i.v. administration, the sodium and water 
reabsorption via its osmotic effect is decreased. Subsequently, a decrease in extracellular fluid volume takes 
place because of an increase in sodium and water excretion. Therefore, no direct nephritic potential of 
Mannitol has been described so far. 
 
 Metformin 
Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with type 2 diabetes, 
lowering both basal and postprandial plasma glucose [Mutschl et al., 2001]. Metformin is not chemically or 
pharmacologically related to any other classes of oral antihyperglycemic agents. Unlike sulfonylureas, 
Metformin does not produce hypoglycaemia in either patients with type 2 diabetes or normal subjects and does 
not cause hyperinsulinemia [Bodmer et al., 2008]. With Metformin therapy, insulin secretion remains 
unchanged while fasting insulin levels and daylong plasma insulin response may actually decrease. Metformin 
improves insulin sensitivity by increasing insulin receptor binding as well as peripheral cellular insulin uptake 
and decreasing intestinal glucose absorption and hepatic gluconeogenesis [Bailey, 1993]. Anaerobic glycolysis 
is stimulated and insulin action at the receptor or post receptor level is increased. No direct nephritic potential 
of Mannitol has been described so far. 
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1.4 In vivo - and in vitro - Methods in Toxicology 
 
The most widely used test models in toxicological studies are mice (mus musculus) and rats (Rattus norvegicus forma 
domestica). Several rat strains, with different pheno- and genotypes, as well as transgenic animals are bred in order to 
meet the different study requirements. Other animal models like canine, monkey and mini-pigs are common in 
toxicological safety assessment. In general, modern toxicology is still based on animal testing to get reliable and 
regulatory accepted data. Because it is not yet possible to simulate the whole complexity of the in vivo situation in an in 
vitro model there is a need on one hand to develop better in vitro test systems and, on the other hand, to develop novel 
methods and technologies to increase the output of animal studies. These novel approaches have to go hand-in-hand 
with traditional toxicological observations to evaluate the usefulness and the added value of novel parameters and/ or 
technologies (see 1.1.2). There are a multitude of endpoints, based on several biological classes of molecule and test 
systems which can deliver further toxicologically relevant information. The complexity of the model systems can span 
from whole organisms down to subcellular compartments, the complexity of the used technologies can range from 
whole genome sequencing to single gene detection. Figure 1-11 gives an overview of a pre-selection of methods and 
models with increasing / decreasing complexity and reliability. With the increasing complexity of the methods the 
amount of data, and therefore the bioinformatics and scientific challenge of analyzing and interpreting, increases. 
Global microarrays for example deliver huge amounts of data points per sample, which makes it necessary to filter out 
the information of interest. Single gene or protein analysis on the other hand deliver less information, but are much 
easier to handle and be implemented into early decision making. 
 
 
Figure 1-11 In drug development, the used test-systems und methods. Methods as well as test-systems are ordered based on there 
complexity in handling as well as their reflection of the in vivo system (in more detail to reflect the human situation) [modified from 
Brandon et al., 2003]. 
 
Consequently there are several test systems available which can deliver relevant and high quality information on test 
compounds and therefore aid in the decision to go on or stop the development of a potential drug candidate.  
The benefit of in vitro models includes their ethical acceptance, their cost efficiency and their higher throughput which 
enables the testing of many of compounds in parallel. On the other hand the question answered by the models has to be 
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very specific and the available information generated can be very limited. This is the reason why in vitro models in 
routine are formally used for a pre-selection of potential drug candidates based on e.g. general cytotoxicity, 
genotoxicity, specific organelle toxicity or interference of the drug with metabolic enzymes or transporters. As in vitro 
systems the perfused kidney, renal tissue slices, isolated nephrons, primary cells and cell lines with renal characteristics 
haven been established [Pfaller et al., 1998]. For routine toxicological assessments, cell lines and primary cells are the 
most efficient models used, based on a combination of easy handling and complexity. 
Several different cell lines are available to study renal related alterations in vitro. Therefore, available cell lines, like 
LLC-PK1 (swine), NRK-52E (rat), MDCK (canine), OK (opossum), HK-2 (human), RPTEC/ hTERT1 (human), have 
been frequently used to assess cytotoxicity, transepithelial electrical resistance, tight junction proteins and inulin uptake 
[Duff et al., 2002, Rached et al., 2008, Jennings et al., 2009, Wieser et al., 2008, Wiesinger et al., 2012]. The analysis of 
the whole genome transcriptomics, using renal cell lines, to evaluate there usability has not yet been fully addressed. 
For the examination of nephrotoxic effects on mRNA in in vitro systems, the permanent cell line NRK-52E cells were 
used. This cell line was described the first time in 1966 and was generated from the cell line NRK-49F. In contrast the 
NRK-52E cells show epithelial morphology and are characterized by an almost complete set of diploid chromosomes 
(only 4% tetraploid). In the past the influence of a polyploidy set of chromosomes on the gene regulation could be 
clearly shown, making these cells more preferable for gene expression analysis [Gottlieb, 2003; Chen, 2006]. 
Additionally, several studies have focused on the mechanism of nephrotoxicity and nephrocarcinogenicity using NRK-
52E cells [Leussink et al., 2003; Rached et al., 2008; Ahn et al., 2010]. In this case publications are available describing 
ROS-induced cell apoptosis by nephropathy inducing reagents [Xiong, 2006]. Furthermore, based on NRK-52E cells, 
the influence of cadmium on the cell cycle, especially on the G2/ M-Phase blocking, could be shown and the impact of 
the increased activity of p53 causing in a increased expression of cell cycle kinases, such as p27 and p21 and a 
reduction of Cdk1 and Cdk2, has been reported [Xie et al., 2006]. 
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1.5 Aim of the work 
 
In the last few decades several studies were published that delivered further insights in to the detection of drug-induced 
nephrotoxicity. Taken together, the outcome of these studies was that several urinary proteins can be used for the 
detection of acute nephrotoxicity in rodent toxicity studies up to 14 days of treatment. These proteins must be 
discriminated between qualified (accepted by the FDA/ EMA) and exploratory (recommended for further evaluations) 
biomarkers.  
The aim of the in vivo studies was to validate the already qualified urinary protein biomarkers and to prove that the 
described exploratory markers can also deliver additional information or to increase the sensitivity and/or specificity of 
the panel already qualified. Additionally, several questions regarding these markers shall be answered: 
 
1. How the markers behaved in both genders? 
2. Can the markers be used for sub-acute toxicity studies, i.e., after 28 days of treatment?  
3. Which of the qualified/ exploratory markers deliver reliable results? 
4. How are the diagnostic properties related to histopathological findings? 
5. How can a recovery period influence the excretion of these urinary biomarkers? 
 
In addition, several alterations on the transcriptional level have been observed and a multitude of potential gene 
expression biomarkers have been proposed in the last few years. Subsequently, novel transcriptional biomarkers were 
identified, characterized and shown to deliver further mechanistic information and to enlarge the availability of 
biomarkers for renal safety assessment with the potential to serve as translational biomarkers for human and other 
species. Therefore, already published mRNAs biomarkers shall be tested for their predictivity of nephrotoxicity and to 
see if there is an improvement over the already published biomarkers. In addition, we aimed to evaluate what the best 
combination of altered genes is for predicting different pathological phenotypes. Mechanistic analysis of Vancomycin-
induced nephrotoxicity shall be performed to obtain on one hand further insights on the underlying toxic processes of 
this compound and on the other hand the potential to show generic alterations which themselves could be used for the 
detection of drug-induced kidney injury. 
 
The aim of the in vitro studies was to test whether the results of the in vivo study can be mimicked and search for in 
vitro specific kidney markers. Since a lot of information about altered transcripts in rat after treatment with 
nephrotoxins is available, the question arose whether or not these findings can be translated and used on in vitro level. 
Therefore, the applicability of NRK-52E cells, a rat cell line, to work in combination with transcriptional biomarkers 
shall be addressed by whole genome transcriptomics as a proof-of-principal analysis. 
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2.1 Materials 
 
2.1.1 Chemicals and Reagents 
 
 
Table 2-1 Cell culture reagents  
Name  Provider Registered office 
CASY®Ton Schärfe System GmbH Reutlingen Germany 
DMEM, w/o glucose and 
sodium pyruvat, w/i L-
glutamin, pyridoxine HCl and 
phenolred 
Gibco/ Invitrogen Karlsruhe, Germany 
DMEM, w/i 4.5g/L glucose,  L-
glutamin and phenolred, w/o 
sodium pyruvat 
Gibco/ Invitrogen Karlsruhe, Germany 
DMEM F12 (1:1), w/i L-
glutamin, 15 mM Hepes, 
glucose and phenolred 
Gibco/ Invitrogen Karlsruhe, Germany 
Epidermal growth factor, final 
10 ng/mL (EGF) 
Sigma Aldrich Steinheim, Germany 
Fetal calf serum (FCS) Hyclone/ Perbio Logan, USA 
Ham´s F12, w/i L-glutamin Gibco/ Invitrogen Karlsruhe, Germany 
Hydrocortisone, final 36 ng/ml Sigma Aldrich Steinheim, Germany 
Insulin, Transferrin, Selenium 
final 5 μg, 5 μg, 5ng (ITS) 
Sigma Aldrich Steinheim, Germany 
PBS Dulbeccos w/i Ca, Mg Gibco/ Invitrogen Karlsruhe, Germany 
PBS Dulbeccos w/o Ca, Mg Gibco/ Invitrogen Karlsruhe, Germany 
Penicillin (10 kU/ ml)-
Streptomycin (10 mg/ ml) 
solution 
Sigma Aldrich Steinheim, Germany 
   
Trypsin/ EDTA-solution  
(0.5%) 
Sigma Aldrich Steinheim, Germany 
Trypsin/ EDTA-solution 
(0.25%) 
Sigma Aldrich Steinheim, Germany 
 
 
 
Table 2-2 Kits and reagents for biochemical assays 
Name Provider Registered office 
Agencourt® RNAClean™ XP Agencourt/ Beckman 
Coulter 
Beverly, USA 
CellTiter-Glo® Luminescent 
Cell Viability Assay 
Promega Madison, USA 
Coomassie Brilliant Blue G250 Merck KGaA Darmstadt, Germany 
Ethanol Lichrosolv® Merck KGaA Darmstadt, Germany 
MessageAmp™ II aRNA 
Amplification Kit 
Ambion/ Applied 
Biosystems 
Austin, USA 
Rat RENA-Strip Kit BioAssay Works® Ijamsville, USA 
RNeasy Mini Kit Qiagen Hilden, Germany 
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Name Provider Registered office 
RNase-free DNase Set Qiagen Hilden, Germany 
RNA 6000 Nano Kit Agilent Technologies Waldbronn, Germany 
RNA 6000 Pico Kit Agilent Technologies Waldbronn, Germany 
Schreddercolumn, QIAshredder  Qiagen Hilden, Germany 
WideScreen® Rat Kidney 
toxicity assay Panel 1 
Merck Millipore 
(Novagen®) 
Billerica, USA 
WideScreen® Rat Kidney 
toxicity assay Panel 2 
Merck Millipore 
(Novagen®) 
Billerica, USA 
 
 
 
Table 2-3 Reagents for molecular biological studies 
Name  Provider Registered office 
Cy3-Streptavidin Amersham Biosciences/ GE 
Healthcare 
Buckinghamshire, England 
DEPC water Ambion/ Applied 
Biosystems 
Austin, USA 
E1BC buffer Illumina Inc. San Diego, USA 
Ethanol Lichrosolv® Merck KGaA Darmstadt, Germany 
High Temperature Wash buffer Illumina Inc. San Diego, USA 
HybE1 buffer Illumina Inc. San Diego, USA 
β-Mercaptoethanol Sigma Aldrich Steinheim, Germany 
Nuklease free water Ambion Austin, USA 
Propanol Merck KGaA Darmstadt, Germany 
 
 
 
Table 2-4 Substances and solutions for in vitro toxicity studies 
Name  Provider Registered office 
DMSO Sigma Aldrich Steinheim, Germany 
AmphotericinB Sigma Aldrich Steinheim, Germany 
Paracetamol Sigma Aldrich Steinheim, Germany 
Doxorubicin Fluka/ Sigma Aldrich Steinheim, Germany 
Puromycin Sigma Aldrich Steinheim, Germany 
Metformin (1,1-
Dimethylbiguanid) 
Sigma Aldrich Steinheim, Germany 
d-Mannitol Sigma Aldrich Steinheim, Germany 
 
 
 
 
2.1.2 Cell lines 
 
The used rat cell line NRK-52E (ATCC Bestellnummer: CRL-1571™) was purchased from ATCC (Manassas, USA). 
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2.1.3 Consumables 
 
Table 2-5 Consumables 
Name Provider Registered office 
Combitips plus, 2, 2,5, 5, 10 mL 
Eppendorf 
Eppendorf Hamburg, Germany 
PCR reaction tubes 0,2 ml Eppendorf Hamburg, Germany 
Pipettes, serological, 1, 2, 5, 10, 
25, 50 ml 
Nunc (Thermo Fisher 
Scientific) 
Langenselbold, Germany 
Pipette tips, non-sterile,  
100-300 μl 
Brand Wertheim, Germany 
Pipettenspitzen, RNase-free, 
sterile, 
10REACH, 20P, 100E, 200, 300, 
1000E 
MolecularBioProducts San Diego, USA 
Reaction tubes, Safe-Lock Tubes, 
RNase-free, 1,5 mL und 2 ml 
Eppendorf Hamburg, Germany 
Reaction tubes, Falcon tubes, 
Plastik, 15 ml 
Greiner bio-one Frickenhausen, Germany 
Reaction tubes, Falcon tubes, 
Plastik, 50 mL (steril) 
BD Biosciences Franklin Lakes, USA 
Roundbottem plate 96-Well Bilatec AG Viernheim, Germany 
Thermosprint® PCR-plate, 96-
Well 
Bilatec AG Viernheim, Germany 
6-Well plate, MultiwellTM 6-Well, 
sterile 
Becton Dickinson Labware Franklin Lakes, 
USA 
96-Well plate, steril, black with 
transparent bottem 
Becton Dickinson Labware Franklin Lakes, 
USA 
96-Well plate, transparent, sterile Becton Dickinson Labware Franklin Lakes, 
USA 
96-Well plate, sterile, white with 
transparent bottom 
Becton Dickinson Labware Franklin Lakes, 
USA 
96-Well plate, white, for 
luminometric assays 
Nunc (Thermo Fisher 
Scientific) 
Langenselbold, Germany 
Cellculture flask, Cellstar, T25 Greiner bio-one Frickenhausen, Germany 
Cellculture flask, Cellstar, T75 Greiner bio-one Frickenhausen, Germany 
Cellculture flask, Cellstar, T175 Greiner bio-one Frickenhausen, Germany 
Cell scraper, sterile Corning Inc. New York, USA 
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2.2 Instruments 
 
Table 2-6 Instruments 
Name Provider Registered office 
   
ADIVIA 1650, Autoanalyzer Siemens Medical Solutions 
Diagnostics GmbH 
Bad Nauheim, Germany 
ADVIA 120 Siemens Medical Solutions 
Diagnostics GmbH 
Bad Nauheim, Germany 
Agilent Bioanalyzer 2100 Agilent Technologies Waldbronn, Germany 
Agilent Bioanalyzer Priming 
Station 
Agilent Technologies Waldbronn, Germany 
BeadChip® Hyb Cartridge 
(Hybridisierungskammer) 
Illumina Inc. San Diego, USA 
Incubator Hera cell Heraeus GmbH Hanau, Germany 
CASY TTC Zellzählsystem Schärfe System GmbH Reutlingen, Germany 
Chemiluminometer Lumistar 
Galaxy 
BMG Lab Technologies Offenburg, Germany 
Clinitek 100 Siemens Medical Solutions 
Diagnostics GmbH 
Bad Nauheim, Germany 
Stainless steel balls Qiagen Hilden, Germany 
Hybridisationoven Illumina Inc. San Diego, USA 
Little Dipper® Illumina® 
BeadChips Prozessor 
SciGene Corp. Sunnyvale, USA 
Illumina BeadArray Reader Illumina Inc. San Diego, USA 
Illumina Sentrix® HumanRef-12 
V1 BeadChip Arrays 
Illumina Inc. San Diego, USA 
Luminex® 200 Total System Luminex Corp. Austin, USA 
Hybex™ Microarray Incubation 
System 
SciGene Sunnyvale, USA 
Microplatespektrophotometer 
MWG Discovery HT-R 
AVISO Jena, Germany 
Laminar-flow steril bench 
Herasafe 
Heraeus GmbH Hanau, Germany 
Automated Glass Coverslipper 
Leica CV5030 
Leica Microsystems Wetzlar, Germany 
Microscope Axiovert 25 Zeiss Jena, Germany 
Microscope Leica Leica Wetzlar, Germany 
Microscope Olympus, BX40G Olympus Optical CO, Ltd Hamburg, Germany 
Microcentrifuge 5415R Eppendorf Hamburg, Germany 
Mirax Scanner Carl Zeiss Jena, Germany 
Multifuge® 3S-R Heraeus (Thermo Fisher 
Scientific) 
Langenselbold, Germany 
Multichanelpipette 10-300µl Eppendorf Hamburg, Germany 
NanoDrop ND-1000  NanoDrop Technologies Wilmington, USA 
NanoDrop ND-2000 NanoDrop Technologies Wilmington, USA 
Pipettes 2-1000μl Eppendorf Hamburg, Germany 
Pipettes 2-1000μl Gilson Middleton, USA 
Pipetting controler, Pipetus®-akku Hirschmann Laborgeräte Eberstadt, Germany 
pH-Meter 766 Calimatic Knick GmbH & Co. KG Berlin, Germany 
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Name Provider Registered office 
QIAcube Qiagen Hilden, Germany 
Refractometer Küss Hamburg, Germany 
Reinstwasseraufbereitungsgerät 
Pure Lab Plus 
ELGA Celle, Germany 
Shaker Titramax® 101 Heidolph Instruments Schwabach, Germany 
Shaker Phero-shaker BIOTEC-FISCHER 
GmbH 
Reiskirchen, Germany 
Spectralphotometer Polarion Tecan Germany GmbH Crailsheim, Germany 
Steril benchank Hera®safe Thermo Fisher Scientific 
(Heraeus) 
Waltham, USA 
Theonyx Liquid Performer AVISO Jena, Germany 
Thermomixer comfort Eppendorf Hamburg, Germany 
Thermocycler, Mastercycler 
gradient 
Eppendorf Hamburg, Germany 
Thermocycler, Primus 96 
advanced 
PEQLab GmbH Erlangen, Germany 
Tissue Lyzer Qiagen Hilden, Germany 
Vacuubrand suction pumpe BVC 
01 
Vacuubrand GmbH & 
CoKG 
Wertheim, Germany 
Vacuum conzentrator 
(Concentrator 5301) 
Eppendorf Hamburg, Germany 
Ventana Discovery 
Immunostainer 
Roche diagnostics Mannheim, Germany 
Ventana Discovery E-bar lable 
printer 
Roche diagnostics Mannheim, Germany 
Vortexer for Agilent-Chips IKA® Werke GmbH  Staufen, Germany 
Vortexer Vortex Genie 2 Scientific Industries Bohemia, USA 
Lab balance Navigator Ohaus Giessen, Germany 
Lab balance Sartorius BP211D Sartorius Göttingen, Germany 
Waterbath Julabo SW22 Julabo GmbH Seelbach, Germany 
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2.3 Software 
 
Table 2-7 Software for data analysis 
Name Provider Registered office 
   
BeadScan Illumina Inc. San Diego, USA 
GenomeStudio 1.1.1 Illumina Inc. San Diego, USA 
ChemDraw® Ultra 8.0 Cambridge Soft 
Corporation 
Cambridge, USA 
2100 Expert software Agilent Technologies Waldbronn, Germany 
Expressionist® Analyst Pro 
Version 5.3.2 
Genedata AG Basel, Schweiz 
GraphPad Prism v. 5.02 GraphPad Software San Diego, USA 
GeneGo’s MetaCore™  
v. 5.3 
GeneGo St. Joseph, USA 
Ingenuity´s IPA™ v. 8.6 Ingenuity Systems, Inc. Redwood City, USA 
Microsoft Office 2007 
Standardpackage 
Microsoft Corps. Redmond, USA 
Microsoft Office 2003 
Standardpackage 
Microsoft Corps. Remond, USA 
Mirax Viewer Version 1.12.22.0 Zeiss Jena, Germany 
OriginLab v. 7.0 OriginLab Northampton, USA 
Abode Photoshop Elements 8.0 Adobe Systems Inc. San Jose, USA 
Abode Acrobat 9 Standard Adobe Systems Inc. San Jose, USA 
ToxWiz v. 2.5 Cambridge Cell Networks Cambridge, UK 
 
  
MATERIALS AND METHODS 
57 
 
2.4 Rat toxicity studies 
 
In the following section the in vivo rat toxicity studies which were investigated will be described in more detail. 
 
 
2.4.1 28-day rat toxicity studies 
 
 
The 28-day rat studies were performed in the AAALAC certified Toxicology facility at Merck Serono, Darmstadt, 
Germany. All studies were applied and performed according Article 8 paragraph 1 of the German Animal Protection 
Welfare Act (DA4/Genehmigung 204). The treatment of the animals, sample collection and preparation, as well as 
measurements of all standard parameters, were done under „Good Laboratory Practice“ guidelines. All non standard 
parameters, like gene expression analysis and the detection of urinary biomarkers, as well as immunohistochemistry 
were performed according to the Merck internal Quality Management System (MSR-QMS). All animal related 
activities were carried out by specialized staff, registered at the Darmstadt Regional Council (DA 4/P V 54-19c20/15). 
 
 
Dose range finding study 
 
Before the final studies were conducted, a dose range finding study was carried out under the same conditions as 
planned for the main studies. The aim of the dose range finding studies was to detect the optimal doses for gene 
expression analysis as well as for the detection of urinary protein biomarkers. Therefore, 6 rats (3♂ + 3♀) per group 
were treated with 4 doses of the 3 model nephrotoxic compounds (based on literature data), with the same treatment 
pattern as described in the following section ”Study Design”. Urine, blood and organ collection were performed after 28 
days of treatment. Histopathological observations were carried out routinely for kidney, urethra, bladder and all organs 
with macroscopic alterations. Significant results of the dose range finding study are reported by Fuchs et al., 2012. 
Based on the findings of clinical-chemical parameters, together with the results of the urinary protein biomarker 
analysis, doses for the main studies were selected (Table 2-9). 
All results reported in this document are exclusively based on the main studies which will be described in more detail 
below. 
 
 
Main 28 day rat toxicity study 
 
All studies were performed according to Good Laboratory Practice (GLP) and in compliance with the German Law on 
the Protection of Animals (German Welfare Act, Article 8a). Wistar rats, 10 weeks old, purchased from Charles River 
Laboratories (Sulzbach, Germany) were randomly divided into groups of 10 animals (5♂ + 5♀). Rats were individually 
housed in type III isolated ventilated Makrolon
®
 cages with a 12 h light/ dark cycle. Standard laboratory chow (Provimi 
Kliba 3433.0, Aalen, Germany) and tap water were provided ad libitum.  
 
 
Study Design 
 
Based on the data from the dose range finding study the doses for the main studies were chosen. Rats were treated with 
either Vamcomycin (Ratiopharm, Ulm, Germany) at dose levels of 50 mg/kg bw or 300 mg/kg bw; or cis-
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diamindichloridplatinum(II) (Cisplatin) (medac GmbH, Hamburg, Germany) at 0.3 mg/kg bw or 0.6 mg/kg bw; or 
Puromycin (Invivogen, Tolouse, France) at 10 mg/kg bw or 30 mg/kg bw. To reduce the total number of animals only 2 
dose groups (low dose (LD) and high dose (HD)) were used. Table 2-9 gives an overview of the used doses and 
abbreviations used.  
In the Vancomycin study the high dose were chosen to show massive changes in renal tissue the low dose was expected 
to show none to minimal changes in histopathology and traditional parameters. The dosing within the Cisplatin study 
was chosen to induce only mild alterations in high dose animals and no changes in traditional toxicological methods in 
the low dose group. Within the Puromycin study moderate to massive changes were expected after high dose treatment, 
while the low dose should show only minimal effects. 
Four time points and the intervals of treatment were chosen, as well as a general overview of the study design, including 
the observed parameters for the single studies as shown in Figure 2-1. 10 Rats (5♂ + 5♀) per dose group and time point 
were treated with Vancomycin or Cisplatin i.p. daily for 7 days and then only once per week. Puromycin animals were 
treated i.p. daily for 14 days and then twice per week. 
 
 
Figure 2-1 Schema of treatment and sample collection of all three main studies. Animals were treated daily for one week and 
then once per week up to 28 days (Vancomycin, Cisplatin) or daily for 14 days and the twice per week (Puromycin). Sample 
collection was performed on days 4, 8, 15 and 29. 
 
These treatment patterns allowed us to analyze acute changes caused by daily dosing and at the same time to study 
recovery periods which can still lead to significant injury after 28 days. 
In all studies urine was collected under cooled conditions on days 3/4, 7/8, 14/15 and 28/29 for analysis of standard 
clinical-chemical parameters and novel urinary protein biomarkers. Therefore, animals were housed in individual 
metabolism cages for 18h (fasted with free access to water) and urine was collected under cooled conditions. For 
standard clinical chemical analysis the urine was used immediately. For the detection of urinary protein biomarkers 
urine was stored at -80°C until required. Subsequent to the urine collection a final blood take, by punctuation of the 
sublingual vein under light isofluorane anesthesia, was made. Animals were sacrificed by CO2 asphyxiation and organs 
were collected for histopathological examination. All organs were fixed in formalin. Tissues for histopathological 
observations (kidney, ureter, bladder, and all organs with abnormal observations in gross pathology) were embedded in 
paraffin. Beside organ collection for standard histopathology, renal tissue was collected for gene expression analysis. 
For this the upper half of the left kidney was dissected and snap-frozen in liquid nitrogen and then stored at -80°C. 
 
An overview of the performed analysis for each individual study is given in Table 2-8. 
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Table 2-8 Overview of analysis performed for each individual study. In addition to 
the displayed analysis, histopathological, clinical chemical and hematological 
analyses were performed for each study. 
Vancomycin     
● Luminex® xMAP® (urinary protein biomarker) 
● RENA-strip™ Dipstick Assay (urinary Kim-1) 
● Immunohistochemistry (Kim-1, Clusterin, Osteopontin) 
● Illumina Whole genome analysis 
   
Cisplatin     
● Luminex® xMAP® (urinary protein biomarker) 
● RENA-strip™ Dipstick Assay (urinary Kim-1) 
   
Puromycin     
● Luminex® xMAP® (urinary protein biomarker) 
● RENA-strip™ Dipstick Assay (urinary Kim-1) 
● Immunohistochemistry (Kim-1, Clusterin, Osteopontin) 
 
 
Substance application 
 
The used compounds in these studies are well described nephrototoxins, so called model compounds (see 1.3.1 
Nephrotoxins used in this study). Because stability information was available for these commercially available 
substances the Central Dispensory (ZDP) of the Non-Clinical Safety Department, Merck Serono, Darmstadt prepared 
the solutions daily under room temperature and minimal light exposure. The used dilutions of Vancomycin were 
prepared with water for injection (wfi), for Cisplatin and Puromycin 0.9% saline was used. 
Animals of the control groups were treated with either 0.9% saline or wfi in the highest volume of the substance treated 
animals. 
 
Table 2-9. Used dose levels for the intraperitoneal treatment of the rats in all three studies. The dose levels 
were evaluated by the results of a dose range finding study. 
Nephrotoxine 
 
low dose high dose Route of 
application 
Vehicel 
Cisplatin 0.3 mg/kg bw 0.6 mg/kg bw i.p.* 0.9% saline 
Puromycin 10 mg/kg bw 20/30 mg/kg bw
#
 i.p.* 0.9% saline 
Vancomycin 50 mg/kg bw 300 mg/kg bw i.p.* wfi** 
* i.p.: intraperitoneal; ** wfi: water for injection; # treatment with 30mg/kg daily on days 1-14, then twice per week with 20 mg/kg. 
 
Sample collection and necropsy 
 
As the major focus for these studies, the kidneys were collected first to avoid RNA degradation caused by autolysis. 
Therefore, the peri-renal capsule was removed and the upper half of the left kidney was snap-froozen in liquid nitrogen. 
Terminal body weights, as well as kidney and liver weights, were recorded. Only kidney, ureter, bladder, liver and 
organs showing macroscopic alterations were investigated histopathologically. Special attention was paid to not exceed 
the fixation time of the kidney over 48 hours, because of the need to use these tissues for future immunohistochemical 
analysis. 
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2.4.2 Additional rat in vivo studies investigated 
 
Innomed/ PredTox 
Within the 6
th
 Framework program the Innomed/PredTox project undertook several studies to identify and evaluate 
novel biomarkers and technologies to enhance the diagnosis of nephrotoxicity. Within this project the failed drug 
candidate 3-pyrrolidineacetic acid, 5-[[[4_-[imino[(methoxycarbonyl) amino]methyl] [1,1_-biphenyl]-4-yl]oxy]methyl]-
2-oxo-, methyl ester,(3S-trans) (FP007SE/ BI-3) was used to study nephrotoxicity. Several omics-data [Matheis et al. 
2011], as well as traditional clinical and histopathological observations are already published. Renal tissue of this 
project was used to investigate 6 transcripts provided by Compugen Ltd. for their ability to predict developing acute 
kidney injury. 
 
University of Wuerzburg 
At the University of Wuerzburg, several studies were performed which focused on renal damage. Two of these studies 
were used to evaluate the transcriptional biomarkers from Compugen Ltd. to test their diagnostic performance.  
 
Gentamycin 
The first study used Gentamycin as one of the most common model compounds for the induction of renal 
tubular damage. Data from clinical pathology and histopathology, as well as urinary protein biomarker 
excretion, are already publically available [Hoffmann et al., 2011]. Rats were treated daily with Gentamycin 
(i.p.) for up to 7 days. Urine was collected on days 1, 3, and 7 with a final necropsy on day 8. Kidneys were 
histopathologically analysed and a part was snap-frozen in liquid nitrogen for gene expression analysis. 
 
Aristolochic acid  
Study Design. 
In this study the doses were chosen based on publically available data which show, that ≥5 mg/kg aristolochic 
acid cause massive tubular degeneration and necrosis after 28 day treatment. The used study had a run-time of 
12 days using the same concentrations like reported by Mengs and Stotzem, 1993 [Mengs et al., 1993]. This 
approach was chosen to get no to minimal renal changes in histopathological observations. With novel 
methods like, the measurement of urinary protein biomarkers and transcriptional analysis it was tested if it is 
possible to predict nephrotoxicity before histopathological alterations manifest on morphological level. 
In this study Male Wistar rats, 6–8 weeks old, weighing approximately 200 g were purchased from Harlan-
Winkelmann (Borchen, Germany) and were randomly divided into three groups of five animals. Animals were 
kept in macrolon
®
 cages (five animals per cage) on a 12 h light/dark cycle and allowed free access to standard 
laboratory chow (SSniff, Soest, Germany) and tap water. Rats were treated with AA (27 % AAII and 65 % 
AAI; Sigma, Taufkirchen, Germany) at dose levels of 0.1, 1 and 10 mg/kg bw per day. AA was administered 
by gavage, five days per week over two weeks. Control animals received an equal volume of tap water. The 
animals were housed in individual metabolic cages during the study. Urine was collected at 24 h and on days 5 
and 12. Blood samples were taken from the retro-orbital plexus under light isoflourane anaesthesia on days 1 
and 5 for clinical chemistry. The animals were sacrificed by CO2 asphyxiation and blood was collected by 
cardiac puncture 24 h after administration of the final dose.  
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Blood samples and aliquots of urine were immediately used for routine clinical chemistry analyses. The 
remaining urine and plasma was stored at -20°C until further analysis. Organs (liver, kidney and bladder) were 
removed and weighed. The left kidney was partitioned transversely in a ratio of approximately 2:1; the larger 
part was stored in formalin. The remainder and the right kidney were snap frozen in liquid nitrogen and stored 
at −80 °C. The liver and bladder were stored in formalin. 
Urine and plasma analyses were carried out at the Laboratory for Clinical Chemistry, University of Wuerzburg, 
on a Vitros 700XR (Ortho-Clinical Diagnostics, Neckarsgemuend, Germany) using standard protocols for the 
determination of these parameters according to the manufacturer’s instructions. The following parameters were 
determined in urine: glucose, GGT (-glutamyl transferase), total protein, creatinine and osmolality. For blood 
samples the following parameters were determined in plasma: creatinine, urea, total bilirubin, aspartate 
aminotransferase, alanine amino transferase, GGT, alkaline phosphatase and total protein. 
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2.5 Histopathology 
 
Preparation of paraffin tissue section for Hematoxilin/ Eosin (HE) staining  
 
The preparation of the tissue sections was performed by experienced personnel to guarantee the high quality of the 
sections. The procedures were performed according standard operation protocols (SOPs). The organs were embedded 
in paraffin and sections for standard Hematoxilin/ Eosin (HE) staining were prepared. The intersection plane of the 
organs is shown in Table 2-10. The thickness of the slices was approximalty 2µm.  
 
Table 2-10 An overview of organs and the intersection plane routinely assessed within the 
Vancomycin, Cisplatin and Puromycin nephrotoxicity studies.  
Organ and tissue Intersection plane 
    
Kidney transversal in the hilus region, 
longitudinal  
Bladder Longitudinal 
Ureter Transversal 
Liver transversal, 
(1x Lobus sinister lateralis,  
1x Lobus dexter medialis) 
Organs with macroscopic alterations  representative areale 
 
 
Hematoxilin/ Eosin (HE) staining 
 
The HE staining was performed in an automated way using the Leica AutoStainer XL in combination with 
coverslipautomat CV5030. Before staining the slides were deparaffinized by using xylol. The slides were then 
rehydrated with decreasing alcohol concentrations and water. After the staining with hemalaun, the slides again had to 
be dehydrated with xylol with additional alcohol incubations in between to cover the slides with entellan, a xylol 
containing mounting medium. A detailed overview is given in Table 2-11. 
 
Table 2-11 Individual steps which were performed for Hematoxilin/ 
Eosin staining of tissue slides. The whole procedure was performed in 
an automated manner. 
Step Reagents/ Dye Time 
      
1 Xylol 2 min. 
2 Xylol 2 min. 
3 Iso-Propanol 3 min. 
4 Ethanol 96% 3 min. 
5 Ethanol 80% 3 min. 
6 Ethanol 70% 3 min. 
7 VE-H2O 3 min. 
8 Hämalaun 4 min. 
Wash tap-H2O 2 min. 
Wash tap-H2O 2 min. 
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Step Reagents/ Dye Time 
      
Wash tap-H2O 2 min. 
12 Eosin 1 min. 
13 Ethanol 96% 10 sec. 
14 Ethanol 96% 10 sec. 
15 Iso-Propanol 1 min. 
16 Iso-Propanol 1 min. 
17 Iso-Propanol/Xylol 2 min. 
18 Xylol 2 min. 
 
The analysis of the HE stained tissue slides were performed by Dr. Stefanie Czasch, pathologist at Global Non-Clinical 
Safety at Merck Serono, Darmstadt. 
In addition the kidney samples were reviewed by Dr. Jürgen Hellmann, Dr. Anja Knippel and Dr. Gundi Müller, 
pathologists at Global Non-Clinical Safety at Merck Serono, Darmstadt. 
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2.6 Immunohistochemistry 
 
Because the tissue was fixed in formalin and embedded in paraffin, the slides had to be prepared in a multi-step 
procedure, which can vary depending on the protein biomarker studied. In a first step the epitopes must be made 
available for antibody binding, including deparaffinization and demasking. Additional steps can be required to block or 
quench endogenous enzymes or biotin prior to antibody staining in order to prevent unspecific binding. In this study an 
indirect method, including streptavidin and biotin labeling, was used for the detection of renal Kim-1, Clusterin and 
Osteopontin. Figure 2-2 gives an overview of the general principal of the method. 
 
Figure 2-2 Schematic workflow of an immunohistochemical protein staining. In a first step, the protein was 
demasked and deparaffinized. The slide was incubated with the first antibody (1st Ab) addressed against the protein of 
interest, and the biotinylated second antibody (2nd Ab), against the 1st Ab. The staining reaction was catalyzed by a 
streptavidin linked horseradish peroxidase, by oxidization of Diaminobenzidine. 
 
After preparing the renal tissue sections, the slides were incubated with an unlabeled primary antibody specific for the 
target protein. In a second step a secondary antibody against the primary antibody was used. This secondary antibody 
has to be raised against the animal species in which the primary antibody was raised. Additionally, it must be 
biotinylated for the subsequent labeling and staining reaction. A detailed list of used antibodies and the performed steps 
is given in Table 2-12 and Table 2-13. 
The tissue then was incubated with a streptavidin/ horseradish peroxidase-complex which has a high affinity to biotin 
and specifically binds to the biotinylated secondary antibody. Horseradish peroxidase (HRP) is the catalyzing enzyme 
used to start the staining reaction initiated by the addition of the substrate diaminobenzidine (DAB). The transparent 
dye, DAB, reacts with H2O2 catalyzed by the HRP leading to a turnover of the transparent form into an insoluble brown 
complex which precipitates in the area of high protein abundance. Finally, a counter staining was performed using 
hematoxilin and bluing reagents, each in order to show unspecific binding of the antibody’s backbone. As quality 
controls the immunohistochemical staining procedure was accompanied by an isotype as well as non 1st Ab controls in 
order to show unspecific binding of the antibody’s backbone. 
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Table 2-12 Overview of the used primary and secondary antibodies for immunohistochemical analysis of Kim-1, Clusterin and 
Osteopontin. In addition the used isotype antibodies are shown, used in the same final concentration as the primary antibodies.  
Antibodies Cell  
Conditioning 
Dilution Incubation  
Time 
Host Provider 
primary antibodies      
Kim-1 / 1:100 1h Goat R&D Systems 
Clusterin CC1 1:100 1h Goat Santa Cruz Biotechnology 
Osteopontin CC1 1:100 1h Rabbit Rockland Inc. 
secondary antibodies      
Anti-goat  1:200 1h Donkey Santa Cruz Biotechnology 
Anti-rabbit  1:200 1h Goat Rockland Inc. 
isotype antibodies      
normal goat IgG   1h Goat R&D Systems 
normal rabbit IgG   1h Rabbit Santa Cruz Biotechnology 
 
All immunohistochemical stainings were performed using the automated Ventana Discovery immunostainer in 
combination with the DAB-Map
®
 detection Kit. The immunohistostainer follows individual staining protocols 
identified by a barcode on each slide. All steps of immunohistochemistry were performed automatically, except for the 
application of primary and secondary antibodies. An overview of the single steps performed is given in Table 2-13. 
 
Table 2-13 The individual steps which were performed for 
immunohistochemical staining of Kim-1, Clusterin and 
Osteopontin on renal tissue slides. The whole procedure was 
performed in an automated manner. 
Step Reagents/ Dye Time 
      
1 Deparaffinization 8 min. 
2 cell conditioning 20 min. 
3 Application of inhibitor D 4 min. 
4 Titration of 1st Ab 60 min. 
5 Titration of 2nd Ab 20 min. 
6 Application of Blocker D 2 min. 
7 Application of SA-HRP D 16 min. 
8 Application of DAB and H2O2 8 min. 
9 Application of Copper D 4 min. 
10 counterstaining (Hematoxilin) 6 min. 
11 Application of bluing reagents 6 min. 
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2.7 Cell Biological Methods 
 
2.7.1 Culture of the permanent cell line NRK-52E 
 
The NRK-52E cells were cultured at 37°C and 5 % CO2 in DMEM high glucose medium (4.5 mg/mL glucose). As 
supplements 10% FCS, 1% NEAA and 1% Pen/Strep were added. The cells were maintained in cell culture flasks until 
80-100 % confluence. Subsequently, the cells were passaged or used for individual experiments. For passaging the cell 
layer was washed with 10 mL PBS without Mg/Ca and then incubated with Trypsin-EDTA solution (0.5% trypsin) for 
10 seconds. The Trypsin-EDTA was removed and the cells were incubated at 37°C and 5% CO until the cells detached 
from the cell culture flask. The cell suspension was taken up in pre-warmed cell culture medium and the cell number 
was determined by using the Casy
®
 Cellcounter by diluting the cell suspension 1:500 in CasyTon™. The appropriate 
number of cells was diluted in medium and plated in multi-well plates for the experiments. For routine cultivation the 
cell suspension was split at ratios between 1:20 up to 1:100, depending on the cell density and the experimental needs. 
Detailed information about the used cell numbers and volumes are given in Table 2-14. 
 
Table 2-14 Overview of cell number, volume of medium and trypsin used for maintenance and 
treatment of different applications of NRK-52E cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.7.2 Cell treatment 
 
To evaluate and characterize the response of the NRK-52E cells to different drugs, cytotoxicity / cell viability assays 
were performed. The cells were cultured in 96-well plates and treated with a minimum of 5 concentrations of each 
compound. Intracellular ATP content, as well as the neutral red uptake (NRU), was evaluated. The cells were cultured 
in cell culture flasks as described under “Culture of the permanent cell line NRK-52E“. Before each experiment, cells 
were seeded in the appropriate cell culture plate at the density needed and cultured for a minimum of 24 h at 37°C and 5 
% CO2. 
The compounds used for the experiments with NRK-52E cells were dissolved in DMSO or PBS and used at a final 
dilution of 1:200 in cell culture medium. This results in a final DMSO concentration of 0.5 % (v/v). The treatment of 
the cells was conducted every 24 h. All experiments were performed independently three times by use of different cell 
passages, and the cells were not used for longer than 18 passages from time of thawing. 
Culture 
vessel 
Area of 
growth 
Cell 
number 
[cell/ mL] 
Volume Volume of 
Trypsin 
Application 
T175 Flask 175 cm² - 20 mL 2 mL Routine culture 
T75 Flask 75 cm
2 - 10 mL 1 mL Routine culture 
96-Well 0,32 cm² 4x10
5 0.1 mL - Cell viability assays 
6-Well 9,5 cm² 2x10
6 1.5 mL - Gene expressions analysis 
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The results of the cytotoxicity tests were then used for choosing the final concentrations for gene expression analysis. 
This was conducted by logistic fitting of the dose response curves derived from the data from 72 h treatment. The TC20 
value is the concentration at which the viability of the cells was reduced by 20%. This concentration was defined as the 
high dose, while the low dose was chosen as the “non observed adverse effect concentration (NOAEC)” based on the 
dose response curve. For the gene expression experiments the compounds were diluted 1000-fold in cell culture 
medium to avoid any influence by DMSO. The final resulting DMSO concentration was therefore 0.1 % (v/v). 
 
 
2.7.3 Cytotoxicity assays  
 
Detection of ATP depletion 
 
The determination of intracellular ATP concentration, as a measure of a 
cells reduced metabolic activity, was used. Therefore, the CellTiter-Glo
® 
assay by Promega was used [CellTiter-Glo
®
-Bulletin, 2011]. The 
principal of the detection of intracellular ATP content reside in the 
universal functions of ATP as one of the most important energy stores. 
ATP is produced, inter alia, within the cells in the mitochondria and 
cannot leave the healthy cell because of the intact membrane integrity. 
Additionally, ATP is only synthesized by healthy and living cells. If cell 
damage takes place, for example caused by a toxic insult, the membrane 
integrity gets lost and the already produced ATP is released. 
Subsequently, no further ATP production is performed leading to a total 
or a reduction in intracellular ATP content.  
In addition, an impact of the test compound directly on the mitochondria 
can lead to a reduction in ATP synthesis by influencing the oxidative chain reaction at the mitochondria membrane, 
which also leads to a reduced intracellular ATP level. 
The detection process is based on the conversion of D-Luciferin to Oxyluciferien. This reaction is catalyzed by 
Luciferase and involves air-oxygen, magnesium cations and ATP (Figure 2-3). The source of ATP, in this case, is the 
intracellular ATP, which is therefore the limiting factor for the reaction. By cell lyses, the ATP content is released under 
controlled conditions. This can be used directly to correlate the emitted bioluminescence light signal to the impact of 
drug treatment on ATP and as a signal of cell death [Crouch, 1993]. 
For the procedure, cells were seeded in a white 96-well plate. The lyophilized CellTiter-Glo
®
 substrate was 
reconstituted in 10 mL CellTiter-Glo
®
 buffer and then mixed 1:2 with cell culture medium. Here, the basal medium, 
without supplements, was used. The supernatant was aspirated and 100 µl of the CellTiter-Glo
®
 reagent/ cell culture 
mix was added into each well. The cells were incubated for approximately 10 min under light rotation (300 rpm) at RT 
until the cells were completely lyzed. Immediately, the plate was measured using a luminometer [CellTiter-Glo
®
-
Bulletin, 2011]. Each data point was evaluated in triplicate, including blank (well without cells) and the vehicle control 
(cells treated with DMSO/ PBS). 
The resulting data were analyzed by calculation of the arithmetic mean over all triplicates and the subtraction of the 
blank value. Afterwards, the mean values of the treatments were related to the corresponding vehicle control to generate 
Figure 2-3 Reaction used to determine the 
intracellular ATP content by using the 
CellTiter-Glo® assay. The reaction of D-
Luciferin catalyzed by air-oxygen, Mg2+, 
Luciferase and the intracellular ATP. The 
whole reaction results in a luminescence 
light signal which can be measured. 
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relative values which were used as the cell viability. For determination of the TC20 and NOAEC level the mean of the 
three biological replicates was used. 
 
 
Neutral red uptake 
 
The neutral red uptake assay (NRU) provides a quantitative estimation of viable cells within a cell culture. The NRU 
method itself was originally developed by Borenfreund and Puerner (1985) [Borenfreund et al., 1985]. It is based on the 
property of living cells to take up the weakly cationic dye by penetration through cell membranes of viable cells by non-
ionic diffusion and accumulation. The supravital neutral red dye then binds to the anionic surface of the lysosomal 
matrix by electrostatic hydrophobic bonds [Winckler et al., 1974; Nemes et al., 1979]. If cellular membrane integrity is 
lost, the dye also can enter the cell debris.  
The neutral red stock (4 mg/mL) was diluted 1:80 with cell culture medium to achieve a final concentration of 50 
µg/mL. The diluted dye was centrifuged for 10 min at 100 x g to remove crystallized precipitates. Cells were seeded in 
black 96-well plates and treated as described in “Culture of the permanent cell line NRK-52E“ and "Cell treatment“. 
After the appropriate time of treatment, the supernatant was replaced with 200 µl of neutral red/ medium mixture. The 
cell culture was incubated for 3 h at 37°C and 5 % CO2. Subsequently, the supernatant was aspirated and the cells were 
carefully washed with pre-warmed PBS. After the soluble (extra cellular) neutral red dye was removed, the viable cells 
were lyzed and the intracellular neutral red dye was solubilized. 300 µl Of 1 % acetic acid in 50 % Ethanol were pipette 
in each well and placed on a shaker (300 rpm) at RT for 10 min, or until the neutral red dye formed a homogeneous 
solution. The absorbance of neutral red was read at a wavelength of 540 nm using a photospectrometer. As described 
for ATP-depletion, each data point was evaluated in triplicate, including blank (well without cells) and the vehicle 
control (cells treated with DMSO/ PBS). 
It has been shown that quantified neutral red is linearly related with cell number [Borenfreund et al., 1985], therefore 
the determined absorbance was directly used to calculate the relative viability based on the corresponding vehicle 
control. The resulting data were analyzed by calculation of the arithmetic mean over all triplicates and the subtraction of 
the blank value. Afterwards, the mean value of the treatments was related to the corresponding vehicle control to 
generate relative values, as a measure of cell viability. 
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2.8 Biochemical Tests 
 
2.8.1 Urinary Protein biomarkers 
 
2.8.1.1 Luminex® xMAP® Technology 
 
The Luminex
®
 xMAP
®
 technology is a novel method for the multiplexed detection of analytes, e.g. proteins, in a single 
sample. It is based on two well established methods, a classical sandwich-ELISA and flow-cytometry. The assay itself 
is performed in a 96-well microtiter plate which allows a higher throughput of samples and easy handling. The samples, 
including the proteins of interest, in this case Kim-1, Timp-1, VEGF, -GST, CystatinC, Clusterin, Osteopontin, 
Lipocalin-2/ NGAL, 2-microglobulin and Calbindin, were mixed with different types of special beads. Each bead type 
has an individual color ID which is characterized by their specific mixture of a red and an infrared dye (Figure 2-4A). 
On the surface of each individual bead type, antibodies are coated against one of the protein to be detected (Figure 
2-4B). In the case of the used WideScreen
®
 assays polyclonal antibodies against the specific urinary proteins are spotted 
on the beads. Immediately after a first incubation step, in which the analytes were captured by their antibodies on the 
different beads, a secondary, polyclonal antibody against the 1st Ab was added.  
 
Figure 2-4 (A) the building up of up to hundred beads filled with different concentrations of two different dyes (red and 
infrared). (B) On each individual bead type, characterized by their specific mixture of dyes, an antibody against the analytes of 
interest is coated which then can be detected by a soluble secondary antibody conjugated to a fluorophore. (C) The principal of 
detection is based on the amount of sample, including the analytes of interest and leading the fluid through two lasers (red and 
green). The red laser identifies the bead type and therefore the identity of the analytes, the green laser quantifies the secondary 
antibody coupled light signal [modified by Virocore, 2012 and teomed, 2012] 
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The secondary antibody is biotinylated, ensuring a signal amplification of the Streptavidin-Pyroerytrin-complex (SA-
PE) needed for the fluorescence detection. The multiplexed quantification is performed by two laser-systems. A green 
laser detects the Pyroerytrin (PE)-conjugate. The fluorescence intensity is proportional to bound protein. This can be 
used to quantify the total amount of protein via a standard curve. A second laser detects the red fluorescence signal to 
identify the bead type and therefore the quantified analytes (Figure 2-4C). From this multiple proteins can be detected in 
parallel in one sample in a more sensitive and sample saving way. 
For a detailed description of the whole procedure see [Hoffmann et al., 2011]. For specific information on used urine 
dilution factors, urine and buffer volumes refer to Table 2-15. 
 
The settings for the measurement are as follows: 
Volume per measurement: 50µL 
Bead count per measurement: 100 
Timeout: 60 seconds 
DDGate: 7500 - 15500 
 
Table 2-15 The used dilution factors, and volumes for the WideScreen® Rat Kidney 
toxicity panel 1 and panel 2. 
  WideScreen® Rat Kidney Toxicity Assay 
 Panel 1 Panel 2 
  Dilution 
Volume 
[Urine : Buffer] Dilution 
Volume 
[Urine : Buffer] 
Standard 1:2 40µL : 40µL 1:50 2 µL : 98 µL 
Slight increase 1:10 8µL : 72µL 1:1000 1µL (1:10): 99µL 
Strong increase 1:100 1µL : 99µL >1:10000 case-by case 
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2.8.1.2 Kim-1 detection via the RENA®-strip Dipstick Assay 
 
The RENA-strip dipstick assay, purchased from BioAssay Works, is based on thin layer chromatography. This so called 
lateral flow assay enables the detection of urinary Kim-1 by the lateral flow of diluted urine samples in combination 
with colloidal gold-conjugated antibodies specific for rat Kim-1. The urine sample comes in contact with two test bands 
driven by capillary force. The first is the test band with the specific antibodies against Kim-1. The second band is a 
control band, containing IgG specific conjugated antibodies, to ensure the right function of the test system. By passing a 
field containing soluble conjugated antibodies a complex of the immobilized anti-Kim-1 antibodies, Kim-1 itself and 
the soluble detection antibodies is formed leading to the appearance of a red band urinary Kim-1 is present. The test 
principal is shown in Figure 2-5. 
 
Figure 2-5 The principal of the lateral-flow technology, where the RENA-strip® dipstick assay is based on. 
The urine containing the analyte is moved by the capillary flow over an area containing gold-conjugated 
antibodies against rat Kim-1. In the following the test line with immobilized antibodies against Kim-1 is passed. 
Finally, the control with anti IgG antibodies is used as quality control. [modified by Cytodiagnostic, 2012] 
 
The band can be analyzed semiquantitatively or quantitatively using a lateral-flow reader. The urine samples were 
diluted 1:2 in borat test tubes before they were exposed to the test-strips. The test-strips were incubated for 15 min at 
RT before measurement with the lateral flow reader purchased from BioAssay Works. The Sandwich Assay protocol 
was used, by which the intensity of the test band with the control band was evaluated. The resulting value was 
multiplied with the lot-specific multiplication factor to get the Kim-1 concentration in nanogram per milliliter. 
 
2.8.2 Hematological parameters 
 
Within the department of clinical pathology of Merck Serono, Non-Clinical Development a hemogram was prepared for 
each individual animal, using standard operation protocols. The measurements were conducted by qualified employees 
of Merck Serono, following “good laboratory practice” (GLP). 
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2.8.3 Clinical-chemsitry Parameters 
 
Within the department of clinical pathology of Merck Serono, Non-Clinical Development standard clinical-chemical 
parameters in serum and urine were measured for each individual animal, using standard operation protocols. The 
measurements were conducted by qualified employees of Merck Serono, following “good laboratory practice” (GLP). 
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2.9 Molecular biological Methods 
 
In the following section, the procedure of gene expression analysis, including RNA purification (see 2.9.1 RNA 
Isolation from renal tissue and cell lines), sample processing (see cRNA-Synthesis), and the hybridization (see 2.9.3.2 
Sample hybridization) will be described in more detail. Figure 2-6 gives an overview of the general workflow necessary 
for the evaluation of global gene expression profiling using the Illumina bead arrays. 
 
 
Figure 2-6 General workflow of the whole 
procedure of gene expression profiling by using the 
Illumina Sentrix bead array. In a first step, the total 
RNA was isolated from the biological sample e.g. 
tissue or cells. Then the quantity and quality of the 
isolated total RNA was conducted. If the RNA 
quality showed a RIN of >7 the concentration of 
total RNA was set to 500 ng in 11µl nuclease free 
water. Subsequently, the first and second strand 
cDNA synthesis was performed in two separated 
cycles over 2 hours, the first at 42°C and the 
second at 16°C. The synthesized cDNA was 
cleaned up by Agencourt beads and directly used 
for the in vitro transcription (IVT) at 37°C for 14 
hours. After the cRNA was synthesized an 
additional clean up using Agencourt beads was 
performed in a similar way. The purified cRNA 
was quantified and the quality was evaluated 
before 750 ng cRNA were hybridized on the 
Illumina RatRef12 v.1 Chips for 20 hours at 58°C. 
The Chips were then washed in an automated 
manner on the Little Dipper platform. 
 
 
 
2.9.1 RNA Isolation from renal tissue and cell lines 
 
The isolation procedure was performed on the QiaCube
®
 system in an automated manner. The protocols used were 
identical to the procedure described in the manual [RNeasy Plus Mini, 2010]. The isolation is based on silica columns 
plus the elimination of genomic DNA by the gDNA eliminator column, both included in the RNeasy Plus Mini Kit. In 
the following the procedure for renal tissue and cell lines will be described in more detail. 
 
Renal Tissue 
The upper part of the left kidney was used for RNA analysis (Sample collection and necropsy). For RNA isolation it 
must be avoided to thaw the frozen kidney tissue because of a loss of RNA quality due to RNA degradation. Therefore, 
the tubes were transferred in liquid nitrogen. Pieces of kidney tissue of ~30 mg were transferred into a 2 mL reaction 
tube and 350 µL RLT buffer (containing 1‰ (v/v) β-Mercaptoethanol) were added. A 5 mm diameter RNase-free, 
stainless steel ball was put into the reaction tube, placed into the TissueLyser
®
 and processed at 30Hz for 2 min to lyse 
and homogenize the tissue sample. The lysate was used as starting material for the RNA isolation. 
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Permanent Cell lines 
The cell culture medium was removed and the cell layer was washed two times with 1mL pre-warmed PBS (with 
Mg
2+
/Ca
2+
) per well. Immediately after the final washing step 350 µL RLT buffer (containing 1‰ (v/v) β-
Mercaptoethanol) were added and the cells collected using a “rubber policeman”. Subsequently, the cell lysate was 
transferred to a shredder column and centrifuged for 3 min at full speed to homogenize the lysate. The lysate was then 
used as starting material for the RNA isolation. 
 
General procedure of the RNeasy mini Plus Kit 
The whole lysate was transferred onto a gDNA eliminator column to remove genomic DNA. The flow-through was 
collected and 350 µL 70% ethanol added. The whole sample was transferred onto a spin column and centrifuged at 
10,000 rpm for 30 sec. The captured total RNA was washed once by adding 350 µl RW1 buffer and twice with 500µL 
RPE buffer, with centrifugation steps in between. After the second washing step using RPE buffer, the spin column was 
centrifuged at full speed for two minutes to dry the silica membrane. The RNA was eluted by adding 40µL RNase-free 
water and analyzed via NanoDrop™ (Determination of RNA concentration via NanoDrop™ System) and Bioanalyzer 
(Determination of quality via the Agilent Bioanalyzer). For storage the RNA samples were kept at -80°C. 
 
 
2.9.2 RNA-Analysis 
 
Determination of RNA concentration via NanoDrop™ System 
 
For the quantification of total RNA or cRNA the NanoDrop™ spectrophotometer was used. For this cuvette-free 
measurement 1 µL sample was pipetted on the sample tablet, which includes a fiber optic. By closing the machine the 
fiber optic makes contact with the liquid surface by which it is opened between the upper and lower part of the sample 
drop. A xenon flashlight penetrates the sample and is detected by a silicium CCD chip. The result is a UV-Vis spectrum 
in the wavelength from 200-750 nm. For the calculation of the concentration the absorption at 260 nm was used. An OD 
= 1 corresponds to a RNA amount of 33 µg/mL. The ratio of absorption at A260 nm/ A280 nm was used as quality 
control. This parameter reveals information about impurities with proteins or aromatic hydrocarbons, like phenol which 
has its maximum absorption at 280 nm. In clean RNA samples the ration should be about 1.8 and 2.0 [Thermo 
Scientific, 2008]. 
 
 
Determination of quality via the Agilent Bioanalyzer 
 
After the quantification of the total RNA and cRNA samples (Determination of RNA concentration via NanoDrop™ 
System) the quality of the RNA was determined. It was important to determine the suitability of the samples for further 
cRNA synthesis (see Determination of quality via the Agilent Bioanalyzer) or the hybridization step (see Illumina
®
 
Technology). Therefore, the Lab-on-a-Chip-Technology from Agilent Technologies was used. The Agilent Bioanalyzer 
uses a special chip system based on electrophoretic measurements. The measuring principle is based on a microfluidic 
technique, which leads to the measurement of RNAs and RNA fragments, by the management of small amounts of 
liquid in a miniaturized channel system (Figure 2-7). 
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For example, the building of the Aglient RNA 6000 Nano chip, used for both species of RNA mentioned above, 
includes a system of small, closed channels and wells, which are etched into a plastic microchip. Under pressure or 
elctrocinetic forces the samples transverse the channels in a controlled way. In separation channels, the single 
compounds of the sample were separated for detection. The detection of individual RNA fragments is performed by a 
fluorescence dye which is added together with the gel matrix into each individual well [Agilent, 2010]. 
By using the 2100 Expert software the detected fluorescence signals are transformed in to electropherograms or gel-like 
pictures for simplification of the analysis. Subsequently, the transformed data was used to calculate a concentration 
value as well as a quality parameter, the so called RNA Integrity Number (RIN). The concentration was calculated by 
the area under the electropherogram in comparison to a standard ladder, included on each chip (Figure 2-8). The 
observed concentration data were used to pre-validate the concentrations measured using the NanoDrop system. Finally, 
the concentrations determined via the NanoDrop system were used only for concentration level adjustment for cRNA 
synthesis and hybridization of cRNA on the Illumina chips, because the data are more reliable than the concentrations 
determined by the Agilent Bioanalyser. The detection of RNA and cRNA samples, as already mentioned above, was 
performed using the Agilent RNA 6000 Nano chip and the corresponding Agilent RNA 6000 Nano kit. The qualitative 
range of the system is about 25 - 500 ng/µL RNA. The Agilent RNA 6000 Nano chip allows the parallel analysis of 12 
samples. The used reagents were equilibrating at room temperature before use, according the user manual. 
 
Figure 2-7 Agilent Lab-on-a-chip based technology of the RNA Nano LabChip (A) and its build 
up with the channel system (B). The measuring principal (C) is based on an electrophoretic 
separation of the sample components and the detection by a fluorescence dye [Abb. Modified by 
Agilent, 2010, ESD, 2009, IMB Microarray Facility, 2010]. 
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Figure 2-8 Electropherograms of total RNA (B) and 
cRNA (C) as well as the corresponding RNA-Ladder 
(A) determined by using the RNA 6000 Nano chip on 
the Agilent Bioanalyzer. [modified by Agilent, 2006] 
As a first step, 500 µL Agilent RNA 6000 Nano gel matrix was pipette into a centrifuge filter column and centrifuged 
for 10 min at 1,500 g. 65 µL gel was mixed with 1 µl Agilent RNA 6000 Nano fluorescence dye by vortexing. 
The gel-dye mix was centrifuged at RT and 13,000 g. The Agilent RNA 6000 Nano chip was put into the priming 
station and 9µL of gel-dye mix were pipette into the cavity marked by “G”. The Priming Station was closed for 30 sec. 
to distribute the gel-dye mix in the channels of the chip.  
Additionally, 9 µL were pipette into the upper gel wells. In all 
sample wells, including the well for the ladder, 5 µL RNA 6000 
Nano Marker were placed. 1 µL sample or ladder was put into 
each well and the whole chip was vortexed for 60 sec. at 2,400 
rpm [Agilent, 2006]. 
The chip was introduced into the Bioanalyser machine and the 
measurement was started. 
For total RNA an electropherogram should have two prominent 
peaks, the ribosomal RNA (rRNA) subunits of the 18s and 28s, 
at 1800nt or 3800nt. (Figure 2-8).  
In this measurement two quality parameters are included. First, 
the 2100 Expert software automatically calculated the ratio of 
28s to 18s rRNA. A high quality RNA sample has a ratio of > 
2.0 while with increasing degradation of the RNA the ratio 
decreases. Because the 28s/18s ratio depends on a variability of 
the included RNA concentration, it is hard to define a threshold for RNA quality. Therefore, a second quality parameter 
can be used. The so called RNA Integrity Number (RIN), also delivers information on the degradation of the RNA 
sample. The RIN value is based on the electrophoretic staining of the RNA sample. The value is between 1 and 10, 
while 1 means highly degradated RNA and 10 RNA with optimal quality (Figure 2-9). This method includes the 
determination of the presence or absence of degradation products, based on the Agilent RNA Integrity Database 
(RINdb). The basis of the RINdb are the analysis of 1300 RNA samples from different tissues of rat, mouse and human 
with different qualities, which were assigned a RIN value. By using bioinformatic, neuronal network analysis of the 
underlying electropherograms, this adaptive and fault-tolerant learning system, allows us to calculate specific 
properties, such as signal areas, -intensities or –ratios of the electropherograms. Figure 2-9 shows the electropherograms 
of samples with RINs from 10 to 1 [Mueller et al., 2010, Schroeder et al., 2006]. Therefore, the RIN value is a highly 
reproducible parameter for the determination of the RNA quality because it includes the whole electropherogram for the 
calculation [Mueller et al., 2010, Schroeder et al., 2006]. Furthermore, the RIN enables the definition of thresholds 
based on individual experiences for specific downstream applications, like real-time PCR or microarray analysis. 
For the microarray experiments presented here, only samples with RINs of >7 were used. This value is based on the 
experience that no significant alterations based on the RNA degradation are expected in the following measurements. 
Because the RIN cannot be calculated for biotinylated cRNA because the samples are already fragmented, the quality 
check limited to study of the electropherograms manually. Typically, electropherograms of well processed cRNA show 
a wide spectrum, reaching from 250 – 5500 nt with its peak at 1000 – 1500nt (Figure 2-8). 
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Figure 2-9 Electropherogramms of total RNA samples with decreases in RNA integrity displayed by the RNA 
integrity number (RIN). RIN 10 gives a typical electropherogram of complete, intact RNA and a RIN of 1 shows 
completely degraded RNA with only on peak at the beginning of the plot indicating the shift to shorter RNA 
fragments. [modified by Schroeder et al., 2006]. 
 
 
2.9.3 Illumina® Technology 
 
In 2005 Illumina marketed a novel technology for the analysis of global gene expression changes [Illumina, 2010]. The 
Sentrix
®
 BeadChip is based on 50 base pairs oligonucleotide sequences, which are labeled with a 29 base address 
sequence. By standard oligonucleotide synthesis, gene specific sequences, based on the NCBI (National Center for 
Biotechnology Information Reference Sequence) reference sequence database, are produced [Barnes et al., 2005]. A 
special multi-step algorithm was used to integrate parameters like the absence of repetitive genomic sequences, 
inequality to other gene sequences, melting temperature and self-complementarily [Illumina, 2006]. After synthesis, 
these oligonucleotide sequences were covalently coated on 3 µm silica beads. On average each bead contains more than 
10
8
 copies of a specific oligonucleotide of an individual transcript and is present approximately 30 times in each sample 
field of the array [Kuhn et al., 2004]. This repetition of sequences and beads serves as internal technical replicates and 
therefore help to make the system stable and deliver reliable and reproducible data. Another characteristic of the 
Sentrix
®
 Bead Array system is the random distribution of the beads in wells, which are etched on to sample fields 
(Figure 2-10) [Steemers et al., 2005]. To address this, the 29 base address sequence is used in a decoding procedure to 
identify the final positions of the beads/ transcripts. For this purpose Illumina developed a decoding algorithm, which is 
based on sequential hybridization and re-hyridisation of the address sequence [Gunderson et al., 2004]. A great 
advantage of the Illumina Bead Chips is the fact that 12 samples can be processed on parallel on the same Chip. This 
allows a higher throughput and a reduction in time and costs.  
The RNA was isolated from the renal tissue or cell lines as described under “RNA Isolation from renal tissue and cell 
lines”. After isolation the RNA was quantified and the quality was determined (see Determination of RNA 
concentration via NanoDrop System). RNA samples with a sufficient quantity and high quality were used for cRNA 
synthesis (see Determination of quality via the Agilent Bioanalyzer). The cRNA also was quantified and qualified and 
afterwards hybridized on the BeadChips (see Illumina
®
 Technology). After washing and staining the BeadChips were 
scanned with the BeadScan by a confocal laser-scanning technology. 
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Figure 2-10 Shown is the (A) Construction of the bead with its coated addresses and probe sequences, as well as (B) the 
developmental process of a Illumina Sentrix® BeadChip. [Figure modifid by Illumina, 2010, Illumina, 2006]. The RatRef-12 v.1 chip 
allows the parallel hybridization of 12 samples per chip and the determination of approximately 22,000 genes per sample. By a 
plasma etching process, ~3 µm cavities were prepared on a silica dish to immobilize the beads on each chip. 
 
 
cRNA-Synthesis 
 
For the cRNA synthesis a modified protocol was used, including the Illumina TotalPrep RNA Amplification Kit from 
Ambion Inc., in combination with the Agenourt RNAClean XP from Beckman Coulter Inc. 
500 ng Total RNA per sample was used in 11 µL nuclease free water in a 0.2 mL 96 well plate. In a first step, single 
stranded cDNA was synthesized from the mRNA containing total RNA sample by using the oligo-dT primer and a 
reverse transcriptase. Table 2-16 shows the preparation of the master mixes used in the procedure. 9μl 1st strand 
synthesis master mix were added to each sample well and incubated at 42°C for two hours.  
Subsequently, for the 2
nd
 strand synthesis, the single stranded cDNA converted to double-stranded cDNA. The second 
strand master mix was prepared directly prior to use and 20 μL were dispensed into each sample well. For the 2nd strand 
synthesis the samples were incubated for additional two hours at 16°C. For cDNA purification a modified procedure 
was used. The cDNA reaction mixture was completely transferred into a round bottom plate and 180 µL of Agencourt 
RNACleanXP bead solution was added to each individual sample. The mixture was incubated at RT for 5 min before 
the plate was placed on a magnetic separator for a minimum of 10 min. The liquid was discard avoiding contact to the 
cDNA-containing beads. The beads then were washed 3 times with 200 µL 70% ethanol before elution of cDNA by 
adding 20 µL nuclease free water. The purified double stranded cDNA was again transferred in a 0.2 mL 96-well plate 
for the IVT reaction. During the IVT reaction, biotinylated UTP-nucleotides were incorporated by an amplification 
reaction creating multiple copies of cRNA. 7.5 μL IVT Master Mix were dispensed into each sample well and the 
reaction was incubated for 14 h at 37°C. Following the IVT reaction, samples were cleaned as described for the cDNA, 
by using 80% ethanol except 70% ethanol. Afterwards the cRNA was quantified and checked for quality. 
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Table 2-16 The single components used for 1st and 2nd stand master mix of the 
reverse transcription of the total RNA samples, as well as the in vitro transcription 
(IVT) master mix. The volumes are given for a single reaction of either 20 µL (1st 
strand RT), 100 µL (2nd strand RT) or 25 µL (IVT). 
1st Strand Reverse Transcription Master Mix for 1 sample 
( 20 µL reaction volume)   
Amount Component  
1 µL T7 Oligo(dT) Primer  
2 µL 10X First Strand Buffer  
4 µL dNTP Mix  
1 µL RNase Inhibitor  
1 µL Array Script (reverse transcriptase)   
   
2nd Strand Master Mix for 1 sample   
(100 µL reaction volume)   
Amount Component  
63 µL Nucelase-free Water  
10µL 10X Second Strand Buffer  
4µL dNTP Mix  
2µL DNA Polymerase  
1µL RNase H   
   
IVT Master Mix for 1 sample   
(25 µL reaction volume)   
Amount Component  
2.5 µL T7 10 Reaction Buffer  
2.5 µL T7 Enzyme Mix  
2.5 µL Biotin-NTP Mix   
 
 
 
Sample hybridization 
 
For hybridization, 750 ng cRNA in 5 µL nuclease-free water was used. The GEX-HYB and GEX-HCB buffers were 
equilibrated at 58°C for 10 min to completely dissolve the salts present. Subsequently, the buffers were cooled down to 
room temperature. 10 µL GEX-HYB buffer were pipette into each cRNA sample and denatured for 5 min at 65°C. The 
reservoirs of the hybridization chambers were filled with 200 µM HEX-HCB buffer to ensure a humid atmosphere 
during the hybridization process. The cRNA sample was vortexed and 15 µL sample was applied to each array of the 
BeadChip. The chips were placed into the hybridization chamber and incubated for 20 h at 58°C under slight shaking 
(speed 5) in the hybridization oven. 
The buffers needed for the washing and staining steps are shown in Table 2-17. The chips were directly transferred 
from the hybridization chamber into a bath of 250 mL E1BC buffer. The foil was removed under the fluid surface and 
put into a new dish with E1BC buffer. The chips were placed into the Little Dipper® and the program was started. In a 
first step, the Chips were dipped for 10 min in 55°C warm high-Temperature wash buffer. This was followed by a 5 min 
washing step in 250 mL fresh E1BC buffer and thereafter in 250 mL 100% ethanol for 10 min. After an additional 
washing step in E1BC for 2 min each chip was dipped into 4 mL of Block E1 buffer for 10 min at 22°C. 
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Table 2-17 Buffers and reagents for the hybridization procedure of the Illumina 
bead arrays.  
Buffer Formulation  
E1BC - 800 mL DEPC water 
- 2.4 mL E1BC-Stock 
High Temperature-Wash 
buffer 
- 630 mL DEPC water 
- 70 mL High Temperature-Wash buffer Stock 
Block E1-buffer containing 
Strepatividin-Cy3 
- 500 mL Block E1-Buffer 
- 500 µl Streptavidin-Cy3-Stock (1 mg/ ml) 
 
Finally, the chips were stained in Block E1 buffer containing Streptavidin-Cy3 for 10 min under light dipping 
movements. After the staining step the chips were finally washed in 250 mL E1BC buffer for 5 min and centrifuged at 
275 g at room temperature for drying. The chips were directly transferred into the Illumina Bead Array Reader and 
scanned at 532 nm and a resolution of 0.8 µm. 
 
 
2.9.4 Quantitative RT-PCR 
 
0.2 U/mL SuperScript™ II Reverse Transcriptase (Invitrogen, Karlsruhe, Germany), 0.3 µg/µl random hexamer primers 
(Roche, Mannheim, Germany), 10 mM deoxy-NTPs (Roche, Mannheim, Germany) and 40 U/µL RNAsin (Promega 
GmbH, Mannheim, Germany) were used to transcribe 4 µg of total RNA to cDNA in 30 µL for 60 minutes at 42°C. 
Transcription of selected genes (Compugen nephrotoxicity signature) was quantified in triplicates using custom-made 
oligonucleotides (Sigma Aldrich, Steinheim, Germany) on the ABI Prism 7000 Sequence Detection System (Applied 
Biosystems, Darmstadt/Germany).  
 
Table 2-18 Oligonucleatides for the transcriptional biomakers included in the Compugen Ltd. Panel. Ccng1 and Isg20 were present 
as two different splice variants. Actv, Actg, Hprt1 and Ywhaz were used as housekeeping genes. 
gene symbol Forward primer → 5´- 3´ Reverse primer → 5´- 3´ 
Biomarker transcripts  
Ccng1 
(splice variant 1) 
CAGAATTGCTGCCTCAATCTAGTCC GGTTTTGCAGATGTACTCGGTTCC 
Ccng1 
(splice variant 2) 
GAGATCCAAGCACTGAAGTATGTAGAGT TCAGGAGTACAGTGGATACATTTCTCTT 
Ei24 AATCTAGGCTGCCTCCTGGAG AGGTCAATTATACAAGGCATGACTTTAG 
Isg20 
(splice variant 1) 
GGGCCACAATGGAGCTCTAC ACAGGTCTCATTCATGGAAAACTATG 
Isg20 
(splice variant 2) 
ACAGCCTGATGCAGACAGC TCTGGTTCATTATCAAGGGAAGTTG 
Tnfrsf12a GATCTGGGTAGGTGGTTGTTGG CGCACACCCTTATAAAAGTCCC 
Housekeepertranscripts  
Actb  GGGAAATCGTGCGTGACATT GCGGCAGTGGCCATCTC 
Actg2 TACCCTATTGAGCACGGCAT CGCAGCTCGTTGTAGAAGGT 
Hprt1 GCGAAAGTGGAAAAGCCAAGT GCCACATCAACAGGACTCTTGTAG 
Ywhaz CAAGCATACCAAGAAGCATTTGA GGGCCAGACCCAGTCTGA 
 
Forty cycles were run with the following parameters: 50ºC for 2 min, 95ºC for 10 min, and then 40 cycles of 95ºC for 
15sec, followed by 60ºC for 1 min, except for Ccng1 splice variant 2 for which the annealing temp was 62
o
C for 
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transcription using SYBR
®
 green chemistry (Applied Biosystems, Darmstadt, Germany). cDNAs were stored at -80°C 
and diluted 1:20 in TE-buffer (10mM Tris pH=8, 1mM EDTA) and PCR reactions were performed with 5 µL of diluted 
cDNA in 20 µL reactions. On every plate an 8 point standard curve, prepared by reverse transcription of universal rat 
RNA (Stratagene, Heidelberg, Germany), was included. 
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2.10 Statistics and mathematical evaluation 
 
2.10.1 General statistical average and error values 
 
Student´s T-Test 
 
The student´s T-Test, developed in 1908 by Wiliam Sealy Gosset, within the Guiness brewery for quality control of the 
brewing process, is a mathematical hypothesis testing method. This statistical test follows a Student´s distribution 
(probability distribution) if the null hypothesis is supported. The null hypothesis says that the mean of both samples 
(e.g. control and treated group) are equal. For the calculation of the probability, the mean and variance of both samples 
are used. In addition, the probability distribution depends on the degrees of freedom, which is calculated by the number 
n of independent observations minus the number of parameters taken in account into the analysis [Draghici, 2003]. The 
number of degrees of freedom for the evaluation of the p-value is given by two unpaired samples n+m-2. Based on the 
t-ratio and by using the degrees of freedom the probability (p-value) can be evaluated out of the probability distribution 
by using tables or statistics software. The t-ratio is the difference between sample means divided by the standard error 
of the difference, calculated by combining the SEMs of the two groups. Therefore, the p-value is used to show whether 
the difference between the mean of two groups is likely to be due to chance. Small p-values indicate that the probability 
that the means of both distributions are equal (null hypothesis) is quite low [Rudolf et al., 2008]. In practice a threshold 
for the significance level is defined, normally 0.05 or 0.01. That means that a p-value of 0.05 indicates a 5% error 
probability to reject the null hypothesis incorrectly. 
 
 
ANOVA 
 
In contrast to the student´s t-test, the analysis of variance (ANOVA) allows the comparison of multiple groups or 
conditions in parallel [Draghici, 2003]. The simplest form of an ANOVA is to compare two groups which correspond to 
the t-test. It can be discriminated between unifactorial (one-way ANOVA) and multifactorial (n-way ANOVA) analysis 
of variance, which are different in the number of factors included into the analysis. A simple ANOVA is based on the 
comparison of the variability between different testing groups and the variability within the testing groups. The 
requirements for an ANOVA are the same as for a t-test, including variance homogeneity and normal distribution of the 
data. The underlying probability distribution is the F-distribution. The mathematical principle of a unifactorial ANOVA 
is the partitioning of the square sum of the total variance (Stotal), which means the square sum of all differences of the 
individual observations from the global mean [Draghici, 2003]. 
 
                      
Equation 1 The fundamental technique of an analysis of variance is a 
partitioning of the sum of squares (S) into components related to the 
individual observations 
 
In this case Sfault is the square sum of variance within the testing group (replicates) [Draghici, 2003], which in principal 
is excepted to be relatively small, because the differences between the replicates of a testing group takes place by 
experimental/ technical error and the biological variation. The Scont stands for the variance of the groups around the 
global average (variation between the groups) and characterizes the variance of the defined condition, like time, 
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treatment and gender. By using the degrees of freedom, the mean square error for Sfault and Scont can be calculated 
[Draghici, 2003]: 
 
         
       
   
             
      
   
 
Equation 2 Calculation of the mean square error of the variance within (A) the groups and (B) 
between the groups to evaluate the F-value by using a analysis of variance (ANOVA). k = number 
of conditions, N = total number of measurements within the dataset, Sfault Square sum of the intra-
group variance, Scont Square sum of the inter-group variance 
 
Based on the F-value and the degrees of freedom k-1 and N-k the p-value can be evaluated [Draghici, 2003]. In 
principal this procedure is identical for multifactorial analysis of variance, with the difference that multiple factors/ 
conditions (e.g. treatment, gender and time) can be taken into account within one analysis. 
 
   
      
   
 
Equation 3 Equation for the calculation of the F-value by a unifactorial 
analysis of variance. MScont = mean square error of the inter-group variance, 
MSF = the mean square error of the intra-group variance  
 
In this work the one-way ANOVA was used to compare the results of the urinary protein measurement, the clinical 
pathological and hematological results of the groups treated with nephrotoxic model compounds with the groups treated 
with the vehicle (control groups). The calculations were conducted using the GraphPad Prism Software (version 5) by 
GraphPad Software Inc. (San Diego, USA). 
 
 
2.10.2 Calculation of renal functional property values 
 
The calculation of renal parameters that reflect the renal functional properties are based on the comparison of 
concentrations of different components in urine and in blood. Out of the ratio from these two observations the clearance 
and therefore the glomerular filtration rate can be estimated. There are a multitude of equations for the calculation of the 
glomerular filtration rate, all of which have advantages and disadvantages. To calculate the creatinine clearance, which 
is widely used in (pre-) clinical trials, the urinary output was multiplied by urinary creatinine concentration, divided by 
the concentration of creatinine in serum (Equation 4). 
 
                     
                   
      
  
 
Equation 4 To calculate the renal clearance of creatinine the urinary volume (Vurine) was multiplied by 
1000, for unit correction, and the urinary concentration of creatinine (cuCrea) and then divided by the 
concentration of creatinine in serum. The units used within the calculation were Vurine  [mL/ 18h], cuCrea 
[mmol/L], csCrea [µmol/L]. 
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2.10.3 Receiver Operating Characteristic curve 
 
The Receiver Operating Characteristic curve (ROC curve) is a statistical method to determine the sensitivity (True 
Positive Rate) and 1-specificity (False Positive Rate) of a diagnostic test in relation to a specific outcome. In our case, 
the ROC curves were used to evaluate the performance of novel urinary protein biomarker to detect histopathological 
alterations. The sensitivity reflects the fraction of animals with pathological kidney damage that the urinary biomarker 
correctly identifies as positive. On the other hand the specificity is the fraction of animals without pathological 
alteration that the biomarker correctly identifies as negative. Therefore, it is a binary classification system, as its 
discrimination threshold is variable. By interpretation of the data it has to be kept in mind that in this work the 
histopathological evaluation serves as the “gold-standard” and the calculated values only reflect how urinary biomarker 
excretion cover histopathological findings. As quantitative values, the area under the ROC curve (AUROC) was 
evaluated as the overall ability of the biomarker to discriminate between those animals with pathological renal damage 
and those without. A perfect result, i.e., no false negative or false positive measurements, has an AUROC of 1.0. For the 
worst case, the analysis of a distinct biomarker will give a result that of a probability of 50% to predict the pathology by 
the biomarker. In this case the calculated AUROC will have a value of 0.5. All calculated values will lie between these 
borders. We decided to highlight values with an AUROC > 0.9 as good biomarkers with a satisfying diagnostic 
performance. However, also biomarkers below 0.9 can be of value. 
By using GraphPad Prism we calculated the sensitivity and specificity using each individual value of the dataset as the 
potential cutoff value. Therefore, many pairs of sensitivity and specificity were calculated. If a higher threshold is 
chosen the specificity of the test will increase, but sensitivity will be lost. By using a lower threshold, the sensitivity of 
the test will be enhanced but it will lose specificity. 
 
Figure 2-11 A schematic overview of the principle of classification rates for the urinary protein biomarker 
measurement compared to pathological alterations observed by histopathology. If an animal shows pathological 
alteration and also the biomarkers deliver a positive result it’s a true positive (TP) outcome. If the biomarker 
delivers a negative result it is false negative (FN). If animals shows no pathological alterations and also the 
biomarkers do not show any changes the result is true negative (TN). In the other case, if the biomarker 
indicates an alteration it is a false positive (FP). Out of these possibilities the sensitivity, accuracy and 
specificity can be deduced. 
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2.10.4 Challenge of statistical analysis of omics-data 
 
The challenge in analysing whole genome gene expression data lays in the enormous amount of single data points 
produced by these genomic technologies. Therefore, specialized computational analyses are needed to identify the 
relevant information in a reliable way and to make it possible to bring the data into a biological context. The field of 
bioinformatics, which is a branch of computational biology, addresses the analysis and management of biological data. 
The analysis of thousands of transcripts within a microarray experiment can be performed using different general 
approaches, depending on the aim of analysis. Four general categories are available for analysing genomics data
3
: 
1. Class discovery 
2. Class comparison 
3. Class prediction 
4. Mechanistic analysis 
 
The class discovery is a general and unbiased look at the data, and enables the discovery of group classes. The principle 
of this analysis approach is the grouping of similar effects of the gene expression pattern, to discover differences and 
similarities of e.g. pathology groups. This method can be used to get a first overview of the dataset or to check whether 
an analysis influences the clustering of the data in relation to each other. The advantage of this method is that class 
discovery is an unsupervised method, which leads to classification on their similarity in expression pattern, independent 
of the group. The mathematical approach used within this study was the principal component analysis. Because of the 
complex mathematical algorithms underlying these statistical approaches, only the principal of the analysis will be 
explained. However, it has to be mentioned that the individual clusters created by these methods do not necessarily have 
any toxicological or biological meaning. To determine whether a clustering is relevant, further analyses are required. 
The class comparison gives further information by comparison of for example untreated with treated animals/ cells to 
identify treatment related differences. In general, almost all parameters of a study can by analysed by this method to 
evaluate their impact of the observed gene expression alteration. The most important factor is that a reliable control 
group is available. Each departure from the normal biological/ physiological phenotype/ genotype can be assumed to be 
related to the compound treatment and therefore predicted as patho-toxicologically relevant. Also biological and 
technical variability has to be taken into account, for which a wide variety of statistical tools can be used. The statistical 
tests used within this study include the t-test (two group comparison) and the analysis of variance (multiple group 
comparison) already described above. However, in case of whole genome gene expression analysis one problem occurs 
when using these statistical tests. Normally, a significance level is assumed to be p ≤ 0.05. Because of the high number 
of genes (~22,000genes) detected within in one experiment (multiple testing), applying a 95% confidence limit on gene 
selection (p ≤0.05) will lead, by chance, to 500 genes detected as significantly altered. To avoid this problem a more 
stringent gene selection is warranted, by using p-value threshold of p ≤ 0.01 together with a fold-change (FC)-ranking, 
which describes a ratio of treated vs. control groups. This approach was expected to deliver reliable results by an 
enhanced reproducibility and a balanced sensitivity and specificity [Shi et al., 2008]. In addition, the q-value by 
Benjamini and Hochberg [Benjamini et al., 2001] was used to minimize misclassification by only taking the p-value 
into account. The q-value is a measure of the false discovery rate, and is therefore a control statistic used to correct in a 
list of rejected hypothesis the expected proportion of incorrect rejected null hypothesis. 
                                                 
3
 Fuchs et al., 2012 
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The class prediction analysis deals with the supervised, computation prediction of a toxicological outcome based on the 
gene expression pattern. The assumption of this kind of testing is that similar pathologies lead to comparable effects on 
the gene expression level. There are two different approaches which can be used to build up such a classification model: 
1. Gene ranking 
2. Use of rational defined gene lists 
 
By ranking genes, a computational algorithm finds the ideal set of genes that can discriminate between different 
phenotypes or pathologies. In this case the ideal gene set is defined by a minimized misclassification rate, i.e. a 
minimum false positive and a minimum false negative classification (Figure 2-11). A multitude of mathematical models 
can be used, including the analysis of variance (ANOVA) [Bushel et al., 2002], the support vector machine weight 
(SVM) [Mundra et al., 2008] and the recursive feature elimination (RFE) [Furlanello et al., 2003]. In the second 
approach an already defined gene list (e.g. by mechanistic link or an already classified and published gene list) can be 
used to build a classification model. In this work three gene lists were used, taken from the literature, to evaluate their 
usability to predict nephrotoxicity, independent of the used method. Many algorithms can be used to build up the rules 
for the classification model, such as discriminant analysis [Nguyen et al., 2002, Orr et al., 2002, Antoniadis et al., 2003, 
Le et al., 2003], classification and regression trees [Boulesteix et al., 2003], support vector machines [Ramaswamy et 
al., 2001, Brown et al., 2000], and k-nearest neighbours [Theilhaber et al., 2002]. In general, all these algorithms are 
developing a rule based on the gene expression data. For an unknown compound, this rule can be then used to predict 
the class of the compound without any further information. 
 
 
Quality control of microarray data 
 
On each Illumina bead array six different quality controls are present which can be used within the GenomeStudio 
software from Illumina. These controls include the control of the laboratory processes of cRNA syntheses, hybridization 
and background up to the generation of the fluorescence signal. 
Firstly, the expression of housekeeping genes can be checked. 14 Different species specific housekeepers are present 
with two oligonucleotide probes on each array. To check the quality of the hybridization process three controls, a Cy3, a 
high and a low stringent hybridization control were used. The Cy3 control is composed of six different oligonucleotide 
probes on each chip and the corresponding Cy3 oligonucleaotides, which are included in the HybE1 buffer. This enables 
the control of the hybridization process, independent of the RNA quality and the preparation process. In contrast, the 
low stringent control contains only four different probes and each of them are characterized by 2 mis-matched pairs, 
leading as a consequence to only a very minimal signal in case of an optimal hybridization. The high stringent control 
does not have any mis-matched pairs and are characterized by a high GC-content, leading to a very strong signal. 
Another control is composed of biotinylated oligonucleotides, and is also included within the HybE1 buffer. This 
control enables the quality check of the secondary staining reaction of the Cy3-dye. For determination of unspecific 
background hybridization reactions also 20 different randomized oligonucleotides are included, which do not match to 
any sequence within the genome of the used species. In addition, unspecific binding reactions of the dye, as well as 
cross reactivity, were detected by this control.  
Based on these controls with the GenomeStudie software, the detection limit was defined and transcripts near the 
background were excluded from the analysis [Illumina, 2004]. No further analysis was conducted within this software 
tool. The signal intensity values were exported from each individual probe and uploaded within the Genedata Analyst 
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software for further analysis. Therefore, in a first step the data were visualized by log-log-plots and box-plot analysis to 
evaluate the general distribution of the data and to identify potential outliers. 
 
 
Normalization of microarray data 
 
To enable comparability of gene expression data generated under different conditions, such as technology, time points 
or experiments, the data has to be normalized [Draghici, 2003]. Such differences between arrays also can appear by 
using different protocols, amounts or quality of mRNA, Scanner setups, cRNA synthesis or hybridization assays. A 
multitude of special algorithms are available to transform gene expression data to eliminate or reduced systemic errors, 
which can lead to discrepancies in signal intensities [Knudsen, 2004]. In general, there are linear and non-linear 
methods. Linear methods are mean or median normalization methods, and adjust the intensity signals by the average 
signal. Here, housekeeper genes can be used as reference points to transform all values relative to these genes. In 
general, these methods are preferable if the data shows a parallel shift in log-log-plots to the midline (bisector). For 
datasets showing a non-linear curve shape in the log-log-plot, like a banana-shaped curve, the non-linear methods are 
preferable. 
In this study the Genedata Analyst software was used to normalize the gene expression data. Within the rat in vivo 
study only slight differences between the individual experiments were detected, with a linear curve shape. Therefore, 
the linear Central Tendency normalization method was used, with the median as a setting factor. The median is the 
value of a dataset, separating the higher half of the processed values from the lower half. In contrast to the arithmetic 
mean, the median is a more robust method in respect of outliers. For each experiment/ array, all probes are shifted by a 
constant sum, such that the median of the normalized data values in each experiment equals the target value, in case of 
this study 100. The generated/ calculated new values show stable differences between each other compared to the 
differences of the original/ non-normalized data. In case of the in vitro data a point wise division was used to normalize 
the datasets. This was possible because it can be assumed that the corresponding vehicle, derived from the same 
passage, is the same biological replicate, so that the ratio of the treated cells and the vehicle control subtract the effects/ 
processes present in the untreated cells. 
 
 
Global Data analysis 
 
Principal component analysis (PCA) 
 
The principal component analysis (PCA) is a vectorial approach, which can be used in toxicogenomics for class 
discovery. It is a visualization tool which aims to reduce the number of multidimensional dataset to fewer dimensions 
(2D/ 3D) with a minimization of loss of information [Draghici, 2003]. It is a mathematical procedure that uses an 
orthogonal transformation to convert a set of observations of possibly correlated variables into a set of values of linearly 
uncorrelated variables – the so called principal components. In a microarray dataset each experiment and each 
individual gene represents a single dimension. For example, in the Vancomycin study reported here, containing 72 
different experiments with ~20,000 genes, the regular results without PCA would be a data cloud of 72 experiments in a 
20,000 dimensional space. Within the PCA, the dimensions become regarded as important dimensions, which strongly 
vary between the experiments/ data. Dimensions with only a low variation within the datasets are often neglected. The 
statistical properties are first order, so the variance of the data is used within the PCA to build the whole dataset in to a 
novel coordinate system with fewer dimensions. The direction of the new axes of the coordinate system, are Eigen 
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values of a square matrix, in this case a correlation matrix of the data. By using the genes of different experiments 
within the PCA, each experiment will be displayed in a graph as a single point. Therefore, the PCA can identify a 
tendency of a dataset, as well as outliers [Draghici, 2003]. It has to be mentioned that not all axes carry an equally 
weight within the PCA. The mathematical transformation is defined in such a way that the 1st principal component 
accounts the most variability of the original data as possible and has therefore the largest possible variance. The same is 
true for the 2
nd
 component under the constraint that it be orthogonal (uncorrelated), to the preceding components. 
 
 
Transcription Factor Analysis in IPA 
 
Transcriptional analysis was conducted by using the Ingenuity Transcription Factor Analysis in IPA
®
. The analysis is 
based on two independent values, a z-score, which can be used as a numerical value of the regulatory influence of the 
individual transcription factors (TF) and an overlap score (Fisher´s Exact Test p-value) indicating whether there is a 
statistically significant overlap of the underlying dataset and the genes regulated by this TF. The regulation z-score 
describes transcriptional regulators that are able to describe observed alterations on gene expression and infer their 
activation state. This predictive process is based on relationships (edges) in the molecular interaction network within the 
datasets and is associated with the literature derived information within the IPA-database of the expected deregulation, 
which can be named as “activating” or “inhibiting”. For the z-score, the calculated value must be interpreted to be 
predictive for the activation state of the activated TF when the parameters given in Table 2-19 are matched. 
 
Table 2-19 Given is the principal of relation of the evaluated z-score and the underlying basic approach for 
interpretation. Ehe expected (in literature descibed associated relationships) regulation directions of the 
transcription regulators can be either “activating” or “inhibiting”. Dependent on the evaluated observed gene 
regulation over all downstream genes (up; down), the sign of the calculated z-score reflects the overall predicted 
activation state of the transcription factor (<0: inhibited; >0 activated).  In practice, the z-score is considered to be 
significant if it is ≥ 2 or ≤ -2. 
Regulation direction  
associated with  
relationship 
 
calculated z-score  
based on the observed  
gene deregulation 
 
Mean observed  
gene regulation over all 
downstream transcripts 
 
Predicted activation  
state of transcription 
regulator 
       activating 
 
≥ 2 
 
up 
 
activated 
activating 
 
≤ -2 
 
down 
 
inhibited 
inhibiting 
 
≤ -2 
 
up 
 
inhibited 
inhibiting 
 
≥ 2 
 
down 
 
activated 
              
 
Analysis of qRT-PCR data by Compugen’s classifier 
 
Average Ct values were calculated from triplicate measurements for each sample. The standard curve was used to 
transform the average Ct to RNA expression levels. The geometric mean of the four housekeeping genes expression 
levels was calculated for each sample, and this value was used as a normalization factor that accounts for the relative 
total RNA amount per sample. The RNA expression was further normalized for each marker, so that the geometric 
mean of the control samples expression levels is a predetermined value (the geometric mean of the control samples used 
to train the classifier, see below). A Random-Forest classifier was used to determine the toxicity status for each sample. 
Both the 4-marker and the 6-marker classifiers use an additional gender parameter, and give numerical results between 
0 and 1. Any sample with a value above 0.4 was considered toxic. A toxicity score was calculated for each group of 
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samples (control, low, medium and high dose), as the percentage of toxic samples in the group. All calculations were 
done using MS-Excel, the classifiers were created and run using R software, embedded in Excel. 
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3.1 Identification of nephrotoxic effects in vivo  
 
In the following sections results from different methods will be presented and described which evaluate the advantages 
and disadvantages of some qualified and exploratory biomarkers in different test settings (see 3.1.1 Results and 
Discussion for the evaluation of urinary protein biomarkers). General histo- and clinical-pathological methods as well 
as hematological, immunohistochemical and gene expression data were analyzed to characterize the underlying 
pathology and to evaluate the performance of these urinary protein biomarkers for their ability to detect substance 
induced nephrotoxicity and renal recovery in a gender independent way. After describing the relevant findings for each 
individual study the results from all methodologies are discussed.  
In a second step gene expression analysis of the Vancomycin study was conducted to obtain a mechanistic 
understanding as well as transcription based biomarker identification (see 3.1.3 Gene expression analyses of renal 
tissue).  
 
3.1.1 Results and Discussion for the evaluation of urinary protein biomarkers 
 
3.1.1.1 Results (Vancomycin) 
 
Histopathological observation (Vancomycin) 
 
Gross pathological kidney-related findings were restricted to high dose animals (300 mg/kg) at all time points. The 
main macroscopic observations were a bilateral pale discoloration, enlargement of the whole organ and a granular 
surface. A holistic overview of the results is summarized in Table 3-1. 
On day 4 in all animals of the high dose treated group (300 mg/kg), treatment-related effects in the kidneys were 
observed. The animals showed a mild to moderate tubular degeneration, which was mainly located in the proximal 
tubules. The tubules were characterized by dilation, showing a flattened basophilic tubular lining epithelium with single 
cell necroses and intraluminal sloughing cells. Moreover, all animals treated with 300 mg/kg Vancomycin revealed 
minimal to moderate eosinophilic casts.  
On day 8 the treatment related tubular degeneration showed an increasing severity (up to massive) in male and female 
rats. However, in general almost all findings were more pronounced in male than in female rats. Also moderate to 
massive tubular dilation was found in male rats, but in female rats this effect was only mild. Still present were minimal 
to moderate cellular and eosinophilic casts. In addition, mixed cellular inflammatory infiltrates were diagnosed in all 
high dose treated animals, both in the interstitium and intraluminal in damaged tubules.  
The first tubular degeneration observation in a low dose treated animal (50 mg/kg) was found on day 15 without any 
further findings. All high dose treated animals (300 mg/kg) showed minimal to massive tubular degeneration in both 
genders, more pronounced in males, at day 15 but with a lower severity compared to day 8. 
A clear reduction in cellular and eosinophilic casts was also observed, although some animals still showed minimal to 
mild effects. Minimal to mild tubular dilation was only observed in individual animals. In all high dose treated male 
rats, but not in females, minimal to moderate mixed cellular interstitial inflammatory infiltrates in the interstitium and 
intraluminal were observed in damaged tubules.  
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Table 3-1 Incidence summary of Vancomycin treatment-related kidney histophatology findings. The number of animals in each 
group of five is shown in parentheses. / ≙ lesion not observed, + ≙ minimal, ++ ≙ mild, +++ ≙ moderate, ++++ ≙ massive, and 
+++++ ≙ high severity of lesion 
    Vancomycin [mg/kg] 
Observation   Male female 
in Kidney time 0   50   300   0   50   300 
Tubular  
Degeneration 
day 4 /  /  
++ (3/5) 
+++ (2/5) 
 /  /  
++ (4/5) 
+++ (1/5) 
 
day 8 /  /  
+++ (2/5) 
++++ (3/5) 
 /  /  
++ (3/5) 
+++ (2/5) 
 
day 15 /  /  
++ (3/5) 
+++ (1/5) 
++++ (1/5) 
 /  + (1/5)  
+ (1/5) 
++ (4/5) 
  
day 29 /   + (4/5)   
+++ (1/5) 
++++ (2/5) 
+++++ (2/5) 
  /   + (3/5)   
++ (2/5) 
+++ (1/5) 
++++ (2/5) 
Tubular  
Dilatation 
day 4 /  /  
+ (1/5) 
++ (2/5) 
 /  /  / 
 
day 8 ++ (1/5)  /  
+++ (2/5) 
++++ (3/5) 
 /  /  ++ (2/5) 
 
day 15 /  /  
+ (1/5) 
++ (2/5) 
 /  /  + (1/5) 
  
day 29 /   /   
+++ (1/5) 
++++ (4/5) 
  /   /   
++ (3/5) 
+++ (1/5) 
++++ (1/5) 
Eosinophilic  
Casts 
day 4 /  /  ++ (5/5)  /  /  
+ (3/5) 
++ (1/5) 
+++ (1/5) 
 day 8 /  /  ++ (5/5)  /  /  + (5/5) 
 
day 15 /  /  
+ (2/5) 
++ (1/5) 
 /  /  
+ (1/5) 
++ (1/5) 
  day 29 /   /   ++ (5/5)   /   /   ++ (5/5) 
Cellular  
Casts 
day 4 /  /  /  /  /  / 
 
day 8 /  /  
++ (1/5) 
+++ (4/5) 
 /  /  + (5/5) 
 
day 15 /  /  
++ (2/5) 
+++(1/5) 
 /  /  + (1/5) 
  day 29 /   /   + (1/5)   /   /   + (1/5) 
Basophilic  
Tubules 
day 4 /  /  /  /  /  / 
 day 8 /  + (3/5)  /  /  + (1/5)  / 
 day 15 /  + (5/5)  /  /  /  / 
  day 29 + (2/5)   /   /   /   ++ (1/5)   / 
Infiltrates day 4 + (1/5)  /  /  /  /  / 
 
day 8 /  /  
++ (1/5) 
+++ (4/5) 
 /  /  
+ (1/5) 
++ (4/5) 
 
day 15 /  /  
+ (2/5) 
++ (1/5) 
+++ (2/5) 
 /  /  / 
  
day 29 /   /   
++ (3/5) 
+++ (2/5) 
  /   /   
+ (2/5) 
++ (1/5) 
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On day 29, in seven (4♂ + 3♀) low dose treated animals (50 mg/kg) minimal tubular degeneration without further 
findings were observed. In all ten high dose treated animals (300 mg/kg) mild to severe tubular degeneration, 
concomitant to mild to massive tubular dilation was observed. Consequently, mild eosinophilic casts were detectable in 
all high dose treated animals (300 mg/kg). Mixed cellular inflammatory infiltrates were again diagnosed in nearly all 
high dose animals with a higher degree of severity in males. Treatment related findings in other organs were limited to 
deposits of fibrin on the liver capsule in both gender accompanied by mixed cellular infiltrates. In addition, individual 
focal small hepatocellular necroses and mixed cellular infiltrates in the serosa of the urinary bladder were observed. All 
these findings were considered to be a sequela of the i.p. application of the test item. 
In summary, histopathologically Vancomycin related changes in the kidneys e.g. tubular degeneration, dilation, cellular 
and eosinophilic casts, were restricted to the high dose animals of all time points with an increase from day 4 to day 8. 
After 15 days of treatment, in addition to the findings in the high dose group, one low dose female rat revealed minimal 
tubular degeneration. After 29 days, nearly all low dose rats showed minimal tubular degeneration in addition the strong 
findings in the high dose group. 
 
 
Clinical, clinical-pathological and hematological observation (Vancomycin) 
 
Only significant observation or relevant parameters in case of the underlying evaluation are shown. Over all the 
parameters, determined effects were more pronounced in male rats compared to females. As shown in Table 3-2 the 
body weight was decrease in high dose treated male and female rats (300 mg/kg) over all time points. In contrast, 
kidney weights showed an increase in all animals treated with 300 mg/kg Vancomycin, from day 3 on. The low dose 
treated rats (50 mg/kg) showed no relevant alterations in body or kidney weight. Statistical significance could not be 
determined for any time or dose group for these two parameters. 
Significant effects were observed for creatinine and blood urea nitrogen (BUN) levels. Significant increases were 
observed in high dose (300 mg/kg) treated male rats from day 7 on. Female rats showed, on day 7 and day 29, the 
strongest increase in serum creatinine and BUN, while also the other time points showed slight elevated serum levels. In 
addition, several low dose (50 mg/kg) treated animals showed slight and partly significant decreases in these two 
parameters.  
Renal functionality was calculated using three different parameters, which are routinely used to evaluate the health 
status of the kidney. First the urinary excretion of sodium and calcium were analysed (Figure 3-1). Changes in urinary 
sodium excretion were only observed in male and female rats treated with high doses (300 mg/kg) of Vancomycin. A 
decrease in urinary excretion of sodium appeared after 4 and 28 days of treatment, while on day 8 and day 15 no 
changes occurred. For urinary excretion of calcium significant alterations in low dose (50 mg/kg) treated animals were 
limited to female rats after 28 days of treatment. In high dose (300 mg/kg) treated female rats a slight, but significant 
decrease on day 4 and a non significant increase at day 14, while male rats showed no alterations on day 4 but a strong 
and significant increase on day 15 followed by a decrease on treatment day 28. The creatinine clearance (Crea Clear) 
was used as an estimation of the glomerular filtration rate (GFR). Therefore, all significant and relevant observations 
were limited to high dose (300 mg/kg) treated animals with two exceptions.  
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Table 3-2 Summary of the body and kidney weight determined for male and female rats treated with 50 mg/kg and 300 mg/kg Vancomycin for up to 28 days. The data of the 
control group are displayed in each table. Significant changes were indicated with * p < 0.05, ** p < 0.01, *** p < 0.001 (ANOVA + Dunnett) 
    Vancomycin [mg/kg] 
  
Male Female 
  Time 0   50   300   0   50   300 
body weight [g] day 3 251.5 ± 4.65 
 
262 ± 8.51 
 
238 ± 5.79 
 
171.75 ± 3.4 
 
167.8 ± 10.26 
 
166.6 ± 6.07 
 
day 7 282.8 ± 9.07 
 
278.6 ± 10.06 
 
251.2 ± 10.47 
 
182.2 ± 4.44 
 
180.8 ± 6.18 
 
170.2 ± 3.9 
 
day 14 304.4 ± 18.61 
 
313.4 ± 11.80 
 
270.6 ± 15.65 
 
186.6 ± 6.27 
 
182.8 ± 5.45 
 
178.8 ± 4.82 
 
day 28 338.2 ± 22.97 
 
337.2 ± 10.08 
 
310.6 ± 8.88 
 
194.6 ± 5.94 
 
191 ± 5.83 
 
190.2 ± 3.96 
             kidney weight [g] day 3 2.04 ± 0.15 
 
2.078 ± 0.18 
 
2.73 ± 0.21 
 
1.35 ± 0.06 
 
1.23 ± 0.06 
 
1.77 ± 0.35 
 
day 7 2.22 ± 0.11 
 
2.06 ± 0.11 
 
4.79 ± 1.00 
 
1.37 ± 0.06 
 
1.38 ± 0.10 
 
1.84 ± 0.26 
 
day 14 2.27 ± 0.04 
 
2.43 ± 0.21 
 
2.59 ± 0.34 
 
1.37 ± 0.05 
 
1.44 ± 0.13 
 
1.57 ± 0.26 
  day 28 2.48 ± 0.34   2.62 ± 0.13   4.69 ± 1.35   1.45 ± 0.05   1.52 ± 0.04   2.7 ± 0.52 
 
A strong increase in variability was observed on treatment day 7 in male rats and a slight, but significant, increase in Crea Clear on day 28 in females. However, almost all high dose 
groups showed a significant decrease in these two parameters except female rats on day 7 and 14 in Crea Clear. 
Several dose and time dependent changes were observed in urinary parameters (Table 3-4). In addition, a dose and time dependent decrease in urinary volume was observed, which 
was most prominent in high dose (300 mg/kg) treated animals on day 29, for both genders. In control animals a time dependent effect was determined also, leading to a lowered 
urinary excretion on day 14. This is probably due to the changing of the treatment schedule, leading to a lowered fluid volume. On day 29, the animals had adapted to the weekly 
treatment pattern. 
Several other relevant urinary components showed strong effects (Table 3-4). Urinary glucose showed significant increased levels earliest on day 3 in male rats of the high dose 
group (300 mg/kg). In female rats no relevant effects were observed up to day 14, while on day 29 the urinary glucose level in male and female rats treated with 300 mg/kg 
Vancomycin, increased up to the 10-fold of the corresponding control animals. 
The measurement of urinary protein showed statistically significant changes only on day 28 in high dose animals (300 mg/kg). However, also at the earlier time points relevant dose 
dependent elevations were observed. The most prominent finding was in one high dose female rat on day 3, which showed a urinary protein excretion of 3.3 g/L (data not shown). 
This leaded to a high mean and standard deviation for the whole group (Table 3-4). 
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Table 3-3 Summary of clinical pathology serum parameter determined for male and female rats treated with saline, 50 mg/kg and 300 mg/kg Vancomycin for up to 28 days. The data of 
the control group are displayed in each table. Significant changes were indicated with * p < 0.05, ** p < 0.01, *** p < 0.001 (ANOVA + Dunnett) 
    Vancomycin [mg/kg] 
 
  
Male female 
   time 0   50   300   0   50   300 
 
Creatinine [mg/dL] day 3 0.12 ± 0.03 
 
0.14 ± 0.02 
 
0.43 ± 0.26 
 
0.19 ± 0.03 
 
0.19 ± 0.02 
 
0.41 ± 0.20 
 
 
day 7 0.11 ± 0.02 
 
0.10 ± 0.03 
 
1.13 ± 0.57 * 0.30 ± 0.06 
 
0.27 ± 0.05 
 
0.41 ± 0.07 * 
 
day 14 0.24 ± 0.01   0.23 ± 0.01 
 
0.38 ± 0.10 * 0.28 ± 0.01 
 
0.25 ± 0.03 * 0.45 ± 0.28 
 
 
day 28 0.23 ± 0.02 
 
0.24 ± 0.04 
 
1.45 ± 0.56 ** 0.30 ± 0.07   0.22 ± 0.06 
 
1.20 ± 0.65 * 
              
BUN [mg/dL] day 3 37.71 ± 4.48 
 
27.14 ± 3.33 
 
84.07 ± 55.43 
 
34.95 ± 5.72 
 
35.31 ± 6.29 
 
72.54 ± 40.21 
 
 
day 7 30.63 ± 2.36 
 
27.14 ± 0.99 * 151.33 ± 41.19 ** 33.51 ± 7.14 
 
34.11 ± 6.29 
 
56.33 ± 14.86 * 
 
day 14 27.98 ± 3.39 
 
28.11 ± 0.89 
 
46.72 ± 7.29 ** 34.83 ± 3.32 
 
31.83 ± 1.95 
 
66.18 ± 49.12 
 
 
day 28 25.22 ± 3.21 
 
29.07 ± 5.58 
 
159.50 ± 46.45 ** 34.95 ± 3.10 
 
32.19 ± 6.74 
 
162.38 ± 58.99 ** 
              
Glucose [mg/dL] day 3 80.00 ± 11.15 
 
86.49 ± 6.62 
 
94.42 ± 9.24 
 
84.69 ± 14.24 
 
87.93 ± 13.02 
 
83.6 ± 8.22 
 
 
day 7 81.44 ± 11.14 
 
91.17 ± 11.99 
 
104.15 ± 18.08 * 85.77 ± 7.92 
 
80.72 ± 11.21 
 
96.94 ± 9.13 
 
 
day 14 98.74 ± 11.14 
 
113.51 ± 11.75 
 
109.19 ± 23.72 
 
89.37 ± 9.75 
 
94.78 ± 17.77 
 
94.06 ± 4.30 
   day 28 110.63 ± 13.52   109.91 ± 20.74   107.03 ± 15.84   92.61 ± 14.67   93.33 ± 9.13   108.11 ± 21.43 
  
Table 3-5 gives an overview of the significant hematological findings. Almost all relevant findings were limited to animals treated with 300 mg/kg Vancomycin. The major effect 
was on white blood cells (WBC), probably due to their crucial role of inflammatory processes during kidney injury. A slight increase in numbers of red blood cells and platelets were 
limited to day 3 and day 7 in male rats of the high dose groups (300 mg/kg). Female rats showed slight and partially significant decreases in these two parameters. The most 
prominent findings were observed in white blood cells in both genders on days 7, 14 and 28. This effect in WBCs was limited to an increase in neutrophils, lymphocytes and 
monocytes. However, also basophils, and large unstained cells showed slight dose dependent alterations, which were limited to individual animals. 
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Table 3-4 Summary of clinical pathology urinary parameter determined for male and female rats treated with saline, 50 mg/kg and 300 mg/kg Vancomycin for up to 28 days. The data of 
the control group are displayed in each table. Significant changes were indicated with * p < 0.05, ** p < 0.01, *** p < 0.001 (ANOVA + Dunnett) 
    Vancomycin [mg/kg] 
 
  
Male female 
   time 0   50   300   0   50   300 
 
Volumen [mL] day 3 27.48 ± 4.98 
 
22.98 ± 7.42 
 
13.28 ± 4.07 ** 8.76 ± 3.10 
 
11.12 ± 2.82 
 
6.28 ± 3.44 
 
 
day 7 27.76 ± 5.05 
 
19.16 ± 6.42 * 13.78 ± 3.52 ** 12.26 ± 5.87 
 
10.22 ± 5.10 
 
12.02 ± 2.69 
 
 
day 14 19.32 ± 4.04 
 
18.88 ± 2.12 
 
18.2 ± 4.97 
 
8.30 ± 3.40 
 
7.74 ± 3.34 
 
8.42 ± 3.96 
 
 
day 28 21.04 ± 6.03 
 
22.28 ± 1.21 
 
8.58 ± 6.3 ** 14.44 ± 5.02 
 
12.92 ± 5.10 
 
4.85 ± 1.96 ** 
              
Glucose [mg/dL] day 3 3.28 ± 1.33 
 
4.5 ± 1.45 
 
6.81 ± 2.34 * 8.72 ± 3.24 
 
7.64 ± 4.66 
 
9.80 ± 6.96 
 
 
day 7 3.64 ± 3.64 
 
4.72 ± 0.82 
 
7.68 ± 3.51 * 7.06 ± 3.64 
 
7.75 ± 5.44 
 
10.74 ± 8.36 
 
 
day 14 5.12 ± 1.12 
 
5.98 ± 0.78 
 
5.19 ± 1.78 
 
7.35 ± 2.74 
 
11.68 ± 5.04 
 
12.29 ± 12.03 
 
 
day 28 5.87 ± 1.33 
 
11.78 ± 5.51 
 
63.17 ± 17.16 *** 4.22 ± 0.97 
 
9.33 ± 4.47 
 
44.32 ± 19.52 *** 
              
total protein [mg/dL] day 3 19.58 ± 7.15 
 
21.3 ± 7.09 
 
26.78 ± 6.16 
 
12.04 ± 5.70 
 
8.88 ± 3.93 
 
83.96 ± 139.75 
 
 
day 7 22.52 ± 22.52 
 
37.92 ± 21.04 
 
36.2 ± 11.22 
 
12.88 ± 7.30 
 
13.10 ± 10.61 
 
12.82 ± 4.78 
 
 
day 14 39.22 ± 7.45 
 
40.36 ± 10.21 
 
30.76 ± 17.33 
 
13.94 ± 4.24 
 
16.66 ± 8.58 
 
13.78 ± 3.83 
 
 
day 28 39.98 ± 12.30 
 
40.3 ± 13.72 
 
74.58 ± 23.28 * 8.76 ± 2.12 
 
13.12 ± 5.04 
 
38.23 ± 9.42 *** 
              
Creatinine [mg/dL] day 3 27.03 ± 6.46 
 
38.83 ± 18.85 
 
52.21 ± 14.43 * 52.32 ± 19.27 
 
40.85 ± 12.81 
 
85.00 ± 64.72 
 
 
day 7 26.39 ± 6.44 
 
38.54 ± 6.23 
 
47.16 ± 7.68 
 
52.15 ± 29.86 
 
64.91 ± 45.83 
 
42.57 ± 10.75 
 
 
day 14 48.95 ± 9.67 
 
48.76 ± 4.56 
 
53.97 ± 15.00 
 
56.85 ± 13.43 
 
71.17 ± 42.67 
 
60.54 ± 22.50 
   day 28 47.9 ± 11.98   41.59 ± 3.14   87.6 ± 51.82 * 37.14 ± 8.14   47.61 ± 21.66   74.46 ± 19.09 ** 
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Table 3-5 Summary of hematological parameter determined for male and female rats treated with saline, 50 mg/kg and 300 mg/kg Vancomycin for up to 28 days. The data of the control 
group are displayed in each table. Significant changes were indicated with * p < 0.05, ** p < 0.01, *** p < 0.001 (ANOVA + Dunnett) 
 
    Vancomycin [mg/kg] 
 
  
Male female 
   time 0   50   300   0   50   300 
 RBC [counts/pL] day 3 8.10 ± 0.19 
 
8.15 ± 0.29 
 
8.64 ± 0.23 ** 8.06 ± 0.43 
 
7.91 ± 0.40 
 
8.38 ± 0.21 
 
 
day 7 8.18 ± 0.18 
 
8.39 ± 0.25 
 
8.81 ± 0.24 ** 8.14 ± 0.19 
 
8.10 ± 0.30 
 
7.94 ± 0.59 
 
 
day 14 8.66 ± 0.52 
 
8.40 ± 0.42 
 
7.88 ± 0.39 * 7.89 ± 0.57 
 
8.13 ± 0.47 
 
7.63 ± 0.27 
 
 
day 28 8.32 ± 0.42 
 
8.67 ± 0.39 
 
8.04 ± 0.32 
 
8.13 ± 0.25 
 
7.98 ± 0.43 
 
7.62 ± 0.09 * 
              PLT [counts/nL] day 3 913 ± 104 
 
1010 ± 98.62 
 
921 ± 127 
 
895 ± 74 
 
876 ± 135 
 
1060 ± 78 * 
 
day 7 896 ± 62 
 
904 ± 62 
 
1063 ± 129 * 946 ± 126 
 
996 ± 63 
 
1314 ± 99 *** 
 
day 14 815 ± 118 
 
879 ± 133 
 
1039 ± 132 * 877 ± 127 
 
944 ± 166 
 
978 ± 118 
 
 
day 28 899 ± 110 
 
888 ± 119 
 
857 ± 81 
 
929 ± 83 
 
847 ± 68 
 
1071 ± 134 
 
              WBC [counts/nL] day 3 6.40 ± 0.77 
 
8.60 ± 1.76 * 7.32 ± 1.16 
 
3.90 ± 1.19 
 
3.56 ± 0.67 
 
4.98 ± 1.05 
 
 
day 7 7.62 ± 0.93 
 
7.90 ± 2.69 
 
16.76 ± 2.52 *** 4.00 ± 1.11 
 
4.94 ± 1.47 
 
6.44 ± 1.25 * 
 
day 14 6.16 ± 1.11 
 
5.70 ± 0.59 
 
9.48 ± 2.31 ** 3.96 ± 1.71 
 
5.66 ± 0.88 
 
6.60 ± 1.80 * 
 
day 28 5.56 ± 1.12 
 
6.30 ± 1.11 
 
9.34 ± 2.14 ** 3.76 ± 0.51 
 
3.50 ± 0.99 
 
7.12 ± 0.46 *** 
              NEU [counts/nL] day 3 0.96 ± 0.14 
 
1.53 ± 0.70 
 
1.33 ± 0.19 
 
0.48 ± 0.13 
 
0.62 ± 0.14 
 
0.79 ± 0.14 ** 
 
day 7 1.38 ± 0.24 
 
1.34 ± 0.35 
 
7.78 ± 1.65 *** 0.51 ± 0.14 
 
0.99 ± 0.72 
 
1.30 ± 0.67 
 
 
day 14 1.29 ± 0.72 
 
0.95 ± 0.30 
 
2.80 ± 0.72 ** 0.73 ± 0.38 
 
0.92 ± 0.46 
 
1.50 ± 0.66 
 
 
day 28 0.96 ± 0.35 
 
1.26 ± 0.43 
 
3.15 ± 1.15 *** 0.70 ± 0.17 
 
0.54 ± 0.18 
 
2.75 ± 0.57 ** 
              Lymph[counts/nL] day 3 5.13 ± 0.79 
 
6.60 ± 1.63 
 
5.53 ± 1.14 
 
3.23 ± 1.09 
 
2.75 ± 0.68 
 
3.85 ± 0.98 
 
 
day 7 5.88 ± 0.83 
 
6.06 ± 2.22 
 
7.73 ± 1.28 
 
3.28 ± 1.12 
 
3.70 ± 0.87 
 
4.84 ± 0.96 * 
 
day 14 4.56 ± 0.89 
 
4.49 ± 0.46 
 
6.20 ± 2.22 
 
3.06 ± 1.29 
 
4.43 ± 1.04 
 
4.78 ± 1.36 
 
 
day 28 4.33 ± 0.79 
 
4.68 ± 0.72 
 
5.68 ± 1.20 
 
2.85 ± 0.54 
 
2.78 ± 0.83 
 
3.94 ± 0.80 
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    Vancomycin [mg/kg] 
 
  
Male female 
   time 0   50   300   0   50   300 
 EOS [counts/nL] day 3 0.12 ± 0.04 
 
0.16 ± 0.06 
 
0.15 ± 0.03 
 
0.07 ± 0.02 
 
0.06 ± 0.01 
 
0.12 ± 0.06 
 
 
day 7 0.11 ± 0.04 
 
0.15 ± 0.07 
 
0.25 ± 0.12 * 0.06 ± 0.01 
 
0.08 ± 0.04 
 
0.07 ± 0.02 
 
 
day 14 0.10 ± 0.04 
 
0.09 ± 0.02 
 
0.17 ± 0.08 
 
0.06 ± 0.02 
 
0.08 ± 0.02 
 
0.10 ± 0.08 
 
 
day 28 0.11 ± 0.05 
 
0.11 ± 0.04 
 
0.14 ± 0.02 
 
0.09 ± 0.02 
 
0.05 ± 0.02 
 
0.13 ± 0.06 
 
              BASO [counts/nL] day 3 0.04 ± 0.01 
 
0.08 ± 0.04 
 
0.09 ± 0.02 * 0.02 ± 0.02 
 
0.03 ± 0.01 
 
0.05 ± 0.02 * 
 
day 7 0.04 ± 0.03 
 
0.06 ± 0.05 
 
0.14 ± 0.07 * 0.02 ± 0.01 
 
0.03 ± 0.01 
 
0.05 ± 0.02 * 
 
day 14 0.05 ± 0.02 
 
0.03 ± 0.01 
 
0.04 ± 0.01 
 
0.02 ± 0.01 
 
0.04 ± 0.04 
 
0.04 ± 0.02 
 
 
day 28 0.04 ± 0.02 
 
0.05 ± 0.01 
 
0.05 ± 0.03 
 
0.03 ± 0.01 
 
0.03 ± 0.01 
 
0.03 ± 0.01 
 
               MONO[counts/nL] day 3 0.13 ± 0.04 
 
0.19 ± 0.03 ** 0.18 ± 0.02 * 0.07 ± 0.03 
 
0.07 ± 0.02 
 
0.13 ± 0.04 * 
 
day 7 0.16 ± 0.07 
 
0.24 ± 0.06 
 
0.73 ± 0.19 *** 0.08 ± 0.04 
 
0.10 ± 0.05 
 
0.14 ± 0.08 
 
 
day 14 0.14 ± 0.03 
 
0.12 ± 0.03 
 
0.25 ± 0.08 * 0.09 ± 0.03 
 
0.14 ± 0.02 
 
0.14 ± 0.07 
 
 
day 28 0.10 ± 0.02 
 
0.16 ± 0.04 
 
0.25 ± 0.10 ** 0.07 ± 0.01 
 
0.07 ± 0.04 
 
0.20 ± 0.03 *** 
              LUC [counts/nL] day 3 0.02 ± 0.01 
 
0.03 ± 0.01 
 
0.04 ± 0.02 
 
0.01 ± 0.01 
 
0.01 ± 0.00 
 
0.01 ± 0.01 
 
 
day 7 0.02 ± 0.01 
 
0.04 ± 0.02 
 
0.10 ± 0.08 * 0.02 ± 0.01 
 
0.03 ± 0.02 
 
0.03 ± 0.02 
 
 
day 14 0.02 ± 0.01 
 
0.02 ± 0.01 
 
0.06 ± 0.04 
 
0.02 ± 0.02 
 
0.03 ± 0.01 
 
0.04 ± 0.02 
   day 28 0.02 ± 0.01   0.02 ± 0.01   0.05 ± 0.02 * 0.03 ± 0.01   0.03 ± 0.02   0.06 ± 0.03 
 Abbreviation: RBC = red blood cells, PLT = platelets, WBC = white blood cells, NEU = neutrophils, Lymph = Lymphocytes, EOS = eosiniphils, BASO = basophils, MONO = monocytes, LUC = large unstained cells. 
 
 
1
0
0
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Figure 3-1 Urinary sodium and calcium excretion, as well as the creatinine clearance for male (○) and female (●) rats treated with 
either saline (control), 50 mg/kg Vancomycin (low dose), or 300 mg/kg Vancomycin (high dose). Data are presented for both genders 
individually by mean ± SD. Significant changes are indicated with * p < 0.05, ** p < 0.01, *** p < 0.001 (ANOVA + Dunnett). 
 
 
Detection of novel qualified and exploratory urinary proteins (Vancomycin) 
 
In Vancomycin treated rats a clear dose and treatment schedule dependency in urinary protein biomarker excretion was 
observed. In addition, differences in the excretion of specific biomarkers between genders were observed. 
In male rats a strong increase in urinary Kim-1, Osteopontin, Calbindin and Clusterin was observed (Figure 3-2a, -g, -h, 
-i) in the high dose group (300 mg/kg). Kim-1 showed a further increase from day 4 to day 8 with a massive decrease in 
Kim-1 excretion on day 15 compared to the earlier time points. On day 29 urinary Kim-1 levels rose again. In the low 
dose group (50 mg/kg) only two of the four animals with histopathological findings showed an increase in urinary Kim-
1 level (Figure 3-2a). The urinary excretion level of Ostoepontin in male rats treated with 300 mg/kg Vancomycin 
showed a strong and significant increase over all four time points (Figure 3-2g). The highest magnitude of urinary 
Osteopontin was measured on day 4 with a constant decrease over up to day 29. The four low dose animals (50 mg/kg) 
on day 29 showed a slightly enhanced elevation of urinary Ostoepontin. Calbindin also showed significantly increased 
level at all time points in the high dose group (300 mg/kg) while in contrast to Osteopontin the strongest increase was 
observed on day 29 (Figure 3-2h). Also on day 4 a strong increase was observed followed by a slight increase on day 8 
and 15. In the low dose group (50 mg/kg) only 3 animals on day 29 showed a marked increase. Significant excretion 
levels of urinary Clusterin were only determined on day 4 and day 29 (Figure 3-2i). The magnitude of urinary Clusterin 
was also strongly elevated on day 8 but with a very high variation between individual animals. 
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Figure 3-2 Excretion of (a) Kim-1, (b) NGAL, (c) b2m, (d) Timp-1, (e) VEGF, (f) CystatinC, (g) Osteopontin, (h), Calbindin28k, (i) 
Clusterin in urine of male rats treated with Vancomycin (low dose: 50 mg/kg; high dose: 300 mg/kg)for 3 days (dots), 7 days 
(squares), 14 days (triangle), and 28 days (rhombus). Data are presented as individual animals and as the mean (bar; n=5). The light 
grey signs indicate no tubular degeneration; the darker grey indicates tubular degeneration (based on histopathology). * p < 0.05, ** p 
< 0.01, *** p < 0.001 (ANOVA-Dunnett). 
 
On day 29 of the low dose group (50 mg/kg) three animals showed a strong increase while one animal with 
histopathological findings showed no alteration.The biomarkers NGAL, 2m, Timp-1 and CystatinC also showed 
strong and significant alterations in there urinary level, but not to the same extent as the other biomarkers. NGAL, for 
example showed no increase on day 4 and a strong and significant increase on day 8 in animals treated with 300 mg/kg 
Vancomycin (Figure 3-2b). On day 29 also a significant increase was observed, but this was matched by a decrease in 
urinary NGAL level in the control animals on day 15 and day 29. In the low dose group (50 mg/kg) no alterations were 
observed. In contrast 2m was increased at all time points of high dose treated animals (300 mg/kg) but without any 
statistical significance (Figure 3-2c). This is probably due to one animal on day 8 and one animal on day 29 showing a 
marked increase far above the other animals (up to 60 fold of the urinary level in the control animals), resulting in an 
extraordinary higher mean. On day 8, one animal showed a slight increase in the low dose group (50 mg/kg) even 
though no histopathological findings were recorded for this rat. The low dose animals on day 29 with tubular 
degeneration showed no alterations.  
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Figure 3-3 Excretion of (a) Kim-1, (b) NGAL, (c) b2m, (d) Timp-1, (e) VEGF, (f) CystatinC, (g) Osteopontin, (h), Calbindin28k, (i) 
Clusterin in urine of female rats treated with Vancomycin (low dose: 50 mg/kg; high dose: 300 mg/kg) for 3 days (dots), 7 days 
(squares), 14 days (triangle), and 28 days (rhombus). Data are presented as individual animals and as the mean (bar; n=5). The light 
grey signs indicate no tubular degeneration found within this animal, the darker grey indicates tubular degeneration observed (based 
on histopathology). * p < 0.05, ** p < 0.01, *** p < 0.001 (ANOVA-Dunnett). 
 
For Timp-1 a time-dependent increase in urinary excretion in the control groups (up to 3 fold on day 29 compared to 
day 4) was detected (Figure 3-2d). In addition, a treatment dependent increase on days 4, 8 and 29 of the high dose (300 
mg/kg) treated animals was observed. While day 4 delivered no statistical significance, day 8 and 29 showed significant 
enhancement of urinary Timp-1. The increase was strongest on day 29. Only one animal on day 15 showed an increased 
level of Timp-1. Low dose animals (50 mg/kg), at all time points, showed a slight increase with an enhanced variability 
within the group compared to the control group. The highest and only significant excretion of urinary CystatinC was 
observed in animals treated with 300 mg/kg for 7 days (Figure 3-2f). 
However, all groups of high dose treated animals showed higher average CystatinC excretion then the control group. In 
addition the variance within the groups of altered CystatinC level increased. Independent on any observed 
histopathology animals of the low dose group (50 mg/kg) showed an increase on day 8, while the affected animals on 
day 29 showed no alteration. 
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In contrast to all other markers mentioned above, the urinary biomarker VEGF showed a dose-dependent decrease over 
all time points (Figure 3-2e). In addition a time-dependent decrease down to a half of the excretion was detected in the 
control animals. -GST was not analysed because most of the animals of the control group lay below the detection 
range of the WideScreen™ assay. 
In female rats treated with Vancomycin, Kim-1, NGAL, Timp-1, Osteopontin, Calbindin and Clusterin showed dose 
dependent changes in urinary excretion, with statistical significance (Figure 3-3a, -b, -d, -g, -h, -i). 
In rats treated with 300 mg/kg Vancomycin urinary Kim-1 was elevated in all animals on days 4, 8, and 29, while day 4 
showed a higher magnitude than day 8 together with a higher intragroup variance (Figure 3-3a); the group mean was the 
highest on day 29. On day 15, only two animals showed an increase in Kim-1 excretion, even though all five animals 
showed renal tubular damage. In low dose treated animals (50 mg/kg) slight changes were limited to two of the three 
animals described to have tubular degeneration. NGAL was statistically significant elevated on days 4 and 8 in the high 
dose group (300 mg/kg), while day 15 and 29 levels were only slightly increased (Figure 3-3b). No alterations in low 
dose (50 mg/kg) treated animals were observed. Comparable to Kim-1, Timp-1 showed an increase in high dose treated 
animals (300 mg/kg) on days 4, 8 and 29, while the magnitude of increase was the highest at the latest time point 
(Figure 3-3d). In addition, the same two animals of the low dose group (50 mg/kg) exclusively showed an increase in 
urinary Timp-1. As described for male rats, Osteopontin was statistically significantly increased at all time points of the 
high dose treated animals (300 mg/kg). The highest urinary excretion was observed on day 8 while the magnitude of 
increase on days 4 and 15 was comparable. The excretion on day 29 was still elevated but slightly below the value of 
days 4 and 15. In low dose treated animals (50 mg/kg) the mean of animals treated for 28 days was also slightly 
increased, while only two of the treated animals (same animals already mentioned from Kim-1 and Timp-1) showed an 
increase. However, one animal not found to indicate morphological changes within the kidney showed a comparable 
increase of urinary Osteopontin. Calbindin showed a strong increase on day 4 in rats treated with 300 mg/kg 
Vancomycin, while the urinary level decreased on day 8 compared to day 4 (Figure 3-3h). The highest magnitude in 
Calbindin excretion was at the latest time point. In low dose treated aminals (50 mg/kg) only two animals on day 15, 
without any histopathological correlation, and the same two animals (female rat 97 and 99) as already mentioned, 
showed a slight alteration. The urinary Clusterin level were statistically significantly elevated in the high dose groups 
on days 4, 8, and 29 (Figure 3-3i). Only two animals on day 15 showed an increase compared to the control animals. In 
low dose treated animals (50 mg/kg) again the same two animals showed an increase in urinary Clusterin, while the 
others, independent if histopathological observations, showed no alteration. 
Further significant alterations in urinary biomarker excretion in female rats were limited to high dose treated animals 
(300 mg/kg) on day 29, which showed an elevated level of 2m. In addition, one animal on day 4 and day 8 showed a 
very strong increase in 2m. Urinary levels of VEGF and CystatinC showed no significant alterations, however in the 
high dose groups on days 4 and 8 CystatinC levels were increased in some animals. 
To evaluate the diagnostic performance of these urinary biomarkers to reflect histopathological changes, Receiver 
Operation Characteristic (ROC) analyses were performed (Table 3-6).  
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Table 3-6 Area-under-the-receiver-operator-characteristic curve (AUROC) for detection of Vancomycin induced nephrotoxicity. 
The area under the curve is used as a measure for the overall ability of a biomarker to discriminate animals without 
histopathological findings in kidney from those with signs of tubular damage (degeneration/ necrosis). Markers with a good 
diagnostic performance (AUROC > 0.90) are highlighted in bold. In addition the 95% confidence interval and the p-value are 
displayed. * = measurement by Luminex® xMAP®, ** = measurement by RENA®-Sticks, # = classical clinical-pathology 
parameter determined by standard procedures. 
Kidney Biomarker Male
 
  Female 
AUROC 95% CI p-value   AUROC 95% CI p-value 
KIM-1* 0.95 0.89 - 1.02 <0.0001  0.90 0.80 - 1.01 <0.0001 
Timp-1* 0.74 0.60 - 0.87 0.0022  0.94 0.87 - 1.01 <0.0001 
VEGF* 0.89 0.81 - 0.97 0.0001  0.67 0.52 - 0.81 0.0292 
ß2-Microglobulin* 0.76 0.63 - 0.90 0.0007  0.70 0.56 - 0.85 0.0084 
Clusterin* 0.98 0.95 - 1.01 <0.0001  0.94 0.88 - 1.00 <0.0001 
Cystatin C* 0.73 0.59 - 0.88 0.0027  0.68 0.53 - 0.83 0.0196 
Lipocalin-2/ NGAL* 0.69 0.54 - 0.83 0.0145  0.76 0.62 - 0.91 0.0006 
Osteopontin* 0.98 0.95 - 1.00 <0.0001  0.94 0.87 - 1.00 <0.0001 
Calbindin * 0.98 0.96 - 1.00 <0.0001  0.88 0.78 - 0.97 0.0001 
KIM-1** 0.86 0.76 - 0.96 <0.0001  0.81 0.69 - 0.94 <0.0001 
BUN
#
 0.91 0.81 - 1.01 <0.0001  0.91 0.82 - 0.99 <0.0001 
Serum Creatinine
#
 0.96 0.91 - 1.01 <0.0001  0.87 0.78 - 0.96 <0.0001 
 
 
In addition detection by using the Luminex
®
 xMAP
®
 technology an alternative detection method for Kim-1, based on a 
Dipstick assay, was analysed. Based on the AUROC, Kim-1 (m: 0.95; f: 0.90), Clusterin (m: 0.98; f: 0.94), Osteopontin 
(m: 0.98; f: 0.94) and BUN (m: 0.91; f: 0.91) performed the best, while BUN showed the lowest AUROC of the four 
markers mentioned. Relevant gender differences were observed for Timp-1 (m: 0.74; f: 0.94), Calbindin (m: 0.98; f: 
0.88), VEGF (m: 0.89; f: 0.67) and serum creatinine (m: 0.96; f: 0.87). 2m (m: 0.76; f: 0.70), CystatinC (m: 0.73; f: 
0.68) and NGAL (m: 0.69; f: 0.76) perfomed poorly. The AUROCs of Kim-1 (m: 0.86; f: 0.81) determined by using the 
Dipstick assay were good but below the values of the Luminex
®
 xMAP
®
 measurement.  
In general it has to be mentioned that rats on day 15, independent of the sex showed the smallest changes in almost all 
urinary biomarkers. This is in good correlation to the histopathological findings.  
 
 
Evaluation of expression of Kim-1, Clusterin and Ostoepontin protein in renal tissue (Vancomycin) - 
immunohistochemical analysis 
 
Kim-1 and Clusterin showed no staining in untreated animals, while Osteopontin showed a slight but constant basal 
expression within corical and medullar tissue of the kidney (Annex 1). 
Representive pictures for Kim-1, Clusterin and Osteopontin stained kidney sections fom male and female rats treated 
with 300 mg/kg Vancomycin are shown in Figures 3-4, 3-5-, 3-6, 3-7, 3-8, 3-9). The low dose treated animals (50 
mg/kg) showed no relevant changes compared to the control animals, except for animals treated for 28 day, which 
showed slightly increased staining compared to the time matched control animals. For each individual finding an 
overview is given spanning from the cortex to the medullary papilla and a detailed picture of the cortical zone and the 
medullary zone. To show the most specific observations in some pictures the inner or the outer zone of medulla is 
shown. 
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Kim-1 
 
 
Figure 3-4 Location of Kim-1 protein in renal tissue of male rats treated with 300 mg/kg Vancomycin is shown for each time point 
of necropsy. An overview picture for each time point (a, d, g, j) shows the whole area from the cortical zone to the medullary 
papilla. In addition two detailed pictures, either of the cortex (b, e, h, k) or the medulla(c, f, i, l) is given. The magnification of the 
overview was ~10 times and of the detailed pictures ~70 times. 
 
In male rats the area of Kim-1 expression was in the cortical zone, reaching into the outer zone of the medulla (Figure 
3-4). In general Kim-1 showed a very dark staining and therefore a strong increase in Kim-1 protein. The highest 
expression was found at the apical membrane of proximal tubular cells.  
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Figure 3-5 Location of Kim-1 protein in renal tissue of female rats treated with 300 mg/kg Vancomycin is shown for each time 
point of necropsy. An overview picture for each time point (a, d, g, j) shows the whole area from the cortical zone to the medullary 
papilla. In addition two detailed pictures, either of the cortex (b, e, h, k) or the medulla(c, f, i, l) is given. The magnification of the 
overview was ~10 times and of the detailed pictures ~70 times. 
 
Most of the medullar staining is located intraluminal and therefore is not a direct protein expression located in this area, 
but a translocation from the proximal tubules by flow in. 
The earliest increase in Kim-1 protein expression was on day 3 with a further increase of protein amount on day 7 
(Figure 3-4a-f). Even though there was strong tubular degeneration and dilatation on day 7, the expression of Kim-1 
was still located on the apical membrane of the proximal tubules. Also the expression in the outer zone of the medulla 
showed a high magnitude of expression. However, the staining within cells decreased from day 3 to day 7 and was 
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replaced by prominent intraluminal amounts of Kim-1 (Figure 3-4 c, f). On day 14 a strong reduction of Kim-1 protein 
compared to the earlier time points was observed (Figure 3-4 g-i). Only individual areas within the cortex were 
observed still expressing Kim-1. No to minimal amount of intraluminal Kim-1 protein was detected in the medulla. The 
amount of Kim-1 protein found on day 28 of high dose (300 mg/kg) Vancomycin treatment, showed an additional 
increase compared to all other time points (Figure 3-4 j-l). In this group also intracellular Kim-1 was observed in the 
medullary zone. 
In female rats treated with 300 mg/kg Vancomycin for up to 28 days, the renal expression of Kim-1 protein gave 
comparable results as reported for male rats. The most prominent difference between both sexes was the location of 
Kim-1 expression.  
In female rats Kim-1 was found in the cortical area, without prominent findings in the medulla. Therefore, on day 3 
high amount of Kim-1 protein was found in the proximal tubules, while only slight amount of intraluminal Kim-1 
protein was observed in the medulla (Figure 3-5. a-c). On day 7 a slight reduction of Kim-1 protein was found 
compared to day 3, but still with a high and specific expression in the cortex. As reported for male rats, on day 14 only a 
minimal stain of renal Kim-1 protein could be observed.  
In addition, minimal staining of Kim-1 in the medulla was found. However, this staining was limited to cellular casts 
and proteinaceous droplets. In good relation to male rats, the strongest expression of Kim-1 protein and over the largest 
area over the tissue was observed on day 28 (Figure 3-5 j-l). In this group also minimal amounts of intracellular Kim-1 
protein were found in the medullary zone. 
 
 
Clusterin 
 
The intrarenal expression of Clusterin showed no gender specific differences in the location of expression, but a 
treatment and severity-dependent alteration (Figure 3-6 a-l; Figure 3-7 a-l). In contrast to Kim-1, especially for female 
rats, the area of Clusterin was not primarily limited to the cortical area. On the contrary, the majority of Clusterin 
protein was found on the cortico-medullary boundary. 
On day 3 of high dose (300 mg/kg) Vancomycin treatment in male rats, Clusterin expression was found, with specific 
tubular staining in the cortical and medullary zone (Figure 3-6 b-c). Significant areas of the cortex remained unstained, 
also showing no damaged tissue, while the outer medullary zone showed the strongest staining (Figure 3-6 a). On day 7 
the expression of renal Clusterin protein in males showed a strong increase in the medulla, but also in the cortical zone 
(Figure 3-6 d). The medullar staining included intracellular as well as intraluminal parts (Figure 3-6 f). Only minimal 
amounts of Clusterin protein was detected on day 14, in both cortical and medullary zone (Figure 3-6 g). Clusterin 
protein staining often correlates with inflammation (Figure 3-6 h). Clusterin in the medulla was formally limited to 
intercellular or intraluminal fluidal accomulations (Figure 3-6 i). On day 28 male rats showed an increase in Clusterin 
protein expression compared to day 3 and day 14. However, the area and intensity of Clusterin protein staining was 
below that observed on day 7 (Figure 3-6 j-l). In female rats (Figure 3-7) the expression pattern of renal Clusterin was 
comparable to males (Figure 3-6), although the expression area in the cortical zone was slightly higher in female rats 
(Figure 3-7). On day 3 a high Clusterin expression was observed, both cortical and medullary (Figure 3-7 a-c). The 
cortical expression of Clusterin in male and female rats was observed in both proximal and distal tubular cells. 
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Figure 3-6 Location of Clusterin protein in renal tissue of male rats treated with 300 mg/kg Vancomycin is shown for each time 
point of necropsy. An overview picture for each time point (a, d, g, j) shows the whole area from the cortical zone to the medullary 
papilla. In addition two detailed pictures, either of the cortex (b, e, h, k) or the medulla(c, f, i, l) is given. The magnification of the 
overview was ~10 times and of the detailed pictures ~70 times. 
 
The staining of Clusterin in the outer medullar and inner medullary zone was often, but not exclusively, limited to 
intracellular staining. Very low amounts of intraluminal Clusterin was observed (Figure 3-7 c). On day7 the Clusterin 
amount showed a reduction in female rats treated with 300 mg/kg Vancomycin, mainly in the medullary area. An 
additional reduction in renal clusterin protein expression compared to day 3 was observed on day 14, while the 
difference between day 7 and day 14 was only marginal (Figure 3-7 g-h).  
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Figure 3-7 Location of Clusterin protein in renal tissue of female rats treated with 300 mg/kg Vancomycin is shown for each time 
point of necropsy. An overview picture for each time point (a, d, g, j) shows the whole area from the cortical zone to the medullary 
papilla. In addition two detailed pictures, either of the cortex (b, e, h, k) or the medulla(c, f, i, l) is given. The magnification of the 
overview was ~10 times and of the detailed pictures ~70 times. 
 
 
The expression in the medullary zone remained constant, while the corical Clusterin expression was further reduced 
compared to day 3 and 7 (Figure 3-7 h). The increase on day 28, already described for male rats (Figure 3-6 j-l), was 
also observed in female (Figure 3-7 j-l) rats, although not as strong.  
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Osteopontin 
 
In contrast to Kim-1 and Clusterin, Osteopontin was found in higher amounts in renal tissue of animals treated with 
water for injection or 0.9% saline. A constant low level expression of Osteopontin protein within proximal tubular cells 
of the cortex and a strong extracellular accumulation over the medullary zone down to the medullary pelvis was 
observed in both genders (see 5.1 Annex 2). In addition, the bladder also showed strong staining of the extracellular 
matrix over the whole organ (Annex 2). 
However, in male rats treated with 300 mg/kg Vancomycin for three days, a slight but noticeable increase was observed 
(Figure 3-8 a-c). The main locations of expression were the cortical tubules and the tubular cells of the outer medullary 
zone (Figure 3-8 b-c). In addition, a staining of the extracellular matrix within the medullar was seen, leading to 
stronger stains within this area (Figure 3-8 a, c). On day 7, a further increase in male rats of renal Osteopontin was seen 
(Figure 3-8 d). This increase was caused by staining of proteinaceous droplets within the proximal tubules and of the 
extracellular matrix within the medulla (Figure 3-8 e-f). The intracellular amount of Osteopontin within renal cells of 
male rats was unchanged at this time. Over the whole kidney a strong reduction in Osteopontin expression in male rats 
treated with 300 mg/kg Vancomycin for 14 days was observed (Figure 3-8 g). However, the stained protein was still 
above the basal expression. Also on day 14 the stain was characterized by proteinaceous droplets and extracellular 
matrix staining (Figure 3-8 h, i). But also intracellular Ostoepontin was detected in the cortical tubular cells (Figure 3-8 
h). On day 28 of Vancomycin treatment with 300 mg/kg, the intensity of Osteopontin staining observed in male rats 
were between day 3 (Figure 3-8 a) and day 7 (Figure 3-8 d) with a stronger relocation into the medullary area (Figure 
3-8 j). Therefore, the remaining Osteopontin at the cortex was limited to luminal accumulations with only individual 
intracellular staining (Figure 3-8 k). In contrast, the medulla showed very strong extracellular staining over the whole 
tissue (Figure 3-8 j, l). 
In female rats treated with 300 mg/kg Vancomycin, the expression of Osteopontin on day 3 was more pronounced than 
in male rats of the same time point (Figure 3-9 a-c). This was seen in corical, proximal tubules and in medullary distal 
tubular cells (Figure 3-9 b, c). Also in female rats a strong staining of the extracellular matrix was observed. Compared 
to day 3 a reduction of renal Osteopontin over the whole tissue was detected (Figure 3-9 d), while the expression in the 
proximal tubular cells remained constant. In the medullary zone, especially in the inner area, the amount of strongly 
stained extracellular matrix components increased strongly (Figure 3-9 f). In contrast to male rats treated with 300 
mg/kg Vancomycin for 14 days (Figure 3-8 g-h), the amount of Osteopontin protein in females did not decrease 
compared to the earlier observations (Figure 3-9 g-h). The staining of Osteopontin, especially in the medullary zone, 
showed no alteration compared to day 7 (Figure 3-9 f, i). However, the expression within the cortex was slightly 
reduced but still present in the proximal tubular cells as well as the luminal (Figure 3-9 h). The expression of 
Osteopontin after 28 days of high dose (300 mg/kg) treatment showed the lowest staining in female rats (Figure 3-9 j-l). 
The intracellular expression within cortico-tubular cells was reduced to a level near to that in control animals (Figure 
3-9 k). However, a very prominent amount of intraluminal Ostoepontin, within proteinaceouce droplets as well as at the 
extracellular matrix, was observed. 
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Figure 3-8 Location of Osteopontin protein in renal tissue of male rats treated with 300 mg/kg Vancomycin is shown for each time 
point of necropsy. An overview picture for each time point (a, d, g, j) shows the whole area from the cortical zone to the medullary 
papilla. In addition two detailed pictures, either of the cortex (b, e, h, k) or the medulla(c, f, i, l) is given. The magnification of the 
overview was ~10 times and of the detailed pictures ~70 times. 
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Figure 3-9 Location of Osteopontin protein in renal tissue of female rats treated with 300 mg/kg Vancomycin is shown for each 
time point of necropsy. An overview picture for each time point (a, d, g, j) shows the whole area from the cortical zone to the 
medullary papilla. In addition two detailed pictures, either of the cortex (b, e, h, k) or the medulla(c, f, i, l) is given. The 
magnification of the overview was ~10 times and of the detailed pictures ~70 times. 
 
 
Expression of the corresponding mRNA of novel urinary protein biomarkers (Vancomycin) 
 
To evaluate if the increase in urinary proteins or renal protein expression was also reflected by gene expression changes, 
the corresponding data was extracted from the whole genome dataset (3.1.3 Gene expression analyses of renal tissue) 
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and fold-changes against the average control animals were calculated. The results are given in Figure 3-10 (male) and 
Figure 3-11 (female). 
 
 
Figure 3-10 Gene expression changes of (a) Kim-1, (b) Lipocalin-2, (c) β2m, (d) Timp-1, (e) VEGF, (f) CystatinC, (g) 
Osteopontin, (h), Calbindin , (i) Clusterin determined in renal tissue of male rats treated with Vancomycin (low dose: 50 mg/kg 
(light grey); high dose: 300 mg/kg (dark grey)) for 3 days, 7 days, 14 days, and 28 days. In parenthesis the gene symbols are 
shown. Data are presented as means of the fold-changes over the average of the time matched control animals (bar ± SD; n=3). 
The range for -2 to +2 is indicated as light grey bands to indicate the strength of alteration. 
 
In both genders almost all gene expression changes appeared in the high dose group (300 mg/kg) of Vancomycin 
treated animals. Exceptions were the animals of the low dose group (50 mg/kg) treated for 28 days with Vancomycin. 
This was found in both sexes, but was more pronounced in male rats. The highest fold-change in male rats was 
observed for Kim-1 (Figure 3-10 a), reaching up to ~107-fold on day 7. On days 3, 14 and 28 a fold-change of ≥ 50 was 
measured. However, on day 14 the variation within the group of three animals was the highest reaching from 7 to 102 
fold induction. Other transcripts showing strong induction were Lipocalin-2 (up to 50-fold), Timp-1 (up to 35-fold) and 
Clusterin (up to 17-fold) (Figure 3-10 b, d, g). All of these transcripts showed the highest intragroup variance after 14 
days of treatment; even this was not nescessarily the lowest value observed. Therefore Lipocalin-2 showed a 
comparable fold-change on day 14 and 28 (40-fold) (Figure 3-10 b) and Clusterin showed a 5-fold lowered value on day 
28 compared to day 14 (Figure 3-10 i). Only a slight increase in the expression level for male rats was observed for 
Osteopontin reaching to a maximum of 3.5-fold with the lowest values on day 3 (2.2) and day 28 (2.7) (Figure 3-10 g). 
In constrast to the transcripts mentioned above, no increased variation within the 14 day high dose (300 mg/kg) 
treatment group could be observed. Calbindin showed no dose- or time-dependent increase but a decrease in gene 
expression (Figure 3-10 h). Therefore a repression of -2.5 on day 3, -3.8 on day 7, and -3.4 on day 28 was detected. No 
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changes were observed for day 14. No alterations on mRNA level were found for β2m, VEGF, and CystatinC, nor in 
the low (50 mg/kg) neither in high dose (300 mg/kg) treated animals (Figure 3-10 c, e, f). 
 
 
Figure 3-11 Gene expression changes of (a) Kim-1, (b) Lipocalin-2, (c) β2m, (d) Timp-1, (e) VEGF, (f) CystatinC, (g) 
Osteopontin, (h), Calbindin , (i) Clusterin determined in renal tissue of female rats treated with Vancomycin (low dose: 50 mg/kg 
(light grey); high dose: 300 mg/kg (dark grey)) for 3 days, 7 days, 14 days, and 28 days. In parenthesis the gene symbols are 
shown. Data are presented as means of the fold-changes over the average of the time matched control animals as the mean (bar ± 
SD; n=3). The range for -2 to +2 is indicated as light grey bands to indicate the strength of alteration. 
 
In female animals the highest fold-indiction was also observed from Kim-1 (~78-fold), but at the latest time point 
(Figure 3-11 a). In addition, no prominent increase from day 3 (~53-fold) to day 7 (~48-fold) was observed. However, 
as observed for male rats, the Kim-1 gene expression on day 14 showed a strong variation, from 1.4- to 65- fold. Also 
comparable to male rats, Lipocalin-2 (up to ~70-fold), Timp-1 (up to ~65-fold) and Clusterin (up to ~15-fold) showed 
the most prominent alterations at the transcript-level (Figure 3-11 b, d, i). Lipocalin-2 showed only a small induction on 
day 14 (~11-fold) compared to days 7 (~63-fold) and 28 (~70-fold). However, no increased variance for the 14 day high 
dose (300 mg/kg) treatment group was detected (Figure 3-11 b). Timp-1 remained relativly constant from day 3 (~22-
fold) to day 7 (~25-fold), with a smaller increase on day 14 (~11-fold) (Figure 3-11 d). Timp-1 showed the highest 
expression in female rats treated with 300 mg/kg Vancomycin on day 28 of treatment (~65 fold). In addition, the gene 
expression of Clusterin showed a different expression pattern over time compared to male rats. On days 3 (~13-fold), 
day 7 (~15-fold) and 28 (~14-fold) a relatively constant fold-change increase was observed, while on day 14 the fold-
induction was only 5.5-fold (Figure 3-11 i). The gene expression of Osteopontin showed only slight alterations, of 
approximately 2.5-fold on days 3, 7 and 28 with no change seen on day 14 to (Figure 3-11 g).  
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Females showed no alterations on mRNA level for β2m, VEGF or CystatinC in the low (50 mg/kg) and high dose (300 
mg/kg) treated animals (Figure 3-11 c, e, f). In addition, Calbindin 28kD remained unchanged over time and dose 
(Figure 3-11 h). 
 
3.1.1.2 Discussion and Conclusion (Vancomycin) 
 
Within this study Vancomycin at doses of 50 mg/kg (low dose) and 300 mg/kg (high dose) caused severe renal damage 
specifically to the tubular system. This was reflected by the strength of response of several of the urinary protein 
biomarkers. In addition, the traditional parameters, serum creatinine and blood urea nitrogen, showed a strong response, 
probably due to the severity of nephrotoxicity induced. The fact that beside these two parameters also urinary glucose 
showed a dose and treatment dependent increase (Table 3-4), without stong alterations on serum level (Table 3-3) 
clearly indicates the detrimental functional effect on proximal tubular cells. Under physiological conditions, renal 
proximal tubular cells reabsorb tubular glucose by the Na
+
/glucose co-transporter SGLT1 in the S3 segment or the 
SGLT2 in the S1/2 segment [Wright et al., 2007]. Other effected urinary parameters, like urinary output, which showed 
a time and dose dependent decrease, mainly in male rats, and the strong increase in urinary total protein excretion, 
corroborate these findings. However, compared to the increase in urinary protein biomarkers, the change in total urinary 
protein was only observed on day 28 of high dose (300 mg/kg) treated animals [Fuchs et al., 2011]. In contrast to urine 
volume, urinary creatinine excretion also showed some significant changes. Therefore, it was decided to normalize 
urinary protein biomarkers with urinary creatinine. This should take in to account any variations in urinary volume and 
composition. Several publications have focused on novel urinary protein biomarkers and used this kind of 
normalization, which results in a better comparability to publicly available data. 
Several indications of inflammatory processes, within the hemogram (Table 3-5) as well as cellular infiltration within 
renal tissue (Table 3-1) were observed. A major impact was observed on white blood cells, while red blood cells 
showed only slight changes. Inflammatory processes are described to play a key role in several kinds of renal injury and 
diseases, although the mechanism(s) are not yet completely understood on a molecular level. A mechanistic evaluation 
of inflammatory processes in Vancomycin induced nephrotoxicity is presented in section 3.1.3 Gene expression 
analyses of renal tissue. 
The strong effects caused by Vancomycin correlates well with the dose range finding study. Data of this study are 
already reported [Fuchs et al., 2012]. 
 
The best performing urinary biomarkers were Kim-1, Clusterin and Osteopontin, as reflected by the AUROC values 
(Table 3-6). Kim-1, one of the most promising urinary biomarkers to bridge between different species and renal 
diseases, showed a good correlation to the histopathological findings in both genders (AUROC values ♂ 0.95; ♀ 0.90). 
However, the magnitude of urinary Kim-1 increase in female rats was much higher (Figure 3-2a; Figure 3-3a), which 
was not reflected histopathologically (Table 3-1). In contrast, male rats showed a higher treatment dependent induction 
of Havcr1 transcripts, which is the related gene to the Kim-1 protein, compared to female rats (Figure 3-10; Figure 
3-11). An important observation in urinary Kim-1 excretion as well as for several other urinary biomarkers (see below) 
was the absence (or only a weak) increase after 14 days. The 7 days that was treatment free up to day 14 reflected a 
recovery of the damaged renal tissue. This was also obvious when referring the histopathological observations (Table 
3-1). The fact that no further increase in urinary Kim-1 could be detected showed that this biomarker has the potential to 
function as a monitoring parameter for renal health status, but also a limitation of sensitivity. Because of this 
RESULTS AND DISCUSSION 
117 
 
discrepancy between the observed minimal to mild tubular effects at this time point, and the lack of increase in urinary 
Kim-1, the detection of only slight renal injury seems not to be possible by using this urinary biomarker. However, 
because only the ectodomain of Kim-1, which is a transmembran receptor, is released into urine, the question arrises if 
the total amount of Kim-1 protein within the kidney is reduced or only the shedding of the ectodomain is inhibited. By 
immunohistochemical analysis of renal Kim-1 protein, it could be shown that the total expression of Kim-1 protein 
depends on the underlying renal damage. Therefore, the absence of urinary Kim-1 elevation on treatment day 14 is a 
direct result of the lowered expression of Kim-1 protein within the kidney. Overall the detection of renal Kim-1 protein 
seems to be more sensitive than the detection of urinary protein. Therefore, the screening of Kim-1 by using tissue 
arrays is a valide method for the assessment of renal diseases and drug induced insults. In both male and female rats, 
generally the major origin of Kim-1 expression is located in the renal cortex but with a wider spread in males compared 
to female rats. The stronger limitation in female rats can be due to the fact that the severity in females was lower than 
that of male rats. In addition, even on day 3 male rats treated with 300 mg/kg Vancomycin showed a similar impact on 
renal tissue to females, and showing the same widespread expression of Kim-1. Therefore, the location of Kim-1 
synthesis seems to be slightly different between sexes and can be assumed to be a major reason for the different 
magnitude in urinary Kim-1 excretion. The difference in the amount of renal Kim-1 can also be assumed to be involved 
in the progression of insult. Kim-1 is described to be involved in the regulation of Th1 and Th2 cell-mediated immunity 
[Mcintire et al., 2003; Mariat et al., 2005; Curtiss et al., 2007], which itself can lead to an increased insult on renal 
tubular cells. It has been described that Kim-1 is involved in the progress of Cisplatin induced nephrotoxicity [Nozaki et 
al., 2011]. Finally, the deterioration in the state of renal health observed on day 28 of treatment, independent of two 
additional recovery periods is also well reflected by the urinary Kim-1 excretion as well as in renal Kim-1 expression 
either on protein or on mRNA level. This points to the fact that Kim-1 can be used independently of the duration of the 
treatment or the interval of drug application because it´s exclusive link to the condition of the kidney. 
High similarities to Kim-1 excretion were observed for Clusterin, which is also one of the FDA, EMA and PMDA 
accepted urinary biomarkers [Fuchs et al., 2011]. Compared to Kim-1 the ROC analysis delivered better values for 
Clusterin (♂ 0.98; ♀ 0.94), which could be due to the higher urinary excretion of Clusterin on treatment day 14 
compared to the control animals (Figure 3-2i Figure 3-3i) and the higher total magnitude of urinary Clusterin. 
Therefore, the only minimal to mild histopathological observation (Table 3-1) are better reflected by urinary Clusterin, 
leading to a higher sensitivity of this biomarker. This is especially true for male rats, but also with some limitation for 
females. In contrast to renal Kim-1 expression, Clusterin showed an expression within renal tissue over almost all 
different tubules. Therefore, the specificity of Clusterin is weaker than Kim-1 because the location of the kidney injury 
cannot be finally linked to any specific tubular segment. Renal Clusterin protein expression reflected the urinary 
excretion of the protein very well. The protein expression of Clusterin was strongly reduced on day 14 and was linked 
to the lowered urinary excretion of this protein. The total amount of urinary Clusterin was much higher (up to 1000-
fold) compared to Kim-1, reflecting the tubular specific damage caused by Vancomycin treatment. Therefore, 
combining the measurement of Kim-1 and Clusterin can be used to distinguish between proximal tubular alterations and 
general tubular damage. 
The urinary excretion of Clusterin, after 28 days of treatment, including three recovery periods, delivered values 
between that of day 3 and day 7 for male rats and the highest values in females (Figure 3-2i; Figure 3-3i). This was not 
reflected by protein expression in renal tissue or on the gene expression level, were male rats showed the lowest 
expression of Clu over all high dose (300 mg/kg) animals (Figure 3-10i). In renal tissue the strongest staining was 
observed for male rats on day 7 and for females on day 3. This may be an indication of a different mechanism of 
involvement of Clusterin in the progression of renal injury, even only truth for a small time shift. Because Clusterin is 
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described to be involved in a multitude of cellular processes, including, immune response via the complementary 
system [Correa-Rotter et al., 1992], apoptosis [French et al., 1994; Hara et al., 2001], growth, proliferation and 
differentiation [French et al., 1993; Witzgall et al., 1994], it can not be described which is the major factor for the 
reduced amount of renal protein. The fact that the urinary amount stayed relatively unaltered can be explained by the 
massive break-down of cells at this time point and as a consequence the release of the still present protein into the 
primary urine.  
Osteopontin, which performed the best within this study, is in contrast to Kim-1 and Clusterin not qualified by the FDA, 
EMA and PMDA. The calculated AUROC (♂ 0.98; ♀ 0.94) values were identical to that of Clusterin and therefore 
above the evalulated values of Kim-1. However, the excretion pattern of urinary Osteopontin showed a clear difference 
over time in relation to the other two markers. The first two time points showed a perfect correlation to the 
histopathological findings, with the highest increase on day 3 in male rats with a slightly lowered increase on day 7 
(Figure 3-2 g) and the time dependent increase from day 3 to day 7 in females (Figure 3-3 g). Urinary Osteopontin 
excretion showed only a slight increase on treatment day 14 and an additional decrease in day 28. This increase at this 
late time point delievered statistically significantly elevated level of Osteopontin, the strength of which was not 
reflected by the magnitude of this urinary protein. The reason for this became clear by evaluating the amount and 
distribution of Osteopontin in renal tissue. While at the first two time points the majority of renal Osteopontin was 
observed to be intracellular in tubular cells, with an increased amount of extracellular Osteopontin on day 7, at the later 
time points the staining of Osteopontin was almost completely limited to the extracellular matrix. Because Osteopontin 
is described to bind to collagen [Chen at al., 1992] this urinary protein biomarker has a clear limitation for usability in 
chronic rodent studies where interstitial fibrosis takes place. Although the protein expression within the kidney 
remained constant over the treatment time, the release into urine was reduced. Additionally, the immobilized 
Osteopontin bound to collagen can bridge different phases of regeneration, as observed on day 14 in male rats (Figure 
3-2 g). Ostepontin can be released with collagen in cases of regeneration and the related degradation of collagen fibers 
(Figure 3-8 d-f, g-i). This will lead to an underestimation of the regeneration of renal tissue but also will increase the 
sensitivity compared to other biomarkers, e.g. Kim-1, which showed no significant increase on day 14. The fact that 
only small fold-inductions of Spp1, the Osteopontin related gene, were observed (Figure 3-10g, Figure 3-11g), together 
with the higher basal expression of renal protein, indicates that the amount of expressed Osteopontin in renal tubular 
cells is constantly higher compared to Kim-1 and Osteopontin. Therefore, it can be hypothesised that Osteopontin can 
be used for a very early prediction of drug-induced tubular damage. Further studies will be needed with earlier time 
point e.g. the first hours after drug application, to evaluate the potential of Osteopontin and to define the framework for 
a potential qualification of this valuable biomarker. The potential involvement of Osteopontin in the progression of 
kidney injury should be taken into account. The fact that Osteopontin is described to be involved in neutrophil 
migration by chemotoxis of a cleavage product (Kim et al., 2008) can increase inflammatory processes by Osteopontin 
accumulation within renal tissue. Additionally, it has been reported that the activation of NF-B, by binding to v3 
integrin of endothelial cells, leads to a protective effect of Osteopontin against apoptosis [Mazzali et al., 2002]. 
Another well performing (non-qualified) urinary biomarker was Calbindin (♂ 0.98; ♀ 0.88). In contrast to Kim-1, 
which is proximal tubular specific and Clusterin/ Osteopontin which are specific for general tubular damage, Calbindin 
is described to be specific for distal tubular and collecting duct injury. In comparison to the three biomarkers mentioned 
above, the different in diagnostic performance between male and female rats was more pronounced for this biomarker. 
Distal tubular damage, which is rarely reported for Vancomycin treatment, therefore the slight but significant increase 
in urinary Calbindin at the earlier time points and the massive increase on treatment day 28 point to the fact that distal 
tubular damage takes place as a secondary effect caused by the predominant proteinuria on day 28. However, the fact 
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that the calculated AUROC values and in general the increase in urinary Calbindin (Figure 3-2 h, Figure 3-3 h) showed 
a good correlation to tubular degeneration, without any discrimination of the different types of tubules, show the high 
sensitivity of this urinary biomarker. An obvious influence of urinary calcium concentrations on the excretion of 
Calbindin could be excluded; even though Calbindin is a family member of vitamin D-dependent calcium-binding 
proteins [Fuchs et al., 2011]. Because in other studies it has been reported that Calbindin showed a dose-dependent 
decrease [Hoffman et al., 2010] it can be hypothised that beside kidney calcification, as reported for Ciclosporin A 
[Aicher et al., 1997] also other mechanisms related to renal damage are involved in the excretion of Calbindin. 
Therefore, the regulation of Calbindin expression seems to be exclusively regulated by alternative pathways, such as by 
induction though the parathyroid hormone, which is a key molecule in calcium homestasis [Hemmingsen et al., 2009]. 
This assumption is supported by the observation that serum phosphate, an inducer of the parathyroid hormone 
[Nakajima et al., 2009], was increased in dose-dependent manner on day 28 (data not shown). 
The induction of Calbindin protein seems not to be regulated on gene expression level, because of the absence of any 
increase in mRNA. Male rats of the high dose (300 mg/kg) group showed a decrease in Calb1 mRNA without any effect 
on urinary protein level. Taken together Calbindin performed very well in this study and the fact that it is one of the few 
described urinary biomarkers which are specific for distal tubular damage, makes this urinary biomarker an important 
addition to the panel of urinary biomarkers. 
A gender dependent response was observed for Timp-1, also a non qualified biomarker, with a clearly better 
performance in female rats (♂ 0.74; ♀ 0.94). While the increase in male rats was only very slight, except on treatment 
day 28, and the basal excretion of Timp-1 protein was higher compared to female rats, the correlation of increased 
amount of urinary Timp-1 to histopathological findings was poor. This discrepancy between both genders could not be 
confirmed by transcriptional analysis. In this case the measurement of Timp1 mRNA delivered the best correlation to 
the histopathological findings - when both genders were taken into account. Another difference was the increase in 
urinary Timp-1 protein in male rats with aging, while the amount of Timp-1 in females stayed constant. It has been 
reported that differences in Timp-1 and MMP-9, the strongest inhibited matrix metalloprotease of Timp-1 protein, in 
male and female rats are present in rat aortic smooth muscle cells [Woodrum et al., 2005]. However, because it can be 
assumed that the functional role of Timp-1/ MMP-9 on the regulation of extracellular matrix degradation, is similar in 
almost all tissues expressing Timp-1, this protein can delivered additional information in relation to the development of 
tubulointerstitial fibrosis, by accumulation of Timp-1 and the resulting imbalance between this protein and MMPs 
[Schnaper et al., 1995]. This is in line with the observation of the highest increase of urinary Timp-1 protein in male rats 
on day 28, with the increasing amounts of fibrotic fibers within high dose (300 mg/kg) treated animals over time and to 
the strongly lowered increase of Osteopontin mentioned above. In contrast to Osteopontin, Timp-1 is therefore a 
potential candidate to monitor chronic kidney diseases, which already has been reported with increasing amount of 
urinary Timp-1 [Liu et al., 2006]. Besides its extracellular inhibitory activity, Timp-1 has in addition anti-apoptotic and 
pro-proliferatory properties [Schnaper et al., 1995]. 
In contrast to the biomarkers mentioned so far, which are more or less exclusively expressed within renal tissue, 
Cystatin C, a qualified biomarker, is not described to be elevated in renal damage. Cystatin C is considered to be a 
proximal tubular biomarker, based on the physiological process of reabsoption of freely circulating Cystatin C by 
proximal tubular cells. If this functional capacity is limited by cellular break-down an increase in urinary Cystatin C can 
be detected. Therefore, the general mechanism of increase in urine is comparable to elevated urinary glucose excretion 
if serum glucose remains constant. The extra renal origin of the Cystatin C is also reflected by analyzing transcriptional 
changes. However, the performance of Cystatin C within this Vancomycin study was quite poor (♂ 0.73; ♀ 0.68). Only 
in male rats treated for 7 day with 300 mg/kg Vancomycin was a significant elevation in urinary Cystatin C observed. 
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The poor performance of this extra renal urinary biomarker was highlighted by the creatinine showed a strong decline in 
all high dose (300 mg/kg) treated animals. Thus less Cystatin C can enter the tubular lumen leading to no or only weak 
alterations in urinary excretion. This assumption was confirmed by comparison of the increase in urinary Cystatin C in 
male low dose (50 mg/kg) treated animals for 7 days and the related creatinine clearance/ GFR which also showed an 
increase in filtration properties. Therefore, the specificity of Cystatin C as a functional biomarker for proximal tubular 
damage is questionable. However, Cystatin C is widely used as alternative method to creatinine clearance because of 
the dependency of this parameter on age, gender and muscle mass [Fuchs et al 2011]. The parallel detection of Cystatin 
C in serum and urine to calculate the Cystatin C clearance would give the benefit of being able to evaluate the renal 
function on the filtration level. In addition, only minimal gender differences in the basal excretion of Cystatin C were 
observed. This fact is important because of the physiological proteinuria described for rats, leading to a higher excretion 
of urinary total protein in male rats (Table 3-4). The amount of Cystatin C seems not to be strongly affected by this 
physiological process. Independently, it has been reported that urinary Cystatin C has been used in clinical studies for 
the detection of structural and functional renal tubular impairment in adults and children without any observed influence 
of the glomerular filtration rate [Herget-Rosenthal et al., 2007]. Therefore, further investigations are needed to avoid the 
underestimation of the potential of this qualified biomarker. 
2m is a qualified functional urinary biomarker which is released into the blood during cellular turnover. Therefore, the 
results derived for 2m in this study were similar to Cystatin C. The diagnostic performance was poor in both male and 
female rats (♂ 0.76; ♀ 0.70), even if individual animals showed a large increase (Figure 3-2c Figure 3-3c). In contrast 
to Cystatin C the observed gender difference in the basal urinary excretion was more prominent, reaching ~6-fold 
higher level in male rats, but this was also masked by the fluctuation within the GFR in male rats. 
By taking the observations of Cystatin C and 2m together it is more likely that these two urinary biomarkers can 
potentially be used as predictors of glomerular damage. Because of the increase in protein load by break-down of the 
filter barrier a saturation of the transport properties of tubular cells will lead to an increase in urinary protein. This is in 
good correlation to previously reported findings, by comparing the diagnostic performance of these biomarkers with 
only glomerulare observations [Dieterle et al., 2010]. Finally, an intrarenal influence of Cystatin C and 2m can be 
excluded because of no time or dose dependent alterations on gene expression level. 
Lipocalin-2, also known as NGAL, also showed poor diagnostic performance within this study (♂ 0.69; ♀ 0.76). 
Although this urinary protein biomarker is not yet qualified by the regulatory authorities for preclinical or clinical use; it 
is one of the most promising urinary parameters studied in clinical trial settings [Mishra et al., 2003, Ding et al., 2007, 
Wagener et al., 2008]. The disadvantage of NGAL is its involvement in the acute phase response [Hoffmann et al., 
2010]. Because of its systemic expression and the free glomerulation filtering, systemic inflammatory processes can 
lead to an increase in urinary excretion of NGAL. Therefore, the complete health status of the test subject has to be 
monitored to exclude sepsis and other inflammatory processes. In case of this study the observed increase in urinary 
NGAL delivered good results for treatment day 7 for male rats and on treatment day 3 and 7 for females. Because of the 
limited magnitude of increase in relation to the basal excretion of NGAL, the discrimination between affected and non 
affected animals was not always possible. In addition, the fact that no massive increase in urinary NGAL was observed, 
even though there were prominent systemic and renal inflammatory processes observed (Table 3-1, Table 3-5) together 
with severe histopathological findings, lead to the suggestion that different extra- and intrarenal factors influenced the 
expression and excretion of NGAL. The impact of specific drug induced mechanisms was previously reported for 
Gentamicin, Ochratoxin A and BI-3 [Hoffman et al., 2010], and NGAL was only a good predictor for gentamicin 
induced nephrotoxicity.  
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In contrast to the findings of urinary NGAL protein, the fold-induction of Lcn2, the corresponding transcript, delivered 
a much better prediction of the health status of the kidney, in both male and female rats. Because Lcn2 has been 
reported in several independent toxicogenomics approaches [Dieterich et al, 2009, Kondo et al., 2009, Wang et al., 
2008], it can be suggested that changes at the mRNA level in response to cell damage are not necessarily paralleled by 
increased protein levels and active secretion/leakage into the tubular convolute. Additionally, there is major evidence 
suggesting that Lcn2 is located in the distal tubule of the nephron, while the protein is also located in the proximal 
tubule, so the protein is probably reabsorbed [Paragas et al., 2011]. Therefore, the specificity of NGAL mRNA is also 
questionable. 
Finally, the non qualified vascular endothelial growth factor (VEGF) showed differences between the genders (♂ 0.89; 
♀ 0.67). While female rats showed no alteration in urinary VEGF, it can be suggested that in general the source of 
VEGF seems to be intra-renal, and was confirmed by the absence of any alterations on gene expression level in male 
and female rats. However, its performance for identifying acute or chronic kidney disease seems to be limited. It was 
already reported that VEGF lead to a slowdown in progression of renal injury by reducing renal fibrosis [Kang et al., 
2001], and preserves renal microvessel structure [Leonard et al., 2008]. In contrast to female rats, males showed a slight 
dose-dependent decrease in urinary VEGF that may explain the better diagnostic potential in males. However, because 
the decrease in urinary VEGF has been described in the context of idiopathic membranous glomerulonephritis (MGN) 
[Honkanen et al., 2000] and the AUROCs were calculated by using tubular degeneration as the comparator, this high 
AUROC seems to be calculated by chance in respect of the comparator. However, because MGN is caused by immune 
complex formation in the glomerulus, formed by antibodies binding to antigens in the basement membrane, leading to 
activation of the C5b –C9 complements a membrane attack complex (MAC) is formed on the glomerular epithelial cells 
[Beck et al., 2010]. In HE staining light microscopically observations, the glomeruli seem to be unaffected by 
Vanomycin. 
So far, many contradictory findings were reported for urinary VEGF to detecte AKI. However, because of the central 
role in reno-protection and the potential to serve as an intrinsic biomarker for glomerular damage, further investigations 
are needed to identify potential endpoints which can be predicted by VEGF in a sensitive and specific way. 
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3.1.1.3 Results (Cisplatin) 
 
Histopathological observation (Cisplatin) 
 
In gross pathology bilateral pale discoloration of the kidneys was found earliest on day 8 in individual low (0.3 mg/kg) 
and high (0.6 mg/kg) dose treated male rats. In addition, rats treated with 0.6 mg/kg Cisplatin showed an enlargement of 
the kidneys. From day 15 on also individual female rats showed pale discoloration as well as kidney enlargement and a 
granular surface of the kidney, especially in the high dose group (0.6 mg/kg). The same observations were observed on 
day 29. An overview of the results is summarized in Table 3-7. 
Microscopically, no Cisplatin-related alterations were detected in animals treated with 0.3 mg/kg, at any time point. 
Therefore, all further data and descriptions refer to animals treated with 0.6 mg/kg Cisplatin.  
The earliest findings (on day 4) were minimal multifocal single cell necroses or tubular cells in two of the five male 
rats. On day 8 minimal to moderate tubular degeneration and up to mild tubular necroses were more prominent, still 
limited to male rats. In contrast, on day 15 one female and all male rats showed minimal to moderate multifocal tubular 
degeneration. In addition, the female rats and one male rat showed concomitant multifocal tubular dilation, while 
tubular necroses were present in the female and three male rats. On day 15 also minimal and a mild infiltration with 
mononuclear inflammatory cells were present in one male and one female, respectively. The last time point (day 29) 
showed comparable findings to those on day 15. Also, all five male animals showed minimal to moderate multifocal 
tubular degeneration, while females revealed no specific findings. In addition to the tubular insult, minimal to mild 
eosinophilic casts were present in single animals of the high dose treated animals (0.6 mg/kg) on days 8, 15 and 29. 
Treatment-related findings in other organs were observed, as early as day 8. Gastro-intestinal alterations, like focal 
erosion of the gastric mucosa with focal edema, hemorrhage and mixed cell infiltration were detected. Subsequently, in 
individual animals the forestomach mucosa showed mild epithelial hyperplasia and the ceacum showed focal mild 
submucosal hemorrhages. The same findings were seen on day 15 but not on day 29. In addition, animals treated for 14 
days also mild to moderate lymphoid depletion in the thymus were present in three male and one female rat.  
Beside tubular degeneration, also regeneration attempts of the tubular lining epithelium were observed. These epithelial 
cells were characterized by large pale cells showing anisocytosis and anisokaryosis. The tubular damage was located in 
the S3 segment of the proximal tubules (pars recta). The severity of the findings in high dose treated animals (0.6 
mg/kg) increased up to day 15. Kidney findings on day 29, related to Cisplatin treatment, were comparable to those on 
day 15. 
 
 
Clinical, clinical-pathological and hematological observation (Cisplatin) 
 
Only significant observation or relevant parameters in case of the underlying evaluation are shown. The tables for all 
three studies (Table 3-8, Table 3-9, Table 3-10) show the same parameters to allow comparison between the different 
compounds, even though some parameters show no relevant effects in one or two compounds. 
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Table 3-7 Incidence summary of Cisplatin treatment-related kidney histophatology findings. The number of animals in 
each group of five is shown in parentheses. / ≙ lesion not observed, + ≙ minimal, ++ ≙ mild, +++ ≙ moderate, ++++ ≙ 
massive, and +++++ ≙ high severity of lesion 
    Cisplatin [mg/kg] 
    male female 
  time 0   0.3   0.6   0   0.3   0.6 
Tubular  
Degeneration 
day 4 / 
 
/ 
 
/ 
 
/ 
 
/ 
 
/ 
 
day 8 / 
 
/ 
 
+ (3/5) 
++ (1/5) 
+++ (1/5) 
 
/ 
 
/ 
 
/ 
 
day 15 / 
 
/ 
 
+ (2/5) 
++(2/5) 
+++ (1/5) 
 
/ 
 
/ 
 
+++ 
(1/5) 
  
day 29 /   /   
+ (4/5) 
+++ (1/5) 
  /   /   / 
Tubular  
Dilatation 
day 4 / 
 
/ 
 
/ 
 
/ 
 
/ 
 
/ 
 
day 8 / 
 
/ 
 
+ (1/5) 
 
/ 
 
/ 
 
/ 
 
day 15 / 
 
/ 
 
++ (1/5) 
 
/ 
 
/ 
 
++ (1/5) 
  
day 29 /   /   +++ (1/5)   /   /   / 
Tubular  
Necrosis 
day 4 / 
 
/ 
 
+ (2/5) 
 
/ 
 
/ 
 
/ 
 
day 8 / 
 
/ 
 
+ (4/5) 
++ (1/5)  
/ 
 
/ 
 
/ 
 
day 15 / 
 
/ 
 
+ (1/5) 
++ (1/5)  
/ 
 
/ 
 
+ (1/5) 
  
day 29 /   /   + (1/5)   /   /   / 
Cellular  
Casts 
day 4 / 
 
/ 
 
/ 
 
/ 
 
/ 
 
/ 
 
day 8 / 
 
/ 
 
+(2/5) 
 
/ 
 
/ 
 
/ 
 
day 15 / 
 
/ 
 
+(1/5) 
 
/ 
 
/ 
 
/ 
  
day 29 /   /   /   /   /   / 
Basophilic  
Tubules 
day 4 / 
 
/ 
 
+ (1/5) 
 
/ 
 
/ 
 
/ 
 
day 8 / 
 
+ (1/5) 
   
/ 
 
/ 
 
/ 
 
day 15 + (1/5) 
 
+ (2/5) 
 
+ (1/5) 
 
/ 
 
+ (1/5) 
 
+ (1/5) 
++(1/5) 
  
day 29 /   + (1/5)   +++ (1/5)   /   + (1/5)   + (2/5) 
Infiltrates 
day 4 / 
 
+ (1/5) 
 
/ 
 
/ 
 
/ 
 
/ 
 
day 8 / 
 
/ 
 
+ (1/5) 
 
/ 
 
/ 
 
/ 
 
day 15 / 
 
/ 
 
+ (1/5) 
 
/ 
 
/ 
 
+ (1/5) 
++(1/5) 
  
day 29 /   /   /   /   /   / 
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Table 3-8 Summary of body and kidney weight determined for male and female rats treated with 0.3 mg/kg and 0.6 mg/kg Cisplatin up to 28 days. The data of the control group are displayed 
in each table. Significant changes were indicated with * p < 0.05, ** p < 0.01, *** p < 0.001 (ANOVA + Dunnett) 
    Cisplatin [mg/kg] 
 
  
Male female 
   time 0   0.3   0.6   0   0.3   0.6 
 body weight [g] day 3 261 ± 11 
 
261 ± 12 
 
256 ± 8 
 
170 ± 6 
 
170 ± 9 
 
170 ± 6 
 
 
day 7 297 ± 4 
 
276 ± 9 * 262 ± 17 *** 192 ± 11 
 
175 ± 11 * 166 ± 6 ** 
 
day 14 314 ± 11 
 
300 ± 12 
 
262 ± 22 *** 192 ± 5 
 
195 ± 7 
 
180 ± 20 
 
 
day 28 349 ± 14 
 
329 ± 20 
 
313 ± 30 *** 207 ± 6 
 
204 ± 5 
 
202 ± 15 
 
              kidney weight [g] day 3 2.02 ± 0.09 
 
2.02 ± 0.22 
 
1.95 ± 0.04 
 
1.38 ± 0.11 
 
1.30 ± 0.13 
 
1.29 ± 0.04 
 
 
day 7 2.24 ± 0.07 
 
2.08 ± 0.17 
 
2.04 ± 0.36 
 
1.48 ± 0.07 
 
1.37 ± 0.16 
 
1.32 ± 0.11 
 
 
day 14 2.34 ± 0.21 
 
2.18 ± 0.25 
 
2.05 ± 0.19 
 
1.51 ± 0.13 
 
1.48 ± 0.10 
 
1.51 ± 0.19 
   day 28 2.34 ± 0.11   2.28 ± 0.16   2.16 ± 0.24   1.49 ± 0.07   1.46 ± 0.14   1.51 ± 0.23 
  
As observed by the limited histopathological findings in female rats treated with 0.3 and 0.6 mg/kg Cisplatin, almost all dominant, statistical significant or biological relevant 
alterations in the clinical pathological parameters were limited to male rats. In addition, in female rats a considerable fluctuation over time was observed with often increased 
parameters on day 3 and day 14 and decreases on day 7 and day 28 (Table 3-8, Table 3-9, Table 3-10). In contrast, the hematological analysis showed in females strong and 
significant effects but below the observed effects in males (Table 3-11). A strong reduction in body weight on days 7, 14 and 28 in male rats treated with 0.6 mg/kg Cisplatin was 
observed. Also low dose treated male rats (0.3 mg/kg) showed reduced (non significant) body weight. In female rats a significant body weight reduction was only determined on day 
7 in both dosing groups. Day 14 and 28 also showed slightly decrease weights. In contrast, the kidney weights showed no relevant alterations in both genders. In serum parameters, 
especially in creatinine and BUN, most findings were in the low dose (0.3 mg/kg) treated male rats (Table 3-9). Therefore, a reduction in serum creatinine was observed on day 3 and 
day 7 in both dosing groups. No relevant alteration at the later time points appeared.  
BUN also was reduced in male rats on day 3, but was followed by an increase on day 7. The slightly elevated level in BUN stayed relatively constant up to day 28. In female rats the 
most prominent effects on BUN were limited to days 7 and 14 of both low (0.3 mg/kg) and high dose (0.6 mg/kg) treated animals. However, statistical significance could only be 
calculated for high dose animals (0.6 mg/kg) on day 29. In male rats serum glucose levels were also elevated in both dosing groups, with the highest values observed on day 7. 
Female rats showed the fluctuation mentioned above within the serum glucose level (Table 3-9). 
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Table 3-9 Summary of clinical pathology serum parameter determined for male and female rats treated with saline, 0.3 mg/kg and 0.6 mg/kg Cisplatin for up to 28 days. The data of the 
control group are displayed in each table. Significant changes were indicated with * p < 0.05, ** p < 0.01, *** p < 0.001 (ANOVA + Dunnett) 
    Cisplatin [mg/kg] 
 
  
Male female 
   time 0   0.3   0.6   0   0.3   0.6 
 Creatinine [mg/dL] day 3 0.25 ± 0.02 
 
0.14 ± 0.02 *** 0.18 ± 0.02 *** 0.29 ± 0.04 
 
0.21 ± 0.04 
 
0.21 ± 0.03 
 
 
day 7 0.23 ± 0.02 
 
0.14 ± 0.04 *** 0.21 ± 0.03 
 
0.28 ± 0.03 
 
0.16 ± 0.03 
 
0.20 ± 0.05 
 
 
day 14 0.24 ± 0.03 
 
0.26 ± 0.02 
 
0.27 ± 0.07 
 
0.27 ± 0.05 
 
0.29 ± 0.03 
 
0.37 ± 0.20 
 
 
day 28 0.25 ± 0.02 
 
0.24 ± 0.02 
 
0.26 ± 0.04 
 
0.28 ± 0.02 
 
0.28 ± 0.03 
 
0.25 ± 0.03 
 
              BUN [mg/dL] day 3 33.15 ± 3.46 
 
29.79 ± 2.50 
 
29.07 ± 3.17 
 
35.19 ± 5.00 
 
34.95 ± 5.39 
 
36.75 ± 3.90 
 
 
day 7 30.27 ± 1.88 
 
32.91 ± 2.45 ** 41.56 ± 6.72 
 
30.75 ± 2.26 
 
35.19 ± 1.97 
 
36.27 ± 5.74 
 
 
day 14 31.59 ± 2.19 
 
30.15 ± 2.63 
 
34.35 ± 7.15 
 
30.39 ± 3.28 
 
35.31 ± 1.61 
 
50.2 ± 44.83 
 
 
day 28 27.62 ± 1.80 
 
28.11 ± 4.52 * 34.83 ± 3.34 
 
32.07 ± 2.46 
 
38.31 ± 3.10 
 
33.03 ± 1.90 ** 
              Glucose [mg/dL] day 3 85.41 ± 13.58 
 
90.09 ± 6.98 
 
92.97 ± 11.86 
 
71.35 ± 10.48 
 
81.08 ± 8.83 
 
80.36 ± 2.05 
 
 
day 7 88.65 ± 10.30 
 
106.67 ± 8.20 * 116.40 ± 10.16 ** 90.81 ± 6.57 
 
89.73 ± 9.74 
 
84.33 ± 7.36 
 
 
day 14 104.15 ± 13.33 
 
108.11 ± 10.74 
 
115.68 ± 18.35 
 
102.7 ± 14.64 
 
95.50 ± 4.93 
 
108.47 ± 18.35 
   day 28 119.28 ± 4.66   108.47 ± 19.84   112.79 ± 15.43   107.39 ± 12.72   77.48 ± 6.62 ** 95.50 ± 10.89 
  
Urinary excretion was not significantly effected in either gender (Table 3-10). However, a slightly reduced urinary volume was determined in high dose (0.6 mg/kg) treated male 
rats, while female rats only showed a relevant decrease in urinary volume on day 7. All high dose (0.6 mg/kg) treated male rats, independent of the time, showed a slight increasing 
tendency in urinary glucose. The most pronounced outcome was detected for male rats treated with 0.6 mg/kg Cisplatin for 7 days. Female rats showed no relevant alteration in 
urinary glucose. Also urinary total protein delivered no time- or dose-dependent alterations. Only a slight, but not statistical significant, increase in low (0.3 mg/kg) and high (0.6 
mg/kg) dose treated animals on day 7 and 28 in male rats was observed. In addition, a very strong and statistical significant reduction in urinary total protein in female rats treated for 
29 day with either 0.3 mg/kg or 0.6 mg/kg Cisplatin was observed. The level of urinary creatinine showed no statistical significant alterations but slight fluctuations between 
individual animals and dose groups (Table 3-10). These fluctuations correlated with the variation in urinary volume. 
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Table 3-10 Summary of clinical pathology urinary parameter determined for male and female rats treated with saline, 0.3 mg/kg and 0.6 mg/kg Vancomycin for up to 28 days. The data of the 
control group are displayed in each table. Significant changes were indicated with * p < 0.05, ** p < 0.01, *** p < 0.001 (ANOVA + Dunnett) 
    Cisplatin [mg/kg] 
 
  
Male female 
   time 0   0.3   0.6   0   0.3   0.6 
 Volumen [mL] day 3 15.30 ± 8.51 
 
16.72 ± 9.49 
 
12.92 ± 4.30 
 
8.32 ± 4.33 
 
8.24 ± 3.70 
 
8.38 ± 3.97 
 
 
day 7 15.68 ± 15.68 
 
17.36 ± 7.07 
 
11.32 ± 10.22 
 
16.68 ± 7.23 
 
13.60 ± 5.82 
 
9.60 ± 2.55 
 
 
day 14 26.24 ± 11.44 
 
21.96 ± 9.14 
 
14.84 ± 1.60 
 
13.56 ± 5.49 
 
10.66 ± 6.26 
 
12.18 ± 7.01 
 
 
day 28 21.28 ± 8.21 
 
14.64 ± 4.53 
 
17.04 ± 8.47 
 
9.96 ± 4.37 
 
15.12 ± 6.38 
 
12.75 ± 3.00 
 
              Glucose [mg/dL] day 3 7.82 ± 5.24 
 
6.81 ± 3.47 
 
8.40 ± 1.65 
 
9.01 ± 7.24 
 
8.97 ± 3.39 
 
8.29 ± 4.03 
 
 
day 7 6.23 ± 6.23 
 
6.16 ± 1.66 
 
20.25 ± 14.87 * 7.10 ± 3.41 
 
5.30 ± 2.30 
 
7.03 ± 1.24 
 
 
day 14 5.08 ± 1.90 
 
5.66 ± 2.29 
 
5.73 ± 0.78 
 
7.89 ± 4.30 
 
9.23 ± 4.32 
 
7.78 ± 4.56 
 
 
day 28 6.56 ± 2.21 
 
9.55 ± 2.22 
 
8.04 ± 3.06 
 
7.78 ± 3.03 
 
4.97 ± 1.66 
 
6.44 ± 0.97 
 
              total protein [mg/dL] day 3 60.80 ± 36.17 
 
43.52 ± 25.22 
 
48.10 ± 14.40 
 
15.78 ± 9.79 
 
12.06 ± 4.10 
 
12.22 ± 6.70 
 
 
day 7 38.26 ± 38.26 
 
42.86 ± 12.6 
 
51.04 ± 24.45 
 
10.40 ± 5.11 
 
7.88 ± 2.71 
 
10.78 ± 3.03 
 
 
day 14 39.14 ± 26.51 
 
32.4 ± 11.93 
 
26.98 ± 17.68 
 
11.18 ± 5.12 
 
12.92 ± 5.71 
 
10.38 ± 5.38 
 
 
day 28 37.76 ± 10.13 
 
44.04 ± 7.43 
 
43.78 ± 20.05 
 
13.02 ± 5.61 
 
4.60 ± 3.01 ** 6.18 ± 1.18 * 
              Creatinine [mg/dL] day 3 68.25 ± 37.13 
 
53.94 ± 29.00 
 
59.71 ± 19.50 
 
67.72 ± 44.31 
 
56.12 ± 18.07 
 
58.21 ± 25.47 
 
 
day 7 49.30 ± 49.30 
 
46.51 ± 14.09 
 
98.25 ± 71.50 
 
41.64 ± 19.27 
 
35.49 ± 13.63 
 
46.21 ± 11.21 
 
 
day 14 38.10 ± 15.06 
 
43.50 ± 15.49 
 
47.57 ± 1.64 
 
47.34 ± 21.86 
 
55.71 ± 22.78 
 
46.44 ± 20.69 
   day 28 52.06 ± 22.98   74.81 ± 22.47   63.29 ± 25.41   60.90 ± 26.94   40.07 ± 11.49   46.70 ± 5.67 
  
 
1
2
6
 
RESULTS AND DISCUSSION 
127 
 
 
Figure 3-12 Urinary sodium and calcium excretion, as well as the creatinine clearance for male (○) and female 
(●) rats treated with either saline (control), 0.3 mg/kg Cisplatin (low dose), or 0.6 mg/kg Cisplatin (high dose). 
Data are presented for both genders individually by mean ± SD. Significant changes were indicated with * p < 
0.05, ** p < 0.01, *** p < 0.001 (ANOVA + Dunnett). 
 
The renal functional properties were only mildly affected by Cisplatin treatment with either 0.3 mg/kg or 0.6 mg/kg 
(Figure 3-12). A strong, significant reduction in urinary sodium excretion was observed after 7 days of high dose (0.6 
mg/kg) treatment in both genders, followed by a slight (non significant) increase on treatment day 14 in male rats. In 
contrast, urinary calcium excretion in male rats showed a decrease on day 3 with an additional significant increase on 
day 14. Significant changes in creatinine clearance where limited to male rats treated with 0.3 mg/kg Cisplatin. A 
significant increase in creatinine clearance was observed after 3 and 7 days of treatment with a return to the normal by 
day 14. The glomerular filtration rate showed no changes in low dose (0.3 mg/kg) treated animals but a slight decrease 
on day 7 and day 14 of high dose (0.6 mg/kg) treated male rats. Only the decrease on day 14 delivered statistical 
significance. 
The most prominent findings within the Cisplatin study were hematological alterations. In contrast to the observation 
within the Vancomycin study, Cisplatin caused a decrease in absolute cell counts. RBCs were only affected in male 
high dose (0.6 mg/kg) treated animals on day 29, while female rats showed no relevant changes. The total counts of 
platelets showed a strong and dose-dependent decrease in both genders on day 14, while on day 29 male rats showed a 
tendency of an increase, and female rats still showed a decrease. The strongest effects were observed for WBC, in a 
time- and dose-dependent manner. A strong decrease in WBCs was earliest detected on days 3 and day 7 in low (0.3 
mg/kg) and high (0.6 mg/kg) dose treated animals of both genders. At later time points a decrease in cell counts was 
still present but less strong. The most effected white blood cell sub-population in Cisplatin treated animals were the 
neutrpophils, eosinophils and basophils. But also lymphocytes showed a reduction in total cell count. No changes were 
observed for monocytes. 
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Table 3-11 Summary of hematological parameter determined for male and female rats treated with saline, 0.3 mg/kg and 0.6 mg/kg Cisplatin for up to 28 days. The data of the control group 
are displayed in each table. Significant changes were indicated with * < 0.05, ** < 0.01, *** < 0.001 (ANOVA + Dunnett) 
 
    Cisplatin [mg/kg] 
 
  
male female 
   time 0   0.3   0.6   0   0.3   0.6 
 RBC [counts/pL] day 3 8.22 ± 0.23 
 
8.24 ± 0.40 
 
8.11 ± 0.31 
 
8.17 ± 0.41 
 
7.78 ± 0.17 
 
7.96 ± 0.29 
 
 
day 7 8.28 ± 0.38 
 
8.35 ± 0.42 
 
8.57 ± 0.51 
 
7.85 ± 0.25 
 
8.02 ± 0.28 
 
8.32 ± 0.51 
 
 
day 14 8.26 ± 0.40 
 
8.22 ± 0.24 
 
8.34 ± 0.40 
 
7.98 ± 0.19 
 
8.01 ± 0.20 
 
7.81 ± 0.28 
 
 
day 28 8.56 ± 0.13 
 
8.41 ± 0.26 
 
8.19 ± 0.17 * 7.96 ± 0.15 
 
8.03 ± 0.29 
 
7.67 ± 0.51 
 
              PLT [counts/nL] day 3 890 ± 64 
 
905 ± 71 
 
930 ± 72 
 
977 ± 123 
 
850 ± 45 
 
949 ± 71 
 
 
day 7 899 ± 98 
 
1020 ± 128 
 
979 ± 63 
 
947 ± 144 
 
983 ± 97 
 
1043 ± 141 
 
 
day 14 939 ± 23 
 
837 ± 78 * 691 ± 60 *** 936 ± 119 
 
855 ± 91 
 
714 ± 78 ** 
 
day 28 800 ± 79 
 
824 ± 19 
 
966 ± 126 
 
921 ± 85 
 
877 ± 29 
 
846 ± 31 
 
              WBC [counts/nL] day 3 8.00 ± 1.09 
 
5.64 ± 1.40 * 5.36 ± 1.50 * 5.90 ± 1.74 
 
4.72 ± 0.79 * 3.84 ± 1.32 ** 
 
day 7 8.20 ± 1.20 
 
6.50 ± 1.17 * 4.28 ± 0.76 *** 6.16 ± 1.83 
 
3.84 ± 0.79 
 
3.32 ± 0.75 ** 
 
day 14 7.38 ± 1.47 
 
6.72 ± 1.26 
 
5.06 ± 1.51 * 7.20 ± 0.92 
 
5.70 ± 1.20 
 
4.20 ± 1.37 
 
 
day 28 7.66 ± 1.81 
 
7.82 ± 0.26 
 
5.66 ± 0.70 * 4.84 ± 0.69 
 
3.86 ± 0.71 
 
4.20 ± 0.55 
 
              NEU [counts/nL] day 3 2.12 ± 0.88 
 
0.77 ± 0.32 ** 0.79 ± 0.18 ** 0.87 ± 0.36 
 
0.84 ± 0.56 
 
0.43 ± 0.12 
 
 
day 7 1.37 ± 0.37 
 
0.74 ± 0.21 ** 0.63 ± 0.21 ** 1.78 ± 1.30 
 
0.51 ± 0.24 * 0.37 ± 0.17 * 
 
day 14 1.26 ± 0.12 
 
1.14 ± 0.38 
 
1.05 ± 0.78 
 
1.75 ± 0.35 
 
1.03 ± 0.32 ** 0.74 ± 0.31 *** 
 
day 28 1.89 ± 0.96 
 
1.42 ± 0.26 
 
1.20 ± 0.49 
 
1.01 ± 0.21 
 
0.70 ± 0.21 
 
0.69 ± 0.17 * 
              Lymph [counts/nL] day 3 5.41 ± 0.39 
 
4.61 ± 1.05 
 
4.31 ± 1.39 
 
4.76 ± 1.43 
 
3.66 ± 0.56 
 
3.23 ± 1.15 
 
 
day 7 6.38 ± 0.93 
 
5.53 ± 0.93 
 
3.43 ± 0.50 *** 4.10 ± 0.79 
 
3.14 ± 0.64 
 
2.80 ± 0.65 * 
 
day 14 5.80 ± 1.28 
 
5.26 ± 0.82 
 
3.78 ± 0.74 * 5.08 ± 0.70 
 
4.41 ± 1.06 
 
3.24 ± 0.99 * 
 
day 28 5.41 ± 0.85 
 
6.02 ± 0.37 
 
4.14 ± 0.51 * 3.60 ± 0.62 
 
2.99 ± 0.76 
 
3.34 ± 0.39 
 
      
 
       
1
2
8
 
 129 
 
    Cisplatin [mg/kg] 
 
  
male female 
   time 0   0.3   0.6   0   0.3   0.6 
 EOS [counts/nL] day 3 0.24 ± 0.09 
 
0.11 ± 0.04 ** 0.10 ± 0.04 ** 0.10 ± 0.04 
 
0.09 ± 0.01 
 
0.06 ± 0.01 * 
 
day 7 0.20 ± 0.03 
 
0.10 ± 0.02 ** 0.09 ± 0.06 ** 0.12 ± 0.05 
 
0.05 ± 0.02 * 0.04 ± 0.02 ** 
 
day 14 0.14 ± 0.03 
 
0.07 ± 0.03 ** 0.07 ± 0.04 ** 0.17 ± 0.16 
 
0.07 ± 0.02 
 
0.05 ± 0.03 
 
 
day 28 0.13 ± 0.02 
 
0.13 ± 0.04 
 
0.10 ± 0.03 
 
0.10 ± 0.04 
 
0.07 ± 0.02 
 
0.06 ± 0.01 
 
              BASO [counts/nL] day 3 0.07 ± 0.02 
 
0.03 ± 0.01 ** 0.02 ± 0.02 ** 0.06 ± 0.03 
 
0.03 ± 0.01 
 
0.02 ± 0.01 ** 
 
day 7 0.07 ± 0.02 
 
0.04 ± 0.02 ** 0.02 ± 0.01 *** 0.05 ± 0.03 
 
0.02 ± 0.01 
 
0.02 ± 0.01 ** 
 
day 14 0.07 ± 0.03 
 
0.04 ± 0.02 
 
0.03 ± 0.01 * 0.04 ± 0.02 
 
0.03 ± 0.02 
 
0.02 ± 0.01 
 
 
day 28 0.07 ± 0.03 
 
0.05 ± 0.01 
 
0.03 ± 0.02 
 
0.04 ± 0.02 
 
0.03 ± 0.00 
 
0.02 ± 0.01 
 
              MONO [counts/nL] day 3 0.12 ± 0.04 
 
0.08 ± 0.04 
 
0.12 ± 0.03 
 
0.09 ± 0.03 
 
0.10 ± 0.03 
 
0.09 ± 0.05 
 
 
day 7 0.15 ± 0.04 
 
0.10 ± 0.03 
 
0.10 ± 0.03 
 
0.10 ± 0.07 
 
0.07 ± 0.02 
 
0.06 ± 0.03 
 
 
day 14 0.10 ± 0.05 
 
0.15 ± 0.08 
 
0.13 ± 0.05 
 
0.12 ± 0.04 
 
0.14 ± 0.06 
 
0.12 ± 0.11 
 
 
day 28 0.15 ± 0.08 
 
0.16 ± 0.04 
 
0.13 ± 0.06 
 
0.07 ± 0.02 
 
0.05 ± 0.02 
 
0.07 ± 0.03 
 
              LUC [counts/nL] day 3 0.03 ± 0.01 
 
0.01 ± 0.01 * 0.01 ± 0.01 ** 0.02 ± 0.02 
 
0.01 ± 0.01 
 
0.01 ± 0.01 
 
 
day 7 0.03 ± 0.01 
 
0.02 ± 0.00 
 
0.01 ± 0.01 *** 0.01 ± 0.01 
 
0.01 ± 0.00 
 
0.01 ± 0.00 
 
 
day 14 0.02 ± 0.01 
 
0.02 ± 0.01 ** 0.01 ± 0.01 
 
0.02 ± 0.01 
 
0.01 ± 0.01 
 
0.01 ± 0.01 
   day 28 0.02 ± 0.01   0.03 ± 0.00   0.02 ± 0.01   0.02 ± 0.01   0.01 ± 0.01   0.01 ± 0.01 
 Abbreviation: RBC = red blood cells, PLT = platelets, WBC = white blood cells, NEU = neutrophils, Lymph = Lymphocytes, EOS = eosiniphilics, BASO = basophilics, MONO = monocytes, LUC = large unstained cells. 
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Detection of novel qualified and exploratory urinary proteins (Cisplatin) 
 
In animals treated with either 0.3 mg/kg or 0.6 mg/kg Cisplatin for up to 28 days the urinary excretion of the evaluated 
biomarker only changed in some limited cases. In male rats urinary Kim-1 showed the most prominent and statistically 
significant alterations, which was time and dose dependent (Figure 3-13a). The low dose (0.3 mg/kg) treated male rats 
showed no alteration, while the high dose treated animals (0.6 mg/kg) showed a significant increase, earliest on day 4. 
However, on this day of urine collection, histopathological observed tubular degeneration/ necrosis were only found in 
two of the five animals. Kim-1 was increased in the urine of all animals on day 4; with higher levels observed on day 8, 
where all five animals showed tubular alterations was higher. Animals treated for 15 and 29 days showed a time-
dependent decrease compared to day 8, but was still significantly elevated.  
 
 
Figure 3-13 Excretion of (a) Kim-1, (b) NGAL, (c) b2m, (d) Timp-1, (e) VEGF, (f) CystatinC, (g) Osteopontin, (h), 
Calbindin28k, (i) Clusterin in urine of male rats treated with Cisplatin (low dose: 0.3 mg/kg; high dose: 0.6 mg/kg) for 3 days 
(dots), 7 days (squares), 14 days (triangle), and 28 days (rhombus). Data are presented as individual animals and as the mean 
(bar; n=5). The light grey signs indicate no tubular degeneration found within this animal, the darker grey indicates tubular 
degeneration observed. * p < 0.05, ** p < 0.01, *** p < 0.001 (ANOVA-Dunnett). 
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Figure 3-14 Excretion of (a) Kim-1, (b) NGAL, (c) b2m, (d) Timp-1, (e) VEGF, (f) CystatinC, (g) Osteopontin, (h), 
Calbindin28k, (i) Clusterin in urine of female rats treated with Cisplatin (low dose: 0.3 mg/kg; high dose: 0.6 mg/kg) for 3 days 
(dots), 7 days (squares), 14 days (triangle), and 28 days (rhombus). Data are presented as individual animals and as the mean 
(bar; n=5). The light grey signs indicate no tubular degeneration found within this animal, the darker grey indicates tubular 
degeneration observed. *p < 0.05, **p < 0.01, *** < 0.001 (ANOVA-Dunnett). 
 
Other urinary biomarkers showing statistical or biological significant changes were 2m, Osteopontin, Calbindin and 
Clusterin (Figure 3-13c, -g, -h, -i). In case of urinary 2m excretion no time or treatment-related elevation in urinary 
level were observed. However, because of the strong variation in opposite directions, the significant result obtained for 
the high dose treated animals on day 15 should be rejected because of the lack of biological relevance. The low dose 
treated male rats (0.3 mg/kg) showed no alterations over time, while animals of the high dose treated group (0.6 mg/kg) 
showed an increase of urinary Osteopontin on day 8 and day 15 in individual animals, while no alterations were 
observed on days 4 or 29, independent of the observed histopathological outcome (Figure 3-13g). Animals of the 
control group showed a decrease in urinary Calbindin level on day 29 leading as a consequence to a calculated p-value 
of <0.05 in low dose treated animals (0.3 mg/kg (Figure 3-13h). In contrast, animals on day 15 of the same treatment 
group showed a significant decrease compared to the corresponding control group. Also on day 15 in high dose treated 
groups (0.6 mg/kg) a statistically significant decrease was observed. However, two animals on day 8 showed a very 
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strong increase, while the other animals, which showed the same severity of renal damage, had no elevated Calbindin. 
In contrast, Clusterin showed no statistically significant changes over the single time points of the high dose treated 
animals (0.6 mg/kg), although a relevant time-dependent increase from day 4 to day 15 was observed. On day 29 
urinary Clusterin levels were still enhanced on average, but below the level of day 15. The other biomarkers, NGAL, 
Timp-1, VEGF and CystatinC (Figure 3-13 b, -d, -e, -f) showed no biological or statistical significant or biological 
relevant changes. 
In female rats the only limited changes in urinary biomarkers was observed. Statistically significant findings were 
measured for Kim-1 in high dose treated animals (0.6 mg/kg) on day 8 (Figure 3-14a), and Osteopontin of the same 
treatment group on day 15. The only female rat showing tubular degeneration and necrosis was clearly identified by 
Kim-1, Osteopontin and Clusterin (Figure 3-14a, -g, -i). The urinary excretion of Kim-1 for example was approximatly 
50-fold higher than the corresponding control and ~35 fold of the other animals of the same group. 
 
Table 3-12 Area-under-the-receiver-operator-characteristic curve (AUROC) for detection of Cislpatin induced 
nephrotoxicity. The area under the curve is used as a measure for the overall ability of a biomarker to discriminate 
animals without histopathological findings in kidney from those with signs of tubular damage (degeneration/ necrosis). 
Markers with a good diagnostic performance (AUROC > 0.90) are highlighted in bold. In addition the 95% confidence 
interval and the p-value are displayed. The AUROC for female rats were not calculated because of only one animal with 
biological important histopathological findings. * =measurement by Luminex® xMAP®, ** = measurement by RENA®-
Sticks, #= classical clinical-pathology parameter determined by standard procedures. 
Kidney Biomarker Male
 
  Female 
AUROC 95% CI p-value   AUROC 95% CI p-value 
Kim-1* 0.95 0.89 - 1.00 <0.0001  / / / 
Timp-1* 0.68 0.53 - 0.82 0.0337  / / / 
VEGF* 0.57 0.41 - 0.73 0.3891  / / / 
ß2-Microglobulin* 0.69 0.53 - 0.85 0.0203  / / / 
Clusterin* 0.81 0.68 - 0.95 0.0003  / / / 
Cystatin C* 0.53 0.37 - 0.70 0.6757  / / / 
Lipocalin-2/ NGAL* 0.56 0.40 - 0.72 0.4755  / / / 
Osteopontin* 0.75 0.60 - 0.90 0.0028  / / / 
Calbindin * 0.58 0.41 - 0.75 0.3291  / / / 
Kim-1** 0.82 0.69 - 0.96 0.0001  / / / 
BUN
#
 0.74 0.57 - 0.91 0.0036  / / / 
Serum Creatinine
#
 0.55 0.38 - 0.72 0.5659  / / / 
 
Osteopontin showed for the same individual female rat an elevation in urine of nearby 6-fold of the control and still 3-
fold to the other animals of the same treatment group. However, NGAL, 2m, Timp-1, VEGF, CystatinC and Calbindin 
showed no or only weak changes for this female rat (Figure 3-14 b, -c, -d, -e, -f, -h). To evaluate the performance of 
these urinary protein biomarker ROC curves were calculated. However, because only one female rat showed 
histopathological changes, it was not possible to calculate ROC curves. The results of this analysis are given in Table 
3-12. In male rats, Kim-1 performed well when using both technologies tested (the Luminex
®
 xMAP
®
 technology (m: 
0.95) as well as the Dipstick assay (m: 0.82)). Clusterin (m: 0.81) was below the defined threshold of 0.90 while 
Osteopontin showed an AUROC of 0.75 and was therefore the third-best parameter determined within the Cisplatin 
study. The other novel urinary protein biomarkers showed AUC values below 0.70 (Timp-1: 0.68; VEGF: 0.57; ß2m: 
0.69; CystatinC: 0.53; NGAL: 0.56; Calbindin: 0.58). The traditional clinical-pathological parameters showed 
inconsistent results. BUN showed an AUC of 0.74 while serum creatinine had the lowest value, with no diagnostic 
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potential (m: 0.55). Kim-1 and Clusterin were the only markers indicating significant or biologically relevant alterations 
in the kidney, while Osteopontin gave a relevant hint only on day 8 and day 15.  
 
3.1.1.4 Discussion and Conclusion (Cisplatin) 
 
The doses of Cisplatin were chosen to induce only mild histopathological changes in high dose and no to minimal 
changes in low dose animals. The main aim was to see whether the urinary protein biomarkers can be used for detection 
of such small changes or predict early developing changes. As shown in the section 3.1.1.3 the expected mild changes 
were induced, especially in male rats. The lack of observations in females, except for one rat, indicates a higher 
resistance of females to cisplatin-induced nephrotoxicity after long-term treatment.  
The only mild renal alterations are reflected among other things by the lack of changes in kidney weight (Table 3-8). 
That did not mean that no strong systemic alterations were caused by Cisplatin treatment. Therefore, the strong decrease 
in body weight of male rats treated with 0.6 mg/kg Cisplatin clearly indicates degree of toxicity caused (Table 3-8). 
Also female rats treated with the same dose showed an effect after 7 days of daily treatment. However, the recovery 
periods lead to only a slight but still present lowered body weight compared to the control group at later time points. 
The most obvious systemic changes were neutropenia, a reduction of white blood cells including neutrophils, 
lymphocytes, eosinophils, basophils and large unstained cells, in both genders (Table 3-11). This effect can be 
attributed to the pharmacological function of Cisplatin, which acts as an inhibitor of proliferation and the 
hematotoxicity of Cisplatin has been previously reported [Khynriam et al., 2001]. In contrast, the platelet count was 
slightly increased in both genders on days 3 and 7 with a strong and statistical significant decrease on day 14. The 
thromocytosis, observed at the earlier times, can be explained by very early anemia. The involvement of nephritis in this 
phenotypical outcome is unlikely because of the lack of dominant infiltrates (Table 3-7) and the general signs of 
systemic inflammatory seen histopathologically.  
The histopathological findings within renal tissue were well reflected by several biomarkers. The best biomarker in this 
case was Kim-1 (Figure 3-13 a), as identified by ROC analysis for male rats (Table 3-12). This urinary protein, which is 
described to be specific for proximal tubular damage, more precisely of the S3 segment [Zhang et al., 2009] delivered a 
AUC of the ROC of 0.95 (0.89-1.00). This underlines the importance of this biomarker, as well as showing a clear 
indication for the mechanism of cisplatin induced nephrotoxicity [Kroning et al., 2000], which is also described to 
specifically hit the part of the S3 segment by enhanced accumulation within this area [Arany et al., 2003]. Beside the S3 
segment also slight effects on the S1 segment of the proximal and the distal tubulus have been described [Arany et al., 
2003; Kroning et al., 2000]. Therefore, the low concentration used within this study seems to hit exclusively the S3 
segment, which was clearly seen by the increase in urinary Kim-1. Beside Kim-1 only Clusterin showed a relatively 
good performance of 0.81 (0.68-0.95). Osteopontin, which was one of the best urinary biomarker within the 
Vancomycin study, had the third highest AUC of 0.75 (0.60-0.90) of the evaluated urinary protein biomarker. Based on 
the slight effects on the kidney seen within this study, it was not unexpected that some biomarkers for general tubular 
damage, like Timp-1, NGAL and VEGF, performed poorly. The same is the case for Calbindin, which is specific for 
distal tubular and collecting duct injury, which also showed a poor performance. Taken together, these results clearly 
show the great benefit of using a panal of urinary biomarker, specific for different areas within the nephron. We can 
conclude that for Cisplatin nephrotoxicity, the area of damage was limited to the S3 segment of the proximal tubular 
convolute. 
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In case of female rats treated with either 0.3 mg/kg or 0.6 mg/kg, even though no ROC curves could be calculated 
because of the lack of positive histopathological findings, the performance of some of the biomarkers were quite good 
(Figure 3-17). Kim-1, Osteopontin and Clusterin showed a clear increase in the individual female rat (Figure 3-17 a, g, 
i) identified to be positive for moderate tubular degeneration, mild dilatation, minimal necrosis as well as mild 
basophilic tubules and infiltrates (Table 3-7). The urinary excretion of 2m and CystatinC, both described to be specific 
for proximal tubular damage, showed no relevant alterations in urinary excretion level. This is reflected by the AUC for 
male rats (0.69 (0.53-0.85) for 2m and 0.53 (0.37-0.70) for Cystatin C) and by the fact that in female rats the affected 
animal did not show a relevant increase of these proteins compared to the others (Figure 3-14 c, f). This gives further 
indication of the questionable specificity of these two urinary biomarkers to be proximal tubular specific.  
Kim-1, Osteopontin and Clusterin all performed better than the traditional serum parameters, creatinine and BUN, with 
AUC values in male rats of 0.55 (0.38-0.72) and 0.74 (0.57-0.91), respectively. The better value for BUN reflects the 
slight dose-dependent increase observed in low dose (0.3 mg/kg) treated animals. In contrast, the reduction in serum 
creatinine, especially in the first week of daily administration, can be due to the reduction in body weight and therefore 
the reduced muscle mass. This was confirmed because male rats, characterized by an increased creatinine clearance 
(Figure 3-12) and a strong reduced body weight (Table 3-8), showed a much stronger reduction (Table 3-9). The poor 
performance of the traditional parameters clearly shows the benefits of the novel biomarkers. The sensitivity of 
functional parameters like the creatinine clearance can be categorized as low for the predictivity of very early and slight 
insults to renal tissue. The effect of a decrease in urinary sodium and calcium excretion (Figure 3-12) can be interpreted 
as the physiologic response to a decrease in renal perfusion to control hypovolemia, which is reflected by the decline in 
urinary output (Table 3-10). In contrast to the situation within the Vancomycin study, where the increase in urinary 
glucose level was determined to be caused by proximal tubular break-down, in Cisplatin treated animals the increase 
(Table 3-10) seems to be caused by an increase in blood sugar level (Table 3-9), which was observed specifically on 
day 7. Therefore, the only prominent treatment related alteration in renal function can defined by a slight increase in 
creatinine clearance in low dose (0.3 mg/kg) treated animals on days 3 and 7 and the alterations within the electrolytes 
in high dose (0.6 mg/kg) treated animals. 
In summary, the novel urinary protein biomarkers, evaluated within this study to allow the detection of only mild renal 
injury, can be used, but with several limitations. Kim-1, which has a special significance within this study because of its 
toxicity target, Clusterin and Osteopontin can be defined as the most promising urinary biomarker. The benefit of the 
combined determination of these three urinary protein biomarkers is the overlapping specificity of the nephron area, 
enabling the identification of the major location of damage. Because of the major changes in Kim-1, the location could 
be further sublocalized as proximal tubular specific. Additionally, further evidence was given by the data presented, that 
the usefulness of 2m and Cystatin C to function as biomarkers for proximal tubular damage is strongly limited.  
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3.1.1.5 Results (Puromycin) 
 
Histopathological observation (Puromycin) 
 
Gross pathological kidney-related findings were restricted to high dose animals (30/20 mg/kg) after 14 and 28 days of 
treatment. The main macroscopic observations on days 15 and 29 were a bilateral pale discoloration, enlargement of the 
whole organ and a granular surface. In addition, minimal accumulation of fluid in the abdomen and the thorax of high 
dose (30/20 mg/kg) treated animals was observed as early as day 8. An overview of the results is summarized in Table 
3-13. 
On day 4 no animal of any group showed effects in the kidneys. On day 8 a minimal vacuolation of the glomerular tufts 
was observed in one male rat and two females of the high dose (30/20 mg/kg) treatment group. Animals treated for 14 
days with high dose (30/20 mg/kg) Puromycin showed mild to moderate multifocal glomerular vacuolations, as well as 
mild to massive tubular degeneration. In addition, mild to moderate tubular dilatation was observed in both sexes. The 
severity was slighty more pronounced in male rats then in females of the same dose group. After 29 days of treatment 
with 30/20 mg/kg (high dose) Puromycin, only one individual male rat survived with mild vacuolation of glomerular 
tufts, moderate tubular degeneration but without dilatation. Female rats of the same dose group showed minimal to mild 
vacuolation of glomerular tufts, minimal tubular degeneration. Minimal tubular dilation was also observed in one 
female rat. Severity of the lesions was slightly more pronounced in the males. 
Beside the described findings also mild to moderate eosinophilic casts were observed in all male and female rats treated 
with 30/20 mg/kg Puromycin for 14 and 28 days. Basophilic tubules were described without a strong treatment 
dependency. 
 
 
Clinical, clinical-pathological and hematological observation (Puromycin) 
 
Only significant observation or relevant parameters in case of the underlying evaluation are shown. The tables for all 
three studies show the same parameters to allow comparison between the different compounds even though some 
parameters show no relevant effects in one or two compounds. 
In almost all clinical-pathological parameter, female rats showed a stronger or even earlier alteration compared to the 
corresponding male animals (Table 3-14- Table 3-17). A slight reduction in terminal body weight was observed on day 
3 in both genders.  
A statistically significant reduction in body weight in female rats was observed after only 7 days of high dose (30/20 
mg/kg) treatment, and remained constant up to day 29. Male rats treated with the same doses showed a significant 
decrease in body weight only on days 14 and 28 (Table 3-14). The kidney weight was less affected then the body 
weight in both genders. On day 8 a significant decrease in both genders was observed, while the later time points 
showed a specific increase in kidney weight. Statistical significance in male rats was limited to day 7 after treatment 
with 30/20 mg/kg Puromycin. 
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Table 3-13 Incidence summary of Puromycin treatment-related kidney histophatology findings. The number of animals in each 
group of five is shown in parentheses. / ≙ lesion not observed, + ≙ minimal, ++ ≙ mild, +++ ≙ moderate, ++++ ≙ massive, and 
+++++ ≙ high severity of lesion 
    Puromycin [mg/kg] 
    male Female 
  time 0   10   30/20   0   10   30/20 
Tubular  
Degeneration 
day 4 / 
 
/ 
 
/ 
 
/ 
 
/ 
 
/ 
 
day 8 / 
 
/ 
 
/ 
 
/ 
 
/ 
 
+ (1/5) 
 
day 15 / 
 
/ 
 
+++ (4/5) 
++++ (1/5) 
 
/ 
 
/ 
 
++ (5/5) 
  
day 29 / 
 
/ 
 
+++ (1/1) 
 
/ 
 
+ (1/5) 
 
+ (5/5) 
Tubular  
Dilatation 
day 4 / 
 
/ 
 
/ 
 
/ 
 
/ 
 
/ 
 
day 8 / 
 
/ 
 
/ 
 
/ 
 
/ 
 
/ 
 
day 15 / 
 
/ 
 
++ (3/5) 
+++ (1/5) 
 
/ 
 
/ 
 
++ (5/5) 
  
day 29 / 
 
/ 
 
/ 
 
/ 
 
/ 
 
+ (1/5) 
Eosinophilic  
Casts 
day 4 / 
 
/ 
 
/ 
 
/ 
 
/ 
 
/ 
 
day 8 / 
 
/ 
 
+++ (1/5) 
 
/ 
 
/ 
 
+ (2/5) 
 
day 15 / 
 
/ 
 
+++ (5/5) 
 
/ 
 
/ 
 
+++ (5/5) 
  
day 29 / 
 
/ 
 
+++ (1/1) 
 
/ 
 
+ (2/5) 
 
++ (3/5) 
+++ (2/5) 
Basophilic  
Tubules 
day 4 / 
 
+ (2/5) 
 
+ (2/5) 
 
/ 
 
/ 
 
+ (1/5) 
 
day 8 / 
 
/ 
 
+ (2/5) 
 
+ (1/5) 
 
/ 
 
/ 
 
day 15 + (2/5) 
 
/ 
 
+++ (1/5) 
 
/ 
 
/ 
 
/ 
  
day 29 / 
 
+ (3/5) 
 
/ 
 
/ 
 
+ (1/5) 
 
/ 
Glomerular  
Damage 
day 4 / 
 
/ 
 
/ 
 
/ 
 
/ 
 
/ 
 
day 8 / 
 
/ 
 
+ (1/5) 
 
/ 
 
/ 
 
+ (1/5) 
 
day 15 / 
 
/ 
 
++ (1/5) 
++ (2/5) 
+++ (3/5)  
/ 
 
/ 
 
++ (5/5) 
  
day 29 / 
  
/ 
  
++ (1/1) 
          
+ (4/5) 
++ (1/5) 
 
Females showed significant alterations on days 8, 15 and 29. In serum, both traditional parameters showed time 
dependent changes in both sexes, but more pronounced in female rats (Table 3-15).  
Serum creatinine significantly decreased on days 3 and 7 in low (10 mg/kg) and high dose (30/20 mg/kg) treated female 
rats, while in male rats the same alteration was earliest observed on day 7. In contrast, both genders showed a strong 
increase in serum creatinine on day 15 in high dose groups (30/20 mg/kg) while the low dose (10 mg/kg) treated 
animals showed no alteration. On day 29 a slight, non significant increase was observed in both sexes and dose groups. 
BUN significantly increased only on days 14 and 28 in male and female rats after high dose (30/20 mg/kg) Puromycin 
treatment. 
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Table 3-14 Summary of body and kidney weight determined for male and female rats treated with 10 mg/kg and 30/20 mg/kg Puromycin for up to 28 days. The data of the control group are 
displayed in each table. Significant changes were indicated with * p < 0.05, ** p < 0.01, *** p < 0.001 (ANOVA + Dunnett). Because only one male rat on day 28 survived, no statistics could be 
performed. Strong changes were indicated with (*) based on comparison groups found to be significant altered 
 
In contrast to male rats females showed a slight but statistically non significant increase in low dose (10 mg/kg) treated animals on day 3 followed by a decrease after high dose 
treatment (30/20 mg/kg). Serum glucose levels showed only mild changes over time and dose, with the exception of male rats treated with 30/20 mg/kg Puromycin for 14 days and 
one individual rat on day 29 (Table 3-15), which showed a strong decrease in serum glucose level. The major alterations in urinanalysis were focused on days 15 and 29 (Table 
3-16). However, some effects were also observed at day 4, for example a halfing in urine volume of male rats treated with 30/20 mg/kg Puromycin. In general the decrease in urinary 
output was more pronounced in male rats than in females but with the strongest impact on days 15 and 29 in both sexes where it was reduced to nearly 25% in males and 50% in 
females. Comparable to the serum glucose level also urinary glucose (Table 3-16) showed only slight changes. Therefore, a slight but non statistically significant increase was 
observable in male rats of the high dose (30/20 mg/kg) treatment group on day 4. In contrast, female rats showed a significant decreased urinary glucose level, both in low (10 
mg/kg) and high (30/20 mg/kg) treated animals While urinary glucose levels remained relatively constant on day 8 a strong impact in female rats was observed on day 15 in high 
dose (30/20 mg/kg) animals, where a 3-fold increase was observed. Only individual male rats on day 28 showed a marked increase in urinary glucose level. The most prominent 
finding in urinary parameters was the increase in urinary total protein. While in male rats no changes after 4 or 8 days was observed, female rats showed a non-significant increase on 
day 8. Subsequently, an extremely strong increase was found in both genders after high dose (30/20 mg/kg) Puromycin treatment on day 15 (~30-fold increase in male (~16.0 g/L) 
and ~330-fold increase in female rats (~26.6 g/L)) compared to the corresponding control animals. 
 
    Puromycin [mg/kg] 
 
  
Male Female 
   time 0   10   30/20   0   10   30/20 
 body weight [g] day 3 255 ± 6   248 ± 6   249 ± 6 
 
170 ± 4 
 
166 ± 6 
 
165 ± 6 
 
 
day 7 275 ± 14 
 
271 ± 8 
 
261 ± 12 
 
178 ± 5 
 
173 ± 7 
 
165 ± 2 ** 
 
day 14 281 ± 13 
 
281 ± 11 
 
255 ± 5 ** 182 ± 10 
 
172 ± 9 
 
167 ± 7 * 
 
day 28 307 ± 14 
 
321 ± 10 
 
227 (*) 180 ± 6 
 
184 ± 10 
 
155 ± 9 *** 
              kidney weight [g] day 3 2.16 ± 0.07 
 
2.11 ± 0.05 
 
2.06 ± 0.18 
 
1.39 ± 0.06 
 
1.37 ± 0.06 
 
1.43 ± 0.10 
 
 
day 7 2.20 ± 0.13 
 
2.06 ± 0.07 
 
1.90 ± 0.30 * 1.49 ± 0.13 
 
1.36 ± 0.08 
 
1.33 ± 0.10 * 
 
day 14 2.15 ± 0.14 
 
1.93 ± 0.17 
 
2.15 ± 0.13 
 
1.41 ± 0.11 
 
1.33 ± 0.09 
 
1.59 ± 0.13 * 
  day 28 2.16 ± 0.12   2.33 ± 0.18   2.22   1.36 ± 0.06   1.45 ± 0.15   1.67 ± 0.23 * 
1
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Table 3-15 Summary of clinical pathology serum parameter determined for male and female rats treated with saline, 10 mg/kg and 30/20 mg/kg Puromycin for up to 28 days. The data of the 
control group are displayed in each table. Significant changes were indicated with * p < 0.05, ** p < 0.01, *** p < 0.001 (ANOVA + Dunnett). Because only one male rat on day 28 survived, no 
statistics could be performed. Strong changes were indicated with (*) based on comparison groups found to be significant altered. 
    Puromycin [mg/kg] 
 
  
Male female 
   time 0   10   30/20   0   10   30/20 
 Creatinine [mg/dL] day 3 0.19 ± 0.01 
 
0.19 ± 0.01 
 
0.19 ± 0.01 
 
0.25 ± 0.02 
 
0.19 ± 0.02 ** 0.14 ± 0.02 *** 
 
day 7 0.21 ± 0.02 
 
0.16 ± 0.02 * 0.17 ± 0.04 * 0.24 ± 0.03 
 
0.19 ± 0.04 
 
0.17 ± 0.04 * 
 
day 14 0.23 ± 0.02 
 
0.20 ± 0.03 
 
1.26 ± 0.82 ** 0.23 ± 0.03 
 
0.23 ± 0.03 
 
0.56 ± 0.18 *** 
 
day 28 0.21 ± 0.01 
 
0.23 ± 0.03 
 
0.32 
 
0.26 ± 0.04 
 
0.27 ± 0.04 
 
0.31 ± 0.07 
 
              BUN [mg/dL] day 3 27.74 ± 1.67 
 
29.43 ± 2.21 
 
29.79 ± 2.50 
 
30.63 ± 2.44 
 
34.95 ± 3.92 
 
28.71 ± 1.07 
 
 
day 7 28.11 ± 2.38 
 
27.98 ± 2.27 
 
34.71 ± 8.03 
 
30.99 ± 1.62 
 
31.71 ± 3.07 
 
34.35 ± 4.04 
 
 
day 14 28.59 ± 2.06 
 
31.83 ± 3.63 
 
345.91 ± 211.81 ** 34.35 ± 1.87 
 
37.23 ± 5.70 
 
194.21 ± 46.72 *** 
 
day 28 27.74 ± 2.95 
 
30.03 ± 1.85 
 
56.45 (*) 31.47 ± 2.02 
 
33.03 ± 2.72 
 
43.48 ± 6.03 *** 
              Glucose [mg/dL] day 3 79.28 ± 9.87 
 
83.60 ± 12.65 
 
84.69 ± 10.89 
 
81.08 ± 14.53 
 
76.04 ± 8.10 
 
78.92 ± 4.49 
 
 
day 7 83.60 ± 13.76 
 
83.24 ± 12.05 
 
90.45 ± 6.55 
 
86.49 ± 5.25 
 
65.95 ± 6.45 * 71.35 ± 5.78 
 
 
day 14 103.06 ± 19.42 
 
83.96 ± 8.70 
 
74.78 ± 17.99 * 79.28 ± 6.98 
 
78.56 ± 5.78 
 
88.29 ± 15.66 
   day 28 113.15 ± 14.49   96.22 ± 10.24   86.49 (*) 84.69 ± 7.85   80.72 ± 7.79   77.84 ± 6.16 
  
The low dose (10 mg/kg) treated animals remained unaltered. While the high amount of urinary protein was constant in female rats, the male rats at this time point showed a further 
increase in urinary protein (~54.6 g/L) on day 28 of treatment (up to ~148-fold) (Table 3-16). In contrast, the level of urinary creatinine showed only mild changes over time and 
dose. A slight decrease in low dose (10 mg/kg) treated animals of both sexes and a significant increase in high dose (30/20 mg/kg) treated male rats was seen on day 4. In addition, a 
slight increase in both genders appeared after 14 days of high dose (30/20 mg/kg) treatment and in low dose (10 mg/kg) treated female rats. The most prominent increase was 
observed for the surviving male rat treated for 28 days with 30/20 mg/kg Puromycin. The renal functional properties showed the most relevant disturbances after 14 days of high 
dose (30/20 mg/kg) Puromycin treatment (Figure 3-15). A strong decrease in urinary sodium excretion was detected on both genders after low (10 mg/kg) and high dose (30/20 
mg/kg) treatment. In female rats the decrease remained low up to day 29 in the high dose (30/20 mg/kg) group. Urinary excretion of calcium showed a strong increase on days 4 and 
8 in animals treated with 30/20 mg/kg Puromycin, followed by a strong decrease on day 15.  
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Table 3-16 Summary of clinical pathology urinary parameter determined for male and female rats treated with saline, 10 mg/kg and 30/20 mg/kg Puromycin for up to 28 days. The data of the 
control group are displayed in each table. Significant changes were indicated with * < 0.05, ** < 0.01, *** < 0.001 (ANOVA + Dunnett). Because only one male rat on day 28 survived, no 
statistics could be performed. Strong changes were indicated with (*) based on comparison groups found to be significant altered. 
    Puromycin [mg/kg] 
 
  
Male female 
   time 0   10   30/20   0   10   30/20 
 Volumen [mL] day 3 20.04 ± 6.90   22.72 ± 6.45   10.74 ± 2.20 * 9.26 ± 4.63   12.92 ± 3.66   8.78 ± 3.72 
 
 
day 7 16.88 ± 7.16 
 
17.76 ± 4.04 
 
15.18 ± 5.68 
 
8.2 ± 3.05 
 
11.7 ± 5.05 
 
8.46 ± 4.94 
 
 
day 14 24.84 ± 10.44 
 
18.76 ± 3.79 
 
6.88 ± 2.94 ** 12.8 ± 1.99 
 
7.42 ± 4.25 
 
6.8 ± 2.96 *** 
 
day 28 23.60 ± 6.81 
 
15.88 ± 5.54 
 
5.50 (*) 11.22 ± 6.41 
 
10.6 ± 5.3 * 6.94 ± 1.84 * 
              Glucose [mg/dL] day 3 5.41 ± 3.12 
 
4.32 ± 0.99 
 
7.21 ± 2.21 
 
10.09 ± 4.70 
 
4.68 ± 0.99 * 6.85 ± 2.96 
 
 
day 7 6.49 ± 2.05 
 
5.05 ± 0.81 
 
6.13 ± 3.02 
 
7.57 ± 3.22 
 
4.50 ± 1.04 
 
6.13 ± 1.61 
 
 
day 14 5.77 ± 4.11 
 
4.32 ± 0.99 
 
6.13 ± 2.73 
 
5.05 ± 0.81 
 
7.93 ± 3.51 
 
14.77 ± 4.66 ** 
 
day 28 4.32 ± 0.99 
 
6.85 ± 2.96 
 
10.81 (*) 6.49 ± 2.73 
 
5.77 ± 2.96 
 
7.21 ± 1.27 
 
              total protein [mg/dL] day 3 43.22 ± 21.00 
 
32.70 ± 24.19 
 
42.40 ± 11.48 
 
14.78 ± 8.26 
 
6.78 ± 2.11 
 
11.42 ± 5.01 
 
 
day 7 44.40 ± 13.57 
 
42.08 ± 13.74 
 
53.36 ± 21.73 
 
12.92 ± 4.40 
 
10.50 ± 2.20 
 
29.90 ± 28.57 
 
 
day 14 48.04 ± 28.02 
 
40.36 ± 13.93 
 
1603.06 ± 586.51 *** 8.64 ± 1.38 
 
19.16 ± 9.59 
 
2656.06 ± 788.6 *** 
 
day 28 37.12 ± 16.76 
 
143.58 ± 56.91 ** 5458.60 (*) 11.90 ± 5.99 
 
101.54 ± 127.86 
 
2801.82 ± 436.65 *** 
              Creatinine [mg/dL] day 3 40.52 ± 15.78 
 
29.72 ± 10.35 
 
63.05 ± 11.63 * 55.71 ± 23.23 
 
34.98 ± 9.83 
 
52.32 ± 19.45 
 
 
day 7 48.05 ± 14.22 
 
44.02 ± 9.62 
 
57.45 ± 25.97 
 
52.64 ± 12.27 
 
35.99 ± 9.76 
 
57.77 ± 12.11 
 
 
day 14 42.51 ± 21.09 
 
41.76 ± 9.48 
 
60.16 ± 17.31 
 
42.17 ± 6.38 
 
72.95 ± 40.33 
 
68.43 ± 25.24 
   day 28 36.61 ± 6.93   62.24 ± 24.41   108.41 (*) 53.74 ± 23.25   57.34 ± 42.48   59.1 ± 17.42 
  
In low dose (10 mg/kg) treated animals only a minimal increase in urinary calcium excretion was observed after 8 days. Creatinine clearance showed an increase on day 4 in males 
and in females on day 8 in high dose (30/20 mg/kg) animals, while a strong decrease was observed on day 15, and stayed low up to day 29.  
In contrast to the hematological findings reported in animals treated with Vancomycin (Table 3-5) or Cisplatin (Table 3-11), Puromycin treated rats showed very strong effects were 
observed in red blood cells and platelets and only minor changes were seen for white blood cells (Table 3-17). Statistically significant findings in the count of RBCs were limited to 
high dose (30/20 mg/kg) treated female rats, which showed a slight increase on day 4 and a strong decrease on day 29.  
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Table 3-17 Summary of hematological parameter determined for male and female rats treated with saline, 0.3 mg/kg and 0.6 mg/kg Cisplatin for up to 28 days. The data of the control 
group are displayed in each table. Significant changes were indicated with * < 0.05, ** < 0.01, *** < 0.001 (ANOVA + Dunnett). 
    Puromycin [mg/kg] 
 
  
Male female 
   Time 0   10   30/20   0   10   30/20 
 RBC [counts/pL] 
 
8.43 ±0.35 
 
8.00 ±0.35 
 
8.44 ±0.63 
 
8.19 ±0.16 
 
8.27 ±0.26 
 
8.58 ±0.05 ** 
  
9.25 ±0.39 
 
8.78 ±0.27 
 
8.82 ±0.45 
 
8.51 ±0.25 
 
8.66 ±0.41 
 
8.44 ±0.46 
 
  
8.49 ±0.37 
 
9.04 ±0.19 
 
9.31 ±1.54 
 
8.09 ±0.18 
 
8.55 ±0.33 
 
8.42 ±0.47 
 
  
8.86 ±0.35 
 
9.05 ±0.35 
 
6.48 
 
8.54 ±0.33 
 
8.78 ±0.27 
 
6.44 ±0.27 *** 
              PLT [counts/nL] 
 
909 ±100 
 
964 ±60 
 
960 ±112 
 
936 ±96 
 
957 ±123 
 
1046 ±80 
 
  
803 ±135 
 
901 ±74 
 
968 ±51 * 934 ±64 
 
910 ±51 
 
1239 ±154 *** 
  
882 ±95 
 
1054 ±87 
 
1617 ±146 *** 1001 ±125 
 
989 ±102 
 
1534 ±137 *** 
  
904 ±107 
 
979 ±88 
 
1804 
 
786 ±62 
 
896 ±172 
 
1423 ±307 *** 
              WBC [counts/nL] 
 
6.17 ±1.31 
 
4.8 ±1.54 
 
4.77 ±1.29 
 
5.05 ±2.35 
 
5.74 ±0.54 
 
5.54 ±1.18 
 
  
7.29 ±2.33 
 
9.23 ±1.59 
 
7.30 ±0.87 
 
5.60 ±1.35 
 
5.43 ±1.49 
 
5.73 ±2.28 
 
  
6.97 ±0.98 
 
7.76 ±1.19 
 
13.29 ±12.61 
 
4.77 ±0.83 
 
5.03 ±0.90 
 
4.76 ±2.73 
 
  
7.04 ±2.04 
 
6.56 ±1.07 
 
5.73 
 
5.27 ±2.26 
 
5.60 ±1.68 
 
6.08 ±1.50 
 
              NEU [counts/nL] 
 
1.16 ±0.28 
 
0.69 ±0.23 * 0.74 ±0.24 * 1.07 ±0.79 
 
0.74 ±0.27 
 
0.68 ±0.06 
 
  
1.86 ±0.72 
 
1.52 ±0.26 
 
1.43 ±0.30 
 
1.32 ±0.67 
 
1.15 ±0.55 
 
1.19 ±0.29 
 
  
1.33 ±0.37 
 
1.41 ±0.29 
 
4.93 ±6.48 
 
1.01 ±0.51 
 
0.91 ±0.09 
 
1.54 ±1.13 
 
  
1.54 ±0.68 
 
1.29 ±0.28 
 
1.09 
 
1.11 ±0.34 
 
1.10 ±0.27 
 
1.30 ±0.61 
 
              Lymph 
[counts/nL] 
 
4.69 ±1.05 
 
3.87 ±1.24 
 
3.84 ±1.39 
 
3.68 ±1.85 
 
4.72 ±0.60 
 
4.52 ±1.10 
 
  
4.98 ±2.07 
 
7.26 ±1.56 
 
5.57 ±0.75 
 
3.92 ±1.12 
 
4.01 ±1.58 
 
4.28 ±2.17 
 
  
5.30 ±0.66 
 
5.90 ±0.95 
 
7.63 ±5.81 
 
3.51 ±0.74 
 
3.83 ±0.87 
 
2.97 ±1.50 
 
  
5.12 ±1.24 
 
4.96 ±0.79 
 
4.27 
 
3.90 ±1.99 
 
4.14 ±1.38 
 
4.51 ±1.12 
 
              
     
 
        
1
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    Puromycin [mg/kg] 
 
  
Male female 
   Time 0   10   30/20   0   10   30/20 
 EOS [counts/nL] 
 
0.10 ±0.02 
 
0.08 ±0.04 
 
0.08 ±0.04 
 
0.11 ±0.05 
 
0.07 ±0.01 
 
0.09 ±0.05 
 
 
 
0.16 ±0.08 
 
0.14 ±0.05 
 
0.09 ±0.02 
 
0.09 ±0.04 
 
0.10 ±0.02 
 
0.05 ±0.01 
 
  
0.11 ±0.04 
 
0.16 ±0.08 
 
0.09 ±0.07 
 
0.11 ±0.04 
 
0.11 ±0.04 
 
0.03 ±0.03 * 
  
0.12 ±0.04 
 
0.12 ±0.02 
 
0.09 
 
0.1 ±0.06 
 
0.15 ±0.07 
 
0.07 ±0.02 
 
              BASO 
[counts/nL] 
 
0.06 ±0.02 
 
0.06 ±0.04 
 
0.05 ±0.02 
 
0.05 ±0.03 
 
0.07 ±0.02 
 
0.07 ±0.04 
 
  
0.08 ±0.04 
 
0.08 ±0.02 
 
0.07 ±0.02 
 
0.07 ±0.02 
 
0.05 ±0.02 
 
0.05 ±0.02 
 
  
0.07 ±0.04 
 
0.09 ±0.03 
 
0.08 ±0.09 
 
0.05 ±0.02 
 
0.06 ±0.02 
 
0.03 ±0.03 
 
  
0.05 ±0.01 
 
0.05 ±0.01 
 
0.03 
 
0.05 ±0.04 
 
0.06 ±0.04 
 
0.03 ±0.01 
 
              MONO 
[counts/nL] 
 
0.14 ±0.04 
 
0.09 ±0.05 
 
0.07 ±0.02 * 0.13 ±0.05 
 
0.12 ±0.05 
 
0.15 ±0.03 
 
  
0.19 ±0.05 
 
0.19 ±0.04 
 
0.12 ±0.04 
 
0.16 ±0.08 
 
0.12 ±0.05 
 
0.13 ±0.05 
 
  
0.14 ±0.05 
 
0.16 ±0.02 
 
0.49 ±0.55 
 
0.08 ±0.02 
 
0.1.0 ±0.03 
 
0.17 ±0.16 
 
  
0.17 ±0.10 
 
0.12 ±0.03 
 
0.22 
 
0.11 ±0.05 
 
0.13 ±0.06 
 
0.15 ±0.06 
 
              LUC [counts/nL] 
 
0.03 ±0.03 
 
0.01 ±0.01 
 
0.01 ±0.01 
 
0.01 ±0.01 
 
0.02 ±0.01 
 
0.03 ±0.00 * 
  
0.02 ±0.01 
 
0.04 ±0.02 
 
0.03 ±0.01 
 
0.03 ±0.02 
 
0.02 ±0.01 
 
0.03 ±0.03 
 
  
0.02 ±0.00 
 
0.04 ±0.02 
 
0.08 ±0.08 
 
0.01 ±0.00 
 
0.01 ±0.01 
 
0.02 ±0.02 
 
  
0.02 ±0.00 
 
0.01 ±0.01 
 
0.04 
 
0.01 ±0.01 
 
0.01 ±0.01 
 
0.02 ±0.01 
 Abbreviation: RBC = red blood cells, PLT = platelets, WBC = white blood cells, NEU = neutrophils, Lymph = Lymphocytes, EOS = eosiniphilics, BASO = basophilics, MONO = monocytes, LUC = large unstained cells. 
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Figure 3-15 Urinary sodium and calcium excretion, as well as the creatinine clearance calculated for male (○) and 
female (●) rats treated with either wfi (control), 10 mg/kg Puromycin (low dose), or 30/20 mg/kg Puromycin (high 
dose). Data are presented for both genders individually by mean ± SD. Significant changes were indicated with * p < 
0.05, ** p < 0.01, *** p < 0.001 (ANOVA + Dunnett). 
 
The most prominent alteration was the strong, time- and dose-dependent increase in total platelet count. This effect was 
most pronounced after 15 days of high dose (30/20 mg/kg) treatment and remained relatively constant up to day 29. 
Statistically significant or biologically relevant findings in the white blood cell populations were limited to individual 
observations of changed neutrophils, eosinophils, monocytes and large unstained cells. The data is summarised in Table 
3-17. 
 
 
Detection of novel qualified and exploratory urinary proteins (Puromycin) 
 
In animals treated with 30/20 mg/kg (high dose) Puromycin for up to 28 days the urinary excretion of the evaluated 
biomarker increased after days 14 and day 28 after high dose treatment (30/20 mg/kg) (Figure 3-16, Figure 3-17). In 
contrast to the treatment schedule of Vancomycin and Cisplatin, Puromycin was administered daily for up to 14 days 
followed by dosing twice per week. In addition, no statistical analysis could be conducted for high dose (30/20 mg/kg) 
treated male rats on day 29 because only one animal survived. The strongest increase in both genders was observed for 
urinary Cystatin C (Figure 3-16f, Figure 3-17f), and Clusterin (Figure 3-16i, Figure 3-17i) after treatment for 14 and 28 
days with 30/20 mg/kg Puromycin. These were also the only time points were renal tubular degeneration, dilatation and 
glomerular vacuolization were observed.  
 
RESULTS AND DISCUSSION 
143 
 
 
Figure 3-16 Excretion of (a) Kim-1, (b) NGAL, (c) b2m, (d) Timp-1, (e) VEGF, (f) CystatinC, (g) Osteopontin, (h), 
Calbindin28k, (i) Clusterin in urine of male rats treated with Puromycin (low dose: 10  mg/kg; high dose: 30/20 mg/kg) for 3 
days (dots), 7 days (squares), 14 days (triangle), and 28 days (rhombus). Data are presented as individual animals and as the 
mean (bar; n=5). The light grey signs indicate no tubular degeneration found within this animal, the darker grey indicates tubular 
degeneration observed. * p < 0.05, ** p < 0.01, *** p < 0.001 (ANOVA-Dunnett). 
 
One exception was was one female animal on day 8 treated with 30/20 mg/kg, which showed mild tubular degeneration 
and necrosis. However, this animal did not show any increase in any of the evaluated biomarkers. 
2m also showed a strong increase in the pathologically affected high dose (30/20 mg/kg) animals, but with a stronger 
variation between individual animals (Figure 3-16c, Figure 3-17c). However, the individual male rat on treatment day 
28 showed no alteration. Male rats in general showed a large variation over all dosing groups (Figure 3-16c), while 
female rats were characterized by a higher excretion of urinary 2m. 
In comparison to Vancomycin and Cisplatin treatment the increase in Kim-1 (Figure 3-16a, Figure 3-17a) after 
Puromycin treatment, was much lower. However, because of the very low background of Kim-1 protein and the 
minimal variablility, this slight increase still lead to significant increases in both male and female rats. 
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Figure 3-17 Excretion of (a) Kim-1, (b) NGAL, (c) b2m, (d) Timp-1, (e) VEGF, (f) CystatinC, (g) Osteopontin, (h), 
Calbindin28k, (i) Clusterin in urine of female rats treated with Puromycin (low dose: 10  mg/kg; high dose: 30/20 mg/kg) for 3 
days (dots), 7 days (squares), 14 days (triangle), and 28 days (rhombus). Data are presented as individual animals and as the 
mean (bar; n=5). The light grey signs indicate no tubular degeneration found within this animal, the darker grey indicates 
tubular degeneration observed. * p < 0.05, ** p < 0.01, *** p < 0.001 (ANOVA-Dunnett). 
 
Gender specific increases in individual urinay biomarkers were detectable. For example, Osteopontin only showed a 
statistically significant increase in male rats on days 15 and 29 of high dose (30/20 mg/kg) Puromycin treatment, while 
Timp-1 only increased significantly in female rats. 
NGAL also showed a significant increase in male rats treated with 30/20 mg/kg Puromycin for 14 days, while the 
remaining animal on day 29 showed no alteration in urinary NGAL excretion (Figure 3-16b). In contrast, NGAL 
showed no significant increase within the groups where histopathological alterations were described. However, a 
statistically significant increase was seen on treatment day 7 of female animals administered with 10 mg/kg Puromycin. 
Low dose (10 mg/kg) treated animals on day 4 and day 15 as well as high dose (30/20 mg/kg) treated animals on day 4 
showed a significant decrease in Calbindin. However, animals which showed tubular degeneration and/or glomerular 
vacuolization did not show any decrease of Calbindin. In contrast, animals from the Puromycin high dose (30/20 
mg/kg) treatment group on day 28 showed a statistically significant increase. 
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In male rats no prominent or statistically significant alterations in VEGF were observed. However, one animal showed 
an increase in urinary VEGF level of 10-fold (Figure 3-16f). This animal was the only one that showed a massive 
glomerular vacuolization and moderate eosinophilic casts. In contrast, female rats showed a statistically significant 
elevation of VEGF after 14 and 28 days of treatment, in a time dependent manner (Figure 3-17f). 
 
Table 3-18 Area-under-the-receiver-operator-characteristic curve (AUROC) for detection of Puromycin induced 
nephrotoxicity. The area under the curve is used as a measure for the overall ability of a biomarker to discriminate 
animals without histopathological findings in kidney from those with signs of tubular damage (degeneration/ necrosis). 
Markers with a good diagnostic performance (AUROC > 0.90) are highlighted in bold. In addition the 95% confidence 
interval and the p-value are displayed. The AUROC for female rats were not calculated because of only one animal with 
biological important histopathological findings. * =measurement by Luminex® xMAP®, ** = measurement by RENA®-
Sticks, #= classical clinical-pathology parameter determined by standard procedures. 
Kidney Biomarker Male
 
  Female 
AUROC 95% CI p-value   AUROC 95% CI p-value 
Kim-1* 1.00 1.00 – 1.00 <0.0001  0.93 0.79 – 1.00 <0.0001 
Timp-1* 0.82 0.69 – 0.95 0.0119  0.90 0.78 – 1.00 <0.0001 
VEGF* 0.77 0.60 – 0.93 0.0341  0.88 0.72 – 1.00 <0.0001 
ß2-Microglobulin* 0.93 0.82 – 1.00 0.0006  1.00 1.00 – 1.00 <0.0001 
Clusterin* 1.00 1.00 – 1.00 <0.0001   0.93 0.80 – 1.00 <0.0001 
Cystatin C* 1.00 1.00 – 1.00 <0.0001  1.00 1.00 – 1.00 <0.0001 
Lipocalin-2/ NGAL* 0.88 0.70 – 1.00 0.0028  0.61 0.41 – 0.81 0.2355 
Osteopontin* 0.99 0.97 – 1.00 <0.0001  0.68 0.52 – 0.84 0.0623 
Calbindin * 0.93 0.85 – 1.00 0.0006  0.76 0.62 – 0.91 0.0053 
Kim-1** 0.65 0.48 – 0.82 0.2231  0.85 0.75 – 0.95 0.0003 
BUN
#
 1.00 1.00 – 1.00 0.0003  0.96 0.91 – 1.00 <0.0001 
Serum Creatinine
#
 1.00 1.00 – 1.00 0.0003  0.90 0.80 – 1.00 <0.0001 
 
Female rats showed no alteration in urinary Osteopontin at any time point or dose group (Figure 3-16g), while male rats 
showed a clear dose- and pathology-dependent increase, specifically on day 14 (Figure 3-17g). 
The results of the ROC analysis are given in Table 3-18. 
Based on the area-under-the-ROC-curves (AUROC), Kim-1 (m: 1.00; f: 0.93), Cystatin C (m: 1.00; f: 1.00),2m (m: 
0.93; f: 1.00) and Clusterin (m: 1.00; f: 0.93) performed the best. However, the traditional parameters BUN (m: 1.00; f: 
0.96) and serum creatinine (m: 1.00; f: 0.90) also performed well within this study. Based on the results of the ROC-
analyses a strong gender specific diagnostic performance of the urinary biomarker was observed, with a better 
performance in male rats observed (Table 3-18). Osteopontin (m: 0.99; f: 0.68) and Calbindin (m: 0.93; f: 0.76) showed 
a much better performance in male rats then in females. Even the calculated AUROC values for NGAL (m: 0.88; f: 
0.61) were below the set threshold of 0.9, but the diagnostic performance was much better in male then in female rats 
treated with Puromycin. In constrast, Timp-1 (m: 0.82; f: 0.90) showed a slightly higher AUROC in females. Also 
better performance in female rats was seen for VEGF (m: 0.77; f: 0.88) which was below the threshold, but still 
indicated a good performance.  
A poor performance was observed for Kim-1 (m: 0.65; f: 0.85) when determined by using the Dipstick assay, which 
was far below the values of the Kim-1 Luminex
®
 xMAP
®
 measurement. 
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Evaluation of expression of Kim-1, Clusterin and Osteopontin protein in renal tissue (Puromycin) 
 
The Puromycin study showed in addition to tubular damage also glomerular effects. The markers evaluated performed 
very well by urinary analysis, as reflected by ROC analysis (Table 3-18). 
The protein expression in control animals showed no time-dependent alteration. Kim-1 and Clusterin showed no 
staining in untreated animals, while Osteopontin delivered a slight but constant basal expression within corical and 
medullar tissue. An overview of control animals is shown in the 5.1 Annex 1. 
Representive pictures for Kim-1, Clusterin and Osteopontin stained kidney for male and female rats treated with 30/20 
mg/kg Puromycin are shown in the figures below. The low dose treated animals (10 mg/kg) showed no relevant changes 
compared to the control animals. For each individual finding an overview is given spanning from the cortex to the 
medullary papilla and a detailed picture of the cortical zone and the medullary zone. To show the most specific 
observations in some pictures the inner or the outer zone of medulla is also shown. 
For Puromycin treated rats it was expected that tubular damage would only appear as a secondary process caused by 
excessive glomerular damage.  
 
 
Kim-1 
Male rats treated with 30/20 mg/kg Puromcin for 3 (Figure 3-18 a-c) and 7 (Figure 3-18 d-f) days showed no staining 
within the cortical or medullary zone. Therefore, no difference compared to the control animals was seen. After 15 days 
a strong increase in tubular Kim-1 proteins appeared, limited to individual proximal tubules (Figure 3-18 g). The 
staining was exclusively found intracellular and not in any proteinaceouse casts (Figure 3-18 h) within the cortex. In 
contrast, the staining of Kim-1 within the medullary zone was limited to intraluminal accumulation, down to the pelvis 
(Figure 3-18 i). On day 28 male rats still showed a high expression of renal Kim-1 protein; although below the intensity 
observed on day 14 (Figure 3-18 j, k). The intraluminal Kim-1 in the medulla was still present, but also reduced 
compared to the earlier time point (Figure 3-18 l). 
In contrast to male rats, females treated with 30/20 mg/kg Puromycin for up to 28 days, showed a slight but significant 
increase in renal Kim-1 proteins within proximal tubular cells as early as three days of treatment (Figure 3-19 b). 
However, the staining was limited to individual cells belonging to one or neighboring tubules (Figure 3-19 a). No 
staining in the medullar was detected. After 7 days of treatment the expression of renal Kim-1 protein was reduced 
compared to day 3, but still above the expression seen in control animals (Figure 3-19 d, e). No Kim-1 was found in the 
medullary zone (Figure 3-19 f). On day 15 a strong increase in Kim-1 protein was observed in the cortex. In contrast to 
male rats at the same time point, the staining of Kim-1 within the renal cortex was wide spread (Figure 3-19 g, h). In 
addition, slight staining of Kim-1 was also observed within intraluminal proteinaceouse droplets (Figure 3-19 h). 
Medullary staining was still limited to intraluminal accumulation (Figure 3-19 i). Comparable to male rats, the area and 
the intensity of Kim-1 expression after 28 days of 30/20 mg/kg Puromycin treatment was also reduced in females 
(Figure 3-19 j). However, distinct areas of Kim-1 expression were detected in proximal tubular regions (Figure 3-19 k).  
Also after 28 days massive proteinaousos casts were found, which showed no to only minimal staining of Kim-1 
proteins. Only in the medullary zone, individual droplets were found (Figure 3-19 l) including Kim-1 stain. 
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Figure 3-18 The location of Kim-1 protein in renal tissue of male rats treated with 30/20 mg/kg Puromycin is shown for each time 
point of necropsy. An overview picture for each time point (a, d, g, j) shows the whole area from the cortical zone to the medullary 
papilla. In addition, two detailed pictures, either of the cortex (b, e, h, k) or the medulla (c, f, i, l) are given. The magnification of 
the overview was ~10 times and of the detailed pictures ~70 times. 
 
Clusterin 
The expression of clusterin in male rats after 30/20 mg/kg Puromycin treatment showed no alterations up to seven days, 
neither in the cortex neither nor in the medulla (Figure 3-20 a-f). After 14 days of treatment individual tubules showed 
slight, but not prominent, expression of renal Clusterin (Figure 3-20 g, h). The staining in the cortical zone was limited 
to cells and was not found in any proteinaceouce casts within the tubular lumen (Figure 3-20 h). 
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Figure 3-19 The location of Kim-1 protein in renal tissue of female rats treated with 30/20 mg/kg Puromycin is shown for each 
time point of necropsy. An overview picture for each time point (a, d, g, j) shows the whole area from the cortical zone to the 
medullary papilla. In addition, two detailed pictures, either of the cortex (b, e, h, k) or the medulla (c, f, i, l) is given. The 
magnification of the overview was ~10 times and of the detailed pictures ~70 times.  
 
In contrast, the medullary luminal staining, especially in the inner medullary zone, was more pronounced (Figure 3-20 
g, i). On day 29, the staining was comparable to day 15 in intensity and area, with the exception that the tubular lumen 
in the medullary zone showed more diffuse, but weaker stained fluids (Figure 3-20 j-l). In female rats treated with 30/20 
mg/kg Puromycin also no increase in renal Clusterin expression on days 4 and 8 were observed, neither in the cortex 
nor in the medulla (Figure 3-21 a-f). On day 14 an increase in Clusterin was detected in individual tubules, without any 
staining of proteinaceous casts (Figure 3-21 g, h). 
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Figure 3-20 The location of Clusterin protein in renal tissue of male rats treated with 30/20 mg/kg Puromycin is shown for each 
time point of necropsy. An overview picture for each time point (a, d, g, j) shows the whole area from the cortical zone to the 
medullary papilla. In addition, two detailed pictures, either of the cortex (b, e, h, k) or the medulla (c, f, i, l) is given. The 
magnification of the overview was ~10 times and of the detailed pictures ~70 times. 
 
As already described for male rats, also, the staining within the medullary zone of females was limited to intraluminal 
fluids (Figure 3-21 i). After 28 days of treatment, the intensity of Clusterin expression increased slightly compared to 
day 14 and the staining was still located in the same areas.  
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Figure 3-21 The location of Clusterin protein in renal tissue of female rats treated with 30/20 mg/kg Puromycin is shown for each 
time point of necropsy. An overview picture for each time point (a, d, g, j) shows the whole area from the cortical zone to the 
medullary papilla. In addition, two detailed pictures, either of the cortex (b, e, h, k) or the medulla (c, f, i, l) is given. The 
magnification of the overview was ~10 times and of the detailed pictures ~70 times. 
 
Osteopontin 
The basal expression of Osteopontin in male and female rats was much more pronounced then for Kim-1 and Clusterin. 
However, in male rats treated with 30/20 mg/kg Puromycin for three days a slight but significant increase in renal, 
cortical Osteopontin was observed (Figure 3-22 a, b). Also in the medullary zone, significant amount of Osteopontin 
protein was found, both intra- and extracellular (Figure 3-22 c). 
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Figure 3-22 The location of Osteopontin protein in renal tissue of male rats treated with 300 mg/kg Vancomycin is shown for each 
time point of necropsy. An overview picture for each time point (a, d, g, j) shows the whole area from the cortical zone to the 
medullary papilla. In addition, two detailed pictures, either of the cortex (b, e, h, k) or the medulla (c, f, i, l) is given. The 
magnification of the overview was ~10 times and of the detailed pictures ~70 times. 
 
These expression patterns remained constant from day 4 to day 8 (Figure 3-22 d-f). On day 14 the intensity and the area 
covered by Osteopontin staining increased strongly compared to days 4 and 8 (Figure 3-22 g- j). Not only minimal 
staining of tubular casts in the cortical or medullarly zone was found (Figure 3-22 h), but strong staining of the 
extracellular matrix was found (Figure 3-22 j). Compared to day 15 the expression of renal Osteopontin was slightly 
reduced on day 29, although the location of staining remained unaltered (Figure 3-22 j-l). 
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Figure 3-23 The location of Osteopontin protein in renal tissue of male rats treated with 30/20 mg/kg Puromycin is shown for each 
time point of necropsy. An overview picture for each time point (a, d, g, j) shows the whole area from the cortical zone to the 
medullary papilla. In addition, two detailed pictures, either of the cortex (b, e, h, k) or the medulla (c, f, i, l) is given. The 
magnification of the overview was ~10 times and of the detailed pictures ~70 times. 
 
In female rats, the expression of renal Osteopontin showed no relevant alteration after three days of high dose (30/20 
mg/kg) Puromycin treatment in the cortex (Figure 3-23 a, b). However, the staining of the inner medullary zone 
appeared to be slightly stronger, especially in the extracellular matrix (Figure 3-23 a, c). After seven days of treatment, 
the intensity of staining further increased, both in the cortex and the medulla (Figure 3-23 d-f). As already described for 
male rats, on day 15 the intensity and area of Osteopontin expression reached the highest degree. Therefore, cortical 
Osteopontin protein was found both intracellular and intratubular (Figure 3-23 h). The intensity of medular staining 
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remained unaltered compared to day 7 (Figure 3-23 i). On day 28, a decrease compared to day 14 over all renal 
compartments was observed; showing an expression still above day 3 levels (Figure 3-23 j-l). 
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3.1.1.6 Discussion and Conclusion (Puromycin) 
 
The doses of 10 mg/kg (low dose) and 30/20 mg/kg (high dose) were chosen to induce mild to moderate glomerular 
damage in high dose and no to minimal glomerular alterations in low dose animals. Almost all of the biomarkers within 
this study are described to be specific for tubular damage; however there is some evidence that several of urinary 
markers can also be used to detect glomerular alteration.  
As shown in section “Histopathological observation (Puromycin)“, the expected moderate changes on the glomerulus 
were only weakly observed, while tubular alterations appeared more prominently then expected. However, the results 
were generally in line with the observations from the dose range finding study [Fuchs et al., 2012]. Because of the 
presense of both glomerular vacuolization and tubular damage, the interpretation of the underlying changes in urinary 
protein profiles is much more complex then for the studies of Vancomycin (see 3.1.1.1 Results (Vancomycin)) or 
Cisplatin (see 3.1.1.3 Results (Cisplatin)). It was assumed that any differences observed between the Vancomycin 
derived results (specific tubular damage only) and the results from the Puromycin treated animals, are caused by a 
glomerular change.  
The fact that the body weigth showed a time- and dose-dependent decrease reflects the strong impact of the Puromycin 
treatment on the animals, even before renal alterations were observed by histopathology. The alteration in kidney 
weight, which showed a decrease on day 8 and an increase on days 15 and 29 in high dose (30/20 mg/kg) treated 
animals, gives evidence that Puromycin can have an effect on the kidney, even before histopathological alterations are 
observed, as was the case on treatment day 7. The increase in kidney weight can be due to a hydronephrosis and 
therefore lead to an increased volume of primary urine within the tubular system. Hydronephrosis describes the 
situation where the urine collecting system of the kidney is dilated [Merck Manuals Home Health Handbook, 2007]. 
These findings are in good correlation with the decrease in urinary output (Figure 3-15) and with the absence of marked 
alterations in white blood cells (Table 3-17), because of the non-inflammatory characteristics of this nephrosis. Because 
the ureter and bladder were always within normal limits (data not shown), the cause of the hydronephrosis must be 
assumed to be related to the kidney. Therefore, the moderate to massive break-down in tubular cells and the prominent 
appearance of tubular degeneration (Table 3-13) can point to the fact that apoptotic cells lead to the obstruction of the 
collecting system of the kidney [Yang et al., 2001]. However, the presense of a hydronephrosis can also explain the 
strong alterations in sodium and calcium excretion, which appeared also in low dose (10 mg/kg) treated animals, as well 
as the impairment of the renal function as displayed by the creatinine clearance. The imbalance in electrolytes, as well 
as the decrease in glomerular filtration rate, can have a strong impact on the evaluated urinary protein biomarkers and 
therefore their predictivity.  
In general, the male rats were more sensitive to Puromycin treatment than females. This was reflected over almost all 
evaluated parameters. The two urinary protein biomarkers most excpected to be affected are Cystatin C and 2m, both 
described to be not of renal origin [Fuchs et al., 2011]. Both biomarkers are assumed to show an increase specifically 
after tubular damage, by a reduced reabsorption after renal tubular break-down. There is already some evidence that 
they are more specific in case of glomerular damage induced proteinuria [Dieterle et al., 2010]. Within this study, this 
was the case for Cystatin C, which showed and very marked and highly specific increase in all rats described to have 
histophatological alterations. Because the source of Cystatin C is not renal but systemic, the detection of this individual 
protein, even highly specific, could not be shown to bring a higher sensitivity compared to the general determination of 
total urinary protein. Subsequently, as it is the case for urinary albumin, which can be used to discriminate between 
glomerular and tubular associated proteinuria, the detection of an individual non-renal, urinary protein, can give further 
information about the area of damage or can in some cases be more sensitive than the detection of total protein in urine. 
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In addition, the diagnostic performance determined by ROC analyses clearly reflects the good correlation of the 
increase in urinary Cystatin C with the histopathological observations (Table 3-18). Because of the appearance of both 
glomerular and tubular damage, no clear assignment for the origin of the urinary Cystatin C is possible. However, by 
comparying the underlying pathologies and the diagnostic performance of Cystatin C over all three studies, the 
hypothized specificity of Cystatin C for glomerular damages is supported. Subsequently, it was also reported that 
Cystatin C is expressed within the proximal tubular cells [Togashi et al., 2011]. Even though the amount of renal 
Cystatin C protein was not altered after Cisplatin treatment, it can be hypothized that the break-down of proximal 
tubular cells leads to a release of intracellular Cystatin C, which then entered the urine. 
2m is described to follow the same mechanism as Cystatin C, and showed a marked and statistically significant 
increase. The reason for the stronger variation between individual animals is currently not clear. The fact, that 2m is 
affected by other physiological conditions reflects the physiological proteinuria described for male rats [Appenroth et 
al., 1986]. Therefore, the basal excretion of 2m in male rats was always higher and characterized by a stronger 
variability between the animals, also when no histopathological alterations were observed. Subseqeuntly, it can be 
hypothized that the strong and statistically significant decrease in creatinine clearance, which is considered to be a 
suitable parameter for the glomerular filtration rate, has a stronger influence on 2m then on Cystatin C. This 
assumption is underlined by the fact that in contrast to Cystatin C no prominent renal expression of 2m itself has been 
described so far. However, the strong increase, as well as the good AUROC values, indicates that 2m is a good marker 
to detect the underlying renal pathology caused by puromycin. The fact that 2m is one of the FDA/ EMA/ PMDA 
qualified biomarkers for acute rat toxicity gives further evidence for the use of this marker in routine toxicological 
studies.  
The remaining urinary protein biomarker, which performed well in both genders were Kim-1 and Clusterin. Based on a 
direct comparison of these two qualified protein biomarkers, it becomes obvious that tubular damages took place, with a 
strong impact to the proximal tubular cells. This is suported by the increase in urinary Kim-1, which is specific for the 
S3 segment of the proximal tubulus. In contrast, urinary Clusterin, which showed a very strong elevation of >100-fold 
over the control animals, indicates general tubular insult. The increase in urinary Kim-1 was further supported by the 
expression of renal Kim-1 protein, which showed strong and specific staining of individual proximal tubulus. In this 
case it is notable that female rats showed a higher concentration of urinary Kim-1, even though the observed renal 
damage was weaker than seen in the males. Additionally, female rats showed individual cells expressing Kim-1 protein 
as early as day 3 (Figure 3-19), even though no histopathological observations were observed. Because of the high 
specificity of the immunohistochemical analysis and the relatively small area of expression, these very slight effects 
might be overlooked during histopathology assessments. However, the urinary Kim-1 levels also showed a very slight 
increase in animals on day 4. Based on the absence of comparable alterations within the control animals, these slight 
events seem to be treatment related. This leads to the conclusion that the immunohistochemical analysis of Kim-1 
protein within renal tissue is highly sensitive and therefore also a potential method for screening by tissue array 
analysis. 
The level of renal expression of Clusterin protein was below that observed for Kim-1. This is remarkable, because of 
the very high amounts of urinary Clusterin excretion seen. This can be explained by the property of Clusterin, that after 
the specific upregulation in renal tissue after an insult, it is directly secreted into the urine [Solichova et al., 2007]. 
Consequently, the intracellular levels of Clusterin protein can be lower. Additionally, Clusterin is expressed in a 
multitude of tissues and secreted into many different bodyfluids [Jones, 2002]. The origin of the urinary Clusterin is not 
nescessarily from the kidney. Especially in this study, were a strong impairment of the renal clearance was observed, 
together with some effects on other organs (data not shown), this assumption can not be rejected. That there is an 
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increase in renal Clusterin expression, together with the high diagnostic performance, also within the Vancomycin and 
Cisplatin studies, makes this qualified urinary biomarker specific and sensitive for the prediction of general tubular 
damage. 
A strong gender difference was observed for urinary Osteopontin excretion, performing much better in male rats treated 
with Puromycin than in females. Male rats showed a pathology-dependent increase on days 15 and 29, while female rats 
showed no changes at all. By comparing the alterations in urinary Osteopontin level with the renal protein expression, it 
becomes clear that also female rats showed an increase in renal Osteopontin expression. Subsequently, the question 
arises why the urinary amount of Osteopontin remained constant. While in male rats the staining of collagen-bound 
Osteopontin, which was specifically observed in the medullary zone, showed only a slight increase, the staining 
intensity within females was much stronger. This could be observed the earliest on day 8, where also a slight increase in 
intracellular expression of Osteopontin within cortical tubular cells was seen. The fact that female rats builded up a 
higher amount of extracellular matrix proteins like collagen, can explain the absence of an increase of urinary 
Osteopontin, because it was trapped within the medullary zone and the bladder. The gender specific up-regulation of 
profibrotic factors can be due to renin, which has been described to mediate profibrotic effects by specific receptor 
binding [Ruester et al., 2006]. Because it is known that the Renin-Angiotensin system showed different responses of 
androgens and oestrogens on normal and diseased kidney, it has been hypothized that oestrogen playes a key role in an 
superior renal function and higher resistiance to renal injury of females. In addition, female rats have been shown to 
have a much stronger proteinuria (Table 3-16), one of the major causes for interstitial fibrosis [Ruester et al., 2006]. 
Finally, urinary Osteopontin delivered only good results in male rats and therefore underestimated the renal injury in 
females. 
The urinary protein biomarker Calbindin also showed a higher sensitivity and specificity in male rats. However, female 
rats showed more significant alterations, specifically decreases, than males. In general the positively diagnosed animals 
of high dose treatment on days 14 and 28, gives evidence that Calbindin showed a pathology-dependent increase in both 
genders. However, application dependent effects, leading to a reduction in urinary Calbindin masked this effect in 
female rats. One possible reason for the decrease in urinary Calbindin is based on hydronephrosis. Calbindin is strongly 
associated with the intraluminal and intracellular calcium homeostasis, based on its role as a calcium binding protein. 
The hydronephrosis-induced imbalance in calcium can be seen to be inversely related. Therefore, the increase in 
calcium excretion (Figure 3-15) is linked to the decrease in urinary Calbindin (Figure 3-16h, Figure 3-17h). However, 
the lack of a strong increase in animals with tubular and/or glomerular damage can also be based on the sensitivity and 
specificity of Calbindin to detect distal tubular damage. Because it was expected that the primary effect of Puromycin 
was glomerular damage and tubular alterations only appeared as a secondary effect caused by proteinuria, the distal 
tubulus may be only weakly affected in female rats, as supported by the histopathological observations (Table 3-13). In 
contrast Timp-1 performed better in female rats the in males. While female rats showed a strong increase in urinary 
Timp-1 in all animals affected by either tubular damage or glomerular vacuolation, males only showed a tendency in 
high dose treated animals on day 15. Two differences between the genders may play a role in the underlying results. 
Firstly, there was a difference in the control animals observed over time. Male rats showed a constant increase in 
urinary Timp-1 from day 3 to day 28, while the urinary Timp-1 level in female remained constant. Therefore, 
differences in the normal growing of the kidney of the juvenile rats seem to have slightly different mechanisms between 
the sexes. Timp-1, a specific inhibitor of matrix metalloproteases (MMPs), is involved in the degradation of the 
extracellular matrix [Brew et al., 2000]. In healthy tissue Timp-1 and the MMP binding partners ensure equilibrium of 
formation and degradation of extracellular matrix [Fuchs et al., 2011]. Because a stronger formation of fibrotic tissue 
was observed in female rats (Figure 3-23), the equilibrium of this steady state seems to have been interrupted and 
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therefore lead to this specific pathological outcome. Consequently, the involvment of Timp-1 in this process of 
extracellular matrix formation can due to the absence of urinary Timp-1 in male rats. However, it is not clear if the 
absence or presence of Timp-1 is caused by the difference in the development of fibrotic tissue or the reason for it. By 
analyzing the diagnostic performance of urinary VEGF to detect Puromycin induced renal damage; there were also 
gender specific differences. Both male and female rats showed elevated AUC in ROC analysis, but still below the 
defined threshold of a well performing biomarker. However, female rats showed a slightly better AUROC (0.88 and a 
95%CI of 0.72-1.00). Also the two high dose female groups on treatment days 14 and 28 showed statistically significant 
results with only low variations, even though the increase was only low, giving further evidence that this urinary 
biomarker can deliver reliable information. Because VEGF has been described to be specific for tubular damage in 
chronic cyclosporine nephrotoxicity [Shihab et al., 2001], or tracolimus induced nephrotoxicity [Ogutmen et al., 2006], 
it can be concluded that the increase in urinary VEGF was caused by the tubular degeneration. Subsequently, this would 
not explain why no stronger increase in male rats was observed and why no increase in urinary VEGF was detected 
within the Vancomycin and/or the Cisplatin study. Because of the involvement of VEGF in a multitude of cellular and 
renal processes, including the promotion of cell proliferation, differentiation and survival of endothelial cells, the 
mediation of endothelium-dependent vasodilatation, the induction of microvascular hyperpermeability and the 
participation in interstitial matrix re-modeling [Schrijvers et al., 2004]. Its role in cell proliferation and differentiation as 
a reason for its increased release is unlikely because of the absence of basophilic tubules in female rats and in this case a 
lower regeneration as observed in males. Consequently, beside the tubular specificity, there is also some evidence that 
VEGF may be predictive for glomerular alteration. It has also been reported to play a key role in diabetic nephropathy 
[Kim et al., 2005] and glomerulonephritis [Matsumoto et al., 1997b, Ostendorf et al., 1999]. The underlying data can be 
interpreted as a response to the glomerular damage, because only in our Puromycin studies were these effects, together 
with the increase in urinary VEGF, observed. The gender difference observed gave further evidence to the role of 
VEGF in extracellular matrix remodeling. Because VEGF has been described to reduce renal fibrosis and stabilizes 
renal function, the increase could be a reaction of the increase in connective tissue in female rats. As an increase of 
VEGF was only observed in Puromycin treated rats, and showed a fundamentally different pathology than the other 
model compounds, further investigations have to be performed to idenfity the major reason for the observed increase in 
urinary VEGF.  
Because of the lack of specific treatment dependent increase and the resulting low diagnostic performance, NGAL 
delivered no reliable information in the Puromycin induced renal damage. The reason for this observation is probably 
due to the low impact of Puromycin on the distal tubular. There is some evidence suggesting that the transcript of the 
Lcn2 gene, encoding for the NGAL protein, is usually expressed in the distal tubule of the nephron, while the protein 
itself is also located in the proximal tubule, so the protein is probably reabsorbed after leaving the distal tubular cells 
[Paragas et al., 2011]. By an absence of strong impact on the distal tubular cells it could be therefore assumed that no or 
only slight induction of NGAL takes place. The involvement of NGAL in inflammatory processes, NGAL is expressed 
by neutrophilic and epithelial cells as a first response to cellular stress and, therefore, is considered to be an acute-phase 
protein, can point to a higher specificity in Nephritic then in Nephrotic pathological outcomes. 
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3.1.1.7 Results of two different technologies for urinary Kim-1 measurement 
 
The data of Kim-1 detection by using the Luminex
®
 xMAP
®
 technology are already reported above (Figure 3-2- Figure 
3-17). Additionally the diagnostic performance of urinary Kim-1 determined by the RENA-Stipe® has been shown in 
Table 3-6 to Table 3-18. In Cisplatin treated animals, which showed weaker pathological alterations within the kidney 
(Table 3-7), an increase in urinary Kim-1 earliest on day 14 in high dose (0.6 mg/kg) treated male rats was observed 
(Figure 3-24 c). In this group also three animals without tubular degeneration showed an increase. The highest increase 
in male rats treated with 0.6 mg/kg Cisplatin was observed after 7 days, while no relevant increase after 15 days was 
seen. On day 29 urinary Kim-1 determination using the RENA-Strip® showed a slight enhancement in urinary level. In 
female rats treated with either 0.3 mg/kg or 0.6 mg/kg Cisplatin for up to 28 days, only one animal on day 15 showed 
renal tubular degeneration as well as dilatation and necrosis (Table 3-7). This individual animal showed a clear 
elevation in urinary Kim-1 within the RENA-strip™ assay (Figure 3-24 d). 
 
 
Figure 3-24 Excretion of Kim-1 in urine of male and female rats treated with Vancomycin (low dose: 50 mg/kg; high dose 300 
mg/kg; Cisplatin (low dose: 0.3 mg/kg; high dose: 0.6 mg/kg) or Puromycin (low dose: 10  mg/kg; high dose: 30/20 mg/kg) for 3 
days (dots), 7 days (squares), 14 days (triangle), and 28 days (rhombus). Kim-1 was determined by a rapid urinary dipstick assay 
(RENA-strip™). Data are presented as individual animals and as the mean (bar; n=5). The light grey signs indicate no tubular 
degeneration found within this animal, the darker grey indicates tubular degeneration observed. * p < 0.05, ** p < 0.01, *** p < 
0.001 (ANOVA-Dunnett). 
 
In contrast to Kim-1 measurement by using the WideScreen™ Rat Kidney Toxicity Assay, the determination by using 
the RENA-strip™ delivered no statistically significant alteration in urinary Kim-1 level after Puromycin treatment 
(Figure 3-24 e, f). The only animal showing an increase in urinary Kim-1 was 1 female rat of the high dose (30 mg/kg) 
group treated for 28 days. However, this animal did not show stronger histopathological changes then the others, 
showing only mild tubular degeneration and minimal glomerular vacuolization. By a direct mathematical comparison 
using linear regression (Figure 3-25 a, c, e) and Bland-Altman analysis (Figure 3-25 b, d, f), some differences between 
the RENA-Strip
®
 dispstick and the Luminex
®
 xMAP
®
 based Widescreen™ assay become clear.  
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The Pearson correlation of the Luminex
®
 xMAP
®
 and the RENA-Strip™ technology was 0.772 within the Vancomycin 
study while the coefficient of determination (r
2
fit) was 0.596 (Figure 3-25 a). In contrast, a good linearity was observed 
by processing the data by a Bland-Altman analysis (Figure 3-25 b). The data points showed a clear tendency to an 
increased positive difference (Luminex
®
 xMAP
®
 minus RENA-Strip™) with a total increase on average. However, this 
results in a bias in urinary Kim-1 detection by these two technologies of 23 ng/mg urinary creatinine and a 95% limit of 
agreement of + 120/-75 ng/ mg urinary creatinine.  
The results of the analysis of the Cisplatin data delivered comparable results. The Pearson correlation was 0.836 (r
2
fit = 
0.699) (Figure 3-25 c). Even the linear regression showed better results within this study, also the linearity within the 
Bland-Altman plot was more pronounced (Figure 3-25 d). However, the bias as well as the 95% limit of agreement was 
high within this study and resulted in values of 52.8 (bias) and +263/-157 (± 1.96SD) ng/ mg urinary creatinine of Kim-
1.  
 
 
Figure 3-25 Bland-Altman analysis and Linear regression of Kim-1 determined by using the WideScreen™ Rat Kidney 
Toxicity Assays (Luminex® xMAP®) and the RENA-strip™ dipstick assay (RENA-strip™). Both analyses are shown using 
absolute, normalized (normalization was conducted against urinary creatinine) value of all animals from the Vancomycin (a-b), 
Cisplatin (c-d) or Puromycin (e-f) treatment. The Bland-Altman-Plot gives the average values on the x-axis and the differences 
of the two methods on the y-axis. The solid line indicates the mean difference or bias, broken lines indicate the 95% confidence 
limit of the bias. Linear regression is displayed by individual animals and a solid line represents the regression line. The broken 
line represents the 95% confidence interval. Additionally, the Pearson correlation (rPerson) and the coefficient of determination 
(r2fit) is given.  
 
Within the datasets of puromycin, where only a limited increase in female rats in urinary Kim-1 level was determind by 
both the Luminex
®
 xMAP
®
 and the RENA-strip™ based approach, the results of the linear regression as well as the 
Bland-Altman analysis are different from the analysis of the Vancomycin and the Cisplatin study. This results in a 
lower coefficient of correlation and linear regression (rPearson = 0.477; r
2
fit = 0.228). In contrast, the Bland-Altman plot 
delivered no linear tendency, but a high variation around 0. Subsequently the biases as well as the 95% limit of 
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agreement were much lower the described for the other evaluations (0.2 (bias) +7.5/ -7.2(± 1.96SD)) ng/ mg urinary 
creatinine of Kim-1. 
 
3.1.1.8 Conclusion of comparison of two different technologies for Kim-1 detection 
 
In summary, both Kim-1 assays evaluated delivered comparable results. However, there are several discrepancies 
between the Luminex
®
 based multiplexing assay and the rapid RENA-strip
®
 dipstick assay. The most important 
difference is the lower sensitivity of the Dipstick assay for urinary Kim-1. This leaded to lower AUROC values, 
suggesting that the histopathological observations are less well reflected.  
Within the Vancomycin and Cisplatin studies, the urinary excretion of Kim-1 caused by treatment was observed in both 
the WideScreen™ and RENA-strip™ assays. In addition, both assays were sensitive enough to record the renal 
recovery, which occured after the first week without daily Vancomycin treatment. It is important to note that the 
observed tubular alterations within this study were very marked, allowing the poorly sensitive RENA-strip
®
 dipstick 
assay to monitor changes in Kim-1. However, the excellent linearity within the Bland-Altman plot showed that the 
differences between the two detection methods were smaller. Therefore, the increase in urinary Kim-1 detected by the 
Luminex
®
 based WideScreen™ assay was much greater compared to the RENA-strip™ assay.  
The lack of Kim-1 determined by the RENA-strip™ assay witin the Puromycin study confirms the poor sensitivity of 
this assay. Kim-1 expression within the renal tissue was shown clearly and the observed pathological alterations were 
actually greater than the severity observed in the Cisplatin study.  
Dependent on the study requirements both assays can be used with some limitations to detect renal damage. However, 
based on the data presented here, the Luminex
®
 based WideScreen™ assay is the preferred assay for multiple reasons. 
Firstly, the sensitivity of the assay is above the observed sensitivity of the RENA-strip™ dipstick assay. In addition, the 
benefit of measuring multiple proteins in one sample at the same time (multiplexing) also enhances the applicability of 
this assay. Finally, the histopathological alterations were better predicted by the WideScreen™ assay. Taken together, 
the WideScreen™ assay is recommendable as a tool to monitor renal health status, during the course of an in vivo study 
without the need for additional animals.  
In contrast, the dipstick assay delivers a fast and reliable result if marked effects in the proximal tubulus are present. 
Therefore, it is feasible that in very early phases of safety evaluation the RENA-strip dipstick assay could be included in 
to the standard panel of tests to get immediate results witout any time delay. However, in contrast to the WideScreen™ 
assays, this dipstick assay cannot be recommended as a stand alone method for decision making, but in combination 
with other methods to get additional hints about the status and the progression of renal damage. 
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3.1.2 Final Conclusion of the evaluation of urinary protein biomarkers 
 
The data presented from all three 28 day rat toxicity studies clearly showed that Kim-1 and Clusterin performed the best 
from the set of qualified urinary protein biomarkers. In addition, Osteopontin, an exploratory biomarker, also delivered 
highly predictive results. However, this biomarker has the disadvantage of only performing well when no fibrosis 
appears during the progress of renal insult. An increase of renal Osteopontin protein expression can be used to indicate 
an increase in protein content, although this methodology is not ideal for screening, due to the strong background levels. 
In contrast, the renal protein expression of Kim-1 and Clusterin has the potential to be used by tissue array applications.  
It was shown that several of the urinary protein biomarkers clearly reflect the actual health status of the kidney, 
including regenerative processes. Therefore, it can be concluded that these biomarker can be used to monitor the 
progression of renal damage in a non-invasive way. In addition, further information can be delivered about the area of 
damage within the nephron. For both the Vancomycin and Puromycin studies the traditional serum parameters, 
creatinine and BUN, also performed well. Therefore, the information about the area of damage is a major advantage of 
these novel urinary biomarkers. For example, within the Cisplatin study, only Kim-1 identified renal proximal tubular 
break-down in a highly specific and sensitive way. 
Other biomarkers showed a tendency for gender specific differences. Timp-1, for example, was more predictive in 
females for all three model nephrotoxins. This could be due to physiological differences between the genders in kidney 
growth, reflected by the time dependent increase in urinary Timp-1 in male control animals. Calbindin showed a better 
predictivity in males. In the Cisplatin and Puromycin studies Calbindin showed treatment dependent decreases in 
animals with no renal damage. Therefore, further research is needed to evaluate the underlying mechanisms of this 
protein in renal pathologies. Because of its unique position as a specific distal tubular damage marker, this urinary 
protein biomarker can deliver important information about the location and progression of nephrotoxicity. 
The two qualified urinary protein biomarker, Cystatin C and 2m, which are described to be of non renal origin, 
performed very poorly in the studies discussed here. Therefore, the assumption that the disturbance of reabsorption of 
these proteins by tubular degeneration leads to an increase in urinary protein must be questioned. This mechanism may 
be relevant in some kinds of drug-induced nephrotoxicity, but based on the data we have generated it seems to be more 
likely due to alternative mechanisms, such as the release of intracellular Cystatin C by tubular cells undergoing 
degradation. 2m also seems to increase in the case of prominent proteinuria by glomerular vacuolization and can be 
therefore used as glomerular specific urinary biomarker. 
NGAL showed a poor performance in all studies. The only relevant increase in urinary NGAL was observed after 3 and 
7 days of Vancomycin treatment (after massive tubular degeneration). Therefore, it could be suggested that NGAL can 
be used only for the very early changes, (i.e. the first days). In addition, the strong involvement of NGAL in 
inflammatory processes and the risks of false positive results lead to the assumption that this urinary protein has more 
disadvantages then benefits and should therefore not been used in 28 day rat toxicity studies. 
The exploratory biomarker VEGF showed some evidence of importance in glomerulopathies. However, further 
experience by testing this urinary protein biomarker in real life situations will be necessary to evaluate whether a 
specific pathology or mechanism can be linked to urinary VEGF release. 
Beside the performance of the urinary proteins as non-invasive biomarkers, the transcripts of the ten used proteins were 
evaluated. It was found that the transcripts of some of the biomarkers performed better on the transcriptional level than 
the urinary proteins. Beside Kim-1 and Clusterin showing very good results on the mRNA level, also Timp-1 reflected 
the histopathological changes very well in both male and female rats. Osteopontin showed a treatment-dependent 
increase in transcripts, but was weaker than the observed increase in Osteopontin protein. Nevertheless, the increase 
RESULTS AND DISCUSSION 
162 
 
over the control group was predictable for the underlying pathological alterations and it can be assumed that, in contrast 
to the Osteopontin protein, these changes are independent of expression of profibrotic factors. The down regulation of 
Calbindin mRNA in animals with tubular damage is only partly reflected by the urinary protein content. However, it is 
in good agreement to other observations reported for transcriptional biomarkers in nephrotoxicity, including the 
Innomed/PredTox project [Matheis et al., 2011]. 
In conclusion, the implementation of Kim-1, Clusterin and Ostoepontin into routine testing for nephrotoxicity is 
strongly recommended. In addition, Cystatin C and total urinary protein seem also to be excellent markers to detect 
potential impairments of the glomerulus. For the question of the best technology to employ, the decision strongly 
depends on the needs. If strong renal effects are expected or the results are needed within very short time, the RENA-
strip™ assay can be recommended, being aware of the poor sensitivity of this assay. For a higher sensitivity and the 
benefit of the multiplexed detection of several proteins, the best solution would be a standard multiplexing assay, like 
the WideScreen™ Rat Kidney Toxicity Assay (now Milliplex xMAP assay). In addition, the evaluation of 
transcriptional biomarkers should also be addressed in pre-clinical safety assessment, based on the good performance of 
some of the transcripts presented here.  
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3.1.3 Gene expression analyses of renal tissue 
 
The aim of the gene expression analysis, using renal tissue from rats treated with different doses of Vancomycin for 
different time points, was to evaluate i) the potential molecular mechanisms in male and female rats which may play a 
key role of the upcoming and established Vancomycin-induced kidney injury and ii) to evaluate potential transcriptional 
surrogate biomarkers for their usability and the mechanistic connectivity to the underlying mechanism. 
 
 
3.1.3.1 Global Analysis 
 
As already described a clear dose-dependency as well as a specific treatment dependent pattern in renal response on 
Vancomycin treatment was observed. In a first step, the whole genome transcriptomics data derived from the Genome 
Studio were normalized by median adjustment, after the whole dataset was analysed by box-plot and Log-Log plot 
using the Genedata Analyst Software tool. Based on the profile display and the background controls included on each 
array of a RatRef bead chip, all values with a signal intensity of <70 were excluded from the analyses for background 
correction.  
All remaining transcripts were analyzed by a principal component analyses (PCA) for potential class discovery. The 
PCAs were compared for a.) gender differences, b.) treatment effects and c.) severity of tubular degeneration (Figure 
3-26). A clear gender difference was observed, especially along component 3, with an increase in similarity along 
component 1 (Figure 3-26 a). In addition, a clear separation of the high dose (300 mg/kg) treated animals was observed, 
with the exception of four animals, all from treatment day 14 (Figure 3-26 b). Finally, the severity of tubular 
degeneration was overlaid to the PCA resulting in a clear serverity-dependent separation of animals without 
histopathological findings (Figure 3-26 c). Only animals with moderate findings or higher (≥ +++) were completely 
separated from the animals without findings. Individual animals with only minimal or mild (+ or ++) changes clusterd 
together near the unaffected animals. Taking all these observations together, the major factor that affects gene 
expression is based on the histopathology and not on the gender or the application of treatment to the test animals. 
Subsequently, by comparison of the gender differences (Figure 3-26 a) and the histopathology (Figure 3-26 c) the 
response of male and female rats after Vancomycin treatment shows a similar progression. It is not expected that within 
one species / strain that any gender difference on gene expression level would be seen. Therefore, to discover whether 
or not the response in male and female rats within individual pathway or transcripts is identical all following analysis 
were performed for male and female rats separately.  
The fact that the low dose (50 mg/kg) treated animals clustered together with the animals of the control group is a 
reflection of only minor individual findings of histopahtological alterations within this group (Table 3-1). The duration 
of treatment seems to be not directly important for the outcome of the PCA, only that the health status of the kidney 
altered with time. Based on the observation already described, a time-dependency from days 3 and 7, as well as a 
recovery effect, were expected for treatment day 14. 
To enable the analysis of the outcome of each individual time, all high dose (300 mg/kg) treatment groups were tested 
by a t-test against the corresponding control group by setting the threshold at p ≤ 0.01 and q ≤ 0.01. 
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Figure 3-26 Principal component analysis (PCA) of the global gene expression dataset from renal tissue from male and 
female rats treated with water for injection (WFI), 50 mg/kg or 300 mg/kg Vancomycin. Each individual dot represents one 
individual experiment including all remaining transcripts. The position within the coordinate system give rationales about 
similarities or differences, whereas component 1 has the highest impact, followed by component 2 and component 3. a.) an 
overview on gender differences (blue = male, red = female). The solid violet line indicates the strong separation between 
male and females while the dotted line indicates only a slight separation. b.) Shown is the position of the treatment groups 
within the PCA (blue = control (WFI), red = low dose (50 mg/kg Vancomycin), green = high dose (300 mg/kg Vancomycin). 
The green circle indicates the clear separation of the high dose group from the control and low dose group. c.) reflection of 
the histopathological observed tubular degeneration within the PCA (blue = no findings, red = minimal, green = mild, yellow 
= moderate, light blue = massiv, violet = servere). The arrow indicates the direction of increasing server. 
 
Female rats treated with 300 mg/kg Vancomycin showed more significantly altered genes compared to male rats. The 
difference was the smallest on day 7 were 4386 genes were altered in males while females showed 7995 alterations 
(~180 % increase). The strongest effect with ~440% (♂ 584, ♀ 2575) more altered genes was observed on day 14. On 
treatment days 3 and day 28 female rats showed ~190% (♂ 2583, ♀ 4918) and ~200% (♂ 2546, ♀ 5071) altered 
transcripts (Figure 3-27), respectively. 
To check whether all these significantly altered genes deliver a reliable and reproducible result with a biological 
relevance, each group was divided by the corresponding control group to generate fold-changes (FC). The cutoff was 
set at FC ≥ 1.5 and FC ≤ -1.5 to see only slightly altered transcripts, which can have a mechanistic relevance. Only 
approximately 37-74% of the significantly altered genes showed an FC above the threshold, depending on the time and 
gender. Subsequently, in all eight groups the percentage of the male rats was above the value calculated for the females 
(Figure 3-27).  
 
Figure 3-27 Significantly altered transcripts with a p ≤ 
0.01 and q ≤ 0.01 for each individual time point for male 
and female rats. Out of these groups the fold-changes 
against the corresponding control groups were calculated 
with a threshold of FC ≥ 1.5. The given percentages reflect 
the proportion of the fold-induced genes from the whole 
group of significant altered genes. 
 
 
 
 
 
However, the higher number of altered genes in female rats, together with the already described differences in 
histopatholigcal severity (Table 3-1) and urinary protein biomarker excretion (Figure 3-2, Figure 3-3, Table 3-6), gives 
further evidence for alternative mechanisms occuring in females. 
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3.1.3.2 Mechanistic Analysis 
 
The underlying list of altered transcript for each individual time point and sex, were uploaded into the Ingenutiy 
pathway software tool and the most prominently altered canonical pathways were analysed. The transcripts and fold-
changes from the individual pathways are given in the Annex 2, Table 5-1 to Table 5-17. In addition, transcription 
factors in toxicological mechanisms were analysed within the IPA software tool. The analysed pathways were included 
into one of the following categories: Inflammation, apoptosis/ cell cycle, or recovery/ rearangement. The results of the 
comparison of the progression over the studied time points in both sexes are given in Table 3-19. It was not excpected 
that all transcripts would be included in these pathways, because several regulatory steps in the signaling pathways are 
not happening on the gene expression level. By comparing the different conditions, several differences were discovered 
in case of gender differences of Vancomycin induced nephrotoxicity. Firstly, the complement system seems to play a 
pivotal role in this drug-induced renal damage [White et al., 2012]. The individual components of the complement 
system remained constantly altered from day 3 to day 28. In male rats this was more pronounced then in females, which 
showed a stronger variation reaching from 31% on day 14 to 40% on days 7 and 28. Therefore, the recovery period, 
which already was described, was also reflected in female rats, while male rats showed no changes in the upregulation 
of the complement components. This can be assumed to be one reason for the lower severity observed in female rats, 
because the role of the complement system, which is a casade of enzyme activations that bridges between the innate and 
the acquired immune response, leads to the clearance of immune complexes and apoptotic cells, and the activation of 
inflammation. Three activation pathways were described for the complementary system, while all of them converge into 
a final pathway, including several activation steps (shown in Figure 3-28). At the end of the cascade, the component C7, 
C8 and C9 form the membrane attack complex (C5b6789; MAC) which integrates into the cell membrane and initiates 
cell lysis. The complement system has already been described to have an important role in ischemic AKI [Arumugam et 
al., 2004] as well as in drug-induced AKI [Quigg, 2003]. It also has been described in the special case of Vancomycin-
induced nephrotoxicity in mice [Dieterich et al., 2009]. A comparison of the gene expression changes of the data 
generated from our study and the publicly available dataset shows that the initial pathways where limited to the classical 
and the alternative pathway, while the Lectin pathway (not shown), which is independent of a Antigen-Antibody 
complex and is initiated by mannose binding lectin, seems not to be involved in either species. The major difference 
between rats and mice seems to be in the formation of the MAC, because no alterations on gene expression for the 
components C7 and C9 where observed in mice, while C8 was down-regulated. However, because of the higly complex 
nature of this mechanism no deeper mechanistic analysis was possible based only on the gene expression data. 
Neverthless, the data generated within this study gave clear evidence that the complement system is strongly involved 
in the progression of Vancomycin-induced renal damage.  
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Figure 3-28 Shown are the classical and the alternative pathway of the complement system for a.) the underlying gene expression 
dataset generated out of the Vancomycin study and b.) a public available dataset of mice treated with 400 mg/kg Vancomycin 
(i.p.) (Dieterich et al., 2009). Red indicates that the transcripts showed a fold-change of ≥ 1.5 (p ≤ 0.01, q≤ 0.01) and green 
indicates that the transcripts showed a fold-change of ≤ -1.5 (p ≤ 0.01, q≤ 0.01). Grey displays that the transcripts are not present 
in the dataset presented here. Within the rat toxicity study (a) almost all components of the complement systems are significant 
up-regulated both in the classical as well as the alternative pathway. In the study used mice, also many transcripts were up-
regulated; even though several key transcripts are not increasingly expressed within renal tissue.  
 
It cannot be assumed that the complement system is one of the initial factors leading to tubular damage, but an 
important factor leading to an amplification of the initial insult. It already had been demonstrated that the filtration of 
complement components into the renal tubular system, as is the case during proteinuric renal damage, leads to tubular 
inflammation and injury [Lenderink et al., 2007]. The fact that the observed injury in female rats was below that 
observed in male rats in correlation to the presents of the complementary system, makes these pathways potential 
targets for AKI prevention. Therefore, inhibition of individual complement components could be shown to protect 
proximal tubules in a rat model of proteinuric kidney disease against renal dysfunction [He et al., 2005]. 
For the detection of drug-induced renal damage, the components of the complement system also seem to be usefull, as 
early transcriptional biomarkers. Consequently, the components C2, C3 and C4 are the most recommendable due to 
there central and initial function. This is supported by observations of C3 upregulation in Cyclosporin-induced proximal 
tubular cell break-down [Kim et al., 2007]. In addition, these transcripts have a strong benefit of bridging between 
species because of the high conservation of the complement system, as could be shown by comparing rat and mouse 
gene expression pattern. In addition the already described biomarker Clusterin interactes directly with the complement 
system in case of renal injury [Correa-Rotter et al., 1992]. Clusterin has an inhibitory effect on the complement system 
and the MAC activity, and therefore can be assumed to have a renoprotective function. However, it is not clear if the 
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regulation of the complement system and clusterin are directly linked, or if apoptotic and remodeling processes, where 
clusterin is also involved, are regulating both independently. 
The involvement of inflammatory processes, which is a normal reaction to cell damage, is also underlined by the 
extravasation of leukocytes (Table 3-19). This process describes the migration of leukocytes from blood to tissue during 
inflammation, and occurs in several steps. In general, three major processes are involved; the capture and tethering of 
endothelial cells and leukocytes, the chemokine mediated rolling and firm adhesion of the leukocytes to the underlying 
endothelial cells, and the transmigration of leukocytes through spaces between the cells. Important chemokines include 
IL-1, TNF- and Cxcl8, among others [Janeway et al., 2005, Aplin et al., 1998]. During this processes several adhesion 
molecules, like P/E-Selectin, 2-integrin, JAMs or ICAM-1, are invovled. Because of the important role of adhesive 
molecules and the ECM, it is not suprising that Timp-1 is involved in this process, by inhibition of MMP-9, secreted by 
leukocytes to degrade the basement membrane to avoid uncontrolled ECM degradation [Agrawal et al., 2006, Clark et 
al., 2011]. During tissue damage this process is also used by monocytes during there development into macrophages 
and an earlier increase in female rats is known, and could be one explanation for the weaker Vancomycin-induced 
nephrotoxicity in female rats. 
Because both the complement system and the leukocyte extravasation are part of the acute-phase response, the IL-6 
signaling, which is an important regulator of lymphocyte stimulation and acute-phase response, was also investigated. 
This signaling cascade can be driven by either IL-6-type cytokines, targeting signal transducers and activators of 
transcription (Stat) family and tyrosine kinases of the Janus Kinase (JAK) family [Haan et al., 2006, Murray et al., 
2007], or by activation of the extracellular signal-regulated kinases (ERK1/2) of the mitogen activated protein kinase 
(MAPK) pathway [Singh et al., 2006]. Both of these pathways have already been discussed to play a pivotal role in 
different mechanisms of drug-induced nephrotoxicity. Cisplatin-induced nephrotoxicity, for example, has already been 
described to be regulated by a MAPK-dependent p38 induction [Francescato et al., 2009], while also a JAK/STAT 
mediated inhibition of Cisplatin-induced apoptosis has been reported [Salahudeen et al., 2008]. Neverthless, 
independent of the underlying mechanism, the results of the IL-6 signaling gave further evidence of the importance of 
acute phase pathways and inflammatory processes in early phases of Vancomycin-induced nephrotoxicity. In addition, 
it was found that in this study Stats seems to play a pivotal role in the response of renal cells to Vancomycin-induced 
tubular damage (Table 3-20). Beside inflammation, also cell death and cell cycle control are very important factors. 
Because apoptosis is a very common event in compound-induced toxicity, this signaling pathway was evaluated in more 
detail (Table 3-19). Apoptosis is a highly coordinated and energy-consuming process, which involves the activation of 
special cysteine proteases (Caspases), and can be discriminated between two major pathways, the intrinsic and the 
extrinsic pathways. It is not possible to discriminate between these two pathways only by analyzing gene expression 
data. Especially the intrinsic pathway, which is triggered by a change in mitochondrial transmembrane potential, leads 
to a release of two main groups of pro-apoptotic proteins from the intermembrane space into the cytosol. These 
important regulators, cytochrome c (CytC), Smac/Diablo and the serine protease high temperature requirement protein 
A2 (Htra2/Omi), will not be necessarily deregulated in the gene level. However, based on the data presented here, there 
is some evidence that the extrinsic singaling pathway was strongly involved in the observed apoptotic processes (Figure 
3-29).
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Table 3-19 The number of invovled transcripts in several pathways as percentage of the total number transcripts. In addition, the p-value is given in parentheses. The percentages were color coded as 
follow: white = < 10%; grey = 10%-20%; green = 20%-30%; yellow = 30%-40%; orange = 40%-50%; red = > 50%. The pathways were grouped in to three categories: Inflammation, Apoptosis/ cell 
cycle and Recovery/ Rearangement. Only genes altered in animals treated with 300 mg/kg Vancomycin (high dose) were analyzed. 
Pathways           
  male     female    
Inflammation  3d 7d 14d 28d  3d 7d 14d 28d 
complement system 
 
40%  
(1.78E-08) 
40%  
(2.56E-05) 
40%  
(4.18E-06) 
43%  
(8.50E-08)  
37%  
(1.71E-05) 
40%  
(2.90E-5) 
31%  
(3.10E-06) 
40%  
(2.29E-05) 
Leukocyte extravasation 
 
12%  
(4.34E-03) 
25%  
(5.01E-08) 
26%  
(7.98E-11) 
18%  
(2.87E-05)  
25%  
(7.71E-11) 
28%  
(3.23E-10) 
17%  
(1.72E-08) 
27%  
(1.46E-09) 
IL-6 Signaling 
 
16%  
(1.18E-03) 
28%  
(1.79E-05) 
26%  
(9.77E-06) 
23%  
(2.04E-5)  
27%  
(1.52E-06) 
31%  
(6.98E-07) 
18%  
(2.41E-05) 
29%  
(4.85E-06) 
Apoptosis/ cell cycle           
Apoptosis Signaling 
 
13%  
(2.95E-2) 
28%  
(2.00E-05) 
28%  
(1.06E-06) 
19%  
(2.26E-03)  
29%  
(1.38E-07) 
32%  
(7.29E-07) 
24%  
(5.84E-09) 
32%  
(1.28E-07) 
Death Receptor signaling 
 
12%  
(5.85E-02) 
21%  
(2.63E-03) 
28%  
(4.04E-05) 
15%  
(5.22E-02)  
28%  
(2.52E-05) 
29%  
(1.06E-04) 
20%  
(5.69E-05) 
31%  
(2.20E-05) 
Cell Cycle control of chromosomal replication 
 
36%  
(4.56E-07) 
45%  
(3.93E-07) 
42%  
(5.55E-07) 
52%  
(3.28E-11)  
45%  
(3.51E-08) 
45%  
(4.50E-07) 
26%  
(1.10E-04) 
55%  
(1.90E-10) 
Recovery/ Rearangement           
Integrin Signaling 
 
8%  
(2.39E-01) 
22%  
(8.76E-06) 
25%  
(8.93E-10) 
15%  
(3.35E-03)  
24%  
(8.06E-10) 
26%  
(1.28E-08) 
19%  
(7.88E-11) 
27%  
(2.16E-09) 
Signaling by Rho Family GTPases 
 
8%  
(1.13E-01) 
22%  
(8.47E-07) 
20%  
(8.78E-08) 
15%  
(2.55E-04)  
22%  
(1.26E-09) 
21%  
(2.73E-06) 
13%  
(2.89E-06) 
22%  
(1.05E-07) 
HMGB1 signaling 
 
17%  
(2.25E-04) 
33%  
(1.06E-08) 
29%  
(7.38E-08) 
27%  
(5.03E-08)  
30%  
(8.00E-09) 
32%  
(5.45E-08) 
25%  
(1.80E-10) 
32%  
(3.33E-08) 
           
 
The Fas-receptor, also known as the death-receptor, which is the initial point of the transmembrane receptor-mediated extrincic signaling, was upregulated in male and female rats 
over all time points. This receptor triggers, after binding of a ligand, Caspase 8/10, which were also upregulated, and can then initiate the execution pathway, resulting in caspase 3 
mediated characteristic cytomorphological features, such as chromatin condensation, DNA fragmentation, membrane blebbing and cell shrinkage [Elmore, 2007]. Alternativly, 
Caspase 8/10 can also activate Bid or Bax, both pro-apoptotic factors in a p53 dependent manner, which as a consequence ends in the intrinsic pathway of apoptosis. Because the 
activation of p53 is based on a phosphorylation, the increase in p53 mRNA observed specifically in male rats, is not necessarily correlated with an elevation in activity. 
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Figure 3-29 Apoptosis signalling; intrinsic and the extrinsic pathways. Red indicates that the transcripts showed a fold-
change of ≥ 1.5 (p ≤ 0.01, q ≤ 0.01). Grey displayes that the transcripts are not present in the our dataset. Within this 
toxicity study almost all Caspases were significantly up-regulated. In addition, several components related to the extrinsic 
pathway and a separate ER stress mediated pathway was activated. 
 
The analysis of downstream genes regulated by p53 gave some evidence that this transcription factor is not prominently 
involved in the response of renal cells to Vancomycin-induced cell death (Table 3-20). However, by comparing the 
ratios of involved molecules for male and female rats over all time points (Table 3-19), it become obvious that apoptotic 
processes occured earlier in female rats, particularly on day 3 (m: 13%; f: 29%). While male rats showed a similar 
invovlment, earliest on day 7 (m: 28%; f: 32%). To underline the assumption that the extrinsic pathway may be 
predominant, also the ratio of the Death Receptor signaling is shown in Table 3-19, reflecting comparable patterns in 
the number of altered transcripts. Beside the activation of Caspase 8/10, the Fas receptor has also been described to 
increase the activation of the NIK protein, which itself can initiate a singaling cascade by phosphorylation, involving 
NF-B [Malinin et al., 1997, Sakurai et al., 2003]. Since NF-B is a very common transcription factor, strongly related 
to processes of immuigenicity, it is also an important mediater of apoptosis by increasing the activity of cIap, which 
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itself is able to activate several Caspases (Caspases 3 and 9) [Shen et al., 2007]. The role of NF-B could only be shown 
for male rats on treatment days 3 and 28 (Table 3-20). For all other groups, it was not possible to calculate any scores. 
Taken this together with the observation of early inflammatory processes in females, which can be assumed to be 
involved in cell death and in the clearance of apoptotic cells, this can be one reason for the general lower progress in 
female rats compared to male. In addition to the already mentioned Caspases, Caspase 12 showed also an upregulation 
in all high dose (300 mg/kg) treated animals (Figure 3-29). Caspase 12 activation is related to endoplastic reticulum 
(ER) stress caused by hypoxia, glucose starvation and perturbation of calcium homeostasis [Yoneda et al., 2001]. Since 
it has been described that Vancomycin is involved in complex formation of the ERp57 protein, which is mainly 
localized in the ER, with calreticulin there is some evidence of a potential involvement of ER stress in Vancomycin-
induced renal insult [Frasconi et al., 2001]. This is supported by the findings that the ERp57/Calreticulin complex is 
associated with cell death and differentiation [Panaretakis et al., 2008]. Even though apoptosis is a relatively general 
mechanism it is a highly predictive indicator of cellular stress and should be always evaluated in case of the detection of 
organ specific toxicity. Therefore, it was not unexpected that the public dataset from Dieterich and colleagues 
[Dieterich et al., 2009], showed similar results to ours. To summarise, Vancomycin-induced apoptosis in rodent kidney 
seems to be a Fas-receptor mediated and Caspase dependent mechanism.  
 
The cell cycle control of chromosomal replication, which showed the highest number of genes being deregulated, 
indicates a high proliferative activity (Table 3-19). In addition, a strong gender difference was observed. While male 
rats showed the lowest ratio, reflecting in this case cyclin-dependent kinases (Cdk), cell division cycle (Cdc) members 
and other molecules involved in the formation of the origin recognition complex (ORC), after 3days of treatment (m: 
36%; f: 45%), female rats showed the lowest ratio on day 14 (m: 42%; f: 26%). Comparable data were observed on days 
7 (m: 45%; f: 45%) and 28 (m: 52%; f: 55%). Based on these results it can be assumed that the induction of 
proliferation in male rats took longer to manifest after an insult. In addition, the replication of renal cells lead to a strong 
recovery on day 14 in both genders, but because of the stronger pathological outcome in male rats, the transcripts 
involved in cell cycle chromosomal replication, remained at an elevated level. Consequently, the highest ratios were 
observed in the latest time point where also the most prominent effects were observed histopathologically (Table 3-1). It 
has been reported that Vancomycin is directly involved in cellular proliferation of proximal tubule cells. Here, 
Vancomycin lead to an increased incorporation in BrdU, followed by the accumulation of cells in the G2/M phase of the 
cell cycle [King et al., 2004]. In our dataset, key components of the G2/M phase of the cell cycle were significantly 
deregulated, namely Cdk1, CyclinA and –B, as well as Cdc25a. 
Beside the inflammatory and apoptotic processes, remodeling and recovery processes play an additional and 
fundamental role in the outcome and progression of Vancomycin-induced nephrotoxic mechanisms. Three major 
processes are involved in the regeneration of tubular cells after toxic insult; migration/anchoring, proliferation and 
repair of physiological functions [Nony et al., 2003]. Proliferation was observed by the changes in cell cycle control of 
chromosomal replication. By evaluating several pathways it becomes obvious that in case of migration/ anchoring, 
integrin mediated signaling plays the most important role in the renal reorganization after Vancomycin-induced tubular 
damage. Integrins are heterodimeric adhesion receptor glycoproteins on the cell surface, which mediate cell migration 
and adhesion by interaction with the cytoskeleton, the ECM and other cells [Hynes, 1992]. Integrins can bind several 
ECM molecules, such as cellular receptors, fibronectin, laminins or collagens and subsequnelty lead to the (re-) 
attachement of the cells to the basement membrane after they have detached because of an insult to the basement 
membrane. Additionally, integrins are responsible for the signal transduction from the extracellular space into the cell. 
The most prominent fold-change alterations in our dataset from both genders were observed for 1-integrin, -integrin 
RESULTS AND DISCUSSION 
171 
 
and 1-integrin, while male rats additionally showed an up-regulation of -integrin,4-integrin, 6-integrin, and -
integrin. Based on the fact that integrins are composed of one and onesubunit and each combination has its specific 
binding and signaling properties, this is potentially an important factor explaining the sex differences. The interaction, 
which is realized by the cytoplasmic tails of the integrins with intracellular signaling/ regulatory molecules, can induce 
several different pathways and therefore different cellular effects. Signaling molecules described to be involved in 
integrin signaling are mitogen-activated protein (MAP) kinase as well as focal adhesion kinase (FAK) and integrin-
linked kinase (ILK) signaling cascades [Juliano, 1994, Delcommenne et al., 1998]. In the data presented here, both in 
male and in female rats, many transcripts showed an up-regulation in almost all of these signaling pathways. Male rats 
showed almost no upregulation of molecules involved in integrin signaling on day 3 and an elevation on days 7 and 14, 
while female rats showed comparable number of involved transcripts on days 3, 7 and 28 (Table 3-19). This is 
remarkable, because in both genders eosinophilic casts were observed at the earliest on day 3 and therefore the 
detachment of necrotic cells already appeared at this early time point. On day 28, where the strongest pathological 
effects were observed in both genders, it was expected that mechanisms of repair and reorganization also showed the 
highest presence and activity. This was only the case in female rats, while males showed a reduction compared to days 
7 and 14. Beside the integrin-driven activation of ERK/MAPK or JNK/SAPK mediated transcription, the growth factor 
receptor PI3K or Wnt-signaling, are also strongly related to the cytoskeleton dynamics of filaments which is a nessecary 
process that allows cellular migration. The polarization of tubular cells, which is one of the first reactions of cells to 
toxin induced cell stress, is also susceptible to actin remodeling. Sublethal cell damage and cell loss is hypothized to 
initiate a migratory response in the denuded area of the nephron followed by an increasing proliferative activity to 
replace lost cells [Nony et al., 2003]. To underline the importance of integrin signalling, the signalling by Rho Family 
GTPases and the Actin Nucleation by ARP-WASP complex is also involved in cellular reorganization processes, 
especially the actin nucleation. The signaling by Rho Family GTPases, which regulates a multitude of cell biological 
processes, including transcriptional regulation via AP-1, morphogenesis, reorganization of the actin cytoskeleton, 
neutrophil activation, phagocytosis, mitogenesis, and apoptosis [Boureux et al., 2007, Ellenbroek et al., 2007, Hall et 
al., 1998], and the High Mobility Group-B1 (HMGB1) signalling, which is a special mechanism of cellular stress and 
injury. Because this pathway is related to gene expression regulation of fibrolysis and cell adhesion, but also in the 
cellular immune response, it can be seen as a link between inflammatory reactions and the repair processes. 
The Rho family is a subfamily of GTPases. Three members of this family have been studied more extensively, namly 
Cdc42, Rac1 and Rho. While Cdc42, described to be associated with the formation of filopodia, gene expression was 
unaffected by Vancomycin treatment, Rac1 and Rho were strongly elevated. Rac1, which is related to actin 
polymerization to form lamellipodia, has also been reported to induce cell proliferation in an NFκB-mediated process. 
In contrast, Rho is a regulator of focal adhesion and actin filament bundling into stress fibers. The formation of stress 
fibers has already been described for other compounds causing nephrotoxic insult on tubular cells, including Cisplatin 
[Imamdi et al., 2004], (1,2-dichlorovinyl)-L-cysteine [de Graauw et al., 2007] and chromium compounds [Dartsch et al., 
1998], and  therefore underlining the importance of these Rho-mediated cellular responses. Several proteins have been 
identified as targets of Rho. 
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Figure 3-30 Overview of intergrin-mediated signaling pathways. Within this general overview only interactions of integrin with proteins of the extracellular matrix (ECM) are displayed. The 
signaling cascade leading to cytoskeletal rearrangement and cell motility, including Rac1, Rho and Rock as key players, is most pronounced. However, all shown integrin-mediated cascades are 
characterized by the upregulation of several molecules and can therefore be assumed to activate the individual downstream processes. Red indicates that the transcripts showed a fold-change of ≥ 
1.5 (p ≤ 0.01, q≤ 0.01). Grey displays that the transcripts are not present in the dataset. The ECM proteins are displayed in grey, even though it is sure that they are present. 
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Because of its central position in downstream regulation, Rock is important. Rock activates Mlc, leading to actomyosin 
contractility, or LIMK, which results in inhibition of Cofilin and causes actin polymerization. Rock has also been 
reported to phosphorylate intermediate filaments, like desmin or vimentin [Sin et al., 1998, Inada et al., 1999]. The 
latter has been frequently reported to be associated with drug-induced renal damage. It is noteworth that the key player 
within the interaction network also showed an increase on the gene expression level. Since all the downstream 
processes and signalings lead to recovery, repair and reorganization, the lowered pathological findings in female rats 
compared to male rats can be due to a higher turnover of dieing cells and new migrating cells. In addition, the repair of 
damaged cells can be assumed to be more effective when there is a stronger activation of integrin signaling molecules 
(Table 3-19). 
The HMGB-1 signaling pathway is not directly linked to integrin-signaling, but involved in assembly of nucleoprotein 
complexes, maintenance of nucleosome structure and regulation of gene transcription. The genes described for this 
mechanism are related to cell adhesion and fibrolysis. In general, the HMGB-1 signaling pathway can be classified as 
being related to inflammation. There are two potential origins for HMGB-1, a DNA binding protein that also can be 
associated with cell surface receptors [Ellerman et al., 2007]. One potential source of HMGB-1 is by secretion from 
macrophages and monocytes after stimulation with toxins. During infiltration of the renal tissue, it is likely that the 
underlying inflammatory processes lead to the release of HMGB-1. This relation to the inflammatory processes 
becomes obvious when comparing the ratio pattern of the HMGB-1 signaling and the inflammatory processes, except 
the complement system. The second mechanism of HMGB-1 release is by necrotic cells. This could be an explanation 
why the HMGB-1 signaling is still relatively active on day 28 in male rats. Even though a high severity on renal tubular 
cell damage was observed (Table 3-1) the apoptotic signaling was reduced at this time point. Therefore, it could be 
assumed that the underlying insult is probably caused by necrosis. Subsequently, the release of HMGB1 has to come 
mainly from this source, especially as the leukocyte extravasation, was reduced on day 28 of Vancomycin treatment. 
Once released HMGB-1 protein can activate inflammatory cells through binding of IL-1, TNF-α, IFN-γ, LPS or 
HMGB1 itself to their own receptors (IL-1R, TNFR1, TLR4, IFN-γR and RAGE, respectively) and conseqeuntly 
activate the MAPK-signaling or the NF-κB pathway. In addition, HGBM-1 can activate cell surface receptors on 
various cell types, including epithelial cells, through JNK, Akt, ERK1/2, PI3K and p38 mediated signaling. HGMB-1 
has also been described to interacte with Rho, Rac1 and Cdc42. These proteins, as already described above, are related 
to cellular reorganization, rearrangement and mortility. It can be hypothized that the activation of these key players 
results in the infiltration of further macrophages. Cells activated by HMGB-1 result in the upregulation of adhesion 
molecules like VCAM1, ICAM1 and RAGE. It has also been described that HMGB-1 interacts with the membrane 
receptors and the extracellular matrix of lamellopodia, and is involed in the release of MMPs by REAG-mediated 
MAPK activation. Taking all this in account, the role of HMGB-1 in drug-induced kidney damage seems to have been 
underestimated. There is only limited information about the involvement of HMGB-1 in drug-induced kidney injury. In 
case of renal ischemia reperfusion injury, the important role of HMGB-1 as a pro-inflammatory cytokine was shown 
[Wu et al., 2010], and also the expression of HMGB-1 in proximal tubular cells has been described [Lu et al., 2011]. 
Research on the potential underlying mechanisms of drug-induced nephrotoxicity, specifically tubular nephritis, and the 
involvement of HMGB-1 protein needs to be addressed in the future. 
Finally, a transcription factor analysis was conducted to identify key transcription factors responsible for alterations in 
gene expression. The most common, toxicologically relevant transcription factors were analysed first; namely Ahr, 
Myc, NF-B, and p53. Even though the physiological ligand of the cytosolic aryl hydrocarbon receptor (Ahr) has not 
yet been discovery, its functional role in physiology and toxicology has extensively been studied [Okey et al., 2007]. It 
is known that Ahr plays a pivotal role in development of T-cells [Li et al., 2001] and hepatocytes [Walisser et al., 2005], 
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hematopoiesis and lymphoid systems [Gasiewicz et al. 2010]. In addition, it is strongly involved in the induction of the 
xenobiotic metabolizing enzymes, mainly Cyp1A1 and Cyp1B1 [Harrigan et al., 2004]. However, in the dataset 
presented here, where Ahr was significantly down regulated in male rats on treatment days 7 28 (Table 3-20), Ahr has 
been related to the upregulation of several collagen proteins, TGF-, Actn1, Fn1, A2m and Spp1. Since renal fibrosis is 
mediated mostly by the fibrogenic cytokine TGF- [Branton et al., 1999], and the other factors mentioned above are 
also strongly involved in the development of fibrogenic tissue, there is some evidence that Ahr is involved in the build 
up of renal fibrosis. This is supported by reports that Ahr-deficient mice are characterized by extensive fibrosis in the 
heart and kidneys [Sauzeau et al., 2010]. Even though the mechanistic role of Ahr in the development of renal fibrosis is 
not yet understood; the results indicate an involvement of the Ahr-receptor within the progression of fibrogenic tissue 
building. Ahr is known to interact with the Ahr-interacting protein (AIP) in an Hsp90-mediated process, which 
enhances the Ahr function [Bell et al., 2000]. Since Hsp90 (Hsp90aa1) is down-regulated by Ahr when active 
[Moennikes et al., 2004], and that Hsp90 is increased during drug-induced nephrotoxcity, the inhibition of Ahr can be 
seen as one potential source of this Hsp90 increase. 
In contrast to Ahr, the transcription factor Myc, involved in a multitude of processes, showed no functional activation at 
any time point. However, this transcription factor showed a strong upregulation on the mRNA level in all dose groups, 
reaching from +3.0 to +7.1 fold in male rats and +2.5 to +9.3 fold in females. Taken together with the very high number 
of related downstream genes (m: 134 to 220; f: 144 to 218), this gives further evidence of the important role of Myc in 
Vancomycin-induced kidney damage. In addition, a treatment-dependent upregulation of Myc was been observed in 
NRK-52E cells after treatment with several nephrotoxins (see 3.2 Identification of potential surrogate transcriptional 
biomarkers in vitro). 
The transcription factor NF-B, which already has been mentioned as being involved in inflammatory processes and 
apoptosis induction (Table 3-19), was assumed to play a key role because of the advanced nephritis. However, the 
calculation of the z-scores was only possible for male rats treated for 3 and 28 days with 300 mg/kg Vancomycin. 
Nevertheless, these groups of animals showed the higest z-score of all evaluated transcription factors. NFB is related 
to several already described biomarkers, namely, Clu, Lcn2, and Spp1, as well as several exploratory transcriptional 
biomarkers, like Cd44, Cyr61, Fn1, Hmox1, or A2m, (3.1.4 Testing of two panels of potential transcriptional 
biomarkers), there is some evidence that NF-B plays a pivotal role in the development of renal tubular responsiveness 
to drug induced alterations. This is supported, again only for male rats, by the activation status of RelA (p65), a binding 
partner of NF-B, which also increases NF-B activity [Bettelli et al., 2005, Gewurz et al., 2012]. 
Finally, the major apoptosis inducing transcription factor p53 was assessed. No significant involvement in the gene 
expression regulation could be evaluated, in male or female rats. Therefore, it must be assumed that the apoptotic 
processes taking part into the kidneys during Vancomycin treatment follows a p53-independent pathway. It has been 
shown for Cisplatin nephrotoxcity, that Src, a proto-oncogen, interacts with phosphorylated PKC, which itself 
regulates MAPK-mediated apoptosis without activation of p53 [Pabla et al., 2011].  
Beside these traditional toxicological related transcription factors, the dataset was screened for specific and significant 
altered factors (Table 3-20). The findings were more pronounced in male rats compared to females. 
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Table 3-20 The predicted activation or inhibition of common toxicological and study specific transcription factors (TF) to evaluate there involvement in gene regulation during Vancomycin induced 
nephrotoxicity. The values represent z-scores calculated by the IPA software tool and the p-value of the individual dataset (in parentheses). The z-score gives the tendency of regulation, while the p-
value gives a measure whether there is a statistically significant overlap between the dataset and the genes regulated by the TF. Z-score ≥ 2 and ≤ -2 were assumed to be predictive. Values between 2 
and -2 are displayed in grey. Green indicates inhibition, red indicates activation. 
 Male     Female    
TFs 
(common) 3d 7d 14d 28d  3d 7d 14d 28d 
Ahr 
-1.76  
(4.03E-15) 
-2.07  
(4.28E-17) 
-1.07  
(3.22E-11) 
-2.36  
(6.66E-16) 
 
-1.84  
(1.60E-10) 
-1.81  
(5.25E-11) 
1.93  
(3.09E-07) 
-1.40  
(1.45E-10) 
Myc 
-0.92  
(1.01E-30) 
-1.42  
(1.50E-46) 
-0.84  
(1-08E-40) 
-0.60  
(2.89E-42) 
 
-0.82  
(6.30E-43) 
-0.51  
(9.71E-42) 
0.45  
(2.54E-43) 
0.43  
(4.45E-46) 
NF-b 
5.04  
(5.37E-14) 
/         
(7.91E-21) 
/         
(3.36E-15) 
4.02  
(1.60E-20) 
 
/         
(1.01E-16) 
/         
(1.85E-14) 
/         
(8.76E-13) 
/         
(1.59E-15) 
p53 
-1.78  
(3.59E-36) 
-0.45  
(7.22E-51) 
0.41  
(2.94E-50) 
-0.60  
(1.43E-45) 
 
0.04  
(5.73E-51) 
0.18  
(2.60E-48) 
-0.30  
(6.87E-41) 
0.252  
(1.30E-49) 
          
TFs (specific)          
PPAR 
-4.01  
(1.50E-30) 
-4.88  
(1.19E-27) 
-3.19  
(2.04E-10) 
-4.89  
(1.53E-37)  
-3.70  
(1.23E-14) 
-2.13  
(4.55E-14) 
-2.39  
(9.15E-11) 
-3.94  
(1.89E-16) 
PPAR 
-2.77  
(2.77E-11) 
-3.75  
(7.25E-12) 
-2.05  
(4.91E-05) 
-3.45  
(2.30E-13)  
-2.60  
(1.77E-05) 
/         
(2.24E-04) 
-1.11  
(4.80E-05) 
-2.43  
(3.29E-08) 
PPAR 
-2.80  
(2.91E-09) 
-3.50  
(7.72E-08) 
/         
(2.01E-05) 
-3.09  
(4.60E-10)  
-2.29  
(6.57E-05) 
-1.82  
(2.32E-05) 
/         
(1.79E-04) 
-3.93  
(6.42E-58) 
RelA 
3.33 
(5.53E-11) 
3.13 
(1.88E-17) 
/         
(3.18E-13) 
3.07 
(2.85E-14)  
/         
(1.88E-13) 
/         
(6.78E-10) 
/         
(3.02E-09) 
/         
(4.42E-12) 
Smad3 
3.25 
(1.04E-08) 
2.71 
(5.10E-09) 
2.05 
(2.20E-06) 
3.13 
(1.60E-12)  
2.42 
(2.50E-06) 
2.14 
(1.02E-04) 
2.01 
(2.91E-07) 
2.31 
(1.19E-05) 
Stat1 
3.28  
(2.01E-09) 
2.55  
(5-83E-17) 
/         
(3.74E-12) 
3.43  
(9.87E-12)  
/         
(2.44E-13) 
/         
(1.75E-11) 
/         
(2.75E-12) 
/         
(2.59E-11) 
Stat3 
2.99  
(2.36E-14) 
3.11  
(1.53E-23) 
/         
(8.10E-16) 
3.35  
(1.54E-21)  
2.07  
(3.90E-15) 
2.44  
(4.53E-15) 
/         
(2.60E-12) 
2.10  
(4.03E-15) 
          
 
PPARα, PPARδ and PPARγ belong to the family of peroxisome proliferator-activated receptors (PPAR). All these transcription factors showed an inhibition in male and female rats 
on treatment days 3 and 28, while male rats in addition showed significant alterations on day 7. The most pronounced inhibition was observed for PPARα predominantly on day 14, 
which reflects the general pattern caused by the recovery of the renal tissue. All of these PPARs are ubiquitary expressed, while PPARα is expressed in high amounts within kidney, 
liver, gut and heart [Tyagi et al., 2011]. 
1
7
5
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The role of PPARs in renal disease is not yet fully understood. Beside their major role in energy homeostasis, more 
specific in -oxidation, they have been described to be also involved in tissue repair and inflammation [Escher et al., 
2000, Berger et al., 2002]. PPARα, PPARδ, and PPARγ have been described to have protectiv effects against ischemia/ 
reperfusion and nephrotoxin induced cortical necrosis as well as inflammatory processes [Baud et al., 2002, Berger et 
al., 2002]. However, PPARα seems to be the most potent protector in case of renal damage. Within the kidney PPARα 
is primarily expressed in proximal tubular cells. Therefore, is has also been described that PPARα ligands prevents 
Cisplatin nephrotoxicity, by inhibition of renal fatty acid oxidation (FAO) and pyruvate dehydrogenase complex (PDC) 
activity [Li et al., 2004]. It has been hypothized that the anti-inflammatory properties of PPARs, by suppressing anoikis 
and inflammatory infiltration in proximal tubular epithelia, are also responsible for the protective effect [Letavernier et 
al., 2005]. However, PPARα has been described to inhibit NF-B [Baud et al., 2007], while PPARδ protein increases 
the activity of the NF-B complex [Di-Poi et al., 2002]. Because NF-B also has curative properties by clearance of 
apoptotic and necrotic cells by macrophages, this can also be assumed to be a mechanism of PPAR protection. A 
potential explanation for the observed differences between the sexes could be the less strong inhibition in females, 
subsequently leading to a higher protection of tubular cells. 
The most dominant activated transcription factor was Smad3. Smad3 is a member of the Smad family of proteins, and is 
related to inflammation, fibrosis, apoptosis and accelerated wound healing [Ashcroft et al., 1999, Inazaki et al., 2004]. 
This transcription factor is induced by TGF- and is involved in cell signalling. Since TGF- itself is known to cause 
renal tubular damage in a Smad3 -independent mechanism, it is hard to discriminate whether or not the interaction of 
these two molecules is important in Vancomycin-induced nephrotoxicity [Dai et al., 2003]. For the interaction it has 
been report that the sensitivity to TGF-β-induced apoptosis is regulated by crosstalk between the Akt/PKB 
serine/threonine kinase and Smad3 [Conery et al., 2004]. However, the fact, that smad3 seems to be significantly 
activated supports the important role of this transcription factor. The combination of an upregulation of TGF- (as 
observed in our study), lead to an activation of several molecules related to the extracellular matrix, like collagens, 
Timp1, Vim, Fbln1 and Spp1. Additionally, TGF-itself can be induced by TGF- activated Smad3, lead to an 
upregulation of Tgfb1 and Tgfb2 gene expression. In case of drug-induced nephrotoxicity, the interaction of TGF- and 
Smad3 has been studied by the progression of chronic cyclosporine nephrotoxicity [Islam et al., 2001, Tao et al., 2011]. 
It could be shown that sodium depletion, as it was the case for treatment day 3 and day 28 (Figure 3-1), enhances 
fibrosis and TGF- expression [Shihab et al., 1997]. The involvement in inflammatory processes became obvious when 
taking into account that Smad3 and RelA can bind each other [Wang et al., 2011]. RelA, which already has been 
described as an interaction partner of NF-B, is strongly related to inflammatory processes [Sanz et al., 2010]. It can be 
assumed, that the regulatory molecules TGF-, Smad3, NF-B and RelA act in a feedback control system because 
TGF-/ Smad signaling has been described to be suppressed by NF-B/RelA [Bitzer et al., 2000]. 
Finally, the last specific and significant activated transcription factor belongs to the Signal Transducer and Activator 
(Stat)-family. In mammals seven Stats have been described [Ihle, 2001]. They are involed in several regulatory 
pathways and signaling cascades. They are most frequently related to Janus kinases (JAK) resulting in the expression of 
several growth factors and cytokines subsequently leading to cell differentiation, migration and proliferation as well as 
apoptotic processes [Aaronson et al., 2002]. In our data, Stat1 and Stat3 showed a significant activation in male rats on 
treatment days 3, 7 and 28 (Table 3-20). In female rats only Stat3 was significantly activated on days 3, 7 and 28. It is 
remarkable that Stat1 and Stat3 showed such high z-scores because these two Stats have been described to be strongly 
related to IL-6 activation [Takeda et al., 1998, Dawn et al., 2004], which itself is involved in a pathway already 
described above (Table 3-19). Beside the induction of inflammatory responses, Stat3 is also related to induced 
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proliferation of renal cells after an insult [Arakawa et al., 2008] and can be therefore assumed to be involved in the 
recovery of renal tissue, as observed within this study (Table 3-1). 
Both Stats have been described to have an important role in nephrotoxicity, especially Cisplatin-induced renal damage 
[Tadagavadi et al., 2010]. The invovlemant of the MAPK-signaling, significant altered after Vancomycin-treatment, 
indicates a central position of this pathway. In general, almost all of the transcription factors directly influence each 
other and delievered a more complex interaction network (Table 3-21). This gives further evidence that the similarity in 
downstream genes and biological mechanisms is of essential importance in Vancomycin-induced nephrotoxicity. 
 
Table 3-21 Relationships between the most relevant transcription factors identified in renal tissue after Vancomycin treatment. The 
relationships were summarized as follow: a: activation, b: regulation of binding, e: expression, i: inhibition, l: localization, m: 
modification, p: phosphorylation, pd: protein-DNA interaction, pp: protein-protein interaction, pr: proteolysis, tl: transclocation, tc: 
transcription. For the identification of the interactions the Ingenuity pathway analysis software IPA® as used. 
  
  
 
NF-b PPAR PPAR PPAR RelA Smad3 Stat1 Stat3 
                 
 
 
        
NF-b 
 
a, b, tl a, e, i, pp, tc a, e, i,pp, tc a 
a, e, l, m, 
pp, b, tc, tl 
a a, p, pp, b, pp, b,  
PPAR 
 
a, e, i, pp, tc 
a, e, i, l, pd, 
pp, tc, tl 
a, e, pp, tc a, tc pp, b - - - 
PPAR 
 
a, e, i,pp, tc a, e, pp, tc 
a, e, i, p, pd, 
pp, pr, b, tc, 
tl 
a, e, tc,  a, e, pp, b,  p, pp, b,  a, e, pd pp 
PPAR 
 
a a, tc a, e, tc,  a, e, pp, tl pp e, tc e - 
RelA 
 
a, e, l, m, 
pp, b, tc, tl 
pp, b a, e, pp, b,  pp 
a, e, m, p, 
pp,  
pr, b, tc, tl 
p, pp pp l, pp, tl 
Smad3 
 
a - p, pp, b,  e, tc p, pp 
a, i, m, p, 
pp, 
pr, b, tc 
a, e, pp pp 
Stat1 
 
a, p, pp, b, - a, e, pd e pp a, e, pp 
a, m, p, 
pp, pr, 
b, tc, tl 
a, e, p, p, b 
Stat3 
 
pp, b,  - pp - l, pp, tl pp a, e, p, p, b 
a, e, i, m, p, 
pd, 
pp, pr, b, 
tc, tl 
  
                 
 
 
The highest number of relationships was observed for each individual transcription factor by interaction with 
themselves, which indicated the strong feedback control mechanism of gene expression. However, also several 
relationshipts could be observed for NF-B-PPARPPAR, NF-B-RelA, NF-B-Stat1 and RelA-PPAR. The Stats 
showed the major interaction between themselves, while PPAR showed interactions with NF-B, RelA and the other 
PPARs. All this gives further evidence for the central role of NF-B as a mediator of multiple processes, including 
inflammation, proliferation, apoptosis and cell growth and recovery.  
Since Vancomycin-induced nephrotoxicity can inhibited by targeting superoxide dismutase [Nishino et al., 2002, 
Nishino et al., 2003], it is assumed that oxidative stress may play a role in cellular damage caused by Vancomycin. A 
key transcription factor in case of oxidative stress is Nrf2, but showed no increase in gene expression or any significant 
elevation by transcription analysis. However, several molecules regulated by this transcription factor or otherwise 
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related to oxidative stress, reactive oxygen species (ROS) or in the response to oxidative stress and the maintenance of 
normal cellular redox states were significantly altered. The upregulated genes were the superoxide dismutase 3 (Sod3), 
heme oxygenase-1 (Hmox1), thioredoxin-disulfide reductase, xanthine dehydrogenase (Xdh), gluthathione peroxidase 2 
(Gpx2), peroxidase 2 (Prdx2), and NAD(P)H dehydrogenase quinone 1 (Nqo1). In addition, NF-B1 and NF-B2, 
RelA, Stat3, Jun, and Fos, involved in many processes like inflammation, proliferation, and apoptosis, showed an 
upregulation that was dependent on the severity of damage. Also an upregulation of the chaperone and stress response 
proteins Hsp90, chaperonin containing Tcp1 (Cct7), FK506 binding protein 5 (Fkbp5) and peptidylprolyl isomerase B 
(Ppib) was observed. Downregulation was observed for catalase (Cat), gluthathione peroxidase 1 (Gpx1), glutamate-
cysteine ligase (Gclc), aflatoxin aldehyde reductase (Afar), cytochrome P450 2E1 (Cyp2E1), gluthathion S-transferase 
alpha 5 (Gsta5). In summary, the gene expression changes suggested that an oxidative stress response has been induced 
by Vancomycin treatment, presumably to help reduce the harmful impact of ROS on renal cells. 
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3.1.4 Conclusion about Gene expression analyses 
 
Several potential key players in the progression of Vancomycin induced nephrotoxicity have been identified and 
discussed. However, the underlying results are based on gene expression data only. Subsequently, the results only show 
one part of a broader picture and should be seen as a starting point of further studies.  
 
 
Figure 3-31 Pathway from the underlying gene expression data generated from renal tissue after 
Vancomycin treatment. The three major processes (inflammation, apoptosis, remodeling) are shown 
with the two major biological mechanisms involved. In addition, the individual processes were 
linked based on identified transcription factors, including oxidative stress.  
 
It could be shown that the three major processes – inflammation, apoptosis and remodeling/ regeneration (Figure 3-31) - 
are the most prominent alterations observed, which were confirmed by the in-life parameters as well as 
histopathological evaluations (see 3.1.1.1 Results (Vancomycin)). Subsequently, further molecular biological/ 
toxicological alterations could be identified. For example, the complement system seems to play a pivotal role in 
Vancomycin induced renal tubular damage. Since similar gene expression alterations were reported for several 
compound-induced renal alterations, this process seems not to be Vanyomycin specific [Kim et al., 2007, Pan et al., 
2009].  This highly conserved acute response showed also a more or less constant activation in male and female rats. In 
addition, the detection of complement components could therefore be assumed to have a degree of diagnostic potential, 
especially as the complement pathway is highly regulated and conserved across species. Another factor which appears 
frequently over all the evaluated biological responses is the involvement of the transcription factor NF-B, which also 
induces complement component 3, and -4b. Since NF-B is a key molecule in inflammatory processes, which was 
present in a treatment dependent manner, but it may also influence apoptosis and regeneration. By taking into account 
that NF-B regulates a multitude of genes not directly related to inflammatory processes and that several of these were 
also degregulated within this study, it is very likely that it may also be involved in these biological events. Furthermore, 
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the way in which this transcription factor counterbalance the beneficial anti-apoptotic properties and the detrimental 
pro-inflammatory activity, gives strong evidence for an involvement of NF-B within this interplay of life and death 
signals. Another important question, related to cell death and survival, is how the apoptotic program is regulated. In this 
case, our data suggest that the induction of apoptosis is primarily induced by the Fas-receptor (FasR). Since the Fas-
receptor is activated by Fas-ligands (FasL) which belongs to the tumor necrosis factor (TNF) family, needs further 
investigation. Further evidence is given by the fact that TNF- has been described to activate a p53-dependent 
apoptosis mediated by NF-B. Therefore, it can be hypothized that an alternative FasR/ TNF- dependent pathway of 
apoptosis exists without the activation of p53 by NF-B. However, the apoptotic process itself seems to be caspase-
dependent because of the upregulation of initiation as well as effector caspases. Consequently, any alteration in 
mitochondrial function, characterized by increased oxygen and ATP production described for Vancomycin, is not 
leading to the release of the apoptosis inducing factor (AIF) and the initiation of a caspase-independent apoptosis.  
Caspase 12 has been reported to be related to endoplasmic reticulum stress, although it is more likely that the up-
regulation of Caspase 12 is due to the inflammation. In contrast to the possible ER-stress, there is much more evidence 
for an involvement of oxidative stress in Vancomycin induced nephrotoxicity, triggered by NF-B, RelA and Stat3. 
Kidney remodelling, which includes cell proliferation, migration and differentiation, is the most comprehensive process 
during renal tubular cell injury. Apoptosis and cellular clearance by inflammatory cells like macrophages are 
fundamental processes in healing of the kidney. Therefore we concentrated on processes directly involved in the 
repopulation of denuded tubular areas, the cell-cell signaling mediated migratory processes and the recovery of the 
cellular shape and properties including the building up of a functional extracellular matrix. Here, integrin-mediated 
pathways seem to play the most important role and are involved in many different downstream signalling events. One 
pathway which was most pronounced was the GTPase-dependent actin nucleation. This process is of importance for 
differentiation, migration and cellular shape recovery, and was driven by de GTPases Rho, Cdc42 and Rac1. Many of 
these cellular processes are not exclusively important in renal tubular cell recovery, but also in the motility of 
monocytes and magrophages infiltration. The same is true for the potential involvement/ influence of HMGB1, which 
on one hand can be induced by secretion from macrophages or by release from necrotic tubular cells. In summary, the 
gene expression data gave further insights in potential processes and signaling pathways of Vancomycin induced 
nephrotoxicity. The data gave strong evidence of an involvement of Stat3, Smad3, and Myc in Vancomycin-induced 
nephrotxicity. Because the data presented are exclusively based on the measure of mRNAs and not on proteins, this 
approach has to be seen as a hypothesis building one. The results were meant to give a statistically significant starting 
point for further investigation. Therefore, the Fas-receptor mediated apoptosis, the influence of NF-B on 
inflammation, apoptosis and recovery has to be addressed. In addition, the background on PPAR inhibition as a 
potential origin of renal cell protection needs further work. Independent of the analyzed processes, the MAPK pathway 
has to be considered, because of the strong evidence for its involvement in Vancomycin-induced nephrotoxicity. 
Because the data point to some similarities in Vancomycin and Gentamycin-induced renal damage, the involvement of 
the MAPK-signaling can be partially extrapolated. Thus it can be hypothized that the p38-MAPK pathway may be 
involved in renal insult induced by Vancomycin. In addition, the increase of NF-B protein, which seems to be 
responsible in Gentamycin induced inflammatory processes of interstitial nephritis, could also be transfered to 
Vancomycin nephrotoxicity. Since this pathway can be initialized by TNF- and TGF- and is mediated by p38/ 
MAPK, this pathway is likely to be involved. However, because the majority of regulatory steps takes place in form of 
phosphorylation events on protein level, analysis on gene expression level only deliveres limited information and needs 
additional studies. 
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3.1.5 Evaluation of putativ transcriptional biomarkers in vivo 
 
In the following section transcriptional biomarkers for the identification/ prediction of compound induced 
nephrotoxicity, taken from renal tissue, were evaluated. A commercialized set of genes in combination with a Random 
Forest classifier were evaluated for their applicability to detected renal damager. This system, consisting of the protocol 
for the SYBR
®
-green based qRT-PCR as well as the analyzing software, was provided by Compugen Ltd. In this 
approach three independent studies were used (see 2.4.2Additional rat in vivo studies investigated). In a second step 
these transcriptional biomarkers, as well as other sets of genes derived from public available datasets (TG-GATEs) as 
well as from literature were tested for their ability to predict renal insult within a whole genome dataset.  
 
 
Compugen Ltd. Classification model: 
 
For testing the Compugen Ltd. based classification system for nephrotoxicity, three independent rat studies 
(Gentamycin, FP007SE/ BI-3, aristolochic acid) were used. Animals within the Gentamycin study showed no 
histopathological alterations within the control group after 7 days of treatment. All five low dose (60 mg/kg) treated 
animals showed mild to high severity of proximal tubular necrosis while all high dose (120 mg/kg) treated animals 
showed a high severity of lesions after the treatment period [Hoffmann et al., 2010]. These results could be reflected by 
using the Compugen classification model. However, only 3 out of the five animals from the original study could be used 
for testing, All three tested control animals showed classification values between 0.1 and 0.2 and therefore were far 
below the classifier threshold of 0.4, subsequently leading to a toxicity value of 0% (0 of 3 animals) (Figure 3-32a). In 
low (60 mg/kg) as well as in high (120 mg/kg) dose treated animals all three rats delivered values above the threshold 
(0.6-0.8) leading as a consequence to a classification of 100 % (3 of 3 animals). However, no differences were observed 
between animals only showing mild insults compared to animals with a high severity of lesions (data not shown). Both 
classifiers, the 4 gene and the 6 gene (including two splice variants of Ccng1 and Isg20; see Table 2-18), delivered the 
same classification. 
In contrast to the Gentamycin study were only one time point of tissue collection was performed (Figure 3-32a), three 
different time points were evaluated within the FP007SE study. The histopathological observations within the FP007SE 
study showed 2 animals of the control group with minimal necrosis within the proximal tubulus after 3 days of 
treatment. In the low dose group (100 mg/kg) one animal showed minimal necrosis after treatment day 1 and two 
animals after treatment day 3. However, at the latest time point no animals were observed showing renal alteration. In 
high dose (1000 mg/kg) treated animals no changes were observed after 1 day of treatment and only one animal showed 
minimal proximal tubular necrosis after 3 days.  
However, after 14 days of treatment 2 rats showed moderate and one animal showed severe tubular damage. Within the 
classification model by Compugen Ltd., in contrast to the Gentamycin study, on day 2 and day 4 a toxicity value of 
20% was calculated. This indicates that in both groups one animal was classified as positive for renal insult (Figure 
3-32b). While in the control group studied after 4 days (classifier value: ~0.49) the positive classified animal had mild 
necrosis, the animal on day 2 (classifier value: 0.52-0.56) was not described to show any pathological alterations. 
However, a good time and dose dependent increase in toxicity values, and therefore in the number of positive classified 
animals per group, was measured. 
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Figure 3-32 The toxicity values derived by the classification model from 
Compugen Ltd. based on the quantification of 4 genes. The classifier 
calculated individual classification value of each individual animal. If the 
value lay above the threshold defined by Compugen Ltd. (0.4) the animal 
was assumed to be possitiv (toxic affected). Out of this the toxicity value 
for the treatment group was calculated be the number of positiv classified 
animals against all animals. Renal tissue of three independent studies were 
used: a.) Gentamycin, b.) FP007SE (BI-3), c.) aristolochic acid. Because 
the samples were provided by the University of Wuerzburg, for any reason 
not for all treatment groups all samples were available. Therefore the total 
number of used samples (n) is displayed in each individual graph.  
 
 
A disadvantage of this result was the lack of coverage of the 
evaluated toxicity values by histopathological observation. One 
animal of the low dose (100 mg/kg) treatment group on day 2 was 
correctly classified (toxicity value 20%), however two animals 
positively classified on day 15 with classification values in the 6 / 4 
gene classifier of 0.37 / 0.4 and 0.57 / 0.58, showed no 
histopathological findings. On day 4, low dose (100 mg/kg) treated 
animals also showed classification values above the threshold and 
must be therefore assumed to be positive. Similarly, in high dose 
(1000 mg/kg) animals, where two animals treated for two days and 
four animals treated for four days were positively classifiered 
without necrotic findings within the kidneys. Therefore, these 
results are categorised as false positives. However, there is some 
evidence that the measured classification and toxicity value could 
be a real prediction of the developing nephrotoxicity. This 
hypothesis is supported by the fact those animals without proximal 
tubular necrosis, even though they are above the threshold, showed 
smaller classification values. Therefore, the alterations caused by 
treatment with FP007SE were specifically established on molecular/ 
transcriptional level and had not yet lead to renal necrosis. 
Witin the study using aristolochic acid (AA), described to be a rodent carcinogen and a highly nephrotoxic compound, 
no histopathological alterations were observed at any time point. However, the classification model showed a clear 
dose-dependent increase in the prediction of incidence of renal damage. In contrast to the other two studies, the 6 gene 
and the 4 gene classification model showed slight differences for the control and the mid dose (1 mg/kg) groups. In the 
6 gene classifier two animals of the control group were predicted to be positive (40% toxicity value) while only one 
animal in the 4 gene classifier lay above the threshold (20% toxicity value) (Figure 3-32c). Subsequently, only one of 
these two animals showed a high classification score while the second was a borderline. In the low dose (0.1 mg/kg) 
treated group only one animal was above the threshold (20% toxicity value), independent of the used classifier. In the 
mid dose (1 mg/kg), either 4 animals in the 6 gene (80% toxicity value) or 3 animals in the 4 gene (60% toxicity value) 
classifier were above the threshold. Independent of the classifier, the high dose (10 mg/kg) treated animals were 
predicted as positive in 100% of the cases (5 of 5 animals). 
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These results deliver further evidence that this transcriptional panel provided by Compugen Ltd. could have the 
potential to really predict renal damager, even before histopathological alterations take place. By assuming this 
hypothesis, the prediction of a developing AA induced kidney injury can be seen as successful. The fact that the mid- 
and high dose samples were increasingly classified as nephrotoxic deliver additional information about the solidity of 
this early prediction. To take into account that the measured values of the gentamycin study, where clear 
histopathological findings were observed, and the FP007SE were some findings could be covered by histopathological 
observed necrosis, these findings give further hints to the great benefit of transcriptional biomarkers, especially in the 
early stages of developing kidney damage. Nevertheless, it must also be mentioned that the detected transcripts are 
involved in a multitude of signaling pathways and pathological processes. Especially in carcinogenicity, this is of 
special interest as Ccng1, a member if the cyclin family, is involved in the eukaryotic cell cycle and in addition is 
inducible by p53 [Endo et al., 1996; Okamoto et al., 1996]. It also was described to be directly involved in renal 
tumorigenesis [Stemmer et al., 2007]. Tnfrsf12a, a member of the tumor necrosis factor receptors, was also described to 
be involved in tumor formation, not only in kidney, but in several organs, such as liver [Mei et al., 2006], esophageal 
[Wang et al., 2006] and skin [Ahlborn et al., 2008]. While Isg20, an exonuclease with specificity to ssRNA, seems to be 
not directly involved in carcinogenic pathway but in inflammatory processes, the inactivation of Ei24 has been 
described to be associated with the formation of invasive cervical carcinoma [Mazumder et al., 2011] because of its role 
as an apoptosis-inducing factor [Chen et al., 2002].  
In summary, changes in gene expression could be observed much earlier than the increase of marker proteins in urine. 
Together, the data generated by the qRT-PCR based classification model suggests that the 4 gene classifier delivered 
comparable results to the 6 gene classification model. Further investigations are needed using additional nephrotoxins 
as well as non nephrotoxic compounds to validate the utility of these transcriptional biomarkers. To check whether 
these transcripts also can be used independently of the underlying method the transcripts were analysed based on the 
Vancomycin study (see below).  
 
 
Independency of transcripts used in the Compugen Ltd. Classification model 
 
To evaluate if the transcripts used within the Compugen Ltd. Classifier can also be used directly as potential 
biomarkers, the intensity values were extracted from the whole genome dataset generated from the samples of the 
Vancomycin study. The intensity values of the control groups were averaged (n=3) (arithmetric mean) and relative ratio 
values of each treated animal were calculated against the average of the corresponding time matched control group. The 
ratios were then averaged (geometric mean) and the data were displayed as log2 normalized values in Figure 3-33. To 
evaluate the relationship of gene expression pattern, the deregulations were ploted against the histopathological 
observations of tubular degeneration. The increase in Ccng1 mRNA was only slightly related to histopathology in 
female rats, while male rats showed no alteration (Figure 3-33a). In addition, the magnitude of Ccng1 induction was 
low, reaching only an level of log2(1), a quasi doubling, in animals with moderate to massive tubular degeneration. 
However, Ccng1, has been described in several studies to be upregulated in renal tissue after gentamycin, Batcitracin 
and Cisplatin induced nephrotoxicity [Ozaki et al., 2009, Wang et al., 2008]. When Vancomycin was administered daily 
at 160 mg/kg i.v. for up to 5 days, no alteration of Ccng1 was observed [Wang et al., 2008]. In contrast Isg20 has not 
been reported in case of drug induced nephrotoxicity. 
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Figure 3-33 Deregulations of a.) Ccng1, b.) Isg20, c.) Ei24, and d.) Tnfrsf12a over the histopathological 
findings (tubular degeneration) from the Vancomycin study. The data are presented as the log2 normalized 
ratios of the averages (geometric mean) over each individual group against the average of the corresponding 
time match control group as bars (lighter grey = male rats; dark grey = female rats). - ≙ lesion not observed, 
+ ≙ minimal, ++ ≙ mild, +++ ≙ moderate, ++++ ≙ massive, and +++++ ≙ high severity of lesion. 
 
Because of its involvement in inflammatory processes, which also play a pivotal role in renal damage and by the fact 
that it is expressed by vascular endothelial cells [Imaizumi et al., 2008], like VEGF, it can be assumed that this 
transcript can have the potential to deliver further information in special cases of renal alteration. Within our 
Vancomycin study, Isg20 showed a clear tendency in both male and female rats from mild to high severe of damage, 
however it has a limited potential as a biomarker because of the low magnitude of increase, which was always below 
log2(1) (Figure 3-33b). A similar situation occurred for Ei24, which also has not been reported to be responsive to drug 
induced renal damage. However, there are several reports of the involvement of Ei24 in case of p53-dependent 
apoptosis [Burns et al., 2001; Mork et al., 2007]. Ei24 showed a similar regulation pattern to Ccng1, also with the 
specific gender differences and the low magnitude of increase (Figure 3-33c). In contrast to Isg20 and Ei24, Tnfrsf12a 
has been described in several approaches with the aim to identify potential biomarkers for nephrotoxicity. For example, 
Tnfrsf12a has been described to be upregulated in e.g. compound A induced nephrotoxicity [Kharasch et al., 2006] as 
well as in ischemic acute renal failure [Yuen et al., 2006]. Within our panel of genes, Tnfrsf12a showed the best 
correlation to histopathological observations (Figure 3-33d). 
Based on our results, it can be concluded that Tnfrsf12a can be used as an exploratory transcriptional biomarker for 
drug-induced renal damge. However, further work on Ccng1, Isg20 and Ei24 is needed before a final decision can be 
made.  
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3.1.4 Testing of two panels of potential transcriptional biomarkers 
 
Beside the transcripts used within the Compugen Ltd. based assay, there are many other potential transcriptional 
biomarkers published. In almost all cases these genes were discovered through large cooperation’s [Fuchs et al., 2011]. 
However, in most of the cases these lists of potential transcriptional biomarker were generated and proven by the 
consortia / cooperation partners themselves, but there are fewer reports of the validation of these biomarkers in an 
independent way. Within the following sections two of these biomarker lists were used to evaluate the applicability of 
these biomarkers to identify renal damage in our Vancomycin study. The two biomarker lists which will be used in the 
following are based on the Toxicogenomic Project in Japan (TG-GATEs) reported by Minowa and colleques [Minowa 
et al., 2012] and a literature based biomarker panel [Wang et al., 2008]. 
 
 
Evaluation of a multigene biomarker panel identified by the Toxicogenomic Project in Japan 
 
The scientific approach within the Toxicogenomics Project in Japan was based on the measurement of whole genome 
transcriptional changes in kidney from rats treated with 41 nephrotoxic and non-nephrotoxic compounds. Two different 
approaches were used, either a single treatment with an observation time of 24h or daily dosing (intravenously or orally) 
for 28 days. Male Sprague-Dawley rats were treated with three different doses (low, middle, and high) of each 
compound. In the single treatment regime renal tissue was collected at 3, 6, 9 and 24h; in the repeated dosing regime on 
days 4, 8, 15 and 29. Gene expression profiles were generated from kidney total RNA using Affymetrix DNA 
microarrays. For more detailed information refere to Minowa et al., [2012]. The identification of the relevant genes was 
based on a computational classification model. The model resulted in a list of 19 probes (Table 3-22) with a reported 
sensitivity of 93% and a selectivity of 90%. 
 
Table 3-22 Originally identified transcripts of the TG-GATEs classification model with their rank of classification. In 
addition the Affymetrix Probe ID is given. 
Rank Probe ID Gene symbol Gene title 
        
1 1387965_at Havcr1 Hepatitis A virus cellular receptor 1 
2 1368420_at Cp Ceruloplasmin 
3 1368627_at Rgn Regucalcin (senescence marker protein-30) 
4 1368497_at Abcc2 ATP-binding cassette, sub-family C, member 2 
5 1370445_at Pla1a Phospholipase A1 member A 
6 1371785_at Tnfrsf12a Tumor necrosis factor receptor superfamily, member 12a 
7 1383605_at LOC360919/ LOC684913 Similar to alpha-fetoprotein 
8 1379889_at Lamc2 Laminin, gamma 2 
9 1377092_at EST EST 
10 1379340_at Lamc2 Laminin, gamma 2 
11 1390579_at RGD1305222 Similar to RIKEN cDNA 1810029B16 
12 1387382_at Hnmt Histamine N-methyltransferase 
13 1370422_at Ripk3 Receptor-interacting serine-threonine kinase 3 
14 1367856_at G6pd Glucose-6-phosphate dehydrogenase 
15 1370333_a_at Igf1 Insulin-like growth factor 1 
16 1367712_at Timp1 TIMP metallopeptidase inhibitor 1 
17 1367977_at Snca Synuclein, alpha 
18 1374070_at Gpx2 Glutathione peroxidase 2 
19 1383675_at EST EST 
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The individual transcripts were exctracted out of the Illumina RatRefv.1.0 whole genome dataset generated from our 
Vancomycin study. However, Ceruloplasmin (rank 2), Insulin-like growth factor 1 (rank 15) and EST (rank 19) were 
not present on the Illumina microarray. In addition, γ-Laminin, which was present in the gene list twice with different 
probes, was only included once (ILMN_1368403). The expressed sequence tag (1377092_at) was found to be 
synonymous with the suppressor of cytokine signaling 3 (Socs-3). 
The intensity values of the control groups were averaged (n=3) (arithmetric mean) and relative ratio values of each 
treated animal were calculated against the average of the corresponding time matched control group. The ratios were 
then averaged (geometric mean) and the data were displayed as log2 normalized values in Figure 3-33. To evaluate the 
relation of gene expression pattern the deregulations were plotted against the histopathological observations of tubular 
degeneration (Figure 3-34a-o). 
Several of the evaluated transcripts showed renal damage related changes. The earliest and strongest up regulation was 
observed for Havcr1, Tnfrsf12a, Lamc2, Timp1 and Gpx (Figure 3-34a, e, f, j, l). Because of the close functional 
relationship between Havcr1, Timp1 and Lamc2, in the interaction with extracellular matrix components and other 
cofactors and their involvement in cellular repair, attachment, migration and organization [Huo et al., 2010, Hellman et 
al., 2006, Mizushima et al., 1998, Miner et al., 1999], it can be assumed that these processes start immediately after an 
insult, even though only minimal histopathological degenerations can be observed. Therefore, these transcriptional 
biomarkers can be used to detect moderate/mild changes in renal cells. Because no strong differences between male and 
female rats were observed, which can be due to the general mechanism of cellular repair, they also can be used 
independently of the sex. Tnfrsf12a is a receptor for Tnfsf12/Tweak and a weak inducer of apoptosis [Tran et al., 2005]. 
However, Tnfrsf12a was also reported to be involved in angiogenesis and endothelial proliferation [Wiley et al., 2001]. 
Furthermore, it is involved in the modulation of cellular adhesion to matrix proteins [Meighan-Mantha et al., 2000]. In 
summary, this transcript seems to play an impotant role in nephrotoxicity. This is underlined by the fact that Compugen 
Ltd. identified this biomarker independently (3.1.4 Testing of two panels of potential transcriptional biomarkers).  
Gpx (glutathione peroxidase) is one of two isoenzymes responsible for the majority of the glutathione-dependent 
hydrogen peroxide reducing activity [Prabhakar et al., 2005, Ng et al., 2007]. Gpx is involved in the oxidative stress 
response, specifically induced by reactive oxygen species (ROS) [Miyamoto et al., 2003], a further indication for the 
mechanism of Vancomycin induced nephroptoxicity. However, beside this strongly up regulated transcript, there are 
also insult-dependent down regulated genes within this biomarker list. These include Rgn, Hnmt and Snca (Figure 
3-34b, g, k). While Hnmt, a histamine N-methyltransferase inactivating histamine and functions as an anti-
inflammatory factor, showed only minimal differences between male and female rats, Rgn and Snca showed a marked 
decrease in gene expression only in male rats. These differences can point to a potential gender difference in the 
mechanism of Vancomycin induced nephrotoxicity. Rgn, a calcium-binding protein, has an important role in calcium 
homeostasis and therefore in modulating Ca
2+
 signaling and Ca
2+
-dependent enzyme activities and processes [Lai et al., 
2011]. Since it is known that elevated intracellular calcium levels can induce apoptosis [Mattson et al., 2003] it can be 
hypothized that a decrease in renal Rgn can lead to less calcium-binding and therefore to an accumulation of Ca
2+
, 
finally leading to apoptosis. In addition, it has been reported that Rgn knockout mice were highly susceptible to 
receptor-mediated apoptosis [Ishigami et al., 2002] and therefore underline the anti-apoptotic role of Rgn. The decrease 
of Snca also lead to a reduction of an anti-apoptotic factor. Snca has been described to reduce caspase-3 activity [Li et 
al., 2005] to inhibit the proteasome formation [Tanaka et al., 2001], a decrease will probably lead to an increase in 
apoptotic events. In summary, the decrease in gene expression could only be observed at later stages when mild to 
moderate changes already were established. 
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Figure 3-34 Gene deregulation of a.) Havcr1, b.) Rgn, c.) Abcc2, d.) Pla1a, e.) Tnfrsf12a, f.) Lamc2, g.) Hnmt, h.) Ripk3, i.) G6pdx, 
j.) Timp1, k.) Snca, l.) Gpx, m.) LOC360919, n.) Socs3, o.) RGD1305222_predicted over the histopathological findings (tubular 
degeneration) from the Vancomycin study. The data are presented as the log2 normalized ratios of the averages (geometric mean) 
over each individual group against the average of the corresponding time match control group as bars (lighter grey = male rats; dark 
grey = female rats). - ≙ lesion not observed, + ≙ minimal, ++ ≙ mild, +++ ≙ moderate, ++++ ≙ massive, and +++++ ≙ high 
severity of lesion. 
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Beside the transcriptional biomarkers mentioned above, also Abcc2 (Figure 3-34c) and G6pdx (Figure 3-34i), showed a 
gender-independent increased gene expression in relation to the observed severity, although they were not as sensitive. 
The increase reached log2(1) earliest when mild to moderate tubular degeneration were observed histopathologically. 
Similar to Ccng1, Isg20 and Ei24 are included in the Compugen Ltd. assay (Figure 3-33a-c), also Pla1a, Ripk3, 
LOC360919, Socs3 and RGD1305222_predicted (Figure 3-34d, h, m, n, o) showed a clear tendency in altered gene 
expression in relation to histopathological observation, but with a relative low magnitude of deregulation. This finding 
can be due to the specific mechanism of Vancomycin-induced nephrotoxicity or based on the fact that the discovery of 
these transcripts was based on a computational classification model, which does not necessarily identify genes with 
strong alterations. 
 
 
Evaluation of a literature based biomarker panel 
 
A list of 48 transcripts, generated by Wang and collogues by doing literature search, delivered a transcript biomarker 
candidate list and tested against 4 nephrotoxicants (Bacetracin, Gentamycin, Cisplatin, Vancomycin) and 3 
hepatotoxicants (4,4-Diaminodiphenylmathane, Ketoconazole, 1-Naphthyl isothiocyanate), delivered promising results 
[Wang et al., 2008]. However, only male Sprague-Dawley rats were treated orally, intravenously or subcuntaneously 
daily with one of the model compounds for up to five days with kidney tissue collection on days 1, 3 and 5. Therefore, 
no data are available about the performance of the transcript panel in more long term treatment or in female rats. As 
mentioned for the gene set identified by Minowa and colleagues (Table 3-22) not all transcripts were present on the 
Illumina RatRef.v1.0 whole genome array. Ceruloplasmin (Cp), glutamate-ammonia ligase (Glul) and solute carrier 
family 21, member 1 (Slc21a1) were not included. 
The benefit of using a larger panel of transcripts, like in this approach, is the possibility to group specific transcripts by 
their reported or expected function. Consequently, the pattern of transcripts within such groups can deliver further 
information about the underlying toxicological processes. The results of the altered genes were grouped and presented 
in Table 3-24 and Table 3-23. 
The most obvious observation in both male and female rats is the early and strong increase in genes of the group 
“regeneration/ repair/ remodeling”. In this group five transcripts showed an increase in renal gene expression even after 
only minimal histopathological observations were recorded. These five genes are Clu, Havcr1, Lcn2, Timp2 and Spp1 
All of which can be also determined on the urinary protein level. In addition female rats showed an increase in gene 
expression for Fn1 and Ctss within this group. However, the majority of changes in these transcriptional biomarkers 
were earliest established when mild to moderate tubular degeneration were observed. This is the case over all functional 
groups used within this analysis. The increase of pro-apoptotic factors in the functional group “apoptosis/ necrosis/ 
oxidative stress”, including Jun or the decrease of anit-apoptotic factors like Rgn, started to change when moderate 
tubular degeneration was observed. This is true for male rats (Table 3-24), where many more down regulated transcripts 
were measured, while female rats (Table 3-25) only showed down regulation of Odc and Ghr, both involved in cell 
growth and proliferation [Chi et al., 2006, Jeay et al., 2001]. The group “acute phase/ inflammatory” gave additional 
information about the underying renal injury and the processes affeceted. In this case A2m and Cd44 delivered the 
earliest and most pronounced results in both male and female rats. A2m, a protease inhibitor and cytokine transporter, is 
described to be increased, on a protein level, in nephritic syndrome. In case of longstanding chronic renal failure A2m 
can lead to amyloid [Picken, 2009]. This can be due to the function of A2m as an inhibitor of MMP, comparable to 
Timp1 [Webster et al., 2006].  
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Table 3-24 Transcriptional biomarker list reported by Wang and colleques [Wang et al., 2008] for the male rats of the 
Vancomycin study. The data are presented as the log2 normalized ratios of the averages (geometric mean) over each 
individual group against the average of the corresponding time match control group. Log2 values are color coded as follow: ≤ 
-2 dark green, -2 to-1 light green, -1 to 1 yellow, 1 to 2 orange, ≥ 2 red. The values are displayed over the histopathological 
findings (tubular degeneration).  - ≙ lesion not observed, + ≙ minimal, ++ ≙ mild, +++ ≙ moderate, ++++ ≙ massive, and 
+++++ ≙ high severity of lesion 
 
Gene Category Histopathological scores [tubular degeneration] 
  - + ++ +++ ++++ +++++ 
Apoptosis/necrosis/oxidative Stress 
    Anxa5 -0.29 -0.39 1.29 1.53 2.70 2.28 
Hmox1 -0.02 0.13 0.64 1.74 1.88 2.20 
Jun -0.08 -0.21 1.06 1.40 1.57 1.13 
Hmox2 -0.57 -0.48 -0.16 -0.69 -0.50 -0.57 
Gadd45a -0.42 -0.38 -0.34 -1.16 -0.85 -0.75 
Odc -1.03 -1.43 -0.31 -1.65 -0.83 -1.20 
Calb1 -0.20 -0.09 0.29 -1.11 -1.26 -1.67 
Ghr -0.30 -0.36 -1.30 -2.10 -1.91 -1.71 
Cat -0.45 -0.66 -0.21 -1.43 -1.88 -2.13 
Rgn -0.33 -1.15 -0.84 -2.31 -4.28 -4.61 
Acute phase/ inflammatory 
     A2m -0.04 0.36 2.11 2.55 3.65 3.53 
Cd44 -0.04 0.10 1.26 2.51 2.93 2.63 
Vcam1 -0.23 -0.49 0.70 0.47 1.63 0.79 
Cd24 -0.16 -0.07 0.55 0.49 1.16 0.63 
Ccnd1 -0.37 -0.38 -0.18 -0.07 0.42 0.55 
Ccng1 -0.25 -0.53 -0.13 -0.30 -0.11 -0.21 
IgKc 0.04 -0.09 -0.12 -0.03 0.07 0.02 
Regeneration/repair/remodeling 
    Clu -0.26 2.81 3.17 3.64 4.05 3.16 
Havcr1 -0.18 4.52 4.39 6.20 6.64 6.50 
Lcn2 -0.59 2.31 3.51 4.58 5.66 5.33 
Timp1 0.06 1.81 2.68 4.10 5.17 4.90 
Fn1 -0.43 -0.64 1.75 2.24 3.07 2.38 
Spp1 -0.62 1.41 1.45 1.21 1.76 1.42 
Ctss -0.45 -0.38 1.12 1.14 1.93 0.65 
Igfbp1 -0.69 0.66 0.56 1.00 1.66 0.87 
Vim -0.11 -0.21 0.43 0.70 1.72 0.95 
Mt1a -0.28 -0.08 -0.25 -0.32 -0.11 -0.15 
Tmsb10 0.03 0.28 0.17 0.29 0.35 0.51 
Cst3 -0.09 -0.43 0.06 -0.39 0.20 -0.37 
Hormon/metabolism/transport   
     Mgp 0.10 0.19 1.17 1.79 2.76 2.01 
Cyr61 -0.04 -0.17 0.13 1.35 2.51 2.62 
Bmp1 0.07 -0.09 0.09 0.04 0.57 0.14 
Slc22a1 -0.37 -0.01 -0.41 -0.28 -0.54 -0.24 
Ugt1a1 -0.29 -0.53 -0.28 -0.41 -0.60 -0.14 
Vegfa -0.36 -0.27 -0.16 -0.52 -0.54 -0.48 
Aldh1a1 -0.40 -0.31 -0.54 -0.64 -1.04 -0.94 
Gstm2 -0.20 -0.88 0.02 -1.06 0.28 -0.55 
Bmp4 -0.31 -0.54 -0.21 -1.04 -0.69 -1.04 
Cyp2d22 -0.34 -0.56 -0.17 -0.95 -1.09 -1.37 
G6pc -0.14 -0.16 -0.32 -0.78 -1.56 -2.07 
Slc22a6 -0.48 -0.04 -0.90 -1.57 -2.07 -1.50 
Oat -0.10 -0.53 -0.05 -1.72 -1.73 -2.02 
Nphs2 -0.38 -0.14 -1.21 -1.64 -1.95 -1.59 
Ngfg -0.65 -0.34 -1.24 -3.32 -3.38 -3.49 
Egf 0.02 -0.18 -0.92 -2.43 -3.70 -4.71 
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Table 3-25 Transcriptional biomarker list reported by Wang and colleques [Wang et al., 2008] for the female 
rats of the Vancomycin study. The data are presented as the log2 normalized ratios of the averages (geometric 
mean) over each individual group against the average of the corresponding time match control group. Log2 
values are color coded as follow: ≤ -2 dark green, -2 to-1 light green, -1 to 1 yellow, 1 to 2 orange, ≥ 2 red. 
The values are displayed over the histopathological findings (tubular degeneration).  - ≙ lesion not observed, 
+ ≙ minimal, ++ ≙ mild, +++ ≙ moderate, and ++++ ≙ massive lesion 
Gene Category Histopathological scores [tubular degeneration] 
  - + ++ +++ ++++ 
Apoptosis/necrosis/oxidative Stress 
   Anxa5 0.16 0.44 1.45 2.26 2.84 
Hmox1 0.02 0.16 1.05 1.53 1.80 
Jun 0.13 0.58 1.03 1.69 1.67 
Hmox2 -0.11 0.17 0.34 0.48 0.56 
Gadd45a 0.04 0.37 0.07 0.19 0.26 
Odc -0.25 0.12 -2.01 -2.77 -1.31 
Calb1 -0.12 0.33 0.26 0.43 -0.12 
Ghr 0.03 0.02 -1.00 -1.04 -0.97 
Cat 0.01 0.13 -0.21 0.05 -0.55 
Rgn 0.29 0.27 -0.55 -0.63 -0.60 
Acute phase/ inflammatory 
    A2m 0.00 0.11 1.27 3.92 3.03 
Cd44 0.03 0.38 1.53 2.64 2.31 
Vcam1 0.11 0.71 1.15 1.90 1.65 
Cd24 0.25 0.84 0.93 1.56 1.65 
Ccnd1 0.15 0.71 0.39 0.68 2.04 
Ccng1 0.28 0.67 0.33 0.82 1.01 
IgKc -0.06 -0.16 -0.20 -0.38 -0.24 
Regeneration/repair/remodeling 
   Clu 0.20 1.77 3.60 4.00 3.81 
Havcr1 -0.11 3.01 4.74 5.93 6.29 
Lcn2 0.08 2.67 3.94 6.15 6.18 
Timp1 0.31 1.92 4.12 4.92 6.12 
Fn1 0.55 1.26 1.75 3.26 3.01 
Spp1 0.24 1.22 1.16 1.38 1.49 
Ctss 0.33 1.32 1.08 2.31 2.14 
Igfbp1 0.21 0.73 1.02 1.70 1.19 
Vim 0.53 0.80 0.51 1.86 1.89 
Mt1a 0.14 0.27 0.32 1.01 0.33 
Tmsb10 -0.15 -0.18 -0.01 -0.03 -0.09 
Cst3 0.38 0.62 0.40 1.13 0.47 
Hormon/metabolism/transport   
    Mgp 0.37 1.55 1.45 2.84 2.69 
Cyr61 0.59 0.95 1.27 2.10 2.63 
Bmp1 0.23 0.28 0.35 0.96 0.62 
Slc22a1 0.16 0.31 0.39 0.58 0.99 
Ugt1a1 0.08 0.50 0.53 1.03 1.32 
Vegfa 0.08 0.30 0.22 0.28 0.14 
Aldh1a1 0.12 0.54 0.17 0.32 0.06 
Gstm2 0.33 0.24 0.33 0.36 0.16 
Bmp4 0.04 0.35 0.22 0.29 0.09 
Cyp2d22 -0.10 -0.04 -0.06 -0.14 -0.28 
G6pc -0.03 0.07 -0.23 -0.32 -1.45 
Slc22a6 0.13 0.53 -0.46 -0.57 -0.50 
Oat 0.20 0.26 -0.21 -0.12 -1.22 
Nphs2 0.40 0.85 -0.60 -0.81 -0.34 
Ngfg 0.10 0.15 -1.08 -1.37 -1.92 
Egf 0.23 -0.01 -0.59 -1.63 -3.72 
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In addition, A2m seems to be strongly related to the induction and function of the complementary system. The A2m 
protein includes multiple domains with homology to the complement component C3 in human [Doan et al., 2007] and 
can act as a negative regulator of the lecitin pathway of the complementary system [Ambrus et al., 2003]. 
Cd44 is a cell-surface glycoprotein, also described to be involved in cell-cell interations, cell adhesion and migration 
[Goodison et al., 1999]. Furthermore, it seems to play a pivotal role in lymphocyte signaling [Taher et al., 1996, 
Ilangumaran et al., 1998]. Cd44 has a close relationship to Osteopontin, which can act as a ligand of the Cd44 receptor. 
Osteopontin modulates the Cd44-dependent chemotaxis or peritoneal macrophages [Zhu et al., 2004] and functions by 
binding to Cd44 and initiating a survival signal via a phospahtidylinositol 3-kinase/Akt pathway [Lin et al., 2001]. 
However, changes were only detectable when mild tubular degenerations were present. In contrast to the gene category 
group “apoptosis/ necrosis/ oxidative stress”, where male rats showed more deregulations, within the group “acute 
phase/ inflammatory” female rats showed more de-regulations, more specifically up-regulation of transcripts. 
Subsequently, Vcam1, Cd24, Ccnd1 and Ccng1 showed an up-regulation but only when massive tubular degenerations 
occurred (Table 3-26). This is remarkable because female rats showed a generally lower renal injury. Even in male rats 
identified with servere degenerations, these transcripts showed no alteration. Based on the general biological function as 
cell adhesion molecules (Vcam1, Cd24) and regulators of cyclin-dependent kinases, it was expected that no marked 
differences between the sexes will be present. However, this can be seen as a hint on differences in the mechanistic 
response of male and female rats, as a consequence leading to differences in the nephrotoxic outcome. Further 
mechanistic investigations on this hypothesis are required. 
Within the last group “Hormone/ metabolism/ transport”, comparable differences between male and female rats were 
observed as described for the group “Apoptosis/ necrosis/ oxidative Stress”. This includes the similar increase in gene 
expression of two transcripts, in this case Mgp and Cyr61 and a relatively strong and widespread decrease in mRNA 
level within male renal tissue. Mgp is an extracellular matrix protein involved in the inhibition of tissue calcification 
[Schurgers et al., 2008], for example in arteries [Luo et al., 1997]. Calcification is a common cause of tubular interstitial 
nephritis as well as acute tubular necrosis [Loh et al., 2009], which is important to detect at very early stages. In 
contrast, the secretory protein encoded by Cyr61 plays an important role in a multitude of processes, such as cell 
proliferation, differentiation, apoptosis and ECM formation [Lee tal., 2007, Si et al., 2006, Todorovic et al., 2005, Lau, 
2011]. It is a member of the Igfbp-family and is described to interact with Vegfa and Vegfc, MMP1, MMP3, as well as 
with Integrin-1 and -3. Even though it has been described in several scientific publications with the aim to identify 
nephrotoxicity [Mishra et al., 2003, Ichimura et al., 2004], the major role of this molecule in the developing and 
establishing renal injury has not yet been discovered. 
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3.1.5 Final resumee on gene expression biomarkers 
 
Several of the reported transcripts can be used as predictive/ descriptive transcriptional biomarkers, delivering reliable 
results. Furthermore, the very early detection, when only minimal histopathological observations are present, indicate 
the high sensitivity of these transcriptional biomarkers. The benefit of the unbiased measurement of a panel of 
transcripts together with the advantage of grouping the transcripts into functional units can deliver additional 
information about the health status of the kidney. However, the major disadvantage of this approach is the risk of a 
misinterpretation by relying on predefined groups. In addition, transcripts like A2m, Cd44, Clu and Cyr61 can be 
grouped in multiple functional units. The fact that for almost all transcripts several functions were described in the 
literature makes this a major challenge of defining a transcriptional biomarker panel. Therefore, for any toxicological 
routine study, a combined approach of measuring urinary proteins, which has to be preferred because of the non-
invasive character of this determination, at several interim time points and a final determination of the gene expression 
changes of the corresponding mRNA species can significantly enhance the drug development process. In addition these 
data will be available earlier than the sometimes very time consuming histopathological reporting. This approach has 
the best chance to be applied in early acute studies, where routinely no histopathology is available or in more long-term 
studies, by evaluation of additional time points. In both cases alteration on urinary protein or renal transcriptional 
changes can be used as a flag of the initiation of renal damage before sever histopathological changes have occured. 
 
As an outlook, based on the data presented here and further literature search the following list of transcriptional 
biomarkers can be extracted and recommended for further evaluation. This list of 40 transcripts were grouped into 10 
functional categories (Apoptosis, Cell Cycle, Proliferation, Cytosceleton, Transporter and metabolism, Metal Ion 
Binding, Oxidativ Stress, Tissue Remodeling, Extracellular Matrix, Inflammation) whereby individual transcripts can 
be present in more than one of these groups. Beside the already described and evaluated transcripts within the 
biomarker panels several additional transcripts were included based on the results of the gene expression data of our 
study and literature data of promising biomarkers. For example, the complement components C3 and C4 were included 
based on their abundance and potential importance for inflammation induced renal cell damage [Brown et al., 2007]. In 
addition, Nqo1, a cytoplasmic 2-electron reductase, often described to be upregulated in the case of drug-induced renal 
oxidative stress [Aleksunes et al., 2010], was included. Finally, Hsp90aa1 was described to play a pivotal role in 
proliferatory processes after toxic insults. Subsequently, it is also an important interaction partner with several 
transcription factors; themselves involved in cellular responses after a renal insult (see 3.1.3.2 Mechanistic Analysis). 
This gene list can be considered as a starting point to evaluate the usefulness of transcriptional biomarkers in pre-
clinical routine studies. It is important to remember that the studies performed to identify theses transcripts for the 
detection of renal damage are based on well known and highly potent nephrotoxiciants. Therefore, novel 
drugs/chemical candidates, with an often weaker toxicological profile and less specific nephrotoxic potential can lead to 
altered sensitivity and specificity. As a consequence, this list of potential transcriptional biomarkers has to be validated 
further with many more test compounds.  
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Table 3-27 Final transcriptional biomarker list for routine use in pre-clinical rat toxicity studies. The 40 individual 
transcripts were grouped into functional categories, while the transcripts can be present in more then one category. 
Gene Symbol Unigene Description 
   Apoptosis 
  Anxa5 Rn.3318 Annexin A5 
Calb1 Rn.3908 Calbindin 1 
Casp3 Rn10562 Caspase 3 
Casp12 Rn.81078 Caspase 12 
Cd24 Rn.6007 CD24 molecule 
Cd44 Rn.1120 Cd44 molecule 
Cdkn1a Rn.10089 Cyclin-dependent kinase inhibitor 1A 
Clu Rn.1780 Clusterin 
Gadd45a Rn.10250 Growth arrest and DNA-damage-inducible, alpha 
Ghr Rn.2178 Growth hormone receptor 
Hmox1 Rn.3160 Heme oxygenase (decycling) 1 
Jun Rn.93714 Jun oncogene 
Nqo1 Rn.11234 NAD(P)H dehydrogenase, quinone 1 
Rgn Rn.10006 Regucalcin (senescence marker protein-30) 
Tnfrsf12a Rn.105040 Tumor necrosis factor receptor superfamily, member 12a 
Cyr61 Rn.22129 Cysteine-rich, angiogenic inducer, 61 
   Cell Cycle 
  Ccng1 Rn.5834 Cyclin G1 
Cdkn1a Rn.10089 Cyclin-dependent kinase inhibitor 1A 
Egf Rn.6075 Epidermal growth factor 
Gadd45a Rn.10250 Growth arrest and DNA-damage-inducible, alpha 
   Proliferation 
  Cd24 Rn.6007 CD24 molecule 
Cdkn1a Rn.10089 Cyclin-dependent kinase inhibitor 1A 
Clu Rn.1780 Clusterin 
Egf Rn.6075 Epidermal growth factor 
Hmox1 Rn.3160 Heme oxygenase (decycling) 1 
Hsp90aa1 Rn.119867 Heat shock protein 90, alpha (cytosolic), class A member 1 
Odc Rn.874 Ornithine decarboxylase 1 
Timp1 Rn.25754 TIMP metallopeptidase inhibitor 1 
   Cytosceleton 
  Lamc2 Rn.9278 Laminin, gamma 2 
Tmsb10 Rn.5983 Thymosin, beta 10 
Vim Rn.2710 Vimentin 
   Transport and metabolism 
 Abcc2 Rn.10265 ATP-binding cassette, subfamily C (CFTR/MRP), member 2 
Gpx Rn.3503 Glutathione peroxidase 2 
G6pd Rn.11040 Glucose-6-phosphate dehydrogenase 
Nqo1 Rn.11234 NAD(P)H dehydrogenase, quinone 1 
   
Metal Ion Binding 
 Cp Rn.32777 Ceruloplasmin 
Ctss Rn.11347 Cathepsin S 
Hmox1 Rn.3160 Heme oxygenase (decycling) 1 
Lcn2 Rn.11303 Lipocalin 2 
Rgn Rn.10006 Regucalcin (senescence marker protein-30) 
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Gene Symbol Unigene Description 
   
   Oxidativ Stress 
  Clu Rn.1780 Clusterin 
Hmox1 Rn.3160 Heme oxygenase (decycling) 1 
Nqo1 Rn.11234 NAD(P)H dehydrogenase, quinone 1 
G6pd Rn.11040 Glucose-6-phosphate dehydrogenase 
   Tissue Remodeling 
 Fn1 Rn.1604 Fibronectin 1 
Lamc2 Rn.9278 Laminin, gamma 2 
Havcr1 Rn.11154 Hepatitis A virus cellular receptor 1 
Spp1 Rn.8871 Secreted phosphoprotein 1 
Timp1 Rn.25754 TIMP metallopeptidase inhibitor 1 
Vim Rn.2710 Vimentin 
Ngfg Rn.11331 Nerve growth factor, gamma subunit 
Nphs2 Rn.86433 Nephrosis 2, idiopathic, steroid-resistant 
Tmsb10 Rn.5983 Thymosin, beta 10 
Cyr61 Rn.22129 Cysteine-rich, angiogenic inducer, 61 
   Extracellular Matrix 
 Cd44 Rn.1120 Cd44 molecule 
Cyr61 Rn.22129 Cysteine-rich, angiogenic inducer, 61 
Havcr1 Rn.11154 Hepatitis A virus cellular receptor 1 
Lamc2 Rn.9278 Laminin, gamma 2 
Mgp Rn.2379 Matrix Gla protein 
Timp1 Rn.25754 TIMP metallopeptidase inhibitor 1 
Ngfg Rn.11331 Nerve growth factor, gamma subunit 
   Inflammation 
  A2m Rn.198688 Alpha-2-macroglobulin 
C2 Rn.98333 Complement component 2 
C3 Rn.11378 Complement component 3 
C4a Rn.155573 Complement component 4A 
Casp3 Rn10562 Caspase 3 
Casp12 Rn.81078 Caspase 12 
Ccng1 Rn.5834 Cyclin G1 
Cd44 Rn.1120 Cd44 molecule 
Clu Rn.1780 Clusterin 
Ctss Rn.11347 Cathepsin S 
Lcn2 Rn.11303 Lipocalin 2 
Hnmt Rn.13145 Histamine N-methyltransferase 
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3.2 Identification of potential surrogate transcriptional biomarkers in vitro 
 
The aim of this evaluation was to check wether or not it is possible to identify transcriptional biomarkers in a renal cell 
line with the potential to bridge to the in vivo situation. Therefore, four nephrotoxic and two non-nephrotoxic 
compounds were administered to NRK-52E cells for up to 72h as a proof-of-principal. 
 
 
3.2.1 In Vitro Cytotoxicity Assay  
 
Before gene expression analysis could be performed the right concentration of the test compounds had to be evaluated. 
This was necessary to avoid a concentration too low to induce any significant gene expression changes a too high a 
concentration so that no enough cells survive the treatment time. Therefore, a dose range finding experiment were 
performed by measure the intracellular ATP concentration, used as an indirect measurement of cell viability. In 
addition, the neutral red uptake assay (NRU) was conducted to check if differences in the cellular responsiveness appear 
by using different cell viability/ toxicity assays. 
 
 
Dose range finding in vitro 
 
The intracellular ATP content can provide information about the viability of the cells as well as give any evidence of a 
potential effect on the mitochondria. To discovery whether or not a compound affects the mitochondria, an additional 
cytotoxicity or cell viability assay must be performed in parallel. For each individual compound, a series of a minimum 
5 concentrations in 4 technical replicates were used. Each experiment was repeated a minimum of 3 times by using 
different passages of NRK-52E cells. These passages were used as biological replicates to ensure validity of the results. 
The TC20 values were calculated for the ATP Test after 72h of treatment, while the cells were treated every 24h (three 
treatment periods). Here the TC20 value is the concentration of the test compound required to reduce the ATP content by 
20% compared to the corresponding vehicle control and calculated by plotting the relative cell viability values on a 
logarithmic scale and perform a sigmoidal fit (Table 3-28). Subsequently, the TC20 values were used as a high dose 
(HD) concentration. An example of such an approach is given in Figure 3-35. 
  
 
Figure 3-35 Example of the evaluation of the NOAEC, 
TC20, and TC50 based on the relative cell viability 
determined by intracellular ATP content. Dose response 
curve of Doxorubicin ploted on a logarithmic scale. In this 
example five concentrations were used to and the NOAEC 
was directly evaluated from the curve by chosing a 
concentration without any alteration. The sigmoidal curve 
was calculated and generated by using the Origin® software. 
The TC50 value is the half maximal toxic concentration 
where 50% of the cells are dead. In contrast, the TC20 is 
defined by the concentration where 80% of the cells are 
alive and 20% are dead. 
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The low dose concentration was chosen to cause no adverse effect (no-observed-adverse-effect-concentration 
(NOAEC)). In contrast, the concentrations for Paracetamol were extrapolated directly from the measured data without 
calculation of the TC values. As negative compounds, Metformin and d-Mannitol were used. As expected no 
cytotoxicity was observed for these compounds. Therefore, Merck internal standard concentrations for cytotoxcity assay 
were used. The calculated values for the used model compounds (Puromycin, Paracetamol, Doxorubicin, Amphotericin 
B, Metformin and d-Mannitol) are given in Table 3-28. In addition to the evaluated concentrations used for the gene 
expression experiment, also the TC50 value is shown. Doxorubicin (TC50: 0.1µM) and Puromycin (TC50: 0.5µM) are the 
most potent compounds used within this experiment. While Paracetamol (TC50: 5000µM) showed only marked effects 
in the millimolar concentration range. This was expected because Paracetamol itself is not nephrotoxic but some of its 
metabolites, specifically para-Aminophenol. Amphotericin B has also shown a high potency to induce proximal tubular 
damage in vitro (TC50: 1.5µM). In addition, for all nephrotoxic model compounds the difference between the observed 
NOAEC and the TC20 was higher (~5-10 fold) than between the TC20 and the TC50 (~2-5 fold). In this case the steepest 
curve was observed for Puromycin, indicating a very tight range of toxicity and underlines the high cytotoxic potential 
of this drug. 
 
Table 3-28 Overview of the calculated concentrations from the dose range finding study. The low 
dose (LD) was determined by evaluation of the non-observed-adverse-effect-concentration 
(NOAEC). As high dose the calculated TC20 was used. In addition the TC50 is displayed 
 
Compounts Abbreviation NOAEC [µM] TC20 [µM] TC50 [µM] 
  
low dose (LD)  high dose (HD) 
 
     Puromycin Pur 0.025 0.35 0.5 
Paracetamol APAP 500* 2000* 5000* 
Doxorubicin Dox 0.001 0.02 0.1 
Amphotericin B AB 0.5 5 1.5 
Metformin Met 20** 100** / 
d-Mannitol Man 20** 100** / 
* Concentrations for Paracetamol could not be calculated because of only slight cytotoxicity. The used 
concentrations were based on direct observations of the measured viability. 
** Concentrations for Metformin and d-Mannitol could not be calculated because of the lack of cytotoxic 
effects. The used concentrations were based on Merck internal standard concentrations. 
. / = not calculatable. 
 
By comparison of the intracellular ATP content and the neutral red uptake it was obvious that the variance between the 
individual biological replicates was much higher by using the NRU assay than within the ATP assay (Figure 3-36).  
Paracetamol only showed slight cytotoxicity in both assays (Figure 3-36a). At concentration > 2 mM a stronger 
decrease could be observed, and increased up to ~20% cell viability at 1 M. Because this concentration is far too high to 
be specific for nephrotoxic effects, it was decided only to use concentrations ≤ 2 mM (Table 3-28). Paracetamol is 
mainly metabolized/ activated in the liver and can produce toxic metabolites. The most important metabolite is N-
acetyl-p-benzo-quinone imine (NAPQI), which is primarily responsible for the toxic (hepatotoxic) effect of 
paracetamol. Beside the liver, the kidney also metabolizes Paracetamol. The general mechanism of toxification by a 
Phase 1 reaction including Cytochrom P450-dependent monooxygeneses is comparable in both organs [Lee et al., 1996; 
Manyike et al., 2000]. In the kidney, Paracetamol is metabolized within the proximal tubular cells or the inner renal 
medullar by the Cytochrom P450-system or the prostaglandin-H peroxide synthetase to NAPQI, leading to tubular/ 
papillar necrosis. Another toxic metabolite formed in the kidney is p-Aminophenol, described to cause necrosis of the 
pars recta and the glomerulus [Carpenter et al., 1981]. 
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Figure 3-36 Cell viability after treatment with three concentrations of a.) Paracetamol, b.) 
Puromycin, c.) Doxorubicin, d.) Amphotericin B, e.) Metformin, and f.) d-Mannitol 
determined with either the determination of the intracellular ATP content (light grey) or 
the neutral red uptake (dark grey).  
 
Based on the cytotoxicity assays by direct comparison of Paracetamol and its metabolite p-Aminophenol (data not 
shown) it was assumed that the NRK-52E cells are not able to metabolize Paracetamol in a sufficient manner. This was 
verified by gene expression analysis of several hepatic and renal metabolizing enzymes from Phase 1 and Phase 2 (data 
not shown). NRK-52E cells are not strongly inducible after treatment with cytochrome P450 inducers like 3-
Methylcholandren, -Naphtoflavon or Dexamethasone. Paracetamol was included into the set of nephrotoxic compound 
with the aim to check whether or not the slight toxicity can be used to detected highly sensitive transcriptional 
biomarkers. 
In contrast, Puromycin showed very strong cytotoxicity in both the ATP and NRU assays (Figure 3-36b). However, 
some differences between the used assays were observed. The calculated viability after treatment with 0.25 µM 
Puromycin resulted in a cell viability of ~60% when using the ATP-assay, while still ~90% of the cells were alive as 
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measured in the NRU assay. The effect of Puromycin on the mitochondria is well described; more dominant for cells of 
the glomerulus than the proximal tubular cells [Hagiwara et al., 2006]. 
Doxorubicin, which is described to cause mitochondrial toxicity [Goormaghtigh et al., 1990] showed no to only slight 
differences between the two used cytotoxicity assays (Figure 3-36c). However, because the value within the NRU assay 
at concentrations of 5 nM was about ~125% viability while the ATP assay delivered a value of near 100% viability, it 
cannot be finally clarified if there is a slight impact on the mitochondria. 
In contrast, a very strong difference between these two assays was observed for Amphotericin B (AB) (Figure 3-36d). A 
treatment with 50 µM AB lead to a relative cell viability of near 0% when using the ATP assay, while the same 
concentration did not lead to any alteration within the NRU assay. Here the very high sensitivity of the detection of the 
intracellular ATP assay becomes clear. The potential effect of AB can be explained by several mechanisms. Thus the 
changes of intracellular Ca
2+
 content, caused by the pore-building potential of AB, may play a role in the ongoing 
mitochnondrial damage [Murchison et al., 2000]. 
The negative controls, Metformin and d-Mannitol, showed no relevant alterations in either assay. Therefore, the highest 
concentration chosen was 100µM. 
 
 
3.2.2  Gene expression analysis of NRK-52E cells 
 
The aim of this apporach was to evaluate the capability to use NRK-52E cells for the detection of transcriptional 
biomarkers with the potential to bridge between the in vitro and the in vivo situation.  
 
 
3.2.2.1 Identification of in vivo nephrotoxicity biomarker in vitro 
 
Gene expression data was derived from whole genome profiles using the Illumina RatRef v.1 Beadarray. In a first step, 
a general overview of the gene expression pattern was investigated (i.e., box-plot and Log-Log plot). Based on the 
profile display and the background controls included on each array of a RatRef v.1 bead array, all values with a signal 
intensity of < 60 were excluded from the analyses for background correction. Statistically significant genes were 
selected by student’s t-test with a p-value cutoff of p < 0.01 for each individual compound. Subsequently, only the 
positive compounds, which were described to be nephrotoxic, were used. The transcripts from these groups were then 
further filtered by selecting genes that showed a deregulation of ≤ -1.5 or ≥ 1.5 fold. The remaining four gene lists, from 
each compound, were used to create a Venn diagram. From this a total number of 192 genes were identified to be 
common across all 4 compounds (Figure 3-37). Out of these 192 altered transcripts, 128 genes were down-regulated 
(FC ≤ -1.5), 64 genes were up-regulated (FC ≥ 1.5). This shows a first obvious deviation from the in vivo data, where 
the majority of transcripts showed an up-regulation. In addition, the magnitude of fold-changes was low compared to 
the in vivo situation, although still statistically significant. The fold-change only exceeded ± 10 in some individuals 
(Figure 3-37).  
The heatmap, which is based on a 2-dimensional hierarchical clustering, automatically sorting transcripts as well as 
samples with a positive correlation together, gives further evidence for the high sensitivity of transcriptional changes. 
Thus the 192 genes grouped all high dose treated cell samples together. In addition, the low dose of Doxorubicin, which 
was the most potent compound, also clustered near to the high dose treatments. However, the fold-changes were far 
below those observed for the high dose treated samples. In contrast, Puromycin, showed a slightly different pattern. The 
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high dose Puromycin treated samples clustered together with the low dose groups of Paracetamol and Amphotericin B, 
while the low dose Puromycin samples were categorized in the same group as d-Mannitol, a negative compound. This 
discrepancy can be explained in two different ways. Puromycin is described to induce glomerular damage, but also 
proximal tubular degeneration and necrosis, while the other compounds primarily target proximal tubular cells. 
Therefore, it can be hypothized that the mechanism of Puromycin toxicity is quite different from the others.  
 
Figure 3-37 2-Dimensional hierarchical cluster of the fold-changes of 192 genes which were significantly altered after 72h treatment 
of NRK-52E cells with high doses of Paracetamol (APAP), Puromycin (Pur), Doxorubicin (Dox), Amphotericin B (AB). In addition, 
the fold-changes of the negative comopunts Metformin (Met) and d-Mannitol (Man) were included. 128 genes showed a down 
regulation (green) and 64 an up-regulation (red). The orange lines identify the positive, while the blue lines the negative compounds. 
Significance was determined by a students t-test (p < 0.01) and a fold-induction of ≤ -1.5 and ≥ 1.5 against the vehicle control. 
 
 
It is also possible that the steepness of the dose-response curve evaluated for Puromycin is a reason for this discrepancy. 
However, all the three replicates of Puromycin treated samples, both high dose and low dose treatment groups (data not 
shown), were very similar. The data showed that also the low dose treated samples showed a deregulation of the 
identified transcripts, even though there was no effect on cellular ATP levels observed. This points to the fact that the 
genes reacted to stress very early and have therefore the potential to act as predictive in vitro biomarkers. The negative 
compounds Metformin and d-Mannitol, as well as the low dose dose Puromycin treated samples, showed no alteration 
in gene expression pattern at all. 
The identified 192 transcripts were analyzed for their involvement in specific biological processes. Therefore, a network 
analysis was conducted by using the IPA
®
 software tool. It was found that from the total number of 19 identified 
networks, the nine highest are connected over one or even more molecules present in the networks (Table 3-29). The 
score only is a numerical value used to rank the networks according their degree of relevance to the eligible molecules 
within the network. The score is based on a calculation of a right-tailed Fisher´s Exact Test und therefore is not a 
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measure of the biological relevance or quality of the network. The building up of networks by IPA
®
 is based on data 
mining and did not take into account which type of sample or tissue were analyzed. However, IPA can be used to get an 
impression on which processes the genes of a dataset are involved and to develop hypotheses for the further network 
analyses. 
Predictably, most of the identified functional networks were related to general cellular processes like Cell-To-Cell 
contacts, cell cycle development and metabolic pathways. Therefore, it was obvious that the system lacked the 
complexity of the in vivo situation. However, there is evidence for the involvement of some transcripts in relation of 
renal insult in vivo. For example, Col3a1 was already described to play a pivotal role in the development of interstitial 
fibrosis [Bielesz et al., 2010] as well as in chronic Cyclosporin induced nephropathy [Oleggini et al., 2000]. In vivo 
Col3a1 shows an up-regulation at the transcriptional level, while in this study it was strongly down regulated. This can 
be due to the fact that the matrix accumulation in the progression of renal interstitial fibrosis is triggered by several 
growth factors, such as TGF-, which is induced by the renin-angiotensin system [Fukagawa et al., 1999]. Gstm5, 
Igfbp6 and Asns gave further evidence of some similarities between the response of renal cells in vivo and the NRK-
52E cells in culture. Although Gstm5 is not reported to be altered in rat in vivo, however, the family member Gstm1 
was identified in several studies [Ozaki et al., 2009, Thomson et al., 2004]. Importantly, within the Ingenuity IPA 
software tool these two transcripts are used synonymously. In addition, the protein product, µGST, is also used as an 
exploratory urinary biomarker, described to be specific for the distal tubulus [Fuchs et al., 2011, Rouse et al., 2011]. 
Similarily, Igfbp6, also is not reported in case of nephrotoxicity, but the family member Igfbp1 is reported relatively 
often. For example, it is described to be up-regulated in Cisplatin-induced nephrotoxicity [Huang et al., 2001] as well as 
mercuric chloride, 2-bromoethylamine hydrobromide, hexachlorobutadiene, mitomycin, amphotericin, and puromycin, 
where it showed a time- and dose-related change [Thukral et al., 2005]. Asns, an asparagine synthase, is responsible for 
the synthesis of asparagine and has been described to be constantly up regulated in isolated primary rat proximal tubular 
cells compared to fresh renal tissue. However, it was also described to be up regulated in male Sprague-Dawley rats 
after induction of acute renal failure by Ischemia/ Reperfusion and treatment of Mercuric chloride [Yuen et al., 2006]. 
In addition, other common genes (Table 3-29) which were not previously described as nephrotoxic biomarkers were 
included in the networks. 
Based on these results, further investigations were performed to discover all potential in vivo biomarkers in vitro. 
Therefore, the generated gene list was evaluated for the overlap of the transcripts with reported, relevant findings within 
in vivo based nephrotoxicity biomarkers. For this the software tools GeneGo Metacore
®
, Ingenuitys IPA
®
 and ToxWiz
®
 
from Cambridge Cellnetwork as well as intensive literature search was conducted. 
 
A list of 44 genes, which are well described potential transcriptional biomarkers, was identified (Figure 3-38).  
Eight out of the 44 transcripts were found to be more frequently mentioned in case of treatment related deregulations in 
case of drug induced renal insult [Sanz et al., 2011, Amin et al., 2004; Davis et al., 2006; Thompson et al., 2004, Huang 
et al., 2001, Dieterich et al., 2009, Akcay et al., 2009, Wang et al., 2008, Fuchs et al., 2011]. These transcripts 
(Tnfrsf12a, Cxcl1, Cd44, Odc1, Cdkn1a, Ccng1, Cyr61 and Fn1), are of special interest and therefore as displayed with 
bold lines in Figure 3-38. These eight transcripts, taken together, were present in five of the nine connected networks. 
Tnfrsf12a, Cxcl1 and Cd44 were included in the “Network 5”, and are involved in Cell-To-Cell integrations, 
specifically over the cell surface [Takahashi et al., 2005]. Cyr61 and Fn1 showed a relationship to “Network 1”. This 
network, which was the highest ranked network, contained the most found transcripts and subsequently the most cross 
connections.  
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Table 3-29 Top 9 networks found within the IPA® database. The score, based on a p-value calculation, of the likelihood that a 
network is significantly, and not by random change, identified, for each functional network is shown. Also the number of molecules 
and the transcripts themselves within the dataset included within the specific networks are shown. Common genes are shown in bold. 
ID Score 
 
Top Functions 
Focus  
Molecules 
Molecules from the list in 
Network 
 
  
   1 40  Cell-To-Cell Signaling and Interaction,  
Tissue Development,  
Dermatological Diseases and Conditions 
22 Aldh2, C5orf13, Calcoco1, 
Col3a1, Cyr61, Fcgrt, Fn1, Gsta4, 
Gstm5, Hla-e, Htra1, Igfbp6, 
Iitga3, Krt15, Mgst1, Rragd, 
S100a1, Serpinf1, Slc7a7, Tagln, 
Tf, Vwf 
2 39  Amino Acid Metabolism,  
Small Molecule Biochemistry,  
Vitamin and Mineral Metabolism 
22 Aars, Asns, Atf4, Baz1a, Ccne2, 
Cdc6, Cdkn1a, Cep70, Csdc2, 
Gars, Lrp8, Mcm10, Meis1, 
Mthfd1, Mthfd2, Ndrg2, Pik3ip1, 
Rbp1, RGD1564040, Rgs2, Rrm2, 
Slc20a1, 
3 30  Cell Cycle,  
Lipid Metabolism,  
Small Molecule Biochemistry 
18 Cryab,Cycs,Edn1,Enc1, Fam189b, 
Fbxo2, Gamt, Maged2, Myc, 
Nme3, Nme7, Nop56, Nppb,Odc1, 
Pink1,Ptgs1, Sfxn1, Slc12a2 
4 27  Cell-To-Cell Signaling and Interaction,  
Cellular Assembly and Organization,  
Cellular Function and Maintenance 
17 Ampd3, Arhgef19, Bhmt, Cnksr3, 
Ech1,Fhl1,Flrt3, Fmo4, Klc4, 
Mpzl2, Mthfd1, Pdk2, Pus7, 
Sec11c, Tm7sf2, Vkorc1, Xpa 
5 27  Cellular Development,  
Cellular Growth and Proliferation,  
Hepatic System Development and Function 
18 Ankrd1, Cd44, Cxcl2, Cxcl13, 
Fhl1, Fst, Krt19, Map2k6, 
Mmp11, Mybl1, Pcolce, S100a13, 
Serping1, Tnfrsf12a, Tnfsf12, 
Tnfsf13, Tnfsf18, Yars 
6 24  Drug Metabolism,  
Endocrine System Development and Function,  
Lipid Metabolism 
16 Abcc3, Aldoc, Asns, Col3a1, Fah, 
Fbxo6, Hist1h2ac, Krt19, Nme3, 
Oplah, Ptpru, Rcbtb2, Slc12a5, 
Slc7a5, Sox11, Stra8 
7 24  Organismal Injury and Abnormalities,  
Inflammatory Disease,  
Respiratory Disease 
15 1100001G20Rik, Adamts2,  
C13orf33, Cars, Col16a1, Col3a1, 
Enpp3, Grp126, Kcnmb4, Kifc2, 
Pomgnt11, Rnd1, Tcea3, 
Tmem176b, Yars 
8 23  Cell Cycle,  
Cellular Development,  
Connective Tissue Disorders 
15 Aen, Armcx1, Ccng1, Col3a1, 
Donson, Eelmo3, Gstm5, Loxl3, 
Rcn33, Rilpl2, Rrp9, Rtn1, 
Selenbp1, Skap2, Znf420 
9 19  Cellular Movement,  
Cancer,  
Cellular Development 
13 Abtb1, Aadhfe1, Boc, Cfd, Cln6, 
Idh1, Igfbp6, Lztfl1, Mettl7a, 
Phyh, Pink1, Slc17a6, Tle2 
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Figure 3-38 44 genes identified out of the dataset of 192 significant (p ≤ 0.01) transcripts with a fold-change ≥ 1.5 and ≤ -1.5, 
to be described in case of nephrotoxicity in rat in vivo. Additionally, the 8 most frequently reported transcripts (red cycle) as 
well as the affiliation to the Top-9 networks (blue cycles) are displayed. Green symbols indicates the treatment dependent down 
regulation of the transcript, while red indicates the upregulation. The ID numbers correspond to the network numbers in Table 
3-29. 
 
Cfd, Idh1 and Igfbp6 were connected to “Network 9” while the last one is also included in “Network 1”. That is also the 
case by observing “Network 8”, were the already mentioned Ccng1, which is involved in the cell cycle, is included 
together with Gstm5 and Col3a1. The last two genes themselves are also part of “Network1”. In general Col3a1 showed 
the highest number of nodes, probably due to the fundamental role of collagen in cellular growth and development. 
Odc1, was only included in “Network 3”, and contains three described potential biomarkers, namely Odc1, Myc, and 
Gamt. Cdkn1a only showed a connection to “Network 2”. Because the encoded protein, p21 of the Cdkn1a gene is as a 
cyclin-dependent kinase inhibitor involved in the regulation of the cell cycle and several other processes, it was 
expected that would also be a relation to “Networks 3, 5, and 8”. However, the database from Ingenuity may be 
incomplete. The same was observed for Myc, a transcription factor described to activate various mitogenic signals, but 
also cell growth and apoptosis [Dominguez-Salo et al., 2007, Cotterman et al., 2008, Kanazawa et al., 2003]. The lowest 
numbers of transcripts were found for “Network 7”, where beside Col3a1 only Rnd1, a small signaling G protein of the 
Rho family of GTPases [Vayssiére et al., 2000, Ridley, 2006] was present.  
The fact that “Network 4” is not linked to any other network and even did not contain any of the frequently mentioned 
transcripts does not necessarily mean that there is no relation between this and other networks. Rather, it can be 
assumed that networks focused on molecules involved in Cell-To-Cell Signaling and Interaction, Cellular Assembly and 
Organization, Cellular Function and Maintenance are linked to networks containing Tissue Development, Cellular 
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development or Cellular Growth and Proliferation. Consequently also the 12 transcripts which are not part of the top-9 
networks, are partly involved in proliferation of cells, like Ephx2 [Zhang et al., 2010], Gpc3 [Cano-Gauci et al., 1999], 
Cryab [Kumarapeli et al., 2008], Gbp2 [Gorbacheva et al., 2002], and Glrx1 [Lofgren et al., 2008] and should not be 
excluded from further investigation. 
In summary, the significantly altered transcripts which were already described in vivo are involved in general cellular 
processes, like proliferation, growth and Cell-Cell integrations. Based on this observation, there is less evidence to 
expect that transcripts involved in e.g. oxidative stress, inflammation, or apoptosis can be used for the general 
prediction of nephrotoxic potential by using NRK-52E cells. It seems more likely that protein or transcripts related to 
general processes of cellular maintenance and recovery are a good source of biomarkers in both in vivo as well as in 
vitro. The set of genes generated from of the overlap over all alterations caused by the four model compounds, which 
are described to have different mechanisms causing renal damage, only reflect an “high level” response of the cells. 
Therefore, these transcripts, together with specific marker genes for the toxicological processes mentioned above, can 
further enhance the information about the specific underlying process resulting from treatment of NRK-52E cells with 
specific compounds. 
The fact that cell lines like NRK-52E cells are characterized by a constant proliferation rate, it must be assumed that this 
can cause major differences between rats in vivo and NRK-52E cells. Therefore, the lack of any statistical significant 
alteration in Lcn2, Clu, or Timp1 can be due to the fact that they a constantly over expressed in NRK-52E cells and no 
further induction is possible. The lack of alteration on the gene expression level of these in vivo biomarkers is supported 
by the observations from Rached, where no to minimal alterations in Lcn2, Clu and Timp1 were observed after 
treatment of NRK-52E cells with either Ochratoxin A, Cisplatin, Cadmium chloride or Potassium bromated [Rached, 
2009]. The fact that also no increase in Havcr1 mRNA was observed can be explained by its association with 
dedifferentiation and proliferative processes. It has been described that HK-2, a human immortalized renal cell line, 
expresses large amounts of Kim-1 protein [Bailly et al., 2002]. Thus the reason for the missing expression changes of 
Havcr1 in NRK-52E cells also can be due to a constant overexpression. Another possibility is the differentiation 
processes, while reaching confluence, lead to a break in Kim-1 gene expression. 
However, based on the strong similarities found between the individual networks, the direct interactions of the 44 
transcripts already described for in vivo nephrotoxicity was evaluated and is shown in Figure 3-39. 9 Genes were found 
in the literature to interact directly or be related to the same processes. Because of the limitation of an in vitro system, 
which lack complex cell-cell interactions, including different cell types and the influence of other tissues or organs, the 
interactions observed are involving cellular processes like proliferation, necrosis, apoptosis, direct cell-cell interactions 
and cell-ECM interactions. In addition, the magnitudes of fold change are given in Figure 3-40a-i. As shown in Figure 
3-39, Cd44 (Figure 3-40a) has a key position within the interaction network hypothized here. It is well known that Cd44 
is a cell adhesion receptor and involved in several biological processes, including support and induction of 
hematopoietic differentiation, cell migration, adhesion and effects on many adhesion mechanisms and interaction with 
cell activation signals [Lesley et al., 1993]. Two of the most prominent and relevant ligands of this receptor are 
hyaluronan and osteopontin, both components of extracellular fluids and matrices [Aruffo et al., 1990, Weber et al., 
1996]. Osteopontin, a promising exploratory urinary protein biomarker in vivo however has poor alterations on the 
transcriptional level. This gives further evidence that also in this process; Osteopontin may play an important role, even 
though no significant induction on mRNA level was observed. Osteopontin induction within NRK-52E cells on the 
protein level was shown by treating the cells with cobalt chloride to mimic hypoxia [Chen et al., 2009]. 
Hyaluronan is a glycoaminoglycan of the extracellular matrix and is described to promote endothelial cell 
morphogenesis in an Odc1 (Figure 3-40b) expression dependent process by binding to Cd44 [Takahashi et al., 2005] 
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Figure 3-39 Hypothized interaction network of transcripts 
included in the list of 44 already described transcriptional 
biomarker in vivo. All 9 included genes were described in 
literature to interact with each other and were involved in either 
apoptosis, proliferation or wound healing. Red indicates up-
regulation and green indicates down-regulation, as can be 
referenced in Figure 3-40. Arrows give activating or inducing 
interations while rounded lines indicate inhibitory interation or 
suppression. The dashed lines display the interaction or 
affiliation of protein to the extracellular matrix (ECM). 
 
 
 
 
 
 
 
 
 
This is notable because Odc1 has been reported in several studies focused on nephrotoxicity as well as in hypoxia 
signalling [Thukral et al., 2005, Tacchini et al., 2004]. In addition, it was also reported to be up-regulated in NRK-52E 
cells after treatment with several nephrotoxic compounds. Hyaluronan deposition is also described to occur in areas of 
interstitial damage and co-localizes with de novo tubular Cd44 expression, as it is the case within the NRK-52E cells 
(Figure 3-40a) [Nishikawa et al., 1993, Sibalic et al., 1997]. Interleukin-8 (IL-8) induces cell arrest by a reduction of 
cell movement on hyaluronan, was accompanied by increased actin polymerization and a more pronounced association 
of Cd44 with the cytoskeleton [Azizl et al., 2000]. These findings are in good agreement to the findings observed here, 
where the transcripts are associated with cellular movement and development, as well as cellular assembly (Figure 
3-38). Another important interaction partner of Cd44 is Fn1 (Figure 3-40d), encoding for fibronectin which is also 
related to the extracellular matrix in multiple processes; However, Fn1 is most frequently reported in case of interaction 
of endothelial cell with lymphocytes. In this case the lymphocyte Cd44 binds to the heparin-binding domain of 
fibronectin [Jalkanen et al., 1992]. Obviously, this cannot be the interaction taking place in this in vitro system, because 
of the absence of other cell types. Therefore, an alternative interaction between these proximal tubular-like cells has to 
be assumed which is leukocyte independent. This is in good agreement to the in vivo situation where it was shown that 
Cd44 is not only expressed in leukocytes entering the kidney during inflammation, but also is highly expressed by 
injured renal tubular epithelial cells [Florquin et al., 2002]. Fibronectin plays a crucial role in wound healing by cell 
adhesion, growth, migration and differentiation in vivo [Pankov et al., 2002], also in NRK-52E cells this mechanism 
seems to have a central role in cellular recovery. Fn1 has been described to decrease the gene expression of Transgelin 
(Tagln) [Hu et al., 2000]. In NRK-52E cells Tagln was observed to be up-regulated (Figure 3-40g), which is 
contradictory as Mgp, which has been described to induces Tagln expression [Steitz et al., 2001], was down-regulated. 
Therefore an alternative regulation of Tagln must be assumed. Fibronectin also induces the gene and protein expression 
of Myc, Mgp and in turn Cd44 (Figure 3-40c, i, a), while it decreased the expressions of Cdkn1a [Han et al., 2006, Pulai 
et al., 2005]. Myc itself has been described to suppress the expression of Cdkn1a and thus is capable of driving cell 
proliferation [de Alboran et al., 2001].  
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Figure 3-40 Deregulation of a.) Cd44, b.) Ocd1, c.) Myc, d.) Fn1, e.) Cdkn1a, f.) Cyr61, g.)Tagln, h.) Col3a1, i.) Mgp. The 
data are presented as the log2 normalized average (geometric mean) ratios of each individual passage against the 
corresponding vehicle control as bars. Pur = Puromycin, Dox = Doxorubicin, APAP = Paracetamol, AB = AmphotericinB, 
Met = Metformin, Man = Mannitol. 
 
Because of the multitude of factors and processes induced by Myc, it is not possible to figure out which of them may 
have the major impact in the progression of cellular renal break-down based on our data. However, increased expression 
of Myc has also been described to drive the apoptotic program by deprivation of survival factors [Askew et al., 1991, 
Evan et al., 1992]. Furthermore, Myc seems to play a pivotal role in cell death caused by tumor necrosis factors, 
chemotherapeutics and environmental stress [Basu et al., 1995, Janicke et al., 1994, Zhan et al., 1997].  
In this study, and based on the identified transcripts, it is notable that the Myc target, Odc1 (Figure 3-40b), was 
increased [Bello-Fernandez et al., 1993]. Consequently, an increase in Odc1 would lead to increased levels of the 
superoxide by an elevation of the polyamine metabolism, followed by oxidative stress as a central mechanism in Myc 
induced apoptosis [Packham et al., 1994, Park et al., 2002]. Additionally, binding interactions between Myc and Cyr61 
has been reported. Cyr61 (Figure 3-40f) or Cysteine-rich protein 61, is a member of a family of growth factor-inducible 
immediate-early genes. It regulates cell proliferation, adhesion, migration and differentiation in a multitude of cell types 
[Tong et al., 2001] and was already reported in a multitude of studies in rat. It has been assumed that Myc is involved in 
multiple processes by direct association with other proteins forming protein complexes to enhance the functionality of 
each individual complex member [Koch et al., 2007]. 
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In case of Myc, which is a strong proto-oncogen found in several tumor cells [Finver et al., 1988, Hoffmann et al., 
2002, Koscianska et al., 2007], is still inducible within NRK-52E cells, even though the cells have a high proliferative 
activity. By the same token, it is interesting to note that Cdkn1a was up-regulated after treatment of NRK-52E cells with 
4 model nephrotoxic compounds, even though Myc and Fn1, described as inhibitors of Cdkn1a expression, are also up-
regulated. It is possible that the observed alterations only take place on the transcriptional level. Because Cdkn1a is 
regulated by many different signaling pathways it is more likely that alternative inducing factors may play a role in the 
regulation of the protein expression. 
 
For these mechanistic interactions, the strength of increase of the transcripts delivered no relevant information (Figure 
3-40). In almost all cases Paracetamol lead to the strongest increases, while Puromycin often resulted in the lowest 
deregulation compared to the vehicle control. The strongest increase was observed for Cdkn1a, Cyr61 and Tagln, 
confirming the central role of these potential transcriptional biomarkers (Figure 3-40e, f, g).  
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3.2.3 Conclusion of transcriptional nephrotoxicity biomarkers in NRK-52E cells 
 
The fact that several transcripts could be identified in NRK-52E cells after treatment with either Puromycin, 
Paracetamol, Doxorubicin or Amphotericin B, which were already described in vivo to be treatment dependently 
deregulated, point to the fact that these molecules play a pivotal role in the progression of renal injury and recovery. It 
also could be shown that several of the transcripts were mechanistically linked to cellular processes and therefore it can 
be hypothesized that these processes are present and of biological importance in both in vitro as well as in the kidney of 
treated rats. The involvement of such fundamental biological pathways including proliferation, apoptosis, and cellular 
recovery and reorganization can also be used to obtain further insights in to the progression of the cellular insult. Thus it 
can be expected that at early time points the transcripts linked to cellular stress and apoptosis will be changed and as a 
secondary response genes leading to proliferation and recovery will start to change.  
However, these preliminary experiments only can be taken as a proof-of-principal, to check whether or not it is possible 
to identify in vivo linked transcriptional alterations in vitro. These results are only a starting point and need further 
confirmation by testing additional compounds and concentrations. Another open question is if the increase in specific 
genes is specific for the detection of nephrotoxic effects. This has to be evaluated by using several non-toxic as well as 
non-nephrotoxic compounds. It can be assumed that the major differences between these two classes of compound will 
be a difference in the toxic doses. The low dose treatment data generated within our study clearly showed that almost all 
of the 192 genes were deregulated at concentrations leading to no cytotoxicity in the ATP and NRU assays (Figure 
3-37). Organ specificity is one of the major problems of in vitro toxicity assays. This is also reflected by data for 
Paracetamol, which is specifically described to be hepatotoxic. The concentration needed to result in cytotoxicity in 
vitro was very high - much higher than normally used for in vitro cytotoxicity assays. Even this high concetractions 
resulted in the alterations of identical genes as the other compounds in much lower concentrations, and gives further 
evidence of the general cellular mechanistic basis of these transcripts. NRK-52E cells have also been described to 
express some other molecules related to more specific toxicological processes, like Hmox1 in oxidative stress [Rached 
et al., 2008]. Therefore, it has to be recommended to further investigate not only the relevant transcripts, but others as 
displayed in Table 3-27 for in vivo studies. To enable the translation or bridging properties of transcriptional 
biomarkers, whether from in vitro to in vivo or from animals to human beings, it is of special interest to evaluate the 
same biomarkers, to get further insights on the potential to discover the safety profile of a compound. 
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3.3 Final Conclusion 
 
The studies presented here deal with several questions related to the toxicological evaluation and implementation of an 
early, sensitive and specific detection system for drug-induced nephrotoxicity. Several rat toxicity in vivo studies were 
conducted to test different urinary and transcriptional biomarkers, as well as different methodological approaches. In 
addition, mechanistic analysis based on whole genome gene expression analysis was performed to get further insights 
on Vancomycin-induced nephrotxicity. Finally, a proof-of-principal investigation was carried out to evaluate the 
usefulness of a renal rat cell line (NRK-52E) for their applicability to detect renal cell death, employing already 
described in vivo gene expression biomarkers. 
Ten urinary proteins were intensively studied by using urine from male and female rats treated with either Vancomycin, 
Cisplatin or Puromycin, in a low and a high dose, for 3, 7, 14 and 28 days. The ten urinary protein biomarkers, namely 
Kim-1, Clusterin, Cystatin C, 2-microglobulin, Osteopontin, Timp-1, Lipocalin-1/NGAL, VEGF, -GST and 
Calbindin, were measured by a Luminex
®
 xMAP
®
 based multiplexed immunoassay (WideScreen™ Rat Kidney 
Toxicity Assay). Kim-1 was analyzed also by using a rapid urinary dipstick assay (RENA™-strips). To enable the 
interpretation of the resulting data in context to substance induced renal pathology, histopathological, clinical 
pathological and hematological analysis were conducted for each individual animal. Based on the results of a 28 day 
dose range finding study, different non-daily treatment schedules were used for each of the test compounds. The 
compounds were applied intra peritoneally for one week daily and then once per week up to 4 weeks for Vancomycin 
and Cisplatin. Puromycin was dosed daily for two weeks followed by twice per week. This scheduling was necessary to 
allow animals to survive the 4 week treatment period as well as allowing the analysis of the urinary protein pattern 
associated with a recovery period. . In addition, immunohistochemical analyses were performed on tissue from the 
Vancomycin and Puromycin studies, as well as whole genome gene expression analysis of kidneys exclusively from the 
Vancomycin study. 
Within the Vancomycin study, which was characterized by the most pronounced tubular degeneration and also showed 
the strongest recovery after the change from daily to weekly treatment, the urinary protein concentrations for Kim-1, 
Clusterin, Osteopontin and Calbindin were strongly increased in both genders. NGAL and Cystatin C also showed a 
slight dose-dependent alteration in both genders, while Timp-1 showed a sex specific increase only in female rats. To 
see the increase of these urinary proteins in context with histopathologically observed renal tubular alterations receiver-
operation-characteristic curves (ROC) were calculated and the area-under-the-ROC (AUROC) was investigated. An 
excellent diagnostic performance within the Vancomycin study, for both genders, was determined for Kim-1, Clusterin 
and Osteopontin. To evaluate the localisation of these three proteins, immunohistochemical analysis was performed. A 
specific and sensitive increase in renal protein was observed for Kim-1 and Clusterin, supported by the fact that Kim-1 
and Clusterin are rarely expressed in healthy rats. Osteopontin also showed an elevated level in renal tissue, which 
further increased with increasing severity of the renal damage. This increase was seen primarily by staining of 
collagenous tissue, with which Osteopontin interacts. In general, the correlation of the observed tubular lesions, the 
evaluated renal protein levels in the tissue and the urinary excretion was very good. 
When looking at the mRNA levels of the ten urinary biomarker proteins, beside an increase in Havcr1 (Kim-1 mRNA), 
Clu (Clusterin mRNA) and Spp1 (Osteopontin mRNA) also a strong increase in Timp1 (Timp-1 mRNA) and Lcn2 
(NGAL mRNA), over the corresponding control animals, was detected. Vegfa (VEGF mRNA), B2m (2-
microglobulin) and Cst3 (Cystatin C mRNA) showed no changes on the transcriptional level. This suggests that the 
related transcripts from the urinary protein biomarkers can also be used / recommended, and in some cases they 
performed better than the urinary proteins.  
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Since the Vancomycin induced toxicity was massive, the Cisplatin study (mild changes on the S3 segment of the 
proximal tubules) was used to further evaluate the sensitivity and specificity of urinary protein biomarker excretion. The 
most prominent changes were observed for urinary Kim-1 excretion. In addition, Clusterin and Osteopontin also 
showed a relevant increase in several animals. This was also reflected by high AUROC values, underlying the 
diagnostic performance of these three markers. The other biomarkers remained unaltered. Since these three proteins, 
specific for tubular damage, also showed the best performance within the Vancomycin study, we can conclude that they 
are the most sensitive urinary biomarkers for tubular damage.  
Less information is available about the performance of these biomarkers to predict glomerular damage; therefore 
Puromycin was used to induce this type of pathology. Since Puromycin caused both tubular as well as glomerular 
adverse effects, a final answer about the changes in urinary protein biomarker specific to glomerular alteration could not 
be given. However, our data give hints to the usefulness of several of the biomarkers to respond to glomerular-induced 
proteinuria. In animals showing pathological changes urinary Kim-1, Clusterin, 2-microglobulin and Cystatin C 
showed the most pronounced increase in excretion, which was also reflected by ROC analysis. Osteopontin and 
Calbindin showed a stronger increase in animals with histopathological findings in male rats than in female, while 
Timp-1 performed better in female rats. Since Kim-1 and Clusterin were shown to be highly sensitive and specific for 
tubular insults the elevation in 2-microglobulin and Cystatin C can be assumed to be linked to the excessive 
proteinuria induced by the vacuolation of the glomerular tufts, subsequently leading to an increase in excretion of these 
extrarenal proteins. This was partly supported in female rats by an increase in VEGF, which maybe a result of 
glomerular basement membrane destruction. By immunohistochemical analysis the early and specific increase in renal 
Kim-1 and Clusterin expression was confirmed. In addition, the gender difference in Osteopontin excretion, 
hypothesised to be caused by a stronger pronounced building of fibrous tissue in female rats, was also confirmed, which 
subsequently has to be seen as a limitation of this biomarker. 
In summary, Kim-1, Clusterin and Osteopontin delivered the best diagnostic performance for drug induced tubular 
degeneration and necrosis. 2-microglobulin and Cystatin C can be used, in combination with the markers above, to 
evaluate a potential influence on the glomerulus. In addition, the immunohistochemical analysis of Kim-1 and Clusterin 
also can be used as an alternative and very sensitive detection method. The remaining markers (Timp-1, Calbindin, 
NGAL and VEGF) need further evaluation because of their inconsistent performance in reflecting the underlying renal 
pathologies.  
The detected values for urinary Kim-1, determined by either the Luminex
®
 xMAP
®
 or the RENA™-strips technology, 
from all three test compounds, were compared by linear regression and Bland-Altman-Analysis. The results of this 
analysis clearly showed that the tendency in both assays was similar, although the Luminex
®
 xMAP
®
 based values 
showed a stronger magnitude of increase and therefore a higher sensitivity in detection. This was especially clear within 
the Cisplatin study where only mild tubular damage was observed, and the RENA™-strips were not effective. 
Therefore, the recommendation for preclinical routine studies would be to use the multiplex assays, which allows the 
detection of multiple proteins in a more sensitive manner. However, the RENA™-strips delivered reliable data in a 
much shorter time period and at a much cheaper cost, whereby the final decision which method to use strongly depends 
on the scientific and resource requirements. 
Since little information is available on the cellular and molecular biological / toxicological mechanism of Vancomycin-
induced nephrotoxicity, analysis of the whole gene expression profile from renal tissue was performed to build a novel 
hypothesis. The Illumina
®
 RatRefv.1 beadarray was used to identify gene expression patterns in a time, dose and gender 
specific manner. In addition, several transcription factors were investigated, based on the initial data analysis, to 
improve our understanding of the involved pathways. The hematologically and histopathologically identified 
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inflammatory processes appear to be driven by NF-B and RelA mediated pathways. In addition, further evidence of an 
involvement of the complement system was shown. For apoptotic processes, it is reasonable to assume a Fas-receptor 
mediated and caspase-dependent mechanism without any prominent involvement of p53. Furthermore, the recovery and 
rearrangement processes which take place after renal insult could be shown to include the activity of specific GTPase 
members - mainly Rho, Rac1 but also Cdc42, which are involved on actin nucleation of migratory processes, as well as 
cellular shape restoration. Within these three major general processes, the transcription factors Smad3, Stat1 and Stat3, 
as well as PPAR, PPAR and PPAR, seem to be involved. With regard to the observed higher sensitivity of male rats 
to Vancomycin treatment, several mechanistic differences, e.g. a later cellular recovery, gave hints to an explanation for 
the increased nephrotoxicity. However, a final and definitive explanation for the gender difference could not be 
identified, based on the gene expression data alone. 
Since it could be shown within the Vancomycin study that some of the urinary protein biomarker related transcripts 
performed even better than the proteins, an evaluation of several gene sets were tested for their usability as 
transcriptional biomarkers. Three sets of transcripts were tested; one provided by Compugen Ltd., one identified from 
the Toxicogenomics Project in Japan (TG-GATEs) and one derived from a literature search. All showed partly 
overlapping mRNAs. Since the Compugen Ltd derived biomarker set only contained 6 transcripts and were never 
published, a test run was conducted by using three already published and described nephrotoxicity studies, namely 
Gentamycin, aristolochic acid and FP007SE. The performance of the Compugen Ltd. system delivered reasonable 
results, with some suggestion of a real predictivity. The Compugen Ltd model was used then on our Vancomycin 
transcriptomics data since all transcripts showed a severity-dependent alteration. The most promising gene expression 
change, in relation to histopathological observations, was Tnfrsf12a. The TG-GATEs prediction model consists of 19 
best ranked genes, was also tested and almost all expression changes were related to an increasing severity of tubular 
degeneration. However, only a few genes resulted in an increase strong enough to be considered to be diagnostically 
useful. From these data, together with the results of the 45 genes picked from the literature, and the overall impression 
from the mechanistic analysis from Vancomycin, a final transcriptional biomarker list was generated containing the best 
performing 40 transcripts. 
A proof-of-principal investigation based on an in vitro system using NRK-52E cells, and global gene expression 
profiling was performed. Several transcriptional alterations were observed that were also described in the in vivo 
approaches, both within this work as well as in literature. The mechanistic analysis showed that the transcripts Cd44, 
Myc, Cyr61, Cdkn1a and Fn1, involved in apoptosis, proliferation and wound healing, were identified to deliver a 
reliable and plausible treatment dependent response. These transcripts require further validation for their usability to 
serve as transcriptional biomarkers in vitro. 
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5.1 Annex 1 Immunohistochemical observations of control animals 
 
Figure 5-1 Displayed are the immunhistochemical staining of renal Kim-1, Clusterin and Osteopotin  protein in representativ male 
and female control rats. No to minimal protein staining could be observed for Kim-1 and Clusterin, while Osteopontin showed some 
background staining formally in the medullary region. 
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Figure 5-2 Shown is the expression/ accumulation of Osteopontin protein in the (A+B) bladder and (C) renal papilla of 
untreated rats. 
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5.2 Annex 2 Signaling pathway related fold-change values of Vancomycin treated rats 
 
Table 5-1 Given are the fold-changes (average of treated rats against average of corresponding control rats) of components of the complement system of male rats treated with either 50 mg/kg (LD) or 
300 mg/kg (HD) Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5).  
Symbol Entrez Gene Name Gene Entrez 
Day 4 Day 8 Day 15   Day 29 
LD HD LD HD LD HD LD HD 
C2 complement component 2 24231 -1,15 5,92 1,25 7,97 -1,19 13,58 -1,03 4,42 
C3 complement component 3 24232 1,17 11,78 1,29 8,35 -1,48 6,16 -1,01 3,15 
C6 complement component 6 24237 1,22 1,90 1,11 1,95 -1,05 2,11 1,11 1,60 
C7 complement component 7 117517 1,50 5,48 1,23 5,66 -1,28 8,41 1,10 4,73 
C1QA complement component 1, q subcomponent, A chain 298566 -1,37 2,88 1,25 4,49 -1,37 6,75 -1,16 2,45 
C1QB complement component 1, q subcomponent, B chain 29687 -1,05 5,72 1,15 7,09 -1,40 12,11 -1,15 4,25 
C1QC complement component 1, q subcomponent, C chain 362634 -1,20 4,33 1,09 4,98 -1,47 9,12 -1,11 3,47 
C1R complement component 1, r subcomponent 312705 -1,39 1,99 1,41 3,39 -1,44 3,26 -1,30 1,58 
C1S complement component 1, s subcomponent 192262 -1,20 1,71 1,60 4,28 -1,31 3,49 -1,02 1,54 
C4B complement component 4B (Chido blood group) 24233|406161 1,67 9,07 -1,19 9,35 -1,40 10,46 -1,30 8,01 
C4BPA complement component 4 binding protein, alpha 24235 1,30 7,08 -1,08 2,10 -1,08 2,36 -1,02 1,95 
C8G complement component 8, gamma polypeptide 296545 -1,59 -2,02 / / -1,21 -1,70 / / 
CFI complement factor I 79126 2,05 5,92 1,06 5,96 -1,27 10,42 -1,21 7,31 
SERPING1 serpin peptidase inhibitor, clade G, member 1 295703 -1,47 1,82 -1,31 2,90 -1,06 2,47 -1,55 1,78 
 
 
Table 5-2 Given are the fold-changes (average of treated rats against average of corresponding control rats) of components of the complement system of female rats treated with either 50 mg/kg (LD) or 
300 mg/kg (HD) Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Gene Entrez 
Day 4 Day 8 Day 15   Day 29 
LD HD LD HD LD HD LD HD 
C2 complement component 2 24231 -1.15 3.64 1.52 15.50 1.16 2.49 1.45 4.48 
C3 complement component 3 24232 -1.06 2.77 1.05 5.48 -1.02 1.77 1.04 3.50 
C7 complement component 7 117517 1.39 7.87 -1.06 8.47 -1.00 2.44 1.97 3.91 
C1QA complement component 1, q subcomponent, A chain 298566 1.23 3.25 1.34 7.74 1.20 2.23 1.73 4.20 
C1QB complement component 1, q subcomponent, B chain 29687 1.05 4.95 1.06 12.69 1.19 3.05 1.93 8.29 
C1QC complement component 1, q subcomponent, C chain 362634 1.36 4.85 1.17 10.38 1.17 2.87 1.77 6.45 
C1R complement component 1, r subcomponent 312705 1.38 3.05 1.32 5.17 1.16 1.91 2.08 3.47 
C1S complement component 1, s subcomponent 192262 1.66 2.79 1.83 4.67 1.24 1.66 2.71 3.32 
C4B complement component 4B (Chido blood group) 24233|406161 -1.05 6.33 1.23 12.25 -1.03 2.13 1.39 6.53 
2
4
9
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Symbol Entrez Gene Name Gene Entrez Day 4 Day 8 Day 15   Day 29 
CFI complement factor I 79126 -1.17 8.59 1.07 11.06 1.01 2.44 2.11 7.19 
SERPING1 serpin peptidase inhibitor, clade G, member 1 295703 1.21 3.59 1.45 5.67 1.04 1.61 1.37 2.41 
 
 
Table 5-3 Given are the fold-changes (average of treated rats against average of corresponding control rats) of leukocyte extravasations of male rats treated with either 50 mg/kg (LD) or 300 mg/kg 
(HD) Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase 311860 / / -1.30 1.99 1.36 2.58 / / 
ACTB actin, beta 81822 / / -1.38 2.05 -1.09 2.25 -1.35 1.94 
ACTN1 actinin, alpha 1 81634 1.24 2.69 1.02 3.60 -1.02 1.95 1.17 4.82 
ACTN4 actinin, alpha 4 63836 -1.53 -1.15 / / 1.10 1.62 / / 
ARHGAP1 Rho GTPase activating protein 1 311193 / / -1.22 1.71 1.02 1.91 / / 
ARHGAP8 Rho GTPase activating protein 8 300115 / / -1.23 1.73 1.14 2.39 / / 
ARHGAP9 Rho GTPase activating protein 9 362893 -1.20 1.58 -1.10 2.60 1.17 2.48 1.04 1.77 
BTK Bruton agammaglobulinemia tyrosine kinase 367901 1.22 1.55 -1.02 1.87 1.07 1.67 / / 
CD44 CD44 molecule (Indian blood group) 25406 1.08 4.19 -1.02 8.18 1.07 4.72 1.15 5.22 
CLDN1 claudin 1 65129 / / -1.11 2.63 1.13 2.05 1.12 2.49 
CLDN2 claudin 2 300920 -1.84 1.05 / / -1.36 1.82 -1.51 1.52 
CLDN3 claudin 3 65130 -1.70 1.55 -1.24 2.64 -1.01 3.52 -1.45 1.76 
CLDN4 claudin 4 304407 -1.12 3.32 -1.17 6.22 1.09 3.95 -1.12 3.21 
CLDN9 claudin 9 287099 -1.31 1.55 -1.07 3.52 1.17 2.24 -1.10 1.83 
CLDN19 claudin 19 298487 / / -1.13 2.37 1.15 1.77 -1.30 1.90 
CTNNB1 catenin, beta 1, 88kDa 84353 / / -1.24 1.86 1.09 2.25 -1.21 1.63 
CTTN cortactin 60465 / / -1.19 1.77 -1.03 1.56 -1.21 1.51 
CXCR4 chemokine (C-X-C motif) receptor 4 60628 / / -1.00 2.31 1.04 2.03 -1.07 1.73 
CYBB cytochrome b-245, beta polypeptide 66021 1.12 2.53 1.03 3.90 1.25 3.16 1.12 2.28 
GNAI2 
guanine nucleotide binding protein,  
alpha inhibiting activity polypeptide 2 81664 / / -1.32 2.19 1.12 2.29 -1.31 1.52 
ICAM1 intercellular adhesion molecule 1 25464 -1.08 2.53 -1.31 4.43 1.19 3.88 1.10 3.40 
ITGA4 integrin, alpha 4 311144 1.11 1.66 -1.10 3.29 1.14 3.10 -1.02 2.14 
ITGB1 integrin, beta 1 24511 -1.23 1.71 -1.28 2.96 1.16 3.36 -1.20 2.42 
JAM3 junctional adhesion molecule 3 315509 / / -1.10 1.74 1.21 2.05 / / 
MAPK1 mitogen-activated protein kinase 1 116590 / / / / 1.08 2.00 / / 
2
5
0
 
 251 
 
Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
MLLT4 
myeloid/lymphoid or mixed-lineage leukemia;  
translocated to, 4 26955 / / / / 1.03 1.58 / / 
MMP7 matrix metallopeptidase 7 25335 1.13 1.67 1.10 13.45 1.09 5.54 1.20 2.81 
MMP11 matrix metallopeptidase 11 25481 / / -1.09 2.52 -1.02 1.65 / / 
MMP12 matrix metallopeptidase 12 117033 1.13 2.13 1.11 13.72 1.03 8.57 1.39 6.90 
MMP14 matrix metallopeptidase 14 81707 -1.29 1.67 -1.27 4.20 1.34 4.33 -1.11 2.03 
MSN moesin 81521 / / -1.16 2.03 1.02 2.51 -1.17 2.36 
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 25513 1.16 1.59 -1.16 2.97 1.24 2.35 -1.20 2.98 
PLCG1 phospholipase C, gamma 1 25738 / / -1.23 1.70 1.35 2.54 / / 
PRKCB protein kinase C, beta 25023 1.12 1.93 -1.32 3.14 1.09 2.90 1.13 1.89 
PRKCD protein kinase C, delta 170538 / / / / 1.25 2.25 / / 
PRKCH protein kinase C, eta 81749 / / -1.23 2.03 1.20 2.72 / / 
PRKCI protein kinase C, iota 84006 / / -1.08 1.51 -1.04 1.64 -1.00 1.78 
PRKD3 protein kinase D3 313834 / / -1.10 1.72 1.08 1.74 / / 
RAC1 ras-related C3 botulinum toxin substrate 1 363875 / / -1.24 2.04 1.08 2.16 -1.23 1.58 
RAC2 ras-related C3 botulinum toxin substrate 2 366957 -1.99 -1.10 -1.17 2.63 1.07 2.42 -1.20 1.52 
RHOA ras homolog family member A 117273 1.23 2.02 1.61 3.68 2.22 3.98 1.56 1.77 
RHOH ras homolog family member H 305341 / / -1.15 2.12 1.02 2.39 / / 
ROCK2 Rho-associated, coiled-coil containing protein kinase 2 25537 / / -1.16 1.59 1.02 1.64 / / 
SIPA1 signal-induced proliferation-associated 1 361710 / / 1.00 1.88 1.01 1.64 / / 
TEC tec protein tyrosine kinase 84492 / / / / 1.18 2.17 / / 
TIMP1 TIMP metallopeptidase inhibitor 1 116510 1.32 15.30 -1.03 33.24 1.57 12.73 2.53 26.73 
TIMP2 TIMP metallopeptidase inhibitor 2 29543 / / -1.17 1.81 1.02 1.59 / / 
VASP vasodilator-stimulated phosphoprotein 361517 / / -1.03 1.89 1.16 1.69 / / 
VCAM1 vascular cell adhesion molecule 1 25361 / / -1.32 3.34 1.16 2.72 -1.18 1.51 
WAS Wiskott-Aldrich syndrome (eczema-thrombocytopenia) 317371 1.18 2.21 -1.03 2.43 1.09 2.02 1.09 2.00 
WIPF1 WAS/WASL interacting protein family, member 1 117538 / / -1.37 2.65 1.40 3.25 -1.22 1.58 
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Table 5-4 Given are the fold-changes (average of treated rats against average of corresponding control rats) of leukocyte extravasations of female rats treated with either 50 mg/kg (LD) or 300 mg/kg 
(HD) Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name 
Entrez Gene 
ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase 311860 1.05 2.22 1.69 3.45 1.16 1.78 1.52 2.83 
ACTB actin, beta 81822 -1.11 2.84 1.19 3.47 -1.02 2.04 1.50 3.82 
ACTN1 actinin, alpha 1 81634 -1.06 2.52 -1.10 1.98 1.08 1.65 1.11 4.90 
ACTN4 actinin, alpha 4 63836 -1.12 1.75 1.44 2.28 1.06 1.58 1.26 2.32 
ARHGAP8 Rho GTPase activating protein 8 300115 1.02 1.85 1.94 3.06 1.09 1.71 1.63 2.82 
CD44 CD44 molecule (Indian blood group) 25406 -1.11 4.31 1.17 5.28 1.02 1.82 1.40 5.14 
CLDN2 claudin 2 300920 -1.05 2.74 1.11 3.41 1.16 1.76 1.27 3.52 
CLDN3 claudin 3 65130 -1.08 3.01 1.60 4.11 1.19 2.04 1.79 4.30 
CLDN4 claudin 4 304407 1.07 5.95 1.31 5.29 1.07 2.82 1.74 6.50 
CLDN9 claudin 9 287099 -1.03 2.28 1.35 2.59 -1.02 1.66 1.05 2.47 
CTNNB1 catenin, beta 1, 88kDa 84353 1.05 2.38 1.29 3.04 1.00 1.61 1.28 2.72 
CTTN cortactin 60465 1.01 2.24 1.22 1.96 1.04 1.54 1.16 2.34 
CYBB cytochrome b-245, beta polypeptide 66021 1.02 2.61 -1.09 3.68 -1.00 1.67 1.11 1.81 
GNAI2 
guanine nucleotide binding protein,  
alpha inhibiting activity polypeptide 2 81664 1.14 1.99 1.52 3.05 1.18 1.64 1.74 3.06 
ICAM1 intercellular adhesion molecule 1 25464 1.11 3.80 1.67 5.67 1.18 2.57 1.68 5.87 
ITGA4 integrin, alpha 4 311144 1.16 2.38 1.24 4.06 1.12 1.73 1.53 2.44 
ITGB1 integrin, beta 1 24511 1.06 2.88 1.34 3.50 1.01 1.89 1.50 3.86 
MAPK1 mitogen-activated protein kinase 1 116590 1.14 1.91 1.47 2.28 1.16 1.52 1.38 2.15 
MMP11 matrix metallopeptidase 11 25481 -1.09 2.19 1.17 3.08 1.07 1.60 1.15 2.02 
MMP12 matrix metallopeptidase 12 117033 -1.10 2.08 -1.10 8.50 -1.10 2.07 1.22 4.42 
MMP14 matrix metallopeptidase 14 81707 1.08 3.31 1.87 5.51 1.14 2.13 2.02 4.09 
MSN moesin 81521 1.06 2.58 1.31 2.86 1.13 1.63 1.61 3.87 
PLCG1 phospholipase C, gamma 1 25738 1.02 1.87 1.80 3.10 1.11 1.76 1.72 2.59 
PRKCB protein kinase C, beta 25023 1.15 2.25 1.23 4.71 -1.00 1.94 1.33 2.41 
PRKCH protein kinase C, eta 81749 1.21 1.57 1.52 2.48 1.26 1.51 1.64 2.49 
PRKD3 protein kinase D3 313834 1.14 2.18 1.28 2.36 1.06 1.52 1.40 2.00 
RAC1 ras-related C3 botulinum toxin substrate 1 363875 1.03 2.34 1.41 2.82 1.12 1.79 1.74 3.36 
RAC2 ras-related C3 botulinum toxin substrate 2 366957 -1.07 2.14 1.53 4.96 1.10 1.57 1.67 2.69 
RHOA ras homolog family member A 117273 2.39 3.64 2.23 2.02 1.66 1.50 2.49 2.57 
RHOH ras homolog family member H 305341 -1.01 1.53 1.22 3.09 1.02 1.51 1.26 1.71 
TIMP1 TIMP metallopeptidase inhibitor 1 116510 1.32 21.76 1.26 24.56 1.19 5.32 4.72 64.51 
VCAM1 vascular cell adhesion molecule 1 25361 1.21 2.88 1.11 3.44 1.15 1.91 1.76 3.28 
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Symbol Entrez Gene Name 
Entrez Gene 
ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
WIPF1 WAS/WASL interacting protein family, member 1 117538 1.03 2.39 1.71 4.39 1.15 1.92 1.61 3.58 
 
 
Table 5-5 Given are the fold-changes (average of treated rats against average of corresponding control rats) of IL-6 Signaling of male rats treated with either 50 mg/kg (LD) or 300 mg/kg (HD) 
Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
A2M alpha-2-macroglobulin 24153 -1.04 5.31 1.03 15.68 -1.01 5.32 1.27 9.20 
CD14 CD14 molecule 60350 -1.04 2.53 -1.21 5.72 1.20 4.73 1.14 4.45 
COL1A1 collagen, type I, alpha 1 29393 1.65 2.25 -1.18 7.16 1.21 3.31 1.24 4.10 
FOS FBJ murine osteosarcoma viral oncogene homolog 314322 1.62 3.50 1.04 4.33 1.05 2.48 1.24 3.18 
HSPB1 heat shock 27kDa protein 1 24471 1.24 1.66 -1.21 3.40 1.15 2.49 -1.17 2.07 
IL1R2 interleukin 1 receptor, type II 117022 1.17 1.54 1.09 3.78 1.05 1.66 1.23 1.76 
IL1RN interleukin 1 receptor antagonist 60582 1.13 2.00 -1.01 3.30 1.08 1.96 1.09 1.89 
JUN jun proto-oncogene 24516 1.03 2.20 -1.09 2.96 1.22 3.37 -1.15 2.08 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 24525 -1.21 -1.89 / / / / -1.37 -2.04 
LBP lipopolysaccharide binding protein 29469 1.24 3.69 -1.21 2.62 1.34 5.19 1.10 6.36 
NFKB1 
nuclear factor of kappa light  
polypeptide gene enhancer in B-cells 1 
81736 1.22 1.62 1.07 1.57 / / 1.18 1.73 
NFKB2 
nuclear factor of kappa light  
polypeptide gene enhancer in B-cells 2 
309452 -1.21 1.88 -1.18 2.45 1.00 2.19 -1.09 1.97 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 24605 -1.16 1.70 -1.18 2.95 1.16 2.71 -1.10 2.37 
RRAS related RAS viral (r-ras) oncogene homolog 361568 -1.38 1.78 -1.42 2.36 -1.07 2.31 -1.27 1.91 
TNFRSF11B tumor necrosis factor receptor superfamily, member 11b 25341 -1.57 -8.49 -1.32 -5.09 / / -3.19 -10.08 
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A 25625 -1.20 2.24 -1.19 4.09 -1.02 3.03 1.06 3.29 
 
 
Table 5-6 Given are the fold-changes (average of treated rats against average of corresponding control rats) of IL-6 Signaling of female rats treated with either 50 mg/kg (LD) or 300 mg/kg (HD) 
Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day/4 Day/8 Day/15 Day/29 
LD HD LD HD LD HD LD HD 
A2M alpha-2-macroglobulin 24153 -1.07 7.03 1.03 13.68 1.00 1.79 1.12 9.23 
CD14 CD14 molecule 60350 -1.10 2.16 1.49 4.25 -1.02 1.94 1.36 4.66 
CEBPB CCAAT/enhancer binding protein (C/EBP), beta 24253 1.08 2.24 1.21 2.98 1.07 1.78 2.16 5.29 
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Symbol Entrez Gene Name Entrez Gene ID 
Day/4 Day/8 Day/15 Day/29 
LD HD LD HD LD HD LD HD 
COL1A1 collagen, type I, alpha 1 29393 1.16 3.28 1.05 4.69 1.04 1.73 1.20 4.72 
CSNK2A1 casein kinase 2, alpha 1 polypeptide 116549 / / 1.18 1.67 / / 1.17 1.52 
CSNK2A2 casein kinase 2, alpha prime polypeptide 307641 1.07 1.92 1.13 1.94 / / 1.18 1.97 
FOS FBJ murine osteosarcoma viral oncogene homolog 314322 1.05 2.52 1.05 2.71 / / 1.20 4.33 
HSPB1 heat shock 27kDa protein 1 24471 1.21 2.91 1.67 2.77 1.01 1.95 1.34 4.02 
IKBKB 
inhibitor of kappa light polypeptide  
gene enhancer in B-cells, kinase beta 
84351 1.03 2.10 1.18 2.03 1.01 1.77 1.34 2.50 
IKBKE 
inhibitor of kappa light polypeptide  
gene enhancer in B-cells, kinase epsilon 
363984 1.06 1.50 1.25 1.83 / / / / 
IL18 interleukin 18 29197 -1.06 1.60 1.26 2.39 / / 1.40 2.15 
IL1B interleukin 1, beta 24494 1.22 2.05 1.27 3.76 / / 1.19 1.78 
IL1R2 interleukin 1 receptor, type II 117022 / / -1.05 1.87 / / / / 
IL1RN interleukin 1 receptor antagonist 60582 -1.03 1.84 -1.09 2.54 / / -1.04 2.08 
IL6R interleukin 6 receptor 24499 / / -1.00 1.58 / / / / 
JUN jun proto-oncogene 24516 1.11 2.61 1.45 3.10 -1.01 1.62 1.45 3.38 
LBP lipopolysaccharide binding protein 29469 1.17 2.41 1.06 4.10 1.08 1.67 1.31 4.97 
MAP2K1 mitogen-activated protein kinase kinase 1 170851 1.06 1.74 1.82 2.73 1.21 1.55 1.60 3.00 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 301363 -1.07 1.91 -1.03 2.29 -1.08 1.51 -1.18 1.98 
MAPK1 mitogen-activated protein kinase 1 116590 1.14 1.91 1.47 2.28 1.16 1.52 1.38 2.15 
MAPK12 mitogen-activated protein kinase 12 60352 / / 1.24 1.53 / / 1.12 1.52 
NFKB2 
nuclear factor of kappa light  
polypeptide gene enhancer in B-cells 2 
309452 -1.14 2.39 1.21 2.94 1.05 2.01 1.30 3.78 
NGFR nerve growth factor receptor 24596 / / 1.00 1.71 / / / / 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 24605 -1.07 2.44 1.25 2.94 1.08 1.75 1.30 3.38 
RELA v-rel reticuloendotheliosis viral oncogene homolog A 309165 -1.01 1.67 1.28 1.97 1.10 1.54 1.30 2.06 
RRAS related RAS viral (r-ras) oncogene homolog 361568 -1.15 2.24 1.30 2.80 1.02 1.79 1.36 3.66 
SRF serum response factor 501099 1.01 1.69 1.59 2.43 / / 1.44 2.68 
STAT3 signal transducer and activator of transcription 3 25125 -1.04 2.10 1.46 3.12 1.18 1.75 1.79 3.55 
TNFRSF11B tumor necrosis factor receptor superfamily, member 11b 25341 -1.14 -2.81 2.22 -2.53 1.10 -1.57 -1.14 -5.45 
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A 25625 1.12 2.96 1.23 3.92 1.09 2.16 1.73 5.68 
TRAF2 TNF receptor-associated factor 2 311786 1.07 1.53 1.08 1.71 / / 1.23 1.82 
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Table 5-7 Given are the fold-changes (average of treated rats against average of corresponding control rats) of Apoptosis Signaling of male rats treated with either 50 mg/kg (LD) or 300 mg/kg (HD) 
Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
BAK1 BCL2-antagonist/killer 1 116502 -1.19 1.75 -1.27 3.50 1.32 3.69 -1.12 2.27 
BCL2A1 BCL2-related protein A1 170929 -1.01 2.34 -1.12 6.35 1.09 4.32 1.01 3.29 
BID BH3 interacting domain death agonist 64625 / / -1.19 1.73 -1.07 1.79 -1.12 1.65 
BIRC2 baculoviral IAP repeat containing 2 60371 / / -1.12 1.54 1.25 2.04 / / 
BIRC3 baculoviral IAP repeat containing 3 78971 1.05 3.74 -1.06 7.09 -1.01 4.33 1.36 3.99 
CAPN2 calpain 2, (m/II) large subunit 29154 / / -1.29 2.24 1.22 2.70 -1.46 1.56 
CAPNS1 calpain, small subunit 1 29156 / / -1.42 1.69 -1.05 2.21 -1.44 1.54 
CASP2 caspase 2, apoptosis-related cysteine peptidase 64314 / / -1.29 2.03 1.31 2.69 / / 
CASP3 caspase 3, apoptosis-related cysteine peptidase 25402 1.08 1.71 -1.32 2.84 1.08 2.93 -1.05 2.26 
CASP6 caspase 6, apoptosis-related cysteine peptidase 83584 / / -1.10 1.62 1.08 1.73 / / 
CASP8 caspase 8, apoptosis-related cysteine peptidase 64044 / / -1.13 1.60 1.07 1.61 1.01 1.52 
CASP12 caspase 12 (gene/pseudogene) 156117 1.23 4.14 -1.08 8.45 1.11 5.05 1.18 5.01 
CASP9 caspase 9, apoptosis-related cysteine peptidase 58918 / / / / 1.11 1.69 / / 
CDK1 cyclin-dependent kinase 1 54237 -1.54 6.01 -1.26 11.09 1.18 4.53 1.98 5.76 
IKBKB 
inhibitor of kappa light polypeptide gene enhancer in B-
cells,  
kinase beta 
84351 / / -1.24 1.75 -1.02 1.92 / / 
IKBKE 
inhibitor of kappa light polypeptide gene enhancer in B-
cells,  
kinase epsilon 
363984 / / / / 1.14 1.51 / / 
MAP2K1 mitogen-activated protein kinase kinase 1 170851 / / -1.32 1.66 1.32 2.35 / / 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 301363 / / -1.18 2.30 -1.04 1.82 -1.12 1.82 
MAPK1 mitogen-activated protein kinase 1 116590 / / / / 1.08 2.00 / / 
MCL1 myeloid cell leukemia sequence 1 (BCL2-related) 60430 / / -1.48 1.76 -1.01 1.90 / / 
NFKB2 
nuclear factor of kappa light  
polypeptide gene enhancer in B-cells 2 
309452 -1.21 1.88 -1.18 2.45 1.00 2.19 -1.09 1.97 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 24605 -1.16 1.70 -1.18 2.95 1.16 2.71 -1.10 2.37 
PARP1 poly (ADP-ribose) polymerase 1 25591 / / -1.43 1.92 1.28 2.43 / / 
PLCG1 phospholipase C, gamma 1 25738 / / -1.23 1.70 1.35 2.54 / / 
RELA v-rel reticuloendotheliosis viral oncogene homolog A 309165 / / -1.27 1.61 -1.01 1.67 / / 
RRAS related RAS viral (r-ras) oncogene homolog 361568 -1.38 1.78 -1.42 2.36 -1.07 2.31 -1.27 1.91 
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A 25625 -1.20 2.24 -1.19 4.09 -1.02 3.03 1.06 3.29 
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Table 5-8 Given are the fold-changes (average of treated rats against average of corresponding control rats) of Apoptosis Signaling of female rats treated with either 50 mg/kg (LD) or 300 mg/kg (HD) 
Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day/4 Day/8 Day/15 Day/29 
LD HD LD HD LD HD LD HD 
ACIN1 apoptotic chromatin condensation inducer 1 305884 1.07 1.60 1.27 1.95 1.02 1.59 1.22 1.94 
BAK1 BCL2-antagonist/killer 1 116502 1.17 2.90 1.79 4.77 1.19 1.93 2.14 5.23 
BCL2A1 BCL2-related protein A1 170929 -1.00 3.12 1.19 6.61 1.08 2.07 1.24 3.28 
BID BH3 interacting domain death agonist 64625 1.05 1.97 1.11 1.92 -1.08 1.61 1.07 2.08 
BIRC2 baculoviral IAP repeat containing 2 60371 1.12 1.54 1.56 1.88 / / 1.30 1.68 
BIRC3 baculoviral IAP repeat containing 3 78971 -1.03 4.70 1.08 5.97 1.02 2.04 1.25 4.34 
CAPN2 calpain 2, (m/II) large subunit 29154 -1.05 2.05 1.51 2.84 1.14 1.79 1.52 2.82 
CAPNS1 calpain, small subunit 1 29156 -1.12 2.55 1.11 2.97 1.01 1.88 1.30 3.71 
CASP2 caspase 2, apoptosis-related cysteine peptidase 64314 -1.00 1.92 1.84 2.91 1.08 1.58 1.50 2.86 
CASP3 caspase 3, apoptosis-related cysteine peptidase 25402 1.05 2.29 1.42 3.26 1.03 1.83 1.41 3.35 
CASP6 caspase 6, apoptosis-related cysteine peptidase 83584 1.01 1.66 1.46 2.11 1.18 1.73 1.28 1.93 
CASP8 caspase 8, apoptosis-related cysteine peptidase 64044 / / 1.01 1.58 / / 1.10 1.81 
CASP12 caspase 12 (gene/pseudogene) 156117 1.19 5.32 1.02 5.72 1.03 2.11 1.32 5.66 
CASP9 caspase 9, apoptosis-related cysteine peptidase 58918 / / 1.38 1.76 / / 1.30 2.03 
CDK1 cyclin-dependent kinase 1 54237 -1.09 6.63 1.01 9.85 1.12 2.72 1.39 6.55 
IKBKB 
inhibitor of kappa light polypeptide gene enhancer in B-
cells,  
kinase beta 
84351 1.03 2.10 1.18 2.03 1.01 1.77 1.34 2.50 
IKBKE 
inhibitor of kappa light polypeptide gene enhancer in B-
cells,  
kinase epsilon 
363984 1.06 1.50 1.25 1.83 / / / / 
MAP2K1 mitogen-activated protein kinase kinase 1 170851 1.06 1.74 1.82 2.73 1.21 1.55 1.60 3.00 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 301363 -1.07 1.91 -1.03 2.29 -1.08 1.51 -1.18 1.98 
MAPK1 mitogen-activated protein kinase 1 116590 1.14 1.91 1.47 2.28 1.16 1.52 1.38 2.15 
MCL1 myeloid cell leukemia sequence 1 60430 -1.19 1.79 1.13 1.86 / / 1.44 2.71 
NFKB2 
nuclear factor of kappa light  
polypeptide gene enhancer in B-cells 2 
309452 -1.14 2.39 1.21 2.94 1.05 2.01 1.30 3.78 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 24605 -1.07 2.44 1.25 2.94 1.08 1.75 1.30 3.38 
PARP1 poly (ADP-ribose) polymerase 1 25591 -1.06 2.15 1.72 3.24 1.06 1.72 1.57 3.70 
PLCG1 phospholipase C, gamma 1 25738 1.02 1.87 1.80 3.10 1.11 1.76 1.72 2.59 
RELA v-rel reticuloendotheliosis viral oncogene homolog A 309165 -1.01 1.67 1.28 1.97 1.10 1.54 1.30 2.06 
RPS6KA1 ribosomal protein S6 kinase, 90kDa, polypeptide 1 81771 / / 1.05 1.96 / / 1.12 1.88 
RRAS related RAS viral (r-ras) oncogene homolog 361568 -1.15 2.24 1.30 2.80 1.02 1.79 1.36 3.66 
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Symbol Entrez Gene Name Entrez Gene ID 
Day/4 Day/8 Day/15 Day/29 
LD HD LD HD LD HD LD HD 
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A 25625 1.12 2.96 1.23 3.92 1.09 2.16 1.73 5.68 
TP53 tumor protein p53 24842 1.11 1.57 1.32 1.69 / / 1.23 1.88 
 
 
Table 5-9 Given are the fold-changes (average of treated rats against average of corresponding control rats) of Death-receptor Signaling of male rats treated with either 50 mg/kg (LD) or 300 mg/kg 
(HD) Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day/4 Day/8 Day/15 Day/29 
LD HD LD HD LD HD LD HD 
BID BH3 interacting domain death agonist 64625 / / -1.19 1.73 -1.07 1.79 -1.12 1.65 
BIRC2 baculoviral IAP repeat containing 2 60371 / / -1.12 1.54 1.25 2.04 / / 
BIRC3 baculoviral IAP repeat containing 3 78971 1.05 3.74 -1.06 7.09 -1.01 4.33 1.36 3.99 
CASP2 caspase 2, apoptosis-related cysteine peptidase 64314 / / -1.29 2.03 1.31 2.69 / / 
CASP3 caspase 3, apoptosis-related cysteine peptidase 25402 1.08 1.71 -1.32 2.84 1.08 2.93 -1.05 2.26 
CASP6 caspase 6, apoptosis-related cysteine peptidase 83584 / / -1.10 1.62 1.08 1.73 / / 
CASP8 caspase 8, apoptosis-related cysteine peptidase 64044 / / -1.13 1.60 1.07 1.61 1.01 1.52 
CASP9 caspase 9, apoptosis-related cysteine peptidase 58918 / / / / 1.11 1.69 / / 
FADD Fas (TNFRSF6)-associated via death domain 266610 -1.51 1.11 / / 1.09 2.53 / / 
HSPB1 heat shock 27kDa protein 1 24471 1.24 1.66 -1.21 3.40 1.15 2.49 -1.17 2.07 
IKBKB 
inhibitor of kappa light polypeptide gene enhancer in B-
cells,  
kinase beta 
84351 / / -1.24 1.75 -1.02 1.92 / / 
IKBKE 
inhibitor of kappa light polypeptide gene enhancer in B-
cells,  
kinase epsilon 
363984 / / / / 1.14 1.51 / / 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 301363 / / -1.18 2.30 -1.04 1.82 -1.12 1.82 
NFKB2 
nuclear factor of kappa light  
polypeptide gene enhancer in B-cells 2 
309452 -1.21 1.88 -1.18 2.45 1.00 2.19 -1.09 1.97 
RELA v-rel reticuloendotheliosis viral oncogene homolog A 309165 / / -1.27 1.61 -1.01 1.67 / / 
TBK1 TANK-binding kinase 1 299827 / / / / 1.12 1.56 / / 
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A 25625 -1.20 2.24 -1.19 4.09 -1.02 3.03 1.06 3.29 
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 246775 -1.07 1.70 -1.22 2.80 1.01 2.71 1.06 1.68 
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Table 5-10 Given are the fold-changes (average of treated rats against average of corresponding control rats) of Death-receptor Signaling of female rats treated with either 50 mg/kg (LD) or 300 mg/kg 
(HD) Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day/4 Day/8 Day/15 Day/29 
LD HD LD HD LD HD LD HD 
BID BH3 interacting domain death agonist 64625 1.05 1.97 1.11 1.92 -1.08 1.61 1.07 2.08 
BIRC2 baculoviral IAP repeat containing 2 60371 1.12 1.54 1.56 1.88 / / 1.30 1.68 
BIRC3 baculoviral IAP repeat containing 3 78971 -1.03 4.70 1.08 5.97 1.02 2.04 1.25 4.34 
CASP2 caspase 2, apoptosis-related cysteine peptidase 64314 -1.00 1.92 1.84 2.91 1.08 1.58 1.50 2.86 
CASP3 caspase 3, apoptosis-related cysteine peptidase 25402 1.05 2.29 1.42 3.26 1.03 1.83 1.41 3.35 
CASP6 caspase 6, apoptosis-related cysteine peptidase 83584 1.01 1.66 1.46 2.11 1.18 1.73 1.28 1.93 
CASP8 caspase 8, apoptosis-related cysteine peptidase 64044 / / 1.01 1.58 / / 1.10 1.81 
CASP9 caspase 9, apoptosis-related cysteine peptidase 58918 / / 1.38 1.76 / / 1.30 2.03 
FADD Fas (TNFRSF6)-associated via death domain 266610 -1.04 1.51 1.54 3.12 1.05 1.56 1.32 2.45 
HSPB1 heat shock 27kDa protein 1 24471 1.21 2.91 1.67 2.77 1.01 1.95 1.34 4.02 
IKBKB 
inhibitor of kappa light polypeptide gene enhancer in B-
cells,  
kinase beta 
84351 1.03 2.10 1.18 2.03 1.01 1.77 1.34 2.50 
IKBKE 
inhibitor of kappa light polypeptide gene enhancer in B-
cells,  
kinase epsilon 
363984 1.06 1.50 1.25 1.83 / / / / 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 301363 -1.07 1.91 -1.03 2.29 -1.08 1.51 -1.18 1.98 
NFKB2 
nuclear factor of kappa light  
polypeptide gene enhancer in B-cells 2 
309452 -1.14 2.39 1.21 2.94 1.05 2.01 1.30 3.78 
RELA v-rel reticuloendotheliosis viral oncogene homolog A 309165 -1.01 1.67 1.28 1.97 1.10 1.54 1.30 2.06 
TBK1 TANK-binding kinase 1 299827 1.07 1.62 1.42 1.81 / / 1.30 1.94 
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A 25625 1.12 2.96 1.23 3.92 1.09 2.16 1.73 5.68 
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 246775 -1.03 2.43 1.25 3.43 -1.01 1.83 1.49 2.22 
TRAF2 TNF receptor-associated factor 2 311786 1.07 1.53 1.08 1.71 / / 1.23 1.82 
 
 
Table 5-11 Given are the fold-changes (average of treated rats against average of corresponding control rats) of Cell Cycle Control Signaling of male rats treated with either 50 mg/kg (LD) or 300 
mg/kg (HD) Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day/4 Day/8 Day/15 Day/29 
LD HD LD HD LD HD LD HD 
CDC6 cell division cycle 6 homolog (S. cerevisiae) 360621 1.01 1.61 -1.04 1.98 1.02 1.59 1.16 2.41 
CDK4 cyclin-dependent kinase 4 94201 -1.46 1.72 -1.32 2.74 1.02 2.45 -1.27 2.09 
CDK6 cyclin-dependent kinase 6 114483 / / -1.11 1.55 / / -1.09 1.53 
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Symbol Entrez Gene Name Entrez Gene ID 
Day/4 Day/8 Day/15 Day/29 
LD HD LD HD LD HD LD HD 
CHEK2 checkpoint kinase 2 114212 -1.02 1.56 -1.14 1.90 1.07 1.66 -1.01 1.53 
DBF4 DBF4 homolog (S. cerevisiae) 312046 -1.06 1.79 -1.06 2.61 -1.07 1.69 1.03 1.72 
MCM2 minichromosome maintenance complex component 2 312538 -1.20 2.53 -1.17 4.06 1.12 3.34 1.40 4.64 
MCM3 minichromosome maintenance complex component 3 316273 1.13 2.48 1.14 3.07 -1.02 1.91 1.46 4.33 
MCM4 minichromosome maintenance complex component 4 29728 1.07 2.09 1.09 2.75 1.03 2.04 1.46 3.55 
MCM5 minichromosome maintenance complex component 5 291885 1.30 1.97 1.15 1.93 1.02 1.59 1.41 2.73 
MCM6 minichromosome maintenance complex component 6 29685 -1.13 4.21 -1.22 6.64 1.09 4.78 1.93 9.03 
MCM7 minichromosome maintenance complex component 7 288532 -1.20 1.77 -1.24 2.62 -1.07 2.45 1.04 2.90 
ORC1 origin recognition complex, subunit 1 313479 1.17 1.65 1.01 1.70 / / 1.28 2.43 
ORC6 origin recognition complex, subunit 6 291927 / / -1.13 2.21 1.11 2.14 1.05 2.03 
RPA2 replication protein A2, 32kDa 59102 / / -1.24 2.31 -1.08 2.30 -1.08 2.29 
 
 
Table 5-12 Given are the fold-changes (average of treated rats against average of corresponding control rats) of Cell Cycle Control Signaling of female rats treated with either 50 mg/kg (LD) or 300 
mg/kg (HD) Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
CDC6 cell division cycle 6 homolog (S. cerevisiae) 360621 -1.02 1.63 -1.03 1.59 / / 1.04 2.71 
CDK4 cyclin-dependent kinase 4 94201 1.00 2.57 1.49 3.87 1.07 1.95 1.43 4.12 
CDK5 cyclin-dependent kinase 5 140908 1.01 1.65 1.27 2.00 / / 1.21 1.98 
CHEK2 checkpoint kinase 2 114212 1.03 1.86 1.02 2.25 / / 1.11 1.86 
DBF4 DBF4 homolog (S. cerevisiae) 312046 1.02 1.91 1.02 2.07 / / 1.12 2.20 
MCM2 minichromosome maintenance complex component 2 312538 -1.10 3.19 1.17 4.15 1.07 2.29 1.56 6.51 
MCM3 minichromosome maintenance complex component 3 316273 -1.03 2.19 -1.08 2.34 -1.03 1.54 -1.07 4.02 
MCM4 minichromosome maintenance complex component 4 29728 -1.01 1.90 -1.06 2.12 / / 1.11 2.94 
MCM5 minichromosome maintenance complex component 5 291885 -1.02 1.63 -1.06 1.65 / / -1.16 2.52 
MCM6 minichromosome maintenance complex component 6 29685 -1.06 4.69 1.18 6.45 1.10 3.07 1.87 13.58 
MCM7 minichromosome maintenance complex component 7 288532 -1.08 2.31 1.23 3.10 1.22 1.90 1.56 4.82 
ORC2 origin recognition complex, subunit 2 301430 1.05 1.61 1.25 1.93 1.03 1.50 1.32 2.49 
ORC6 origin recognition complex, subunit 6 291927 1.09 1.91 1.32 2.54 1.11 1.71 1.35 3.42 
RPA2 replication protein A2, 32kDa 59102 1.07 2.00 1.41 2.93 1.05 2.06 1.52 4.50 
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Table 5-13 Given are the fold-changes (average of treated rats against average of corresponding control rats) of Integrin Signaling of male rats treated with either 50 mg/kg (LD) or 300 mg/kg (HD) 
Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase 311860 / / -1.30 1.99 1.36 2.58 / / 
ACTB actin, beta 81822 / / -1.38 2.05 -1.09 2.25 -1.35 1.94 
ACTN1 actinin, alpha 1 81634 1.24 2.69 1.02 3.60 -1.02 1.95 1.17 4.82 
AKT1 v-akt murine thymoma viral oncogene homolog 1 24185 / / -1.18 2.03 -1.05 1.85 -1.19 1.67 
Arf2 ADP-ribosylation factor 2 79119 / / -1.25 1.64 1.27 2.25 / / 
ARPC3 actin related protein 2/3 complex, subunit 3, 21kDa 288669 / / -1.43 2.02 1.06 2.17 / / 
ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa 297518 / / -1.39 1.66 1.17 2.06 / / 
ARPC5 actin related protein 2/3 complex, subunit 5, 16kDa 360854 / / -1.23 1.75 1.14 2.26 / / 
ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa 54227 -1.05 2.09 -1.28 2.96 1.24 2.95 1.15 3.07 
ASAP1 
ArfGAP with SH3 domain,  
ankyrin repeat and PH domain 1 
314961 / / -1.11 2.01 1.06 1.70 / / 
CAPN2 calpain 2, (m/II) large subunit 29154 / / -1.29 2.24 1.22 2.70 -1.46 1.56 
CAPNS1 calpain, small subunit 1 29156 / / -1.42 1.69 -1.05 2.21 -1.44 1.54 
CAV1 caveolin 1, caveolae protein, 22kDa 25404 / / 1.12 1.59 / / / / 
CTTN cortactin 60465 / / -1.19 1.77 -1.03 1.56 -1.21 1.51 
ILK integrin-linked kinase 170922 / / -1.21 1.61 1.05 1.75 / / 
ITGA1 integrin, alpha 1 25118 -1.33 1.56 -1.25 2.26 1.39 2.84 / / 
ITGA4 integrin, alpha 4 311144 1.11 1.66 -1.10 3.29 1.14 3.10 -1.02 2.14 
ITGA5 integrin, alpha 5 315346 / / -1.08 2.34 -1.01 1.68 -1.07 1.73 
ITGAM integrin, alpha M 25021 / / 1.09 1.71 / / / / 
ITGAX integrin, alpha X 499271 / / 1.02 1.66 / / / / 
ITGB1 integrin, beta 1 24511 -1.23 1.71 -1.28 2.96 1.16 3.36 -1.20 2.42 
ITGB4 integrin, beta 4 25724 1.16 1.67 -1.03 3.44 1.08 3.46 -1.01 3.28 
ITGB6 integrin, beta 6 311061 / / -1.43 2.37 1.33 2.85 1.07 2.23 
ITGB7 integrin, beta 7 25713 / / 1.07 1.60 1.07 1.53 / / 
MAP2K1 mitogen-activated protein kinase kinase 1 170851 / / -1.32 1.66 1.32 2.35 / / 
MPRIP myosin phosphatase Rho interacting protein 116504 / / -1.33 1.87 1.23 1.97 / / 
MYL9 myosin, light chain 9, regulatory 296313 1.36 1.66 1.00 2.94 1.21 1.58 1.01 1.82 
NCK2 NCK adaptor protein 2 316369 / / -1.34 1.73 1.19 2.07 / / 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 24605 -1.16 1.70 -1.18 2.95 1.16 2.71 -1.10 2.37 
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 25513 1.16 1.59 -1.16 2.97 1.24 2.35 -1.20 2.98 
PIK3R6 phosphoinositide-3-kinase, regulatory subunit 6 497932 / / 1.17 1.53 / / / / 
PLCG1 phospholipase C, gamma 1 25738 / / -1.23 1.70 1.35 2.54 / / 
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Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
RAC1 ras-related C3 botulinum toxin substrate 1 363875 / / -1.24 2.04 1.08 2.16 -1.23 1.58 
RAC2 ras-related C3 botulinum toxin substrate 2 366957 -1.99 -1.10 -1.17 2.63 1.07 2.42 -1.20 1.52 
RALB v-ral simian leukemia viral oncogene homolog B 116546 / / -1.40 1.51 1.31 2.07 / / 
RGD1309537 
similar to Myosin regulatory light chain 2-A,  
smooth muscle isoform 
501203 -1.31 1.59 -1.32 2.83 1.19 2.98 -1.15 2.28 
RHOA ras homolog family member A 117273 1.23 2.02 1.61 3.68 2.22 3.98 1.56 1.77 
RHOB ras homolog family member B 64373 -1.27 2.53 -1.51 4.07 1.27 3.39 -1.13 2.30 
RHOC ras homolog family member C 295342 / / 1.01 1.79 1.72 2.92 -1.54 1.31 
RHOG ras homolog family member G 308875 / / -1.22 2.05 1.10 2.32 -1.23 1.58 
RHOH ras homolog family member H 305341 / / -1.15 2.12 1.02 2.39 / / 
RHOJ ras homolog family member J 299145 / / -1.31 3.33 1.40 2.87 -1.27 1.66 
RHOQ ras homolog family member Q 85428 / / -1.22 2.12 1.43 2.33 / / 
RND3 Rho family GTPase 3 295588 / / -1.24 2.15 1.10 1.96 -1.10 1.82 
RRAS related RAS viral (r-ras) oncogene homolog 361568 -1.38 1.78 -1.42 2.36 -1.07 2.31 -1.27 1.91 
TLN1 talin 1 313494 / / -1.23 1.85 1.23 2.25 -1.31 1.51 
TSPAN4 tetraspanin 4 293627 / / -1.06 1.63 1.08 2.02 1.07 1.70 
VASP vasodilator-stimulated phosphoprotein 361517 / / -1.03 1.89 1.16 1.69 / / 
WAS Wiskott-Aldrich syndrome 317371 1.18 2.21 -1.03 2.43 1.09 2.02 1.09 2.00 
WIPF1 WAS/WASL interacting protein family, member 1 117538 / / -1.37 2.65 1.40 3.25 -1.22 1.58 
 
 
Table 5-14 Given are the fold-changes (average of treated rats against average of corresponding control rats) of Integrin Signaling of female rats treated with either 50 mg/kg (LD) or 300 mg/kg (HD) 
Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase 311860 1.05 2.22 1.69 3.45 1.16 1.78 1.52 2.83 
ACTB actin, beta 81822 -1.11 2.84 1.19 3.47 -1.02 2.04 1.50 3.82 
ACTN1 actinin, alpha 1 81634 -1.06 2.52 -1.10 1.98 1.08 1.65 1.11 4.90 
ACTN4 actinin, alpha 4 63836 -1.12 1.75 1.44 2.28 1.06 1.58 1.26 2.32 
ACTR3 ARP3 actin-related protein 3 homolog 81732 -1.10 1.98 1.31 2.56 1.06 1.65 1.19 2.30 
AKT1 v-akt murine thymoma viral oncogene homolog 1 24185 -1.09 2.19 1.04 2.17 -1.04 1.68 1.05 2.73 
Arf2 ADP-ribosylation factor 2 79119 -1.10 1.69 1.13 2.53 1.15 1.60 1.31 2.44 
ARPC3 actin related protein 2/3 complex, subunit 3, 21kDa 288669 -1.15 1.94 1.50 3.03 1.17 1.72 1.53 4.01 
ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa 297518 -1.08 2.03 1.39 2.99 1.11 1.67 1.39 2.95 
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Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
ARPC5 actin related protein 2/3 complex, subunit 5, 16kDa 360854 -1.09 1.92 1.53 2.47 1.07 1.54 1.39 2.86 
ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa 54227 1.03 2.68 1.38 3.89 1.04 1.97 1.56 5.20 
CAPN2 calpain 2, (m/II) large subunit 29154 -1.05 2.05 1.51 2.84 1.14 1.79 1.52 2.82 
CAPNS1 calpain, small subunit 1 29156 -1.12 2.55 1.11 2.97 1.01 1.88 1.30 3.71 
CTTN cortactin 60465 1.01 2.24 1.22 1.96 1.04 1.54 1.16 2.34 
ILK integrin-linked kinase 170922 -1.10 1.95 1.11 2.02 -1.04 1.58 1.20 2.11 
ITGA1 integrin, alpha 1 25118 -1.04 2.10 1.52 3.13 1.02 1.59 1.51 1.79 
ITGA4 integrin, alpha 4 311144 1.16 2.38 1.24 4.06 1.12 1.73 1.53 2.44 
ITGB1 integrin, beta 1 24511 1.06 2.88 1.34 3.50 1.01 1.89 1.50 3.86 
MAP2K1 mitogen-activated protein kinase kinase 1 170851 1.06 1.74 1.82 2.73 1.21 1.55 1.60 3.00 
MAPK1 mitogen-activated protein kinase 1 116590 1.14 1.91 1.47 2.28 1.16 1.52 1.38 2.15 
MPRIP myosin phosphatase Rho interacting protein 116504 1.14 2.30 1.52 2.95 1.11 1.55 1.36 2.42 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 24605 -1.07 2.44 1.25 2.94 1.08 1.75 1.30 3.38 
PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 29431 1.01 2.15 1.32 2.81 1.05 1.56 1.32 3.29 
PLCG1 phospholipase C, gamma 1 25738 1.02 1.87 1.80 3.10 1.11 1.76 1.72 2.59 
RAC1 ras-related C3 botulinum toxin substrate 1 363875 1.03 2.34 1.41 2.82 1.12 1.79 1.74 3.36 
RAC2 ras-related C3 botulinum toxin substrate 2 366957 -1.07 2.14 1.53 4.96 1.10 1.57 1.67 2.69 
RALB v-ral simian leukemia viral oncogene homolog B 116546 1.03 1.93 1.63 2.70 1.12 1.66 1.31 2.64 
RGD1309537 
similar to Myosin regulatory light chain 2-A,  
smooth muscle isoform 
501203 -1.03 2.35 1.64 3.01 1.04 1.63 1.60 4.30 
RHOA ras homolog family member A 117273 2.39 3.64 2.23 2.02 1.66 1.50 2.49 2.57 
RHOB ras homolog family member B 64373 1.02 4.49 1.26 4.50 1.14 2.39 1.90 5.26 
RHOC ras homolog family member C 295342 -1.07 1.93 2.07 4.69 1.23 1.83 1.81 3.89 
RHOG ras homolog family member G 308875 1.24 2.23 1.43 3.30 1.21 1.76 1.46 2.56 
RHOH ras homolog family member H 305341 -1.01 1.53 1.22 3.09 1.02 1.51 1.26 1.71 
RHOJ ras homolog family member J 299145 1.24 1.97 1.64 3.02 1.15 1.56 1.71 2.88 
RHOQ ras homolog family member Q 85428 1.00 1.88 1.77 2.98 1.16 1.57 1.68 2.94 
RND3 Rho family GTPase 3 295588 1.09 1.90 1.25 2.13 1.08 1.61 1.33 2.80 
RRAS related RAS viral (r-ras) oncogene homolog 361568 -1.15 2.24 1.30 2.80 1.02 1.79 1.36 3.66 
TLN1 talin 1 313494 1.11 1.99 1.70 2.93 1.19 1.62 1.62 2.53 
WIPF1 WAS/WASL interacting protein family, member 1 117538 1.03 2.39 1.71 4.39 1.15 1.92 1.61 3.58 
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Table 5-15 Given are the fold-changes (average of treated rats against average of corresponding control rats) of Signaling by Rho Family GTPases of male rats treated with either 50 mg/kg (LD) or 300 mg/kg 
(HD) Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
ACTB actin, beta 81822 / / -1.38 2.05 -1.09 2.25 -1.35 1.94 
ACTR3 ARP3 actin-related protein 3 homolog 81732 / / / / 1.13 1.97 / / 
ARHGEF2 Rho/Rac guanine nucleotide exchange factor (GEF) 2 310635 / / -1.26 2.49 1.41 3.18 / / 
ARPC3 actin related protein 2/3 complex, subunit 3, 21kDa 288669 / / -1.43 2.02 1.06 2.17 / / 
ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa 297518 / / -1.39 1.66 1.17 2.06 / / 
ARPC5 actin related protein 2/3 complex, subunit 5, 16kDa 360854 / / -1.23 1.75 1.14 2.26 / / 
ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa 54227 -1.05 2.09 -1.28 2.96 1.24 2.95 1.15 3.07 
CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 309175 -1.08 1.82 -1.20 2.79 1.05 2.63 -1.53 1.52 
CDC42EP5 CDC42 effector protein (Rho GTPase binding) 5 361505 / / -1.10 1.92 -1.02 1.82 -1.18 1.58 
CDH17 cadherin 17, LI cadherin (liver-intestine) 117048 / / 1.09 1.66 -1.00 1.52 1.20 1.76 
CFL2 cofilin 2 (muscle) 366624 / / -1.20 1.73 1.24 2.24 / / 
CYBB cytochrome b-245, beta polypeptide 66021 1.12 2.53 1.03 3.90 1.25 3.16 1.12 2.28 
CYFIP1 cytoplasmic FMR1 interacting protein 1 308666 / / -1.35 1.61 1.09 2.12 / / 
DES desmin 64362 / / -1.14 2.48 1.06 2.36 -1.11 1.98 
FOS FBJ murine osteosarcoma viral oncogene homolog 314322 1.62 3.50 1.04 4.33 1.05 2.48 1.24 3.18 
GNA15 guanine nucleotide binding protein , alpha 15 89788 / / 1.12 2.14 1.04 1.56 1.14 1.82 
GNAI2 
guanine nucleotide binding protein ,  
alpha inhibiting activity polypeptide 2 
81664 / / -1.32 2.19 1.12 2.29 -1.31 1.52 
GNB2L1 
guanine nucleotide binding protein ,  
beta polypeptide 2-like 1 
83427 -1.52 1.14 -1.26 2.22 1.15 2.39 / / 
GNG10 guanine nucleotide binding protein, gamma 10 114119 -1.18 1.64 -1.30 2.62 1.11 2.50 -1.24 1.96 
GNG13 guanine nucleotide binding protein, gamma 13 685451 1.06 2.01 -1.05 2.28 -1.05 1.58 1.26 2.19 
ITGA4 integrin, alpha 4 311144 1.11 1.66 -1.10 3.29 1.14 3.10 -1.02 2.14 
ITGA5 integrin, alpha 5 315346 / / -1.08 2.34 -1.01 1.68 -1.07 1.73 
ITGB1 integrin, beta 1 24511 -1.23 1.71 -1.28 2.96 1.16 3.36 -1.20 2.42 
JUN jun proto-oncogene 24516 1.03 2.20 -1.09 2.96 1.22 3.37 -1.15 2.08 
LIMK1 LIM domain kinase 1 65172 / / -1.12 1.95 1.12 1.90 -1.02 1.71 
MAP2K1 mitogen-activated protein kinase kinase 1 170851 / / -1.32 1.66 1.32 2.35 / / 
MAPK1 mitogen-activated protein kinase 1 116590 / / / / 1.08 2.00 / / 
MSN moesin 81521 / / -1.16 2.03 1.02 2.51 -1.17 2.36 
MYL9 myosin, light chain 9, regulatory 296313 1.36 1.66 1.00 2.94 1.21 1.58 1.01 1.82 
NFKB2 
nuclear factor of kappa light  
polypeptide gene enhancer in B-cells 2 
309452 -1.21 1.88 -1.18 2.45 1.00 2.19 -1.09 1.97 
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Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
NOX4 NADPH oxidase 4 85431 -1.63 -2.98 -1.37 -3.26 1.08 -1.52 -1.19 -3.05 
PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 29431 / / / / 1.04 1.77 / / 
PAK2 p21 protein (Cdc42/Rac)-activated kinase 2 29432 / / / / 1.04 1.58 / / 
PARD3 par-3 partitioning defective 3 homolog (C. elegans) 81918 / / -1.28 1.59 1.02 1.84 / / 
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 25513 1.16 1.59 -1.16 2.97 1.24 2.35 -1.20 2.98 
PRKCI protein kinase C, iota 84006 / / -1.08 1.51 -1.04 1.64 -1.00 1.78 
RAC1 ras-related C3 botulinum toxin substrate 1 363875 / / -1.24 2.04 1.08 2.16 -1.23 1.58 
RELA v-rel reticuloendotheliosis viral oncogene homolog A 309165 / / -1.27 1.61 -1.01 1.67 / / 
RHOA ras homolog family member A 117273 1.23 2.02 1.61 3.68 2.22 3.98 1.56 1.77 
RHOB ras homolog family member B 64373 -1.27 2.53 -1.51 4.07 1.27 3.39 -1.13 2.30 
RHOC ras homolog family member C 295342 / / 1.01 1.79 1.72 2.92 -1.54 1.31 
RHOG ras homolog family member G 308875 / / -1.22 2.05 1.10 2.32 -1.23 1.58 
RHOH ras homolog family member H 305341 / / -1.15 2.12 1.02 2.39 / / 
RHOJ ras homolog family member J 299145 / / -1.31 3.33 1.40 2.87 -1.27 1.66 
RHOQ ras homolog family member Q 85428 / / -1.22 2.12 1.43 2.33 / / 
RND3 Rho family GTPase 3 295588 / / -1.24 2.15 1.10 1.96 -1.10 1.82 
ROCK2 Rho-associated, coiled-coil containing protein kinase 2 25537 / / -1.16 1.59 1.02 1.64 / / 
SEPT9 septin 9 83788 / / -1.31 1.77 1.07 1.72 / / 
STMN1 stathmin 1 29332 -1.55 1.31 -1.40 1.94 1.03 1.94 / / 
VIM vimentin 81818 / / -1.25 3.54 1.28 2.62 -1.08 1.75 
WAS Wiskott-Aldrich syndrome 317371 1.18 2.21 -1.03 2.43 1.09 2.02 1.09 2.00 
WIPF1 WAS/WASL interacting protein family, member 1 117538 / / -1.37 2.65 1.40 3.25 -1.22 1.58 
 
 
Table 5-16 Given are the fold-changes (average of treated rats against average of corresponding control rats) of Signaling by Rho Family GTPases of female rats treated with either 50 mg/kg (LD) or 300 
mg/kg (HD) Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
ACTB actin, beta 81822 -1.11 2.84 1.19 3.47 -1.02 2.04 1.50 3.82 
ACTR3 ARP3 actin-related protein 3 homolog 81732 -1.10 1.98 1.31 2.56 1.06 1.65 1.19 2.30 
ARHGEF2 Rho/Rac guanine nucleotide exchange factor (GEF) 2 310635 -1.11 2.10 1.70 3.74 1.15 1.74 1.73 3.14 
ARPC3 actin related protein 2/3 complex, subunit 3, 21kDa 288669 -1.15 1.94 1.50 3.03 1.17 1.72 1.53 4.01 
ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa 297518 -1.08 2.03 1.39 2.99 1.11 1.67 1.39 2.95 
ARPC5 actin related protein 2/3 complex, subunit 5, 16kDa 360854 -1.09 1.92 1.53 2.47 1.07 1.54 1.39 2.86 
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Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa 54227 1.03 2.68 1.38 3.89 1.04 1.97 1.56 5.20 
CDC42EP1 CDC42 effector protein (Rho GTPase binding) 1 315121 1.04 1.59 -1.01 1.55 / / 1.09 1.83 
CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 309175 1.01 2.70 1.23 3.52 1.00 1.56 1.38 3.19 
CDC42EP5 CDC42 effector protein (Rho GTPase binding) 5 361505 1.04 1.52 1.43 2.15 / / 1.29 2.31 
CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) 84407 1.18 1.60 1.06 1.83 / / 1.16 1.51 
CFL2 cofilin 2 (muscle) 366624 -1.02 1.67 1.56 2.02 / / 1.45 2.79 
CYBB cytochrome b-245, beta polypeptide 66021 1.02 2.61 -1.09 3.68 -1.00 1.67 1.11 1.81 
CYFIP1 cytoplasmic FMR1 interacting protein 1 308666 1.05 1.78 1.51 2.56 / / 1.33 2.38 
DES desmin 64362 -1.05 2.14 1.41 2.14 1.06 1.66 1.40 3.85 
DIAPH3 diaphanous homolog 3 (Drosophila) 290396 -1.00 1.66 -1.13 1.65 / / -1.09 1.56 
FOS FBJ murine osteosarcoma viral oncogene homolog 314322 1.05 2.52 1.05 2.71 / / 1.20 4.33 
GNA15 guanine nucleotide binding protein, alpha 15 89788 / / -1.11 1.72 / / -1.03 1.56 
GNAI2 
guanine nucleotide binding protein,  
alpha inhibiting activity polypeptide 2 
81664 1.14 1.99 1.52 3.05 1.18 1.64 1.74 3.06 
GNB2L1 
guanine nucleotide binding protein,  
beta polypeptide 2-like 1 
83427 -1.06 2.10 1.29 3.11 1.14 1.69 1.59 3.31 
GNG10 guanine nucleotide binding protein, gamma 10 114119 1.00 2.46 1.50 3.72 1.07 1.84 1.27 3.34 
GNG13 guanine nucleotide binding protein, gamma 13 685451 -1.04 1.71 -1.05 1.86 / / 1.11 2.44 
ITGA4 integrin, alpha 4 311144 1.16 2.38 1.24 4.06 1.12 1.73 1.53 2.44 
ITGA5 integrin, alpha 5 315346 -1.00 1.86 -1.04 1.85 / / 1.14 2.11 
ITGB1 integrin, beta 1 24511 1.06 2.88 1.34 3.50 1.01 1.89 1.50 3.86 
JUN jun proto-oncogene 24516 1.11 2.61 1.45 3.10 -1.01 1.62 1.45 3.38 
LIMK1 LIM domain kinase 1 65172 1.08 1.75 1.07 1.73 / / 1.13 3.02 
MAP2K1 mitogen-activated protein kinase kinase 1 170851 1.06 1.74 1.82 2.73 1.21 1.55 1.60 3.00 
MAPK1 mitogen-activated protein kinase 1 116590 1.14 1.91 1.47 2.28 1.16 1.52 1.38 2.15 
MAPK12 mitogen-activated protein kinase 12 60352 / / 1.24 1.53 / / 1.12 1.52 
MSN moesin 81521 1.06 2.58 1.31 2.86 1.13 1.63 1.61 3.87 
MYL9 myosin, light chain 9, regulatory 296313 1.14 1.97 1.12 1.79 / / 1.16 2.40 
NFKB2 
nuclear factor of kappa light  
polypeptide gene enhancer in B-cells 2 
309452 -1.14 2.39 1.21 2.94 1.05 2.01 1.30 3.78 
PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 29431 1.01 2.15 1.32 2.81 1.05 1.56 1.32 3.29 
PAK2 p21 protein (Cdc42/Rac)-activated kinase 2 29432 / / 1.25 1.59 / / 1.29 1.61 
PARD3 par-3 partitioning defective 3 homolog (C. elegans) 81918 1.10 1.70 1.28 1.86 / / 1.38 2.44 
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 25513 -1.11 1.97 1.25 2.15 / / 1.03 2.99 
RAC1 ras-related C3 botulinum toxin substrate 1 363875 1.03 2.34 1.41 2.82 1.12 1.79 1.74 3.36 
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Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
RELA v-rel reticuloendotheliosis viral oncogene homolog A 309165 -1.01 1.67 1.28 1.97 1.10 1.54 1.30 2.06 
RHOA ras homolog family member A 117273 2.39 3.64 2.23 2.02 1.66 1.50 2.49 2.57 
RHOB ras homolog family member B 64373 1.02 4.49 1.26 4.50 1.14 2.39 1.90 5.26 
RHOC ras homolog family member C 295342 -1.07 1.93 2.07 4.69 1.23 1.83 1.81 3.89 
RHOG ras homolog family member G 308875 1.24 2.23 1.43 3.30 1.21 1.76 1.46 2.56 
RHOH ras homolog family member H 305341 -1.01 1.53 1.22 3.09 1.02 1.51 1.26 1.71 
RHOJ ras homolog family member J 299145 1.24 1.97 1.64 3.02 1.15 1.56 1.71 2.88 
RHOQ ras homolog family member Q 85428 1.00 1.88 1.77 2.98 1.16 1.57 1.68 2.94 
RND3 Rho family GTPase 3 295588 1.09 1.90 1.25 2.13 1.08 1.61 1.33 2.80 
ROCK2 Rho-associated, coiled-coil containing protein kinase 2 25537 -1.17 1.56 1.50 1.93 / / 1.20 1.74 
SEPT9 septin 9 83788 1.04 1.87 1.38 2.40 / / 1.56 2.46 
STMN1 stathmin 1 29332 1.19 2.93 1.70 4.41 1.25 1.86 1.75 3.48 
VIM vimentin 81818 -1.01 1.82 1.77 2.99 / / 1.77 3.42 
WAS Wiskott-Aldrich syndrome 317371 -1.09 2.11 -1.05 2.54 / / 1.04 1.68 
WASF1 WAS protein family, member 1 294568 -1.02 1.51 1.20 1.79 / / 1.12 1.74 
WIPF1 WAS/WASL interacting protein family, member 1 117538 1.03 2.39 1.71 4.39 1.15 1.92 1.61 3.58 
 
 
Table 5-17 Given are the fold-changes (average of treated rats against average of corresponding control rats) of Signaling by HMGB1 Signaling of male rats treated with either 50 mg/kg (LD) or 300 mg/kg 
(HD) Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
AKT1 v-akt murine thymoma viral oncogene homolog 1 24185 / / -1.18 2.03 -1.05 1.85 -1.19 1.67 
CCL2 chemokine (C-C motif) ligand 2 287562 / / 1.06 2.26 / / 1.11 1.84 
FOS FBJ murine osteosarcoma viral oncogene homolog 314322 1.62 3.50 1.04 4.33 1.05 2.48 1.24 3.18 
HAT1 histone acetyltransferase 1 296501 / / -1.25 1.67 1.02 2.16 / / 
ICAM1 intercellular adhesion molecule 1 25464 -1.08 2.53 -1.31 4.43 1.19 3.88 1.10 3.40 
IFNGR1 interferon gamma receptor 1 116465 -1.29 1.65 -1.42 2.43 1.07 2.77 -1.17 1.76 
IFNGR2 interferon gamma receptor 2 360697 -1.26 1.58 -1.31 2.64 1.15 2.80 -1.23 1.64 
JUN jun proto-oncogene 24516 1.03 2.20 -1.09 2.96 1.22 3.37 -1.15 2.08 
KAT2A K(lysine) acetyltransferase 2A 303539 / / -1.20 1.63 1.02 1.67 / / 
MAP2K1 mitogen-activated protein kinase kinase 1 170851 / / -1.32 1.66 1.32 2.35 / / 
NFKB1 
nuclear factor of kappa light  
polypeptide gene enhancer in B-cells 1 
81736 1.22 1.62 1.07 1.57 / / 1.18 1.73 
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Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
NFKB2 
nuclear factor of kappa light  
polypeptide gene enhancer in B-cells 2 
309452 -1.21 1.88 -1.18 2.45 1.00 2.19 -1.09 1.97 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 24605 -1.16 1.70 -1.18 2.95 1.16 2.71 -1.10 2.37 
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 25513 1.16 1.59 -1.16 2.97 1.24 2.35 -1.20 2.98 
PIK3R6 phosphoinositide-3-kinase, regulatory subunit 6 497932 / / 1.17 1.53 / / / / 
PLAT plasminogen activator, tissue 25692 / / -1.21 2.44 1.39 3.06 -1.05 1.70 
RAC1 ras-related C3 botulinum toxin substrate 1 363875 / / -1.24 2.04 1.08 2.16 -1.23 1.58 
RBBP7 retinoblastoma binding protein 7 83712 -1.14 -2.55 -1.07 -1.59 1.05 -1.69 -1.07 -1.87 
RELA v-rel reticuloendotheliosis viral oncogene homolog A 309165 / / -1.27 1.61 -1.01 1.67 / / 
RHOA ras homolog family member A 117273 1.23 2.02 1.61 3.68 2.22 3.98 1.56 1.77 
RHOB ras homolog family member B 64373 -1.27 2.53 -1.51 4.07 1.27 3.39 -1.13 2.30 
RHOC ras homolog family member C 295342 / / 1.01 1.79 1.72 2.92 -1.54 1.31 
RHOG ras homolog family member G 308875 / / -1.22 2.05 1.10 2.32 -1.23 1.58 
RHOH ras homolog family member H 305341 / / -1.15 2.12 1.02 2.39 / / 
RHOJ ras homolog family member J 299145 / / -1.31 3.33 1.40 2.87 -1.27 1.66 
RHOQ ras homolog family member Q 85428 / / -1.22 2.12 1.43 2.33 / / 
RND3 Rho family GTPase 3 295588 / / -1.24 2.15 1.10 1.96 -1.10 1.82 
RRAS related RAS viral (r-ras) oncogene homolog 361568 -1.38 1.78 -1.42 2.36 -1.07 2.31 -1.27 1.91 
SERPINE1 serpin peptidase inhibitor, clade E, member 1 24617 1.09 1.93 1.13 4.84 1.14 2.15 1.24 6.63 
TLR4 toll-like receptor 4 29260 / / 1.10 1.56 / / / / 
TNFRSF11B 
tumor necrosis factor receptor superfamily,  
member 11b 
25341 -1.57 -8.49 -1.32 -5.09 / / -3.19 -10.08 
TNFRSF1A 
tumor necrosis factor receptor superfamily,  
member 1A 
25625 -1.20 2.24 -1.19 4.09 -1.02 3.03 1.06 3.29 
VCAM1 vascular cell adhesion molecule 1 25361 / / -1.32 3.34 1.16 2.72 -1.18 1.51 
 
 
Table 5-18 Given are the fold-changes (average of treated rats against average of corresponding control rats) of Signaling by HMGB1 Signaling of female rats treated with either 50 mg/kg (LD) or 300 mg/kg 
(HD) Vancomycin for up to 28 days. Genes were selected by t-test of HD treated rats (p ≤ 0.01, q ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5). 
Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
AKT1 v-akt murine thymoma viral oncogene homolog 1 24185 -1.09 2.19 1.04 2.17 -1.04 1.68 1.05 2.73 
HAT1 histone acetyltransferase 1 296501 -1.28 1.62 1.31 2.19 -1.08 1.59 1.32 3.39 
ICAM1 intercellular adhesion molecule 1 25464 1.11 3.80 1.67 5.67 1.18 2.57 1.68 5.87 
IFNGR1 interferon gamma receptor 1 116465 -1.03 2.56 -1.08 3.02 1.09 1.67 1.30 2.96 
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Symbol Entrez Gene Name Entrez Gene ID 
Day 4 Day 8 Day 15 Day 29 
LD HD LD HD LD HD LD HD 
IFNGR2 interferon gamma receptor 2 360697 1.15 2.53 1.47 3.97 1.01 1.66 1.34 3.04 
JUN jun proto-oncogene 24516 1.11 2.61 1.45 3.10 -1.01 1.62 1.45 3.38 
KAT2A K(lysine) acetyltransferase 2A 303539 1.02 1.71 1.24 1.98 1.10 1.53 1.16 2.43 
MAP2K1 mitogen-activated protein kinase kinase 1 170851 1.06 1.74 1.82 2.73 1.21 1.55 1.60 3.00 
MAPK1 mitogen-activated protein kinase 1 116590 1.14 1.91 1.47 2.28 1.16 1.52 1.38 2.15 
NFKB2 
nuclear factor of kappa light  
polypeptide gene enhancer in B-cells 2 
309452 -1.14 2.39 1.21 2.94 1.05 2.01 1.30 3.78 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 24605 -1.07 2.44 1.25 2.94 1.08 1.75 1.30 3.38 
RAC1 ras-related C3 botulinum toxin substrate 1 363875 1.03 2.34 1.41 2.82 1.12 1.79 1.74 3.36 
RELA v-rel reticuloendotheliosis viral oncogene homolog A 309165 -1.01 1.67 1.28 1.97 1.10 1.54 1.30 2.06 
RHOA ras homolog family member A 117273 2.39 3.64 2.23 2.02 1.66 1.50 2.49 2.57 
RHOB ras homolog family member B 64373 1.02 4.49 1.26 4.50 1.14 2.39 1.90 5.26 
RHOC ras homolog family member C 295342 -1.07 1.93 2.07 4.69 1.23 1.83 1.81 3.89 
RHOG ras homolog family member G 308875 1.24 2.23 1.43 3.30 1.21 1.76 1.46 2.56 
RHOH ras homolog family member H 305341 -1.01 1.53 1.22 3.09 1.02 1.51 1.26 1.71 
RHOJ ras homolog family member J 299145 1.24 1.97 1.64 3.02 1.15 1.56 1.71 2.88 
RHOQ ras homolog family member Q 85428 1.00 1.88 1.77 2.98 1.16 1.57 1.68 2.94 
RND3 Rho family GTPase 3 295588 1.09 1.90 1.25 2.13 1.08 1.61 1.33 2.80 
RRAS related RAS viral (r-ras) oncogene homolog 361568 -1.15 2.24 1.30 2.80 1.02 1.79 1.36 3.66 
TNFRSF11B 
tumor necrosis factor receptor superfamily,  
member 11b 
25341 -1.14 -2.81 2.22 -2.53 1.10 -1.57 -1.14 -5.45 
TNFRSF1A 
tumor necrosis factor receptor superfamily,  
member 1A 
25625 1.12 2.96 1.23 3.92 1.09 2.16 1.73 5.68 
VCAM1 vascular cell adhesion molecule 1 25361 1.21 2.88 1.11 3.44 1.15 1.91 1.76 3.28 
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5.3 Annex 3 Overview of viability values of NRK-52E cells  
 
 
Table 5-19 Given are the viability ± Standarddeviation (SD) values in percentage of vehicle control of NRK-52E cells 
treated with one of five concentrations of either Puromycin Paracetamol, Doxorubicin, AphotericinB, Metformin, d-Mannitol 
for 72h. Values are presented for ATP-depletion as well as neutral red uptake assay over five concentration [µM]. 
  
conc. [µM] 
Puromycin 
 
0,025 0,25 2,5 25 250 
       ATP mean (viability) 99% 68% 0% 2% 3% 
 
SD (viability) 2% 2% 0% 0% 0% 
       NRU mean (viability) 104% 90% 0% 0% 0% 
 
SD (viability) 8% 7% 0% 0% 0% 
       
       
  
conc. [µM] 
Paracetamol 50 250 500 1000 2000 
       ATP mean (viability) 114% 100% 113% 103% 83% 
 
SD viability 6% 13% 7% 8% 10% 
       NRU mean (viability) 109% 111% 119% 96% 73% 
 
SD (viability) 30% 22% 19% 16% 14% 
       
       
  
conc. [µM] 
Doxorubicin 0,0005 0,005 0,05 0,5 5 
       ATP mean (viability) 97% 91% 64% 21% 6% 
 
SD (viability) 2% 2% 2% 11% 1% 
       NRU mean (viability) 116% 123% 68% 10% 0% 
 
SD (viability) 34% 37% 26% 3% 2% 
       
       
  
conc. [µM] 
Amphotericin B 0,05 0,5 5 50 125 
       ATP mean (viability) 105% 115% 84% 0% 3% 
 
SD (viability) 3% 7% 9% 0% 0% 
       NRU mean (viability) 130% 112% 110% 118% 9% 
 
SD (viability) 41% 18% 30% 51% 4% 
       
       
  
conc. [µM] 
Metforimin 
 
50 100 250 500 1000 
       ATP mean (viability) 102% 103% 104% 96% 84% 
 
SD (viability) 5% 3% 2% 10% 11% 
       NRU mean (viability) 125% 127% 134% 133% 131% 
 
SD (viability) 25% 68% 58% 63% 37% 
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conc. [µM] 
d-Mannitol 
 
0,5 5 50 500 5000 
       ATP mean (viability) 104% 104% 106% 107% 107% 
 
SD viability 1% 8% 3% 1% 6% 
       NRU mean (viability) 132% 141% 131% 132% 141% 
 
SD viability 58% 64% 54% 48% 51% 
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5.4 Annex 4 Transcriptional FC values of NRK-52E cells after treatment with (non-)nephrotoxic compounds 
 
Table 5-20 Given are the fold-changes (FC; average of treatment against average of corresponding vehicle control) of significant altered transcripts (t-test p ≤ 0.01, fold-change ≥ 1.5/ ≤ -1.5) in NRK-
52E cells after treatment with either the TC20 or the NOAEC of Puromycin, Paracetamol, Doxorubicin, or AmphotericinB. In addition the transcriptional alterations of the identified transcripts after 
treatment with two negative compounds, Metformin and d-Mannitol are displayed.   
Gene symbol Accession No. 
AmphotericinB Doxorubicin Puromycin Paracetamol Metformin d-Mannitol 
LD HD LD HD LD HD LD HD LD HD LD HD 
              Aars XM_001077503.1 1,45 1,93 1,12 1,64 1,00 1,72 1,29 1,69 -1,10 1,05 -1,05 -1,04 
Abcc3 NM_080581.1 -1,18 -1,68 -1,12 -1,41 -1,10 -1,58 -1,29 -1,83 -1,00 1,02 -1,04 -1,16 
Abtb1 NM_001005902.1 -1,36 -1,81 -1,12 -1,13 -1,13 -1,58 -1,33 -1,60 -1,10 -1,12 -1,14 -1,07 
Adhfe1 NM_001025423.1 -1,54 -2,37 -1,46 -1,67 -1,07 -1,94 -1,64 -2,27 1,16 1,04 -1,10 -1,07 
Aldoc NM_012497.1 -1,69 -2,56 -1,22 -2,00 -1,05 -2,34 -2,06 -2,99 -1,09 -1,09 -1,06 -1,04 
Ampd3 NM_031544.1 -1,06 -2,01 -1,30 -1,55 -1,15 -2,09 -1,44 -3,31 -1,05 -1,13 -1,06 -1,08 
Ankrd1 NM_013220.1 1,10 6,99 1,24 9,03 -1,02 2,65 1,56 18,18 -1,19 -1,22 -1,08 -1,07 
Arhgef19_predicted XM_342965.3 -1,35 -2,57 -1,21 -1,68 1,03 -1,76 -1,37 -2,38 1,00 -1,02 -1,08 -1,08 
Armcx1 NM_001024367.1 -1,27 -2,07 -1,22 -2,24 -1,04 -1,89 -1,43 -3,83 1,01 -1,10 1,02 1,07 
Asns NM_013079.1 1,57 2,48 1,25 1,82 1,12 2,04 1,64 2,75 1,08 1,18 1,22 1,19 
Atf4 NM_024403.1 1,36 1,85 1,16 1,59 -1,01 1,70 1,19 1,87 1,05 1,00 -1,01 1,02 
Atp8b3_predicted XM_001076355.1 -1,41 -2,25 -1,30 -1,55 -1,12 -1,79 -1,37 -2,54 -1,19 -1,09 -1,33 -1,24 
B4galt4 NM_001012018.1 -1,32 -2,24 -1,10 -2,05 -1,05 -1,62 -1,30 -2,93 -1,07 -1,09 -1,11 -1,03 
Baz1a_predicted XM_001079067.1 1,32 1,90 1,25 1,42 1,05 1,71 1,44 1,91 1,09 1,15 1,10 1,04 
Bhmt NM_030850.1 -1,29 -1,67 -1,16 -1,28 -1,05 -1,72 -1,34 -1,86 -1,03 -1,11 -1,01 1,01 
Boc_predicted XM_001060215.1 -1,51 -3,25 -1,35 -2,13 -1,03 -1,80 -1,57 -3,67 -1,03 -1,03 -1,16 -1,17 
C1qtnf1 NM_001007675.1 -1,66 -3,93 -1,30 -2,00 -1,03 -2,36 -1,55 -3,23 1,04 1,04 -1,02 -1,06 
Calcoco1 NM_139190.1 -1,42 -2,88 -1,33 -1,20 -1,06 -1,74 -1,38 -1,84 -1,02 -1,12 -1,16 -1,30 
Cars_predicted XM_001065753.1 1,46 1,59 1,07 1,50 1,04 1,53 1,30 1,70 -1,02 1,02 1,03 1,03 
Ccne2_predicted XM_001064132.1 1,55 2,00 1,24 -1,11 1,08 1,96 2,27 2,68 1,11 1,16 1,17 1,06 
Ccng1 NM_012923.1 1,16 2,20 1,60 2,51 1,16 1,71 1,74 2,73 1,07 1,07 1,06 -1,00 
Cd44 NM_012924.2 1,35 2,15 1,18 2,17 -1,00 1,79 1,36 3,43 -1,02 -1,08 -1,05 -1,02 
Cdc6_predicted XM_340896.3 1,30 2,22 1,14 -1,26 1,04 1,71 1,79 2,25 -1,15 -1,02 1,07 1,08 
Cdkn1a NM_080782.3 1,18 2,65 2,17 4,04 1,10 2,11 2,02 5,40 1,15 1,24 1,16 -1,02 
Cep70 NM_001017470.1 -1,30 -1,80 -1,21 -1,76 -1,11 -1,66 -1,49 -2,33 1,01 -1,04 -1,02 -1,04 
Cfd XM_001077068.1 -1,64 -1,93 -1,48 -1,57 -1,10 -2,19 -1,85 -2,12 -1,07 -1,13 -1,04 1,02 
Cln6_predicted XM_236325.3 -1,49 -3,57 -1,32 -2,91 -1,10 -2,38 -1,70 -5,10 -1,08 -1,14 -1,18 -1,11 
Cnksr3 NM_001012061.1 1,21 1,95 1,34 2,09 1,12 1,93 1,50 2,58 1,06 1,10 1,10 1,17 
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Col16a1 XM_345584.3 -1,35 -1,95 1,00 -1,51 1,03 -1,54 -1,15 -2,11 1,06 1,01 -1,06 1,05 
Col3a1 NM_032085.1 -2,56 -5,97 -1,35 -3,05 -1,09 -4,60 -1,83 -6,29 1,09 1,02 -1,12 -1,04 
Coro2a_predicted XM_575819.1 -1,25 -1,74 -1,19 -1,28 -1,06 -1,56 -1,27 -1,78 1,04 -1,02 1,10 1,01 
Cryab NM_012935.2 1,13 2,28 1,19 3,80 1,07 1,75 1,16 4,61 -1,04 1,00 1,01 -1,04 
Csad NM_021750.1 -1,34 -2,86 -1,19 -1,98 -1,05 -1,94 -1,47 -2,65 1,04 1,05 1,03 -1,01 
Csdc2 XM_001077363.1 -1,31 -1,98 -1,16 -1,39 -1,05 -1,75 -1,30 -1,96 -1,02 1,00 -1,07 -1,17 
Cxcl1 NM_030845.1 1,34 11,43 1,61 1,67 -1,02 1,03 1,35 2,99 1,08 1,06 1,21 1,28 
Cxcl13 NM_001017496.1 -1,91 -3,25 -1,25 -1,88 -1,02 -2,71 -1,96 -3,28 1,06 -1,12 -1,03 1,05 
Cycs NM_012839.2 1,35 2,24 1,19 1,74 1,04 1,53 1,34 2,20 1,04 1,08 1,13 1,12 
Cyr61 NM_031327.2 1,03 3,16 1,67 2,61 1,02 1,61 1,56 3,39 1,01 1,03 1,02 1,14 
Dci NM_017306.3 -1,33 -2,11 -1,22 -2,99 -1,02 -1,89 -1,57 -2,49 1,03 -1,08 -1,00 1,08 
Ddah1 NM_022297.2 1,26 3,33 1,28 2,39 1,13 1,79 1,39 3,16 -1,11 1,02 1,00 -1,02 
Donson NM_001008287.1 1,25 1,64 1,17 -1,14 1,08 1,56 1,70 2,17 1,05 1,06 1,18 1,00 
Ech1 NM_022594.1 -1,49 -3,00 -1,23 -1,48 -1,06 -1,85 -1,58 -2,10 1,00 -1,00 -1,06 -1,12 
Edn1 NM_012548.1 -1,06 4,22 1,74 4,18 -1,00 1,70 1,72 6,37 1,09 1,07 1,04 1,06 
Elmo3 NM_001030028.1 -1,17 -2,09 1,01 -1,40 -1,08 -1,61 -1,09 -1,48 1,00 -1,02 -1,03 -1,12 
Enc1 NM_001003401.1 1,19 1,68 1,32 1,41 1,13 1,66 1,44 2,38 1,06 1,07 1,10 1,08 
Enpp3 NM_019370.1 -1,21 -2,24 -1,34 -2,09 -1,19 -2,57 -1,28 -2,82 -1,09 -1,09 -1,24 -1,31 
Ephx2 NM_022936.1 -1,22 -1,88 -1,07 -1,81 1,12 -1,59 -1,13 -1,88 1,17 1,07 1,08 1,09 
Ergic3_predicted XM_001066442.1 -1,71 -1,96 -1,31 -1,28 -1,24 -1,72 -1,70 -2,02 -1,09 -1,15 -1,22 -1,35 
Eva_predicted XM_236197.3 -1,21 -1,79 1,03 -1,70 -1,07 -1,72 -1,12 -2,22 -1,07 -1,10 -1,00 1,00 
Fah NM_017181.2 -1,56 -1,98 -1,33 -1,83 -1,07 -1,59 -1,70 -2,92 -1,04 -1,07 -1,18 -1,03 
Fbxo2 NM_053511.1 -1,36 -1,70 -1,24 -1,77 -1,15 -1,54 -1,36 -1,74 -1,21 -1,26 -1,16 -1,19 
Fbxo6b NM_138917.2 -1,39 -1,90 -1,23 -1,14 -1,10 -1,71 -1,60 -2,12 -1,09 -1,10 -1,28 -1,15 
Fcgrt NM_033351.1 -1,63 -2,67 -1,19 -1,28 -1,11 -1,79 -1,40 -1,89 1,02 1,02 -1,07 -1,10 
Fhl1 NM_145669.2 1,48 3,64 1,27 2,49 1,13 2,46 1,96 5,23 1,09 1,05 1,05 1,02 
Flot1 NM_022701.1 -1,33 -2,23 -1,32 -1,67 -1,02 -1,30 -1,51 -2,00 1,00 -1,01 -1,10 -1,14 
Flrt3_predicted XM_001080226.1 1,30 2,65 1,20 2,03 1,04 2,24 1,65 3,71 -1,03 1,07 1,01 -1,03 
Fmo4 NM_144562.1 -1,07 -1,63 -1,17 -1,23 -1,05 -1,51 -1,21 -1,62 -1,05 -1,11 -1,20 1,00 
Fn1 NM_019143.1 1,21 2,55 1,34 2,88 1,08 1,55 1,68 3,49 1,06 -1,01 1,14 1,28 
Fst NM_012561.1 1,20 2,29 1,72 3,72 1,07 2,04 1,93 4,57 -1,07 1,16 1,11 1,10 
Gamt NM_012793.1 -1,44 -1,74 -1,25 -1,55 -1,04 -1,78 -1,46 -1,70 -1,01 -1,05 -1,10 1,00 
Gars XM_216152.4 1,40 1,42 1,10 1,51 -1,01 1,58 1,47 1,69 -1,05 -1,04 -1,11 -1,15 
Gja12_predicted XM_573100.2 -1,64 -1,99 -1,08 -1,48 -1,21 -1,64 -1,56 -1,65 -1,17 -1,14 -1,15 -1,17 
Gpc3 NM_012774.1 -1,05 -1,90 1,04 -7,31 1,01 -1,99 -1,19 -10,15 -1,01 -1,05 1,07 1,11 
2
7
2
 
 273 
 
Gene symbol Accession No. 
AmphotericinB Doxorubicin Puromycin Paracetamol Metformin d-Mannitol 
LD HD LD HD LD HD LD HD LD HD LD HD 
Gpr126_predicted XM_001071417.1 1,26 2,42 1,24 2,74 1,09 1,87 1,19 3,60 1,04 1,05 -1,02 1,01 
Gsta4 XM_001059683.1 -1,28 -2,19 -1,01 -1,54 -1,15 -1,95 -1,37 -2,09 1,08 -1,06 1,06 1,07 
Gstm1 NM_017014.1 -1,82 -2,31 -1,20 -1,56 -1,13 -2,40 -1,81 -2,10 -1,09 -1,11 -1,15 -1,09 
Hist1h2ao_predicted XM_344599.2 1,19 1,96 1,30 2,11 1,10 2,52 1,41 5,45 1,03 1,04 1,03 1,03 
Htra1 NM_031721.1 1,06 2,71 1,49 3,80 1,05 1,51 1,32 4,60 -1,08 -1,11 1,01 1,08 
Idh1 NM_031510.1 -1,17 -2,05 -1,22 -1,90 1,02 -1,68 -1,33 -2,25 -1,03 -1,04 1,01 -1,10 
Ifi35 NM_001009625.1 -1,39 -1,57 -1,13 -1,54 1,05 -1,71 -1,30 -1,36 -1,05 -1,10 -1,07 -1,00 
Igfbp6 NM_013104.2 -1,75 -6,64 -1,36 -4,08 -1,08 -3,25 -1,98 -6,79 1,13 1,11 1,12 1,01 
Isg20l1_predicted XM_341874.3 1,13 3,34 1,89 2,78 1,17 1,71 1,59 3,81 1,02 -1,05 1,07 1,21 
Itga3_predicted XM_340884.2 1,23 1,18 -1,05 1,87 1,05 1,95 1,29 1,96 1,07 1,31 -1,07 -1,14 
Ivns1abp_predicted XM_213898.4 1,30 1,72 1,13 1,21 1,02 1,54 1,63 1,59 -1,00 1,01 1,07 1,05 
Kazald1 NM_001033064.1 -1,73 -3,52 -1,36 -2,47 -1,07 -2,84 -1,91 -4,00 -1,03 -1,02 -1,12 -1,03 
Kcnmb4 NM_023960.2 -1,28 -2,07 -1,21 -1,11 -1,10 -1,71 -1,22 -1,58 -1,03 -1,07 -1,14 -1,13 
KIFC2 NM_198752.1 -1,54 -2,11 -1,22 -1,71 -1,14 -2,11 -1,45 -2,56 -1,08 -1,19 -1,16 -1,11 
Klc4 NM_001009601.1 -1,43 -1,89 -1,06 -1,32 -1,06 -1,68 -1,34 -1,95 -1,15 -1,16 -1,12 -1,03 
Krt15 NM_001004022.2 -1,37 -2,19 -1,04 -1,43 -1,05 -1,83 -1,04 -2,65 -1,07 -1,09 1,07 1,03 
Krt19 NM_199498.1 -1,73 -6,54 -1,46 -3,61 -1,13 -4,60 -1,40 -9,09 -1,07 -1,25 -1,05 -1,08 
LOC304500 XM_222190.3 -1,29 -1,68 -1,16 -1,37 1,02 -1,59 -1,25 -1,64 -1,05 -1,07 -1,16 -1,04 
LOC360228 NM_001003706.1 -1,75 -2,01 -1,05 -1,41 1,03 -1,71 -1,54 -1,78 -1,04 -1,23 -1,04 1,03 
LOC497685 XM_579547.1 -1,31 -2,30 -1,28 -1,27 -1,11 -1,75 -1,53 -1,91 -1,04 -1,11 -1,18 -1,19 
LOC497723 XM_579534.1 1,40 1,41 1,41 1,59 1,15 1,62 1,57 1,72 1,36 1,24 1,27 1,24 
LOC497767 XM_579388.1 -1,54 -3,16 -1,14 -1,62 -1,04 -2,07 -1,51 -2,69 1,00 -1,12 -1,05 -1,04 
LOC499120 XM_001078762.1 -1,26 -1,69 -1,31 -1,67 -1,03 -1,54 -1,31 -2,23 -1,05 -1,09 -1,04 -1,06 
LOC499201 XM_579934.1 1,54 1,85 1,30 1,53 1,15 1,15 1,29 3,13 1,18 1,06 1,11 1,08 
LOC679409 XM_001054960.1 -1,06 -1,79 -1,21 -1,86 -1,08 -1,61 -1,51 -3,01 -1,04 -1,09 -1,10 -1,13 
LOC684490 XM_001067912.1 1,58 3,70 1,36 1,69 1,07 2,03 1,87 3,40 -1,07 1,04 1,10 1,13 
LOC687840 XM_001080312.1 -1,36 -2,33 -1,02 -1,75 -1,09 -2,35 -1,41 -2,11 1,00 -1,04 1,02 1,01 
Loxl3_predicted XM_232107.4 -1,36 -1,64 -1,18 -1,37 -1,18 -1,65 -1,31 -1,69 -1,12 -1,05 -1,29 -1,25 
Lrp8_predicted XM_342877.2 1,31 1,61 1,18 1,32 1,11 1,69 1,44 2,04 1,06 1,11 1,08 1,06 
Lrrc56 NM_001024902.1 -1,58 -2,19 -1,15 -1,83 -1,10 -2,07 -1,50 -2,63 -1,13 -1,25 -1,04 -1,03 
Lztfl1 NM_001024266.1 -1,41 -1,95 -1,22 -1,45 -1,05 -1,61 -1,54 -2,08 -1,04 -1,06 -1,05 -1,01 
Maged2 NM_080479.2 -1,28 -1,74 -1,13 -1,37 -1,02 -1,72 -1,35 -2,19 -1,05 -1,11 -1,18 -1,18 
Map2k6 NM_053703.2 -1,04 -1,66 -1,30 -1,65 -1,06 -2,17 -1,25 -2,20 1,02 1,03 -1,04 1,01 
Mcm10_predicted XM_001071383.1 1,44 1,69 1,03 -1,51 1,09 1,53 1,75 1,35 -1,02 1,06 1,03 -1,06 
Mettl7a NM_001037355.1 -1,52 -2,67 -1,55 -1,74 -1,19 -2,22 -1,98 -2,58 -1,10 -1,04 -1,28 -1,27 
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Mettl7a NM_001037355.1 -1,44 -1,85 -1,27 -1,55 -1,17 -1,81 -1,64 -2,13 -1,20 -1,20 -1,11 -1,15 
MGC94199 NM_001007746.1 -1,28 -1,96 -1,21 -2,06 1,04 -1,55 -1,44 -2,74 -1,02 -1,10 -1,07 -1,00 
Mgp NM_012862.1 -2,17 -3,45 -1,84 -2,31 -1,17 -3,66 -2,56 -3,74 1,11 1,01 -1,01 1,23 
Mgst1 NM_134349.2 -1,22 -2,19 -1,11 -1,81 -1,02 -1,77 -1,30 -1,70 1,05 1,04 1,03 -1,01 
Mmp11 NM_012980.1 -1,39 -2,27 -1,23 -1,85 1,01 -1,58 -1,47 -2,50 1,17 1,10 -1,06 -1,07 
Mpst NM_138843.1 -1,42 -1,97 -1,21 -1,70 -1,04 -1,73 -1,45 -1,72 -1,06 1,01 -1,07 -1,13 
Ms4a11_predicted XM_001075502.1 -1,18 -1,52 1,09 1,02 -1,05 -1,56 1,09 1,55 1,03 -1,02 1,06 1,02 
Mthfd1 NM_022508.1 1,21 1,79 1,24 1,62 1,04 1,72 1,50 2,24 -1,02 1,01 1,06 1,04 
Mybl1_predicted XM_232620.3 1,15 1,78 1,28 1,16 1,04 1,75 1,75 2,90 1,08 1,09 1,03 1,05 
Myc NM_012603.2 1,30 2,64 1,20 2,03 -1,01 2,12 1,50 2,62 -1,02 -1,06 1,08 1,02 
Myh14 XM_001080622.1 -1,58 -2,68 -1,24 -1,84 -1,07 -1,90 -1,57 -2,68 1,01 -1,16 -1,17 -1,08 
Myh6 NM_017239.1 -1,71 -2,65 1,05 -1,61 -1,05 -1,63 1,04 -2,01 -1,03 -1,06 1,08 1,16 
Ndrg2 NM_133583.1 -1,55 -2,30 -1,11 -1,41 -1,09 -1,94 -1,64 -2,70 -1,15 -1,14 -1,08 1,04 
Nme3 NM_053507.1 -1,45 -1,55 -1,15 -2,27 -1,10 -1,84 -1,41 -1,68 -1,07 -1,10 -1,13 -1,02 
Nme7 NM_138532.1 -1,30 -2,07 -1,29 -1,59 1,00 -1,51 -1,47 -2,23 1,00 -1,05 1,01 -1,06 
Nol5a NM_001025732.1 1,25 2,47 1,20 1,42 -1,00 1,71 1,51 1,88 -1,14 -1,04 1,08 1,01 
Nppb NM_031545.1 1,17 5,60 1,48 12,85 -1,05 2,19 1,55 23,09 -1,07 -1,08 1,10 1,10 
Nrep NM_178096.2 -1,45 -1,74 -1,21 -2,09 -1,07 -1,69 -1,31 -2,53 -1,14 -1,07 -1,02 1,05 
Odc1 NM_012615.1 1,38 1,77 1,02 1,50 1,01 1,93 1,58 2,68 1,01 1,04 -1,03 -1,08 
Oplah NM_053904.1 -1,16 -1,76 1,07 -1,51 1,04 -2,28 -1,28 -2,16 -1,02 -1,06 1,09 1,24 
Pcolce NM_019237.1 -1,35 -1,63 -1,15 -1,06 -1,10 -1,57 -1,33 -1,61 -1,07 -1,07 -1,16 -1,14 
Pdk2 NM_030872.1 -1,50 -2,45 -1,04 -1,30 -1,01 -1,85 -1,41 -1,82 -1,00 -1,08 -1,03 1,05 
Phyh NM_053674.1 -1,31 -2,24 -1,08 -2,24 1,06 -1,90 -1,68 -3,52 -1,00 1,14 1,13 1,09 
Phyhd1 NM_001013081.1 -1,91 -4,55 -1,24 -1,60 -1,16 -3,46 -1,80 -2,95 -1,09 -1,12 -1,12 -1,09 
Pik3ip1 NM_001017453.1 -1,20 -2,90 -1,33 -2,96 -1,06 -2,25 -1,73 -5,48 1,03 1,13 -1,15 -1,09 
Pink1_predicted XM_216565.4 -1,21 -1,92 -1,12 -1,24 -1,02 -1,58 -1,36 -1,79 1,04 -1,06 -1,09 -1,12 
Pomgnt1 NM_001007747.1 1,23 1,96 1,28 2,77 1,07 1,78 1,30 2,76 1,04 1,06 1,10 1,22 
Ptpru XM_342930.2 -1,55 -2,14 -1,06 -1,43 -1,02 -1,60 -1,21 -2,38 -1,03 -1,07 -1,02 -1,02 
Pus7_predicted XM_001061692.1 1,33 1,75 1,18 1,06 1,08 1,73 1,51 1,67 -1,03 1,12 1,13 1,10 
Rbp1 NM_012733.4 -2,06 -6,27 -1,31 -4,91 -1,06 -1,90 -1,28 -4,58 1,02 1,01 -1,05 -1,04 
Rcbtb2 NM_199084.1 -1,18 -2,10 -1,26 -2,28 -1,06 -1,66 -1,26 -2,90 1,01 1,04 -1,04 -1,10 
Rcn3_predicted NM_001008694.1 -1,50 -1,92 1,11 -1,84 1,05 -2,21 -1,14 -2,28 1,10 1,05 1,12 1,16 
RGD1304580 NM_001009283.1 -1,50 -2,19 -1,22 -1,49 -1,09 -2,25 -1,34 -2,12 -1,05 -1,05 -1,10 1,07 
RGD1306063_predicted XM_214137.3 -1,32 -1,60 -1,24 -1,43 -1,12 -1,54 -1,59 -1,79 -1,07 -1,13 -1,09 -1,07 
RGD1306107_predicted XM_227412.4 -1,18 -1,96 -1,17 -1,50 -1,08 -1,64 -1,25 -2,25 -1,06 -1,12 -1,02 -1,10 
2
7
4
 
 275 
 
Gene symbol Accession No. 
AmphotericinB Doxorubicin Puromycin Paracetamol Metformin d-Mannitol 
LD HD LD HD LD HD LD HD LD HD LD HD 
RGD1307392_predicted XM_001060869.1 -1,45 -1,65 -1,26 -1,70 -1,16 -1,50 -1,43 -1,87 -1,06 -1,14 -1,14 -1,11 
RGD1307396_predicted XM_341029.3 -1,30 -2,34 -1,13 -1,97 1,01 -1,79 -1,21 -3,05 1,00 -1,07 1,09 -1,04 
RGD1307493_predicted XM_001080742.1 1,27 2,08 1,24 1,21 -1,02 1,71 1,47 1,91 -1,08 1,06 1,07 1,08 
RGD1307524_predicted XM_219909.4 -1,64 -2,52 -1,37 -1,69 1,02 -1,66 -1,46 -1,90 1,02 -1,08 -1,20 -1,19 
RGD1307682 NM_001024760.1 -1,43 -1,92 -1,19 -1,48 -1,08 -1,76 -1,33 -1,59 -1,15 -1,11 -1,16 -1,15 
RGD1308013_predicted XM_001068272.1 -1,33 -4,02 -1,20 -3,14 -1,06 -2,79 -2,28 -8,64 1,06 1,09 1,04 -1,02 
RGD1309263_predicted XM_214574.4 -1,17 -1,27 -1,02 -1,53 1,00 -1,53 -1,25 -1,54 -1,10 -1,08 -1,06 -1,08 
RGD1311307 NM_001025719.1 1,02 2,04 1,27 3,21 1,09 1,88 1,24 3,68 -1,02 -1,04 -1,01 1,09 
RGD1560177_predicted XM_001057282.1 1,04 2,06 1,16 2,03 -1,03 1,55 1,18 2,81 -1,11 -1,06 -1,12 -1,06 
RGD1560453_predicted XM_574890.2 -1,17 -1,61 -1,22 -1,65 -1,07 -1,60 -1,27 -2,00 -1,14 -1,04 1,01 -1,01 
RGD1560673_predicted XM_001078819.1 -1,23 -1,52 -1,12 -1,43 -1,07 -1,69 -1,53 -1,94 -1,06 -1,10 -1,07 -1,03 
RGD1560911_predicted XM_001062704.1 -1,46 -1,75 -1,05 -1,33 -1,04 -2,06 -1,43 -1,48 1,06 -1,10 1,10 1,16 
RGD1561254_predicted XM_001065019.1 1,18 1,75 1,28 1,71 1,05 1,51 1,39 2,16 1,01 1,05 1,14 1,07 
RGD1562852_predicted XM_001067836.1 -1,33 -1,86 -1,21 -1,55 -1,08 -1,86 -1,60 -2,05 -1,08 -1,17 -1,02 -1,02 
RGD1563521_predicted XR_007378.1 1,23 2,27 1,11 1,28 -1,04 1,81 1,37 2,02 -1,05 -1,06 1,00 1,01 
RGD1564040_predicted XM_001062502.1 1,48 3,12 1,17 1,54 1,01 1,99 1,69 2,81 -1,02 -1,03 -1,04 1,01 
RGD1565950_predicted XM_001071965.1 -1,47 -1,84 -1,04 -1,34 1,10 -1,75 -1,58 -2,42 1,08 -1,00 1,10 1,23 
Rgs2 NM_053453.1 1,33 2,53 1,71 2,03 1,16 2,69 2,36 2,84 1,14 1,16 1,37 1,29 
Rilpl2 NM_001004205.1 -1,28 -1,79 -1,35 -1,67 -1,04 -1,72 -1,53 -2,16 -1,01 -1,05 -1,16 -1,00 
Rnd1 NM_001013222.1 1,03 2,28 1,32 5,10 -1,08 1,87 1,45 7,57 -1,04 -1,08 -1,04 -1,04 
Rnu3ip2_predicted XM_343469.3 1,04 1,98 1,05 1,44 -1,08 1,51 1,20 1,69 -1,06 -1,03 -1,11 -1,08 
Rragd_predicted XM_001063809.1 1,07 -1,91 -1,23 -1,57 -1,02 -2,05 -1,68 -2,59 -1,01 1,05 -1,02 -1,14 
Rrm2 NM_001025740.1 1,72 2,49 1,40 -1,88 1,11 1,92 2,21 2,77 1,06 1,20 1,23 1,13 
RT1-S3 XM_001072449.1 -1,34 -2,34 -1,23 -1,49 -1,07 -1,89 -1,43 -2,03 1,01 -1,02 1,02 1,01 
Rtn1 NM_053865.1 -1,33 -1,61 -1,25 -1,54 1,00 -1,51 -1,01 -1,19 -1,02 -1,08 -1,18 -1,21 
S100a1 NM_001007636.1 -1,95 -3,88 -1,37 -2,16 -1,17 -2,24 -1,87 -2,05 1,01 -1,03 1,02 1,01 
S100a13_predicted XM_215607.3 -1,85 -3,20 -1,41 -2,53 -1,07 -2,09 -1,88 -2,71 -1,07 -1,13 -1,14 -1,06 
S100a16_predicted XM_342291.3 -1,29 -2,17 -1,19 -1,34 -1,08 -1,74 -1,91 -2,26 1,01 -1,06 -1,08 -1,06 
Sec11c NM_153628.1 1,39 1,65 1,33 2,45 1,10 1,54 1,59 2,53 1,14 1,09 1,20 1,08 
Selenbp1 NM_080892.1 -1,57 -3,16 -1,53 -2,88 -1,10 -3,15 -1,58 -3,88 -1,00 -1,12 -1,03 -1,03 
Serpinf1 NM_177927.2 -1,52 -1,67 -1,02 -1,38 -1,04 -1,57 -1,25 -1,55 -1,03 -1,06 1,02 1,05 
Serping1 NM_199093.1 -2,24 -4,44 -1,17 -1,95 -1,05 -3,52 -1,66 -3,62 1,04 -1,02 -1,05 1,02 
Sfxn1 NM_001012213.1 1,29 1,56 1,13 1,27 1,19 1,77 1,52 1,82 1,14 1,24 1,20 1,10 
Skap2 NM_130413.1 -1,18 -1,70 -1,14 -1,36 -1,05 -1,62 -1,30 -1,55 -1,09 -1,06 -1,11 -1,08 
Slc12a5 NM_134363.1 -1,19 -1,88 -1,37 -1,39 -1,21 -1,55 -1,47 -1,86 -1,00 -1,02 -1,17 -1,11 
2
7
5
 
 276 
 
Gene symbol Accession No. 
AmphotericinB Doxorubicin Puromycin Paracetamol Metformin d-Mannitol 
LD HD LD HD LD HD LD HD LD HD LD HD 
Slc17a6 NM_053427.1 1,46 2,24 1,50 2,45 1,06 1,62 1,66 1,34 1,04 -1,17 1,20 1,10 
Slc20a1 NM_031148.1 1,29 2,04 1,17 2,10 -1,05 1,61 1,56 2,20 -1,15 -1,12 -1,12 -1,10 
Slc27a1 NM_053580.2 -1,37 -1,97 -1,35 -1,24 -1,12 -1,74 -1,49 -1,99 -1,15 -1,12 -1,16 -1,13 
Slc7a5 NM_017353.1 1,66 2,75 1,11 1,13 -1,01 2,36 1,55 1,88 1,01 1,14 1,05 1,12 
Slc7a7 NM_031341.1 -1,17 -1,60 1,03 -1,20 -1,01 -1,58 -1,27 -1,53 1,07 1,01 1,10 1,07 
Sox11 NM_053349.1 1,25 2,33 1,04 1,05 1,03 1,62 1,26 1,96 1,04 1,08 1,10 1,05 
Tagln NM_031549.1 -1,01 5,50 1,32 3,60 1,02 2,51 1,34 7,15 -1,15 -1,12 1,03 1,15 
Tcea3 NM_001015008.1 -1,63 -1,91 -1,03 -1,55 1,02 -2,11 -1,58 -1,91 1,06 -1,02 1,09 1,22 
Tekt1 NM_053508.2 -1,61 -1,92 -1,31 -1,51 -1,21 -1,76 -1,43 -1,80 -1,17 -1,16 -1,17 -1,26 
Tf NM_001013110.1 -1,68 -2,46 -1,18 -1,90 1,01 -2,40 -1,71 -3,08 1,09 -1,06 -1,00 1,12 
Thra NM_031134.2 -1,19 -2,47 -1,19 -2,82 -1,05 -1,61 -1,44 -4,01 1,10 -1,02 1,03 -1,03 
Tle2 NM_001039013.1 -1,13 -1,61 -1,10 -1,30 -1,07 -1,56 -1,30 -2,10 -1,01 -1,11 -1,04 1,03 
Tm7sf2 NM_001013071.1 -1,40 -1,89 -1,04 -1,61 -1,05 -1,73 -1,15 -1,67 -1,04 1,07 1,08 1,00 
Tm7sf2 NM_001013071.1 -1,31 -2,20 -1,10 -1,69 -1,03 -1,67 -1,16 -1,86 -1,10 1,04 -1,01 -1,05 
Tmem176b NM_134390.2 -1,97 -3,78 -1,25 -2,07 1,00 -5,41 -1,62 -2,18 1,06 -1,07 -1,03 1,08 
Tnfrsf12a NM_181086.2 1,09 1,55 1,27 2,42 1,09 1,62 1,28 2,74 1,04 1,10 1,09 -1,03 
Tnfsf12 NM_001001513.2 -1,50 -2,02 -1,54 -1,54 -1,20 -1,66 -1,42 -1,91 -1,12 -1,02 -1,22 -1,22 
Tnfsf13 NM_001009623.1 -1,52 -2,58 -1,29 -2,10 -1,06 -2,65 -1,41 -2,64 1,03 -1,14 -1,01 1,03 
Tnfsf18_predicted XM_344166.3 1,37 3,99 1,17 2,03 1,11 1,94 1,76 7,30 1,03 1,10 1,12 1,01 
Tst NM_012808.1 -1,58 -1,98 -1,27 -1,48 -1,09 -1,80 -1,50 -2,15 -1,12 -1,22 -1,14 -1,10 
Vkorc1 NM_203335.2 -1,37 -1,81 -1,11 -1,66 -1,03 -1,54 -1,29 -1,53 1,13 1,08 1,09 1,09 
Vwf XM_001066203.1 -1,13 -1,70 -1,09 -1,57 1,05 -1,17 -1,18 -2,15 1,01 -1,02 1,03 1,09 
Xpa_predicted XM_001071899.1 -1,18 -1,59 -1,07 -1,41 1,00 -1,56 -1,46 -1,91 1,13 1,11 1,07 1,07 
Yars NM_001025696.1 1,29 2,33 1,13 1,35 1,05 1,58 1,33 1,94 -1,04 -1,03 1,04 1,08 
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